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Despite intensive research, the cellular and molecular mechanisms involved in 
human cellular susceptibility to prion infection remain poorly defined, in part due to 
the continuing lack of cultured human cells that are susceptible to infection with 
human prions. Such culture models would present distinct advantages including 
speed and expense compared with animal models, and would provide systems in 




, the basis of cellular 
susceptibility, the nature of the species barrier and the mechanism of prion 
propagation in situ. 
This study sought to examine whether non-neuronal cells might provide 
opportunities to establish human cell lines replicating human prions. A human 
follicular dendritic cell-like cell line (termed HK) was obtained, further characterised 
and then tested for its ability to support human prion replication. The mechanisms of 
internalisation, intracellular trafficking and the eventual fate of exogenous PrP
Sc
 
taken up by these cells were also examined. This thesis similarly examined the 
cellular response of human embryonic stem cells (hESC) to acute exposure to human 
and animal prions.  
PrP
C 
was found to be abundantly expressed by HK cells and HK cell extracts were 
found to support conversion to PrP
Sc
 in a cell-free conversion assay. However, HK 
cells exposed to infectious brain homogenates failed to accumulate PrP
Sc
 or become 
infected in vitro. Exposed HK and hESC did display a readily detectable, time 
dependent uptake of PrP
Sc 
from medium spiked with prion-infected brain 




codon 129 genotype of the human source and the recipient cells. The exposed cells 
showed intensely labelled intracellular accumulations of PrP
Sc 
with coarse granular 
morphology, largely in the juxtanuclear region of cytoplasm. However, when the 
brain-spiked medium was withdrawn and cells were given control medium, the 
intensity and extent of PrP
Sc
 immunostaining rapidly diminished. Co-localisation 
studies implicated caveolae-mediated endocytic uptake of exogenous PrP
Sc
, 
apparently preceding uptake via clathrin coated pits in HK cells. Evidence suggesting 
that the endosomal recycling compartment and lysosomes are involved in 
intracellular trafficking and degradation of exogenous PrP
Sc
 was also found.  
Understanding the cell biology of these processes may help to explain why the 
majority of cultured cells are refractory to prion infection in vitro. Internalization of 
misfolded PrP and its subsequent degradation in the lysosomal compartment might 
function as a self-protective cellular mechanism, serving to eliminate non-native, 
presumably dysfunctional and potentially dangerous PrP
 
conformers, whether 
generated endogenously or acquired through exposure to exogenous prion infectivity.
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1. INTRODUCTION 
 
1.1 PRIONS – OVERVIEW 
The concept of prion diseases originated in the field of transmissible spongiform 
encephalopathies (TSEs), which are invariably fatal neurodegenerative disorders of 
the central nervous system, naturally occurring in humans and a wide range of 
animals. The term “spongiform” relates to the neuropathological alteration of brain 
tissue (sponge-like vacuolation in the grey matter) in affected individuals. Prions are 
a novel class of infectious pathogens in which a misfolded host-encoded protein 
appears to be the main component of the disease-causing agents. The normal cellular 
prion protein (PrP
C
) was first discovered in the context of its pathogenic “scrapie” 
isoform (PrP
Sc
), which plays a key role in the development of TSEs.  
The nature of the infectious agents responsible for TSEs has been a matter of debate 
for many years. The prototypic prion disease scrapie, which naturally occurs in sheep 
and goats, was recognised in Europe over 200 years ago (McGowan, 1922). Its 
transmissibility was first demonstrated by J. Cuille and P. Chelle in 1936 who 
performed intraocular inoculation of sheep with infected brain (Cuille and Chelle, 
1936). In 1954 the concept of “slow virus” infection was proposed by B. Sigurdsson, 
which included “rida” in sheep (the Icelandic name for the scrapie prion infection) 
(Sigurdsson, 1954). The transmissibility of scrapie to other mammalian species 
(goats, rats, mice, and hamsters) was also demonstrated (Cuille and Chelle, 1939; 
Chandler, 1963; Chandler and Fisher, 1963; Zlotnik, 1963) and the long incubation 
period was considered to result from a “species barrier” (Pattison, 1965). Unlike 
other infectious diseases of bacterial, viral, or viroid origin, the pathogen appeared to 
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be resistant to inactivation by UV and ionizing radiation, but was affected by 
chaotropic agents (Alper et al., 1966; Marsh et al., 1974; Ward et al., 1974; Alper et 
al., 1978; Diener et al., 1982), thus indicating an infectious agent devoid of nucleic 
acid. A protein as a pathological agent was proposed in 1967 by I. Pattison and K. 
Jones (Pattison and Jones, 1967) and the existence of more than one strain of scrapie 
and a model for the scrapie agent self-replication was proposed by the mathematician 
J. Griffith (Griffith, 1967). However, these proposals were met with scepticism and 
were relatively neglected by the scientific community as they challenged the central 
dogma of molecular biology, that genetic information flows from DNA to RNA to 
protein. In 1982, the physician and scientist of the Johns Hopkins University School 
of Medicine, R. Johnson summarised the situation: “The unorthodox properties of 
the spongiform encephalopathy agents have created a mystique about their possible 
nature. Exotic fantasies have evolved of an agent devoid on nucleic acids but 
representing self-replicating membranes, proteins or polysaccharides.” (Johnson, 
1982).  
In the 1920s, the two sets of neurological cases reported independently by H. 
Creutzfeldt and A. Jakob (Creutzfeldt, 1920; Jakob, 1921) were given the name 
Creutzfeldt-Jakob disease (CJD) by W. Spielmeyer in 1922. In 1936 the initial 
description of Gerstmann-Sträussler-Schienker disease (GSS) suggested that this was 
an inherited disease rather than acquired by transmission despite its characteristics of 
spinocerebellar ataxia with a distinctive neuropathological phenotype (Gerstmann et 
al., 1936; Gajdusek and Zigas, 1957; Gajdusek and Zigas, 1959). In the 1950s C. 
Gajdusek was attracted to the highlands of Papua New Guinea by reports of a 
mysterious epidemic, primarily afflicting women and children called kuru that was 
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ravaging the native tribes of the Fore people (Gajdusek and Zigas, 1957; Gajdusek 
and Zigas, 1959). Kuru was characterised by progressive ataxia and 
neurodegeneration. In 1959 W. Hadlow pointed out the striking similarity between 
scrapie and kuru at their neuropathological, clinical and epidemiological level. This 
lead to the hypothesis that kuru could be a transmissible disease (Hadlow, 1959) and 
specifically that it was transmitted by ritual cannibalism (Gajdusek, 1977). Kuru was 
successfully transmitted to chimpanzees in 1966 (Gajdusek et al., 1966), and this was 
followed by the successful transmissions of sporadic CJD in 1968 (Gibbs, Jr. et al., 
1968) and GSS in 1981 (Masters et al., 1981). However, it is important to note that 
not all forms of GSS were successfully transmitted (Brown et al., 1994a; Tateishi 
and Kitamoto, 1995; Parchi et al., 1998). These pioneering studies established that 
kuru and CJD, which were considered to be diseases of unknown etiology, belonged 
to the same group of diseases. Gajdusek was awarded by the Nobel Prize in 1976 for 
his work on kuru. 
The term “prion” was coined by a Nobel Laureate, S. Prusiner in 1982 as an acronym 
denoting “small proteinaceous infectious particle that resists inactivation by 
procedures which modify nucleic acids” (Prusiner, 1982). Additional investigations 
demonstrated further anomalies peculiar to prion diseases. Most prominent is the 
absolute requirement for the presence of the normal cellular prion protein, PrP
C
 
(Bueler et al., 1993), and interplay with the pathogenic protease resistant disease 
associated conformer of this prion protein, termed PrP
Sc
 after the first described prion 
disease, scrapie, in sheep. In 1982, a fragment of the prion protein termed PrP
27-30 
was discovered and further molecular cloning studies of the prion protein gene 
revealed that the PrP
27-30 
was the truncated proteinase K-resistant core of the disease-
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associated prion protein, PrP
Sc
, which had the same amino acid sequence as the 
normal cellular prion protein, PrP
C
 (Bolton et al., 1982; Prusiner et al., 1982; 
Chesebro et al., 1985; Oesch et al., 1985; Hope et al., 1986; Meyer et al., 1986) and 
was shown to retain infectivity (Riesner, 2003). Prion protein was shown to be 
encoded by a chromosomal gene and not by the nucleic acid of an infectious scrapie 
particle. Levels of PrP mRNA were observed to remain unchanged throughout the 
course of scrapie infection (Basler et al., 1986). PrP
Sc
 was therefore suggested to be a 
misfolded, disease associated isoform derived from host’s own PrP
C
, which is an 
abundantly expressed glycosylphosphatidylinositol- (GPI-) anchored plasma 
membrane protein (Hope and Manson, 1991; Prusiner, 1998). In 1998 Prusiner 
proposed the “protein only” hypothesis of prion replication in which he states that an 
abnormal isoform, PrP
Sc
, of the normal cellular prion protein, PrP
C
, is capable of 
recruiting the PrP
C
 to undergo a change of conformation into PrP
Sc
 without the 
presence of DNA (or RNA) (Prusiner, 1998). These key observations have allowed 
the identification of a wide spectrum of human and animal prion diseases (Figure 
1.1) (Ironside, 1996; Ironside, 1998).  
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Figure 1.1: Classification of prion diseases of humans and animals 
Human prion diseases can be classified and further sub-classified as idiopathic: sporadic 
Creutzfeldt-Jakob disease (sCJD), sporadic fatal insomnia (sFI), variably protease-sensitive 
prionopathy (VPSPr); hereditary: familial Creutzfeldt-Jakob disease (fCJD), familial fatal 
insomnia (FFI), Gerstmann-Sträussler-Schienker disease (GSS); and acquired: kuru, 
iatrogenic Creutzfeldt-Jakob disease (iCJD), variant Creutzfeldt-Jakob disease (vCJD). 
Animal prion diseases are sub-classsified as: scrapie, atypical scrapie, transmissible mink 
encephalopathy (TME), chronic wasting disease (CWD), bovine spongiform encephalopathy 
(BSE), bovine amyloidotic spongiform encephalopathy (BASE), exotic ruminant 
encephalopathy (EUE), feline spongiform encephalopathy (FSE). 
 
Since the Central Veterinary Laboratory in England reported the first case of a novel 
prion disease in cattle, termed bovine spongiform encephalopathy (BSE) in 1987, 
TSEs have attracted a broad interest (Wells et al., 1987; Parchi et al., 1997). This 
prion disease was transmitted via livestock feed supplemented with bone and meat 
meal derived from unrecognised prion-infected animal sources, most likely from 
scrapie infected sheep. BSE was shown to be transmissible, highly pathogenic and 
retaining its biological identity after crossing between species either naturally or 
experimentally (Bruce et al., 1994; Bruce et al., 1997). In 1996, yet another novel 
TSE was discovered, this time in humans, which was termed new variant CJD or 
vCJD (Will et al., 1996). Histopathological, biochemical, and epidemiological 
evidence suggests that vCJD is most likely to be a result of orally ingested infectious 
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BSE prion agent and is believed to have caused over 200 cases of vCJD worldwide 
(Chazot et al., 1996; Collinge et al., 1996; Will, 1996; Hill et al., 1997a; Prusiner et 
al., 1998) (http://www.cjd.ed.ac.uk/vcjdworld.htm). Moreover, four cases of vCJD 
infection have been reported to be caused by blood transfusion (Llewelyn et al., 
2004; Peden et al., 2004; Wroe et al., 2006; Peden et al., 2010), in which prions were 
transmitted by from patients in the pre-clinical phase of the disease.  
The majority of the recent clinical applications involving human stem cell therapies 
are still critically dependent in their development on poorly characterised human and 
animal bioproducts as well as isolating blood products for therapies (Reubinoff et al., 
2000; Lanzendorf et al., 2001; Mitalipova et al., 2003; Hovatta et al., 2003; Cowan 
et al., 2004; Klimanskaya et al., 2005; Fletcher et al., 2006; Ludwig et al., 2006). 
The potential for inadvertent prion transmission in humans by emerging cellular 
therapies has received comparatively little attention from the public health point of 
view (Cobo et al., 2006; Akimov et al., 2008; Akimov et al., 2009; Cushman et al., 
2010). The main prion protein characteristics and spectrum of prion diseases related 
to this project are described in more detail in the sections that follow.  
 
1.2 THE PRION PROTEIN 
The prion protein (PrP) is a fundamental prerequisite for all prion diseases and is 
expressed in a variety of different vertebrate classes including fish, reptiles, birds, 
and mammals. This PhD project employed mammalian (human) cell culture systems 
and involved the use of human and bovine prions. Here, PrP always refers to the 
mammalian prion protein. Some of the cellular processes mentioned in this thesis 
may also correlate with prion protein processes in other vertebrates. Interestingly, 
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there is an obvious sequence homology between some parts of mammalian and non-
mammalian prion proteins, indicating that many of the important structural and 
functional features are most likely conserved (Calzolai et al., 2005; Lysek et al., 
2005; Rivera-Milla et al., 2006; Ji and Zhang, 2007). In this thesis, the terms used for 
the different prion protein forms are stated in Table 1.1, except where citing the work 
of others, when terminology used as in the original publication is adopted. It is also 
important to note the terminology used for prion protein in the experimental part of 
this thesis when referring to the pre-treatment procedure used in the visualisation 
process (for example, when pre-treatment of cells with proteinase K and/or guanidine 
thiocyanate is used). 
The form of the prion protein detected by confocal microscopy in cells exposed to infectious prion 
infected brain homogenates. When proteinase K or guanidine pre-treatment was not included in the 
immunocytochemical procedure four forms of prion protein could be detected: brain derived PrPSc





Partially protease-resistant form of the prion protein, seen in biochemical analysis (Western blot) 
after proteinase K digestion, not necessarily synonymous with PrPSc
PrPres
Abnormal prion disease-associated form of the prion protein, denoted after scrapie, also visualised 
by confocal microscopy after incorporating the proteinase K and guanidine pre-treatment in the 
immunocytochemical procedure of cells exposed to prion infected brain homogenate
PrPSc
Normal cellular form of the prion proteinPrPC
Prion protein, product of the prion protein genePrP
Gene encoding prion protein in other speciesPrnp
Gene encoding prion protein in humans and sheepPRNP
DefinitionTerm
 
Table 1.1: Terms used for the different prion protein forms  
 
1.2.1 The prion protein gene  
The human prion protein gene was first described in 1986 (Liao et al., 1986) and the 
complete DNA sequence is available at the Internet bioinformatics site (GenBank, 
accession number AL133396). In humans, the prion protein gene (PRNP) is a single 
copy gene, located on the short arm of chromosome 20 and is composed of two 
exons and a single intron that span about 15 kb (Figure 1.2). The entire open reading 
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frame (ORF) containing the complete 762 bp long DNA sequence encoding the 253 
amino acid residues of human prion protein is located within the exon 2 (Sparkes et 
al., 1986; Prusiner, 1991a). PRNP transcription is controlled via a promoter region 
located upstream of exon 1 and contains a single major transcription start site 
(Puckett et al., 1991) unusually rich in G, C nucleotides. Those within the mRNA 
transcript could potentially be involved in the secondary structure formation if bound 
to the GC rich region of the open reading frame (Goldmann, 1993).  
 
Figure 1.2: Diagrammatic representation of PRNP and PrP mRNA 
The PRNP open reading frame ORF (green) is located within exon 2. Figure source (Kong 
and Bessen, 2008). 
 
The prion protein gene is often classified as a housekeeping gene, based on the 
absence of a TATA box in the prion promoter. However, there are highly conserved 
motifs for binding transcription factors and a consensus heat shock factor binding 
site present in the immediate 5’ region (Basler et al., 1986; Puckett et al., 1991; 
Westaway et al., 1994; Saeki et al., 1996; Baybutt and Manson, 1997; Inoue et al., 
1997; Shyu et al., 2002). Expressions of both PrP
C
 mRNA and protein are 
developmentally regulated, increasing postnatally with distinct time course for 
specific regions as observed in rat, hamster and mouse brains (Lieberburg, 1987; 
McKinley et al., 1987; Lazarini et al., 1991; Manson et al., 1992). Induction of Prnp 
mRNA expression was first detectable around the ninth embryonic day of mouse, 
coinciding with the transition from anaerobic to aerobic metabolism (Miele et al., 
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2003). The genes encoding prion protein of various species were also sequenced in 
1986 (Basler et al., 1986; Liao et al., 1986; Locht et al., 1986). Most animals 
including cattle, sheep and mice have their prion protein gene composed of three 
exons with the ORF within exon 3, which is analogous to exon 2 of the human prion 
protein gene (Prusiner, 1998). The prion protein gene was shown to be highly 
conserved across many animal species, suggesting functional importance for the 
prion protein (Lee et al., 1998; Van Rheede et al., 2003; Premzl and Gamulin, 2007).  
DNA variations of the human prion protein gene fall into two categories: mutations 
that are associated with a prion disease and are highly penetrant, and polymorphisms 
that do not themselves directly result in disease, but which can have an influence on 
susceptibility to prion infection or a profound effect on the clinical features of the 
resultant disease (Figure 1.3) (Palmer et al., 1991; Collinge et al., 1991b; Goldfarb et 
al., 1992; Windl et al., 1996; Zeidler et al., 1997; Parchi et al., 1999a). More than 
thirty pathogenic mutations including point mutations resulting in amino-acid 
substitution, deletion or insertion of additional octapeptide repeats have been 
described to date (Kong et al., 2004; Mead et al., 2006). These are linked to, or have 
been associated with specific familial prion diseases phenotypes (reviewed Kong et 
al., 2003). From the over twenty natural PRNP polymorphisms, only the 
polymorphism at codon 129 (encoding either methionine or valine) has been 
proposed to play a role in human disease susceptibility or have an effect on disease 
phenotype (Collinge et al., 1991a; Goldfarb et al., 1992; Monari et al., 1994; Parchi 
et al., 1996; Zeidler et al., 1997; Deslys et al., 1998; Lee et al., 2001; Brandel et al., 
2003).  
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Figure 1.3: Diagrammatic representation of the primary prion protein structure 
including post-translational modifications, polymorphisms and pathogenic mutations 
The numbers indicate amino acid residue position in the prion protein. Single letter 
designation for respective amino acids is used to denote polymorphisms (blue and black 
type) and mutations linked to the human prion diseases are indicated above (red type). The 
mature form of human PrP
C
 contains 208 amino acids (23-230). The secretory signal peptide 
(1-22) is indicated at the extreme of the N-terminus (green). The hydrophobic peptide region 
(231-253) (orange) is cleaved when the GPI anchor is attached (purple). The octapeptide 
repeats are indicated at amino acid positions 51-91 (grey boxes). The regions forming three 
α-helixes and two β-sheets are indicated by blue and red boxes respectively. The arrowhead 
at amino acid 90 indicates the major cleavage site for proteinase K. The two potential sites 
for N-linked glycosylation (CHO) are illustrated at residues 181 and 197 and one disulfide 
bond (S-S) connecting the helixes 2 and 3 at cysteine residues 179-214 is also shown. Figure 
modified from (Kong and Bessen, 2008). 
 
Additional studies have suggested that the PRNP codon 129 genotype also may have 
an influence in survival (Alperovitch et al., 1999; Pocchiari et al., 2004), the 
neuropathology of sCJD (Parchi et al., 1999b; Kovacs et al., 2000), protease 
cleavage of PrP
Sc 
(Parchi et al., 2000), PrP
Sc
 amyloid formation (Baskakov et al., 
2005) and oligomerisation of PrP
Sc
 (Lewis et al., 2006). The most dramatic influence 
of the polymorphism at codon 129 so far observed is in its effect in vCJD (Brandel et 
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al., 2009). All genetically tested and pathologically confirmed cases of vCJD have 
been determined to be homozygous for methionine at this polymorphism. However, 
three individuals with methionine/valine (MV) genotype at the codon 129 were 
recently reported: one as a possible vCJD case (based on the clinical features and 
tests) as post-mortem examination was not performed (Kaski et al., 2011) and two 
pre-clinical vCJD infection where one individual received a blood transfusion and 
one haemophiliac individual received blood products from donors incubating vCJD 
(Peden et al., 2004; Peden et al., 2010). Interestingly, these patients died without any 
sign of neurological symptoms. Nonetheless, the accumulation of PrP
Sc
 in the spleen 
was confirmed in post-mortem examination. In addition to vCJD, the association of 
codon 129 genotype and disease is also observed in the genotype frequencies of the 
sCJD (Table 1.2), in which homozygosity (either MM or VV) is more commonly 
associated with the disease (Brown et al., 1992; Parchi et al., 1999b; Head et al., 
2004a; Head et al., 2004b; Bishop et al., 2009). The one divergence from this 
tendency is within the UK cases of growth hormone transmitted iCJD, in which MM 
homozygotes represent the smallest proportion of patients (Brandel et al., 2003). 
ReferencesVV  (%)MV  (%)MM  (%)PRNP codon 129 genotype
www.cjd.ed.ac.uk, Annual Report 2010 
(Jan MacKenzie – study co-ordinator)
325711iCJD  (UK) *
Brandel et al., 200900100vCJD  (UK)
www.cjd.ed.ac.uk, Annual Report 2010 
(Jan MacKenzie – study co-ordinator)
191962sCJD  (UK)
Bishop et al., 200911.544.544Normal population  (UK)
 
Table 1.2: Comparison of PRNP codon 129 frequencies within the normal population 
and CJD affected patients in UK 
* 51 % iCJD cases were available with codon 129 genotype information 
 
It is important to note that codon 129 occupies the second position of the four amino 
acids responsible for creating the β-sheet 1 and therefore may affect elements of the 
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tertiary structure which could be important when PrP
C
 is being recruited into PrP
Sc
 
conversion (Petchanikow et al., 2001). Methionine homozygosity at codon 129 was 
shown to be conserved within many mammalian species: cattle, sheep, rat, mice (Jew 
and Schatzl, 2005). 
The effect of Prnp polymorphisms on the infection was also observed in animals. In 
mice the codons 108 and 189 are known to be associated with progression of the 
disease (Westaway et al., 1994; Moore et al., 1998) and in sheep three polymorphic 
sites of the codons 136, 154 and 171 have a profound effect on the susceptibility and 
pathogenesis (Hunter, 2003; Hunter, 2007). 
 
1.2.2 The normal cellular form of the prion protein, PrP
C
 
The post-translational processing of the PRNP product consists of the removal of an 
amino terminal signal peptide consisting of 22 amino acid residues serving as an 
endoplasmic reticulum signal peptide, allowing insertion of the nascent PrP
C 
into the 
secretory pathway during synthesis. Another step of post-translational processing is 
removal of the carboxy terminal hydrophobic peptide formed by 23 amino acids 
residues and the subsequent covalent addition of the GPI moiety to serine at amino 
acid 231. The GPI anchor mediates prion protein attachment to the cell surface (Stahl 
et al., 1987; Prusiner, 1991b). PrP
C
 is a monomeric protein occurring as a mixture of 
three major forms: un-glycosylated, mono-glycosylated and di-glycosylated, due to 
highly branched carbohydrate moieties attached at asparagine residues 181 and 197 
(Haraguchi et al., 1989). The physiological significance of PrP
C 
glycosylation is 
unclear. Nevertheless, protein glycosylation affects other protein properties, such as 
intracellular trafficking and ligand binding (Stanley, 1987; Paulson, 1989; Lis and 
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Sharon, 1993)The stability of PrP
C
 was also suggested to be modulated by N-
glycans, however the experimental evidence is still lacking (Hornemann et al., 2004). 
Interestingly, the N-terminal region of PrP
C
 is unstructured, while the globular C-
terminal part consists of three α-helical and two very short anti-parallel β-plated 
sheets regions (Pan et al., 1993; Riek et al., 1996; Riek et al., 1998; Govaerts et al., 
2004).  
The early computational analysis of circular dichorism and low-resolution infrared 
spectroscopy studies indicated the high α-helical (40% of the protein) and the 
relatively low β-sheet content (3% of the protein) (Bazan et al., 1987; Pan et al., 
1993; Huang et al., 1994). The use of nuclear magnetic resonance spectroscopy at 
acid pH (Riek et al., 1996; Prusiner, 1998; Hornemann et al., 2004) and later 
crystallography (Knaus et al., 2001; Haire et al., 2004) refined the structural 
properties of PrP
C
. It was found that the long flexible NH2-proximal half of the 
molecule is unstructured, whereas the globular COOH-proximal half forms three α-
helices corresponding, for the human PrP
C
, to the residues 144-154, 173-194 and 
200-228, interspersed with an antiparallel β-pleated sheets formed by β-strand at 
residues 128-131 and 161-164 (Figure 1.4). The structurally less defined N-terminal 
region consists of residues 23-124 (N-terminus to the β-sheet 1) and contains a 
stretch of several the octapeptide repeat sequences (Hornshaw et al., 1995; Flechsig 
et al., 2000) which are 24 bp encoding the same eight amino acids, with five repeats 
present in the human sequence that has been shown to bind metal ions. These are 
flanked by two positively charged clusters, CC1 (amino acids 23-27) and CC2 
(amino acids 95-110). The hydrophobic region (amino acids 111-134) between these 
two domains is also known as the HC region. The structure is stabilised by 
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connecting the helixes 2 and 3 by a single disulfide bond occurring between cysteine 
residues 179 and 214 (Turk et al., 1988; Riek et al., 1996; Riek et al., 1997; Zahn et 
al., 2000).  
 
Figure 1.4: Structural features of the tertiary structure of the cellular prion protein 
The cellular prion protein is anchored into a lipid bilayer. The N-terminal part (grey) is, as 
deduced from NMR spectroscopy, unstructured. The octapeptide repeats region is marked in 
(green). The ribbon schematics represent the α-helices (purple) and the short β-strands are 
illustrated by arrows (orange). The two highly branched glycosyl groups attached at 
asparagines residues 181 and 197 are shown (yellow). Figure source 
(http://www.fbs.leeds.ac.uk/staff/Hooper_N/prion.htm). 
 
The structure of the globular domain of human PrP
C
 is homologous to various other 
mammals as it is conserved within many species (Lopez et al., 2000; Lysek et al., 
2005). Notably, despite the low sequence homology between PrP
C
 in turtle, frog, or 
chicken and mammalian PrP
C
, the major structural features of the protein are 
preserved in those non-mammalian species (Calzolai et al., 2005). PRNP is 
abundantly expressed in CNS and cells of lymphoid tissues, but it is also expressed 
in other cell types (http://biogps.org/#goto=genereport&id=5621) and its 
predominant localisation is in cholesterol-rich lipid rafts or caveolae-like domains of 
the plasma membrane (Paratcha and Ibanez, 2002; Taylor and Hooper, 2006). 
Molecular dynamics simulations have suggested that the NH2-terminal domain of 
PrP
C
 may interact with membrane lipids and traverse the surface of the membrane 
(DeMarco and Daggett, 2005).  
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1.2.3 PrP
C
 turnover in the cell  
Notwithstanding the minute amount of truncated and transmembrane forms, the 
normal cellular form of prion protein is typically found a GPI-anchored to the outer 
leaflet of the cell membrane (Taylor and Hooper, 2006). Similar to other GPI-
anchored proteins, PrP
C 
is synthesised as a precursor form with N- and C- terminal 
signal peptides and is translocated into the endoplasmic reticulum co-translationally. 
The N-terminal signal peptide is cleaved soon after translocation, and the C-terminal 
signal peptide is replaced by a preassembled GPI-anchor in a transamidation 
reaction. Subsequently, high-mannose glycans are added and one disulfide bond is 
formed. The glycans are then trimmed and modified as the protein traverses the 
Golgi complex on its way to the plasma membrane, where it is then anchored via its 
GPI moiety. PrP
C
, like other GPI-anchored proteins, is predominantly found attached 
to low-density, detergent insoluble membrane domains (DRM), rich in cholesterol 
and sphingolipids (Naslavsky et al., 1997; Taylor and Hooper, 2006) 
Membrane rafts have been consensually described as small (10-200 nm), 
heterogeneous, highly dynamic, sphingolipid- and sterol-enriched domains that 
compartmentalise cellular processes and can occasionally be stabilised to form larger 
platforms through protein-lipid or protein-protein interactions (Pike, 2006). Despite 
some uncertainties, most of the evidence suggests a critical role for these distinctive 
membrane domains in the biology of the cell surface. Membrane rafts have been 
shown to be involved in pathogen invasion, regulation of protein and lipid sorting 
and also in intracellular signalling (Goot and Harder, 2001; Schuck and Simons, 
2004; Pelkmans, 2005; Murphy et al., 2006). Raft association of PrP
C 
was proposed 
to control the distribution of mature prion protein among distinct regions of the 
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plasma membrane, with sphingolipid or cholesterol depletion resulting in extensive 
redistribution of PrP
C
 at the cell surface (Galvan et al., 2005).  
The association of PrP
C 
with lipid rafts is dynamic, as a substantial fraction of the 
protein found in non-raft membrane, on its way to coated pits (Sunyach et al., 2003). 
Study of cholesterol depletion also suggests that raft association is required for 
correct folding of PrP
C
 as well as for the export of the protein to the Golgi complex 
and correct glycosylation (Sarnataro et al., 2004; Campana et al., 2005). In addition, 
PrP
C 
that does not associate with rafts in the ER was shown to undergo 
conformational changes that modify protease sensitivity, suggesting that the 
immature protein may be misfolded and subjected to ER quality control mechanism 
(Sarnataro et al., 2004). PrP
C
 subjected to endocytic recycling (Sunyach et al., 2003) 
can be found in secretory cytoplasmic granules (Fournier et al., 2000). Moreover, 
localisation of PrP
C 
in caveolae-like domains and evidence for PrP
C 
internalisation 
via non-clathrin coated vesicles has also been reported, leading to the contention that 
clathrin-coated vesicles may not participate in PrP
C 
trafficking (Vey et al., 1996; 
Kaneko et al., 1997a; Peters et al., 2003; Marella and Chabry, 2004).  
Caveolae are flask-shaped invaginations of the plasma membrane. The shape and 
structural organisation of caveolae (~ 60 nm in diameter) are conferred principally by 
caveolin, a dimeric protein that binds cholesterol. It inserts loop into the inner leaflet 
of the plasma membrane, and self-associates to form a striated caveolin coat on the 
surface of the membrane invaginations (Razani et al., 2001). Although PrP
C 
lacks the 
expected signal sequences for intracellular internalisation, recent evidence supports a 
role of clathrin coated vesicles in the internalisation of PrP
C 
(Shyng et al., 1994; 
Sunyach et al., 2003; Taylor et al., 2005; Taylor and Hooper, 2007). Additional 
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studies employing cell surface biotinylation, live cell microscopy of GFP-tagged 
PrP
C
 and electron microscopy also support the proposal that clathrin-coated vesicles 
and the classical endosomal organelles are involved in endocytosis of PrP
C 
(Shyng et 
al., 1994; Magalhaes et al., 2002; Sunyach et al., 2003; Brown and Harris, 2003; 
Taylor et al., 2005).  
Moreover, the results from studies using dominant negative approaches support a 
role for dynamin and clathrin in the internalisation of PrP
C 
(Magalhaes et al., 2002; 
Taylor et al., 2005). Clathrin mediated endocytosis involves the concentration of 
high-affinity transmembrane receptors and their binding of ligands into “coated pits” 
on the plasma membrane (~ 120 nm in diameter), which are formed by the assembly 
of cytosolic coat proteins, mainly by clathrin. Molecules are carried into the cell by 
invagination and pinching-off of pieces of the plasma membrane in the form of 
endocytic vesicles encapsulated by polygonal clathrin coat (Conner and Schmid, 
2003).  
In addition to these findings, it has been proposed that lipoprotein receptor-related 
protein and/or laminin receptor may play a major role in the subcellular trafficking of 
PrP
C 
(Gauczynski et al., 2001; Gauczynski et al., 2006). However, it is still unknown 
whether the endocytic cycle of PrP
C 
is dependent on any physiological ligand. It may 
be presumed that cytosolic factors that participate in clathrin-mediated endocytosis, 
such as small GTP binding Rab proteins (Zerial and McBride, 2001) could have an 
important role in controlling PrP
C 
trafficking. Rab proteins, such as Rab 6, generally 
involved with retrograde transport of PrP
Sc 
to ER, may also regulate trafficking of 
PrP
C 
(Beranger et al., 2002).  
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Evidence that PrP
C 
can be also found in the cytosol of various cultured cells and 
brain neurons have been shown (Ma and Lindquist, 1999; Ma and Lindquist, 2001; 
Yedidia et al., 2001; Wang et al., 2005; Dron et al., 2009) and despite this, cytosolic 
PrP
C
 was originally proposed to be cytotoxic and perhaps involved in the 
neurodegenerative process found in prion diseases (Ma and Lindquist, 1999; Ma and 
Lindquist, 2001). However it has been found in the cytosol in subpopulations of 
neurons in several areas of normal healthy brain (Mironov et al., 2003) and also 
cytosolic PrP
C 
was reported in various neuronal cell systems in vitro without 
exhibiting neurotoxic activity (Roucou et al., 2003; Fioriti et al., 2005). It is 
important to note that most studies pertaining to the pathogenic role of cytosolic PrP
C
 
have been performed on genetically engineered cells in a non-infectious context 
(Dron et al., 2009).  
There are major unanswered questions concerning the physiological regulation of the 
endocytic cycle and of the fate of recycled PrP
C
, following each cycle of 
internalisation. The misfolded, mutant or wild-type forms of PrP have been shown to 
be degraded by ER-associated degradation (ERAD) during which they are 
ubiquitinated and degraded by proteasome (Zanusso et al., 1999; Jin et al., 2000; Ma 
and Lindquist, 2001; Yedidia et al., 2001; Ma et al., 2002; Cohen and Taraboulos, 
2003). A small fraction of endocytosed PrP
C
 was shown to be degraded by 
lysosomes (Shyng et al., 1993; Mayer et al., 1994), but a major fraction returns to the 
cell surface. In addition to the overall observations, studies originally intended to 
clarify the intracellular transfer of PrP
Sc 
have led to the observation that part of the 
recycled PrP
C 
is also secreted to the extracellular medium in association with 
exosomes (Fevrier et al., 2004; Porto-Carreiro et al., 2005; Robertson et al., 2006). A 
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diagrammatic summary of PrP
C 
production, localisation and trafficking is illustrated 





































 is translocated co-translationally into endoplasmic reticulum (A) where the 
N-terminal signal sequence is cleaved by a signal peptidase. After translocation, the C-
terminal GPI-signal peptide is replaced by a preassembled GPI anchor. Subsequently, the 
disulphide bond is formed and the glycans are added. The protein is then transported through 
the Golgi complex (B) to the cell surface where it resides in the plasma membrane (C) and in 
lipid rafts (D). PrP
C 
can be then endocytosed via clathrin-coated pits (E) or caveolae coated 
vesicles (F). PrP
C 
can be subsequently transported back to the cell surface via recycling 
vesicles (G). PrP
C
 can be degraded through the endosomal/lysosomal pathway (H), or by the 
proteasomes (I). Extracellular PrP
C
 can be associated both with exosomes (J) and without 
GPI-moiety (K) indicating phospholipase or protease mediated shedding.  
 
1.2.4 Putative functions of PrP
C
  
The cellular prion protein has been the subject of intense research because it is 
considered to be the essential factor in the pathogenesis of prion diseases (Bueler et 
al., 1993). Understanding the pathogenesis of TSEs accordingly requires a better 
definition of the functional properties of the normal prion protein. Despite marked 
PrP
C 
sequence conservation among species and advances in the determining PrP
C 
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is especially abundant in brain regions characterised by a high degree of 
synaptic plasticity, for example the hippocampus (Sales et al., 1998), and because of 
its predominant localisation at synapses (Manson et al., 1992; Fournier et al., 1995; 
Moser et al., 1995; Sales et al., 1998; Herms et al., 1999; Moya et al., 2000; 
Haeberle et al., 2000; Laine et al., 2001; Kovacs et al., 2005; Godsave et al., 2008) a 
role in synapse formation and function has been proposed for the normal cellular 
prion protein (Maglio et al., 2004). Some combined data indicate that PrP
C 
could 
modulate neuronal excitability, synaptic activity, function and regulation (Collinge et 
al., 1994; Herms et al., 1999; Mallucci et al., 2002), which are suggested to be the 
neural basis for some of the systemic brain functions attributed to PrP
C
. Normal 
cellular prion protein was also indicated to be involved in the regulation of circadian 
rhythms and sleep patterns (Tobler et al., 1996; Tobler et al., 1997; Huber et al., 
1999; Huber et al., 2002) and interestingly, links between sleep and memory/learning 
were previously observed (Born et al., 2006). At least two definite molecular 
interactions of PrP
C 
with hippocampal cell surface proteins, LN and hop/STI1, may 
mediate effects of PrP
C 
on memory consolidation, and it was suggested that PrP
C 
modulates memory conservation through both these interactions. Further evidence 
for the hypothesis that PrP
C 
plays an important role in memory and cognition was 
observed in humans. The presence of valine at codon 129 of PRNP in at least one 
allele was linked with worsened cognitive performance in elderly individuals (Berr et 
al., 1998; Kachiwala et al., 2005).  
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Participation in transmembrane signalling processes involved in neuronal survival 
and neurite outgrowth mediated by PrP
C 
was also supported by several lines of 
evidence (Graner et al., 2000; Chen et al., 2003; Maglio et al., 2004; Kanaani et al., 
2005; Lopes et al., 2005; Santuccione et al., 2005; Watts and Westaway, 2007; 
Aguzzi et al., 2008a). A role in signal transduction was inferred from the localisation 
of PrP
C
 in lipid rafts and PrP
C 
has also been suggested to play role in neuroprotection 
by acting as a sensor of oxidative stress or by counterbalancing apoptotic signals 
(Kuwahara et al., 1999; Milhavet et al., 2000; Bounhar et al., 2001; Roucou et al., 
2005; Roucou and LeBlanc, 2005; Khosravani et al., 2008; Haigh et al., 2009). The 
antiapoptotic function for PrP
C
 was proposed to occur via a PrP
C
-mediated decrease 
in the expression of several proapoptotic proteins, as PrP
C 
expression in a PrP
C
-null 
neuronal cell line can be shown to decrease the levels of p53, Bax, and caspase-3, 
and increased levels of Bcl-2 (Kim et al., 2004). Several studies suggest a functional 
role of PrP
C
 in cellular copper metabolism and maintenance of the accurate oxidative 
balance, possibly through a regulation of intracellular copper transport (Brown et al., 
1997a; Brown et al., 1997b; Pauly and Harris, 1998; Brown et al., 1999; Brown et 
al., 2001; bio Klamt et al., 2001; Vassallo and Herms, 2003). A very recent study 
indicated that neuronal expression of PrP
C 
is essential for long-term peripheral 
myelin maintenance (Bremer et al., 2010).  
1.2.4.2 PrP
C 
in immune system 
It has been proposed that the normal cellular prion protein plays an important role in 
the development and maintenance of the immune system, as well as in specific 
cellular immunological responses (Burwinkel et al., 2004; Cartier et al., 2005) as 
lymphocyte activation and proliferation (Li et al., 2001; Bainbridge and Walker, 
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2005). The function of PrP
C 
outside the nervous and immune systems has not been 
clarified, but some putative roles have been suggested based on data obtained from 
transgenic mice and expression of PrP
C
. 
1.2.4.3 Other functions of PrP
C
 





generally interpreted as evidence for developmental roles of PrP
C 
in cell 
proliferation, differentiation and programmed cell death (Lieberburg, 1987; 
McKinley et al., 1987; Manson et al., 1992; Sales et al., 2002; Miele et al., 2003). 
PrP
C 
may have an impact on the ability to regulate the self-renewal/differentiation 
status of stem cells (Miranda et al., 2011) and sustain self-renewal of long-term 
hematopoietic stem cells under stressful conditions (Zhang et al., 2006). PrP
C
 has 
also been suggested to stimulate cell signalling of a caveolin-1 dependent activation 
of the tyrosine kinase Fyn (Mouillet-Richard et al., 2000). The suggestion of role in 
cell adhesion was based on observations that PrP
C 
interacts with the laminin receptor 
and its precursor (LRP/LR) as well as with the neuronal cell adhesion molecule 
(NCAM) (Rieger et al., 1997; Rieger et al., 1999; Graner et al., 2000; Gauczynski et 
al., 2001; Schmitt-Ulms et al., 2001; Mange and Lehmann, 2002; Santuccione et al., 
2005; Parkyn et al., 2008). Moreover, PrP
C 
has been proposed to be involved in the 
processing of sensory information by the olfactory system (Le Pichon et al., 2009).  
It seems unlikely that a protein as strongly conserved among species as PrP
C 
has 
evolved purely for the purpose of determining susceptibility to prion disease in 
organisms. If the function of PrP
C 
were entirely unrelated to prion disease 
pathogenesis, PrP
C 
would be just one of the many proteins whose function awaits 
clarification. Understanding of the functional roles of PrP
C 
has been confounded by 
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the striking lack of phenotype reported for the first Prnp knockout mouse (Bueler et 
al., 1992). Moreover, Prnp ablation does not evoke disease, even when induced 
postnatally (Mallucci et al., 2002). Therefore, prion pathology is unlikely to develop 
due to a simple loss of PrP
C 
function.  
Nevertheless, it might seem unlikely that a single protein could have so many 
functions as described above. It needs to be taken in account that most of the 
suggestions regarding PrP
C
 function originate from single reports and there is a 
suspicion that each of these reports represents a specific aspect of a more complex 
system. It could be that the specific biological role of PrP
C 
is entirely dependent on 
the cell type in which it is expressed, the precise localisation within the cell in 
respect to the different plasma membrane environments and the level or differential 
expression of any processed variants of the wild-type protein or partner proteins. 
Additionally, studies of genetically modified animals are also controversial, perhaps 
dependent on the gene deletion approach used, the genetics and species background, 
and also compensatory mechanisms, all of which may influence the outcomes. 
 
1.2.5 The abnormal disease associated form of the prion protein, PrP
Sc
  
1.2.5.1 The prion concept 
The ‘protein only’ hypothesis postulates that prion replication results from a change 
in PrP conformation whereby an abnormal isoform (PrP
Sc
) of the cellular 
prion protein (PrP
C
) is capable of inducing PrP
C
 to undergo a change of 
conformation into PrP
Sc
 without the presence of DNA (or RNA) (Griffith, 
1967; Prusiner, 1982). PrP
Sc
 was shown to have the same amino acid 
sequence as the normal cellular prion protein, PrP
C
 (Bolton et al., 1982; 
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Prusiner et al., 1982; Chesebro et al., 1985; Hope et al., 1986; Stahl and 
Prusiner, 1991). The distinctive properties of either the infective or the 
cellular prion proteins are defined by post-translational modifications and the 
majority of the research in the prion field is focused on the mechanism by 
which PrP
C
 is converted into PrP
Sc 
(Pan et al., 1993). Modification of the 
prion protein can result in a disease-associated protease-resistant isoform and 
as protease resistance does not specify that the isoform is capable of 
transmitting disease. The term PrP
Sc
 is generally used to denote the 
pathogenic, infectious isoforms and PrP
res
 the protease resistant isoform (the 
N-terminally truncated proteinase K resistant core form of PrP
Sc






Arguments for prions being composed largely or exclusively of PrP
Sc
 include: 
 No viral particles, bacteria, fungi or protozoan parasites have been found to be 
associated with prion diseases (Baker and Ridley, 1996b). 
 Prions are encoded by a chromosomal gene of the host, not by a nucleic acid in the 
infectious scrapie prion particle (Alper et al., 1966; Alper et al., 1967; Oesch et al., 
1985; Basler et al., 1986; Bellinger-Kawahara et al., 1987; Bellinger-Kawahara et 
al., 1988; Kellings et al., 1992; Kellings et al., 1993; Kellings et al., 1994). 
 PrPSc and scrapie infectivity copurify (Prusiner, 1982; Prusiner et al., 1983; Hope et 
al., 1986). 
 Procedures that denature or hydrolyse PrPSc reduce the prion titres (McKinley et al., 
1983; Bolton et al., 1984). 
 PrPSc experimentally transmitted from one species to another results in PrPSc 
replication with amino acid sequence characteristic of the recipient sequence, 
suggesting that the hosts PrP
C 
was recruited to conversion into PrP
Sc 
by the donor 
agent (Scott and Fraser, 1989; Prusiner et al., 1990; Weissmann, 1991). 
 PrP0/0 mice are resistant to prion infection, suggesting that PrPC is essential for prion 
diseases (Bueler et al., 1993; Prusiner et al., 1993). 
 The rate of PrPSc formation is rapidly increased in mice overexpressing PrPC and 
leads to shorter incubation times (Scott et al., 2000). 
 Mutations in the human prion protein gene result in the formation of infectious PrPSc 
and are linked to inherited human prion diseases (Kovacs et al., 2002). 
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 Synthetic prions produced in Escherichia coli can infect transgenic mice 
overexpressing truncated PrP
C
 (Legname et al., 2004). 
 
Despite the increasing body of evidence in favour of the prion hypothesis, there is 
still ongoing debate about the exact composition of the infectious agent and the 
mechanisms by which pathogenesis occurs. Discovery of animal brain tissues 
containing high titres of prion infectivity but undetectable levels of PrP
res
 (Lasmezas 
et al., 1997; Barron et al., 2007) and the converse, the presence of high levels of 
accumulated PrP
res 
without apparent infectivity (Narang, 2002; Piccardo et al., 2007) 
challenge the protein-only theory. More conventional explanations for TSE diseases 
based on virions, viruses, and other infectious agents containing small RNAs have 
been proposed (Rohwer, 1984; Bellinger-Kawahara et al., 1988; Manuelidis et al., 
1988; Rohwer, 1991; Narang, 2002). The finding that retroviral RNA co-precipitates 
with PrP
Sc 
and that short (< 4 kb) RNA fragments are released after nuclease 
digestions from purified infectious fractions added weight to these proposals 
(Akowitz et al., 1990; Akowitz et al., 1994; Simoneau et al., 2009). Moreover, 
addition of polyanions such RNA was observed to promote prion protein misfolding 
cyclic amplification, a cell free model of prion replication (Deleault et al., 2007). 
 





The synthesis of PrP
C 
is a rapid event (measured in minutes) and once in the plasma 
membrane this protein has a half-life of approximately 5 hours. In contrast, the 
formation of PrP
Sc 
has been estimated from minutes (Goold et al., 2011) to hours and 
the proposed time for degradation exceeds 24 hours, however months have also been 
suggested (Caughey et al., 1989a; Caughey et al., 1989b; Borchelt et al., 1990; 
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, undergo different patterns 
of proteolytic cleavage which are highly dependent on their secondary and tertiary 





 display different and complex banding patterns in Western blots 
(Lawson et al., 2005).  
Proteolytic processing of PrP
C
 termed α-cleavage is carried out by ADAM/TACE 
matrix metalloproteases and occurs at amino acid residue 111 yielding a 17 kDa 
fragment denoted C1 (Vincent et al., 2001) which is further degraded in the cell. The 
N-terminal cleavage fragment of PrP
C 
is released extracellularly. The cleavage of 
PrP
Sc 
termed β-cleavage is carried out instead by calpains at amino acid residue 88 
and this processing yields a 19-21 kDa fragment denoted C2. The C2 fragment 
corresponds to un-glycosylated PrP
27-30
 (Chen et al., 1995; Yadavalli et al., 2004) 
and was found to accumulate both intracellularly and extracellularly (Caughey et al., 
1989a; Hope and Manson, 1991; Borchelt et al., 1992) suggesting that the rate of 
PrP
Sc 
formation is most likely higher than its rate of degradation.  
PrP
C 
structure contains 40% α-helix and only 3% β-sheet content (described in 
section 1.2.2), while PrP
Sc 
is composed of 30% α-helix and 43% β-sheet content (Pan 
et al., 1993; Prusiner, 1998). It is proposed that PrP
C 
converts into its abnormal 
disease-associated isoform when the region corresponding to two α-helices at amino 
acid residues 108-144 fold into β-pleated sheets (Prusiner, 1998). These structural 
differences results in the two prion protein isoforms having different biochemical 
properties and characteristics (Table 1.3) (Figure 1.6).  
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Disease associated form, PrPScCellular form, PrPCProperties
Forms aggregatesMonomericSedimentation properties
Days, stable (T1/2 ~ 15 hours in vitro, ~ months)Hours, rapidly metabolised (T
1/2 ~ 5 hours)Turnover
Mixture of un-, mono-, and di-glycosylated formsMixture of un-, mono-, and di-glycosylated formsGlycoforms
Partially protease resistantProtease sensitivePK sensitivity












For many years prions were considered “non-degradable” and once formed almost 
impossible to break down entirely. This concept was based on the resistance of 
infectious prions to conventional procedures for sterilisation such as heat and 
formalin-treatment and a lack of convincing evidence for a cellular turnover of PrP
Sc 
in neuronal cells. However, recently described degradation of prions in vivo by 
immune cells, i.e. macrophages (Carp and Callahan, 1981; Beringue et al., 2000), 
and in vitro by dendritic cells (Luhr et al., 2002) and bovine macrophages (Sassa et 
al., 2010) has generated great interest. The possibility that degradation of PrP
Sc 
might 
also occur in neurons was proposed in studies where constitutively prion-infected 
mouse neuroblastoma cell line treated with anti-PrP antibodies exhibited decreased 
levels of PrP
Sc 
in the cells (Peretz et al., 2001; Enari et al., 2001). This effect was 
thought to reflect an inhibition of the prion protein conversion by the antibody 
blocking the conversion process, paralleled by a cellular degradation of the pre-
existing PrP
Sc
. Studies of branched polyamine-induced clearance of PrP
Sc 
suggests 
that lysosomal proteases might be involved in the slow degradation of prions in 
infected cells (Supattapone et al., 2001; Luhr et al., 2004a; Luhr et al., 2004b; 
Okemoto-Nakamura et al., 2008), however the specific proteases responsible for this 
still remain to be determined. A recent observation hypothesizes that PrP
Sc
 inhibits 
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the 26S proteasome, thus precluding its degradation via that route (Kristiansen et al., 
2007; Goldberg, 2007; Deriziotis and Tabrizi, 2008). Stimulation of PrP
Sc
 
degradation in prion infected cell lines has recently been described by using 
substances such as imanitib mesylate, trehalose and lithium that are able to increase 
the efficiency of autophago-lysosomal breakdown of proteins (Ertmer et al., 2004; 
Aguib et al., 2009; Heiseke et al., 2009). However, none of these substances was 
effective in curing prion infected mice from disease (Yun et al., 2007; Aguib et al., 
2009). 
It has not been possible to produce a high resolution structure for PrP
Sc
, because of 
its insolubility in the detergents used in the crystallisation approach. The highest 
resolution PrP
Sc 
structure thus far obtained was reported by Wille and colleagues 
(Wille et al., 2002; Caughey et al., 2009) and a trimetric arrangement of the PrP
Sc 
was suggested as a minimal assembly of the abnormal prion protein isoform 
(Govaerts et al., 2004; DeMarco and Daggett, 2004; DeMarco et al., 2006). PrP
Sc 
is 
partially resistant to proteinase K (PK) (McKinley et al., 1983), while PrP
C
 is readily 





, with and without PK digestion, is generally used not only in 
research, but also in diagnostic tests to distinguish between the two isoforms of the 
prion protein (Figure 1.6). In normal cell or tissue samples, three PrP
C
-specific bands 
corresponding to a mixture on N-terminally truncated and differentially glycosylated 
forms of the prion protein are detected by Western blot. In prion infected cell or 
tissue samples, three PrP
Sc
- specific bands are typically observed after PK digestion, 
corresponding to un- (~ 19-21 kDa), mono- (~ 24 kDa), and di- (~ 27-30 kDa) 
glycosylated forms. 
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) and their Western blot profiles with and without PK treatment 
The cellular isoform (PrP
C
) is present in the normal cell (left), and the pathogenic isoform 
(PrP
Sc
) is a major component of the infectious material (right) (the α-helices are indicated in 





, with and without PK digestion, show the characteristic PK sensitivity of 
PrP
C
 - disappearance after PK digestion. On the other hand, the three glycoforms of PrP
Sc
 
(di-, mono-, and un-glycosylated) are still present, although shifted to lower Mr, representing 






. It is noteworthy that PrP
res
 
is fully infectious. Picture modified from (Riesner, 2002) and 
(http://www.cmpharm.ucsf.edu/cohen/). 
 
1.2.7 Mechanism of prion protein conversion 




 conversion process has not yet been determined 
precisely. Two models have been proposed in order to explain the propagation of 
PrP
Sc
, the “template-directed refolding” model (Gajdusek, 1988; Prusiner and 
DeArmond, 1990; Aguzzi and Polymenidou, 2004) and the “seeded nucleation” 
model (Come et al., 1993; Telling et al., 1994; Telling et al., 1995; Kaneko et al., 
1997b; Aguzzi and Polymenidou, 2004). The latter is the more widely accepted and 
it proposes co-existence of the two isoforms of PrP in balance which strongly favours 
PrP
C 
in non-disease states. The monomeric form of PrP
Sc 
is thought to be harmless 
and it is the small oligomeric forms of PrP
Sc 
which propagate by recruiting PrP
Sc 
monomers to form PrP
Sc 
oligomers, which are proposed to be infectious. The 
“template-directed refolding” model proposes the spontaneous conversion as a rare 
Chapter 1   Introduction 
  30 
event which may be prevented by a high energy barrier between the two isoforms of 
PrP. The present PrP
Sc 
acts as a template for PrP
C 
to be recruited to form a pathogenic 
conformation (Aguzzi and Polymenidou, 2004; Caughey et al., 2009). An alternative 
modified model supposes the existence of an auxiliary factor (“protein/cofactor X”) 
(Telling et al., 1994; Telling et al., 1995; Kaneko et al., 1997b) where PrP
C
 is in 
equilibrium with PrP* which binds to the putative protein X. PrP
Sc 
is able to interact 





1.2.8 Possible site for conversion and PrP
Sc
 localisation in cells  
Prion conversion is thought to occur predominantly at a site where two protein forms 
meet and physically interact (Caughey and Raymond, 1991; McKinley et al., 1991; 
Arnold et al., 1995; Prusiner, 1998; Barmada and Harris, 2005; Pimpinelli et al., 




trafficking is less well studied 
and represents an important challenge, largely due to the lack of specific antibodies 
that can detect it in situ and the need to denature the protein by guanidine in order to 
expose PrP
Sc 
epitopes (Taraboulos et al., 1990a).  
A number of studies have implicated various intracellular compartments as the sites 




subcellular distribution and 
trafficking in the brains of infected animals (Jeffrey et al., 1994a; Jeffrey et al., 
1994b; Fournier et al., 2000; Barmada and Harris, 2005; Godsave et al., 2008), 
primary neurons (Shyng et al., 1993; Sunyach et al., 2003; Galvan et al., 2005) and 
in constitutively infected cell cultures (Borchelt et al., 1992; Beranger et al., 2002). 
Knowledge of the precise site and mechanism of conversion is important, as 
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inhibition of conversion is a promising therapeutic option. The balance of evidence 
suggests that the conversion process occur either at the cell surface in association 
with lipid rafts, or more likely intracellularly along the endocytic pathway (Caughey 
and Raymond, 1991; Borchelt et al., 1992; Jeffrey et al., 1994b; Taraboulos et al., 
1995; Godsave et al., 2008; Marijanovic et al., 2009; Goold et al., 2011).  
Irrespective of its site of formation, PrP
Sc 
has been shown to localise to lipid rafts in 
the plasma membrane (Jeffrey et al., 1994b; Vey et al., 1996; Naslavsky et al., 
1997). A recent publication using a sophisticated cell culture model suggests that the 
plasma membrane is the primary site of prion conversion and that this occurs much 
faster than previously thought, within one minute after prion exposure (Goold et al., 
2011). In addition, PrP
Sc 
localisation in both early and late endosomes, as well as 
lysosomal compartments and multivesicular organelles has been observed (Caughey 
and Raymond, 1991; McKinley et al., 1991; Borchelt et al., 1992; Laszlo et al., 
1992; Jeffrey et al., 1994a; Arnold et al., 1995; Fournier et al., 2000; Pimpinelli et 
al., 2005; Godsave et al., 2008; Caughey et al., 2009). Accumulation of PrP
Sc 
was 
also observed in the perinuclear Golgi region (Barmada and Harris, 2005). A more 
recent report described accumulation of high amounts of PrP
Sc 
in the endosomal 
recycling compartments (Marijanovic et al., 2009). Under conditions of mild 
proteasome inhibition, cytoplasmic PrP aggregates (e.g. aggresomes) were also 
observed (Ma et al., 2002; Kristiansen et al., 2005). The presence of extracellular 
PrP
Sc
 was reported to be associated with exosomes (Fevrier et al., 2004; Robertson et 
al., 2006; Vella et al., 2007; Vella et al., 2008a; Vella et al., 2008b), thereby 
suggesting a possible process of cell-to-cell propagation of infection (Figure 1.7). 
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aggresomes
exosomes  
Figure 1.7: Proposed sites of PrP
Sc
 localisation in constitutively infected cells 
Prion infected cell culture models established to date revealed PrP
Sc
 presence and 
accumulation at the cell surface in association with lipid rafts, early endosomes, trans-Golgi 
compartments, late endosomes, lysosomes, multi-vesicular bodies, aggresomes and 







Another recent investigation has proposed the mediation of PrP
Sc
 in vitro 
intercellular transfer between neuronal cells and between bone-marrow derived 
dendritic cells and neurons by means of tunnelling nanotubes (TNTs) (Gousset et al., 
2009). Since dendritic cells can interact with peripheral neurons in lymphoid organs 
(Huang et al., 2002), TNT-mediated intercellular transfer (Gousset et al., 2009) was 
proposed to spread PrP
Sc 
from the peripheral site of entry to the PNS by 
neuroimmune interactions with dendritic cells and to be involved in the spreading of 
PrP
Sc 
within neurons in the CNS in vivo (Aucouturier et al., 2001; Gousset et al., 
2009). 
Although the data do seem to be somewhat contradictory this may be caused by the 
different approaches used (whole animals vs. cultured cells), cell types (neurones, 
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neuroblastoma cells etc.) and experimental paradigms (chronic infection vs. acute 





has been proposed to localise to both chemical (Kitamoto et al., 
1992; Fournier et al., 2000; Kovacs et al., 2005) and electrical (Kovacs et al., 2005) 
synapses. However, a recent cryo-EM study did not show any evidence of PrP
Sc 
synaptic localisation (Godsave et al., 2008). Neuronal damage has been suggested to 
result from a loss of the normal prion protein function or a gain of toxic properties of 
disease-associated prion protein isoform (Chiesa and Harris, 2001).  
The potential role of PrP
C 
loss of function in prion diseases has been predominantly 
studied in PrP
C 
knock-out mice. These are described as normal in their development 
and behaviour (Bueler et al., 1992; Manson et al., 1994). However, some signs of 
slight alterations in neuronal function, such as disruption in synaptic function in 
PrP
C
-deficient mice have been reported (Collinge et al., 1996; Tobler et al., 1996; 
Colling et al., 1996; Herms et al., 2001; Carleton et al., 2001; Fuhrmann et al., 
2006), but no synaptic loss, myoclonic seizures or neuronal degeneration could be 
observed. Neurotoxic properties of PrP
Sc 
have been proposed based on observations 
showing that PrP
Sc 
colocalises with the histopathological changes observed in prion 
diseases (DeArmond et al., 1987; Jendroska et al., 1991; Jeffrey et al., 1994a). 
Moreover, synthetic fragments of prion protein displayed neurotoxic properties and a 
tendency to aggregate into fibrils in vitro (Forloni et al., 1993).  
As previously mentioned, several inherited prion diseases contain only low levels of 
PrP
res 
in the brain of affected individual despite a fatal clinical disease (Tateishi et al., 
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1992; Medori et al., 1992a; Medori et al., 1992b; Collinge et al., 1995). Further 
arguments against extraneuronal PrP
Sc 
neurotoxicity have been proposed in a study 
by Brandner and colleagues, where they transplanted neuronal tissue from PrP
C 
overexpressing mice to PrP
C 
knock-out mice that were subsequently inoculated with 
infectious prions. High levels of PrP
Sc 
accumulation and prion disease characteristic 
histopathological changes were observed in the transplanted grafts. However, these 
signs were completely absent in PrP
C 
deficient tissue despite the graft-derived PrP
Sc 
being spread extracellularly to the host brain tissue (Brandner et al., 1996a). Study of 
prion disease inoculated mice expressing mutant PrP
C 
lacking the GPI-anchor 
developed minimal brain pathology and neurological dysfunction despite the 
accumulation of multiple PrP
Sc
-containing amyloid plaques (Chesebro et al., 1985). 
Moreover, it was shown that depletion of neuronal PrP
C
 in mice with established 
CNS scrapie infection prevented progression to clinical stage of prion disease and 
resulted in long-term survival of infected animals (Mallucci et al., 2003). 
Additionally, no cytopathic effect of PrP
Sc
 can be observed in prion infected cells 
cultured in vitro (Naslavsky et al., 1997). Overall these studies indicate that neither 
loss of PrP
C 
function nor gain of toxic PrP
Sc 
properties can fully explain prion-
induced neurodegeneration. One explanation, therefore is that the PrP
C → PrPSc 
conversion process, which might include a toxic intermediate PrP-species (Hill et al., 
2000; Hill et al., 2003; Collinge and Clarke, 2007) may trigger signalling that could 
alter cell functions and/or initiate some toxic cascades contributing to 
neurodegeneration processes in prion diseases (Sandberg et al., 2011). 
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1.3 PRION DISEASES 
1.3.1 Human prion disease 
1.3.1.1 Molecular classification of PrP
Sc 
 
Prion diseases are rare and fatal neurodegenerative diseases. At microscopic level, 
they exhibit four principal neuropathological features: spongiform vacuolation, 
extensive neuronal loss, astrocytosis and microglial proliferation, as well as an 
accumulation of the disease-associated isoform of the prion protein in the brain. 
Among all TSEs the human diseases are unique as they can be sporadic, inherited, or 
acquired in their origin (Wadsworth et al., 2003; Gambetti et al., 2003; Ironside and 
Head, 2004). The human prion diseases primarily affect the nervous system; 
however, vCJD has been shown to have a peripheral involvement in secondary 
lymphoid tissues (Kong and Bessen, 2008). 
The causative factor for all prion diseases is thought to be the misfolding of the host 
PrP
C
 protein into the disease-associated prion protein conformation, PrP
Sc
. Exposure 
of naïve host to exogenous PrPSc can lead to prion protein misfolding and result in 
the onset of neurodegenerative disease. Hence, prion diseases are transmissible, but 
are caused by a novel unique pathogen that lacks a prion-specific nucleic acid 
genome (Prusiner, 1982; Prusiner, 1998). Nevertheless, the cause of sporadic CJD, 
the commonest form of human prion disease, remains unknown. 
Biochemical analysis employing PK digestion followed by Western blot analysis 
reveals PrP
Sc
 heterogeneity in the form of the size of the protease-resistant core 
fragment (PrP
res
) and in the relative amounts of the three possible glycoforms of the 
protease-resistant core fragments. Proteolysis under defined conditions digests 





 types differ in the extent of N-terminal (and sometimes 
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C-terminal) truncation following proteolysis with PK. Generally, there are three 
protease-resistant polypeptide fragments present differing in their molecular weight 
due to the occupancy of the two N-linked glycosyl groups and these are designating 
glycoforms of the prion protein. Using a combination of PrP
res
 fragment size and 
glycoform ratio has proven to be very useful for the classification of different human 
prion disease phenotypes according to molecular and genetic criteria (Monari et al., 
1994; Collinge et al., 1996; Parchi et al., 1996; Parchi et al., 1997; Hill et al., 2006). 
According to Parchi and Gambetti nomenclature, PrP
Sc 
can be classified into three 
operational groups denoted type 1, type 2 (A or B) (Figure 1.8), and ~ 8 kDa low 
molecular weight fragment type (Parchi et al., 1996; Parchi et al., 1997). The A or B 
types are referred to the glycosylation site occupancy. Type A is characterised by a 
prominent mono-glycosylated (or rarely un-glycosylated) PrP
Sc 
fragment and the 
type B by high occupancy of both potential glycosylation sites (Parchi et al., 1997; 
Head et al., 2004b). Recently, a smaller C-terminal fragments consisting of 12-13 
kDa were identified in some forms of sCJD (Zou et al., 2003; Notari et al., 2008) but 
these could only be detected when antibodies recognising the extreme C-terminus of 
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Lane 1         2        3                  4          5         6
 
Figure 1.8: Representation of PrP
Sc
 types found in human prion diseases 
Western blot analysis of sporadic CJD (S) or variant CJD (V) brain sample shows the three 
major protein polypeptide glycoforms (lane 1-3). Samples were analysed without (-) and 
with (+) proteinase K digestion. The limited digestion of PrP
Sc
 with PK, which removes the 
N-terminal proportion of the prion protein, reveals PrP
res
 types (lanes 4-6). The migration of 
the protease-resistant PrP
res
 glycoforms is marked (right). The shading intensity is indicating 
the relative amount of each PrP polypeptide in relation to the other glycoforms. The 
molecular weight is indicated in kilodaltons (left). PrP
res
 isotypes 1, 2A and 2B are defined 
by the molecular weight of the un-glycosylated PrP
res
 polypeptide and by the ratio of the 
three PrP
res
 glycoforms (marked beneath). Figure was a kind gift from Dr Head. 
 
The majority of sCJD cases were found to be PrP
Sc 
type 1. This is also true for 
familial CJD cases (Gambetti et al., 2003) and a small amount of type 1 PrP
Sc
 has 
been suggested to be present in all CJD cases (Yull et al., 2006; Parchi et al., 2009). 
Type 2A PrP
Sc 
is found in a minority of sCJD, sporadic fatal insomnia (FFI) and 
some familial CJD (fCJD) cases. Many sCJD patients (20% or more) have both type 
1 and type 2 present in the same or different brain regions (Puoti et al., 1999; Head et 
al., 2004a; Head et al., 2004b; Schoch et al., 2006; Uro-Coste et al., 2008). In vCJD, 
the PrP
Sc 
glycoforms have a similar molecular weight to those found in type 2A 
PrP
Sc
, but the ratio of the three PrP
Sc 
glycoforms differs (predominance of di-
glycosylated form) and thus vCJD “glycoform signature” is designated as type 2B 
PrP
Sc
 (Figure 1.8). In Gerstmann-Sträussler-Schienker syndrome a 7-8 kDa PrP
Sc
 
polypeptide was recognised associated with various pathogenic mutations sometimes 
alone and in other cases or regions in combination with type 1 PrP
Sc
 (Parchi et al., 
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1998; Piccardo et al., 1998; Piccardo et al., 2001). The majority of UK iCJD cases 
showed to be of the Parchi and Gambetti type 2A (in association with PRNP codon 
129 MV or VV) (Heath et al., 2006) reviewed by (Ironside, 2008). 
 
1.3.2 Idiopathic forms of human prion diseases  
Sporadic forms of human prion diseases comprise two prion disease phenotypes: 
sporadic Creutzfeldt-Jakob disease (sCJD) and sporadic fatal insomnia (sFI). In sFI 
the PrP
Sc
 level is much lower when compared to sCJD cases and immunostaining for 
PrP is usually negative or minimal in limited brain areas (Parchi et al., 1999a; 
Gambetti et al., 2003). Moreover a novel phenotype of human sporadic prion disease 
with distinct clinical and neuropathological features was recently identified by 
Gambetti and co-workers and termed protease-sensitive prionopathy (PSPr) 
(Gambetti et al., 2008), which was later changed to variably protease sensitive 
prionopathy (VPSPr) (Zou et al., 2010). Abnormal PrP associated with this 
phenotype was shown to be less aggregated and largely sensitive to PK digestion. 
Proteolytic treatment produces a “ladder-like” profile of PrP
res
 after electrophoretic 
migration ranging from ~ 6 to 29 kDa (Gambetti et al., 2008). Recently, some 
additional cases of VPSPr were identified in the UK and the Netherlands (Head and 
Ironside, 2009; Jansen et al., 2010; Head et al., 2010). 
 
1.3.3 Hereditary forms of human prion diseases 
Inherited prion diseases are associated with autosomal-dominant pathogenic or 
insertional PRNP gene mutations (shown in the upper half of Figure 1.3), many of 
which exhibit high penetrance in the population and represent 10-15% cases of 
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human prion diseases (Masters et al., 1981; Windl et al., 1996; Windl et al., 1999; 
Gambetti et al., 2003; Kovacs et al., 2005). Autosomal dominant inheritance of CJD 
was first reported almost 90 years ago (Kirschbaum, 1924; Meggendorfer, 1930). 
However, most PRNP mutations are heterozygous and not all appear to be 
pathogenic (Chen et al., 1997; Silvestrini et al., 1997). Variability in the clinical and 
pathological findings such as age of onset or duration was observed to be linked with 
particular mutation (Prusiner and Scott, 1997; Kovacs et al., 2002; Kovacs et al., 
2005). It was also proposed that some carriers of some mutations in PRNP (low 
penetrance) can live long healthy lives without developing clinical signs of prion 
disease (Pocchiari et al., 1993; Spudich et al., 1995; Mitrova and Belay, 2002). The 
pathogenic mutations identified up to date (over 30 pathogenic mutations) are 
classified as point mutations resulting in amino-acid substitution or premature stop 
codon, and insertion of additional octapeptide repeats (Mead et al., 2006). These 
mutations are thought to cause changes in the amino acid sequence, thus impairing 
the stability of the tertiary structure of the prion protein which is then more readily 
convertible to the disease associated form (Wadsworth et al., 2003). According to 
clinicopathological features of the disease phenotype the inherited prion diseases are 
classified as familial CJD (fCJD), Gerstmann-Sträussler-Schienker disease (GSS) 
and fatal familial insomnia (FFI).  
 
1.3.4 Acquired form of human prion diseases 
The acquired prion diseases account for less than 1% of all human prion disease 
cases and these include kuru, iatrogenic CJD (iCJD) and variant CJD (vCJD) and the 
prion infection is either associated with accidental transmission via medical or 
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surgical practices or acquired orally. The acquired human prion diseases caused by 
human-to-human transmission of the infectious agent are iCJD, kuru, and the bovine-
to-human caused prion disease is vCJD.  
Kuru, first reported in 1959 (Gajdusek and Zigas, 1957; Gajdusek and Zigas, 1959), 
was linked to ritualistic endocannibalism the of indigenous tribes in the Eastern 
Highlands province of Papua New Guinea, during which bodies of deceased relatives 
were consumed as a mark of respect (Gajdusek, 1977; Alpers, 1979). The disease has 
gradually declined with cessation of cannibalism in the late 1950s and kuru is now 
thought to be extinct as no children born after cannibalism ceased have developed it. 
1.3.4.1 Variant CJD 
vCJD was first described in 1996 (Will et al., 1996) as a new form of CJD. 
Histopathological, biochemical, and epidemiological evidence all suggests that vCJD 
is most likely to be a result of cross-species transmission by orally ingested bovine 
spongiform encephalopathy (BSE) prion agent via BSE-contaminated food products 
(Will et al., 1996; Collinge et al., 1996; Lasmezas et al., 1996; Bruce et al., 1997; 
Hill et al., 1997a; Prusiner, 1998; Scott et al., 1999). It is now widely accepted that 
vCJD and BSE are caused by the same prion strain (Hill et al., 1997a; Ward et al., 
2006) and vCJD is so far the only known example of zoonotic human prion disease. 
Removal of the meat and bone meal supplements from livestock feed in the late 
1980s has significantly reduced the prevalence of BSE in UK. As a result, human 
exposure to BSE has also been greatly reduced consequently resulting in a reduced 
vCJD incidence in human population, as shown on the Figure 1.9.  
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Figure 1.9: Epidemiology of BSE and vCJD in UK and Europe  
The survey of BSE cases (indicated pink and dark blue) is represented by a number of cases 
in thousands and vCJD (indicated red and light blue) is represented by a number of cases in 
hundreds. Graph is showing the course development of BSE and vCJD in United Kingdom 
(UK) (pink, red) and European countries (EC) (dark and light blue) from 1988 to 2011. The 
BSE figures are only until year 2010 as the UK BSE data were only given to 2010 and in 
Europe there has only been one case in the Netherlands as at January 2011 and 2 in 
Switzerland as at May 2011. Figure kindly provided by Jan MacKenzie (NCJDRSU Study 
Co-ordinator). 
 
The clinicopathological features of vCJD are distinct from most of the human prion 
diseases (Ironside, 2002; Ironside and Head, 2004). Unlike sporadic and inherited 
CJD, vCJD affects also the lymphoreticular system (Hill et al., 1997a; Hill et al., 
1999; Wadsworth et al., 2001), most likely as a reflection of the peripheral route of 
exposure (Ramasamy et al., 2003). vCJD is typically found in younger individuals 
(with mean age of onset around 28 years, ranging between 12 to 74 years of age) 
when compared to sCJD (with mean of 65 years at onset). The clinical duration of 
the illness in vCJD affected individuals is longer (median time 13 months) than the 4 
months for sCJD (MM1), but comparable to that of 16 months for sCJD (MM2) 
individuals.  
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As of September 2012, 176 primary cases of vCJD have been identified in the UK 
(176 dead, 0 alive) and 51 from outside UK (49 dead, 2 alive) 
(http://www.cjd.ed.ac.uk). All symptomatic sufferers of vCJD have been identified in 
UK and France to be homozygous for methionine (M) at PRNP codon 129 genotype 
(Brandel et al., 2009; Bishop et al., 2009; Peden et al., 2010). However, individuals 
who are heterozygous or homozygous for valine (V) at codon 129 appears to be 
susceptible to vCJD/BSE prion agent, although may be found to have a more 
prolonged incubation period when compared to MM individuals as suggested by the 
appendix study (Hilton et al., 2004; Ironside et al., 2006; Kaski et al., 2011) and 
recent transmission studies employing gene-targeted human transgenic mice (Bishop 
et al., 2006). The first case recognised to be transmitted horizontally via blood 
transfusion from pre-sypmtomatic vCJD sufferer (MM at codon 129) was in 2003. 
This case was identified through a collaborative study between UK National Blood 
Services, the National CJD Research and Surveillance Unit, and the Office of 
National Statistics (Llewelyn et al., 2004; Hewitt et al., 2006).  
Further cases of human-to-human transmission of vCJD linked to blood transfusion 
and blood product therapy were subsequently identified and these were two 
individuals of MM genotype (Wroe et al., 2006; HPA, 2007) and two of MV 
genotype (Peden et al., 2004; Peden et al., 2010). The biological strain properties of 
PrP
res
 originating from vCJD (or BSE) were shown to remain unaltered after 
secondary human-to-human transmission (Bishop et al., 2008). Subsequently, 
neuropathological features and PrP
res
 profiles of the secondary cases were found to 
be indistinguishable when compared to those of primary cases (Wroe et al., 2006). 
However, it can be speculated that there must be a variety of environmental, 
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individual, genetic, or cellular determinants which may influence susceptibility or 
resistance to BSE/vCJD because the estimated number of individuals exposed, and 
predictive models of how many individuals may acquire the disease (Ghani et al., 
2000; Valleron et al., 2001; Ferguson et al., 2002; Ghani et al., 2003; Huillard 
d'Aignaux et al., 2003) were dramatically greater than the actual numbers of patients 
who have as yet developed vCJD. 
The remarkably long incubation period that proceeds the neurological symptoms 
indicate that important events in prion disease pathogenesis might take place in 
extranervous sites (Aucouturier and Carnaud, 2002). Following peripheral infection, 
PrP
Sc
 can be detected in the spleen, lymph nodes and other lymphoid tissues long 
before CNS involvement (Eklund et al., 1967; Kimberlin and Walker, 1979; Hilton 
et al., 1998). However, the spleen might not be the principal organ involved in 
infection via the oral route as infectivity can be found first in the Peyer’s patches 
(Kimberlin and Walker, 1979). This indicate that the gut-associated lymphoid tissues 
(GALT) could have a similar processing and replicative function for inocula routed 
intestinally (van Keulen et al., 1996; Heggebo et al., 2000; Andreoletti et al., 2000; 
Heggebo et al., 2002). Interestingly, splenic PrP
Sc
 accumulation is not detectable in 
cattle naturally infected with BSE (Somerville et al., 1997), although it can be found 
in experimental animal models including BSE-infected mice (Maignien et al., 1999) 
and sheep (Foster et al., 2001).  
The peripheral lymphoid organs are believed to be important and perhaps 
indispensable in the transmission process and development of the neurodegenerative 
(Aucouturier and Carnaud, 2002). The cell types likely to be involved in 
propagations of prions were suggested to be low density (Clarke and Kimberlin, 
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1984), long-lived and mitotically quiescent cells (Fraser and Farquhar, 1987). 
Follicular dendritic cells (FDCs) are believed to play a key role in the peripheral 
pathogenesis of prion diseases and have long been suggested to be a major site of 
prion replication and accumulation in the germinal centres of spleen, lymph nodes, 
and mucosa-associated lymphoid tissue following experimental or natural 
contamination with infectious prions (Kitamoto et al., 1991; McBride et al., 1992; 
Hill et al., 1997a; Hill et al., 1997b; Mabbott et al., 1998; Sigurdson et al., 1999; 
Andreoletti et al., 2000; Beekes and McBride, 2000; Mabbott et al., 2000; Heggebo 
et al., 2002; Ramasamy et al., 2003; reviewed by Mabbott and MacPherson, 2006). 
FDCs of the germinal centres of lymphoid organs exhibit all these characteristics and 
moreover they are characterised by high levels of PrP
C
 expression (McBride et al., 
1992). Functional FDCs appear to be essential (Mabbott et al., 2000; Montrasio et 
al., 2001; reviewed by Mabbott and MacPherson, 2006) for the obligate peripheral 
phase of infection in some murine scrapie models, but it is still not entirely clear 
whether they are the only site of lymphoreticular prion replication or accumulation 
(Blattler et al., 1997; Kaeser et al., 2001).  
1.3.4.2 Iatrogenic CJD 
iCJD is the second most common acquired human prion disease after kuru. These 
cases are a result of accidental transmission of prion infection during the course of 
medical treatments or surgical procedures, reviewed (Collins et al., 2004; Aguzzi et 
al., 2008b). The first reported case of iCJD was in 1974 and was associated with 
transplantation of a corneal graft derived from a donor who had died of sCJD (Duffy 
et al., 1974). iCJD has been identified in over 400 cases world-wide over the past 30 
years (Duffy et al., 1974; Will, 2003; Brown et al., 2006) including 65 cases from 
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UK (http://www.cjd.ed.ac.uk). The majority of cases were acquired by transmission 
of prions via contaminated human dura mater grafts, and human pituitary hormones 
derived from pooled tissues from deceased individuals that included material from an 
individual or individuals suffering from unrecognised TSEs. A minority of cases 
were associated with neurosurgery using contaminated EEG electrode implantations, 
surgical operations using contaminated instruments or apparatuses, and 
transplantation of corneal graft from undiagnosed CJD infected patients (Bernoulli et 
al., 1977; Masters and Richardson, Jr., 1978; Davanipour et al., 1984; Powell-
Jackson et al., 1985; Brown et al., 1985a; Brown et al., 1985b; Buchanan et al., 
1991; Fradkin et al., 1991; Healy and Evans, 1993; Brown et al., 2000; Collins et al., 
2004; Brown et al., 2006). The incubation period can range from 2 to 38 years 
(median period 7 years) (Heckmann et al., 1997).  
Molecular genetic studies have shown that the majority patients developing iCJD 
after receiving pituitary-derived human growth hormone therapy were homozygous 
for either methionine or valine at codon 129 of the PRNP gene (Collinge et al., 
1991a; Brown et al., 1994b). The study of UK iCJD cases revealed notably higher 
number of cases of VV genotype indicating possible contamination by infectious 
material of VV genotype (sCJD) (Brown et al., 1992).  
 
1.3.5 Animal prion diseases 
Prion diseases have also been found to afflict a number of different animal species, 
either occurring naturally, or caused by consumption of prion contaminated food or 
induced experimentally as a tool for study of prion diseases. 
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Scrapie, naturally occurring in sheep and goats, was the earliest described prion 
disorder. The term scrapie was coined from observations of behavioural changes in 
afflicted animals which were “scraping” or rubbing themselves against surfaces in 
the field. Scrapie is found world-wide, except in Australia and New Zealand and has 
never been shown to pose a threat to human health (Brown, 1998). 
Chronic wasting disease (CWD) is another naturally occurring prion disease which 
afflicts non-domesticated or captive wildlife deer, elk, and moose (Williams and 
Young, 1982; Williams and Young, 1993; Williams, 2005). CWD is found mainly in 
North America and Canada (Sigurdson, 2008). As yet, no evidence has been shown 
for CWD transmission to humans. 
A number of prion diseases afflicting other animal species have been recognised to 
be associated with BSE through consumption of prion contaminated meat and bone 
meal feed. Spongiform encephalopathy was found in domestic cats, feline (FSE) and 
mink (TME), exotic ruminants (EUE) and primates kept in Zoos (Leggett et al., 
1990; Wyatt et al., 1991; Kirkwood and Cunningham, 1994; Prusiner, 1998; Bons et 
al., 1999). In each case, association with BSE was geographically evident and was 
verified by experimental transmission studies (Fraser and Foster, 1994; Collinge et 
al., 1996; Bruce et al., 1997; Fraser, 1998; Baron and Calavas, 2005; Barron et al., 
2007).  
BSE was first identified in the late 1980s in UK as an epizootic epidemic of 
previously unknown disease of cattle (Wells et al., 1987; Wilesmith, 1988; Anderson 
et al., 1996) and it was classified as prion disease upon the discovery of protease-
resistant prion protein in the brain material of the affected cattle (Hope et al., 1988). 
BSE was a result of industrial cannibalism in which cattle feed was enriched with 
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meat and bone meal derived from unrecognised prion-infected animal sources 
(rendered sheep or cattle offal) (Wilesmith, 1991; Wilesmith et al., 1992). The meat 
and bone meal animal feed was also exported to many other countries, resulting in 
BSE identified throughout Europe and in some North American and Asian countries 
(Smith and Bradley, 2003). Since 1988 this practise has been forbidden in the UK. 
The BSE epidemic reached its peak in 1992 with over 35,000 cattle infected. By 
2003 BSE had become a rare disease, but still has not been completely eradicated 
from British or European cattle (http://vla.defra.gov.uk/science/docs/sci_tse_stats 
_gen.pdf). 
No evidence of PrP
Sc
 accumulation in lymphoid tissues or in other systematic tissues 
in field cases of BSE was shown (Wells et al., 2005). BSE was proven as 
transmissible to mice, cattle, sheep, pigs and non-human primate marmoset, domestic 
cats, wild cats and range of exotic ungulates in zoos (Dawson et al., 1990a; Dawson 
et al., 1990b; Baker et al., 1993a; Baker et al., 1993b; Kirkwood and Cunningham, 
1994; Fraser and Foster, 1994; Baker and Ridley, 1996a; Bruce et al., 1997). The 
BSE agent was shown to retain its biological identity after crossing between species 
either naturally or experimentally (Bruce et al., 1994; Bruce et al., 1997; Hope et al., 
1999; Stack et al., 2002).  
Extensive surveillance for BSE in Europe and Japan has identified several cases of 
“atypical” BSE which has been termed bovine amyloidotic spongiform 
encephalopathy (BASE) characteristic with distinctive neuropathological profile 
from that found in conventional BSE comprising relative lack of neuronal 
vacuolation and PrP-immunoreactive amyloid mini-plaques in the brain stem  
(Biacabe et al., 2004; Casalone et al., 2004). 
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1.4 MODELS FOR STUDYING PRION DISEASES  
1.4.1 In vivo models for studying prion diseases - Animal models  
In medical research, animal diseases are often used as convenient and relevant 
models of human disease, and that is the case for human prion diseases. 
Transmission studies in the field of prion research have been undertaken for many 
years, more commonly using scrapie, as this was the first prion disease to be 
characterised. Accordingly, sheep and goats were originally used to for such studies 
and sheep are still used today. However, the use of small rodents (mice, hamsters and 
others) is often preferred, because of the case of their ease of maintenance and 
genetic manipulation. They are also cheaper to house and have relatively shorter 
gestation times, incubation periods, and life spans. Non-human primates, such as the 
cynomolgus macaques (Lasmezas et al., 2005) and squirrel monkey (Williams et al., 
2007), have been found relevant to transmission studies of human prions because 
they are evolutionary closer to humans and therefore could neuropathologically and 
physiologically model human disease more precisely. To investigate the species 
barrier effect on transmission of prion diseases, mouse lines expressing prion gene 
sequences from other species have been developed (Scott and Fraser, 1989; Telling 
et al., 1994; Bruce et al., 1997; Hill et al., 1997a; Scott et al., 1999; Barron et al., 
2001; Asante et al., 2002; Kitamoto et al., 2002; Taguchi et al., 2003; Asano et al., 
2006; Asante et al., 2006; Bishop et al., 2006; Cancellotti et al., 2006; Kobayashi et 
al., 2007; Beringue et al., 2008). It is well known that transmission of prion diseases 
is more efficient within species rather than between species (Bruce et al., 1994). The 
species barrier is defined by the observation that transmission to a different species 
results in a significantly longer incubation period or even sometimes the absence of 
clinical disease (Carp et al., 1994). An inverse correlation between the length of the 
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incubation period and the logarithm of the dose of PrP
Sc 
in the inoculum was 
observed and this allowed for the development of rapid bioassays (Prusiner et al., 
1980a; Prusiner et al., 1980b; Prusiner et al., 1982).  
Several prion diseases (scrapie, BSE, FSE, sCJD, vCJD, kuru fCJD, FFI and one 
GSS variant) have been successfully transmitted to experimental animals, including 
rodents and non-human primates (Kimberlin and Walker, 1989; Kitamoto et al., 
1991; Lasmezas et al., 1997; Carp et al., 1998; Lasmezas et al., 2001). The 
neuropathological diversity, such as the severity and distribution pattern of the 
vacuolation in mice, as well as length of incubation time have been very useful to 
distinguish between strains of prion agents (Bruce et al., 2001).  
Experimental methods for the production of transgenic mice have developed rapidly 
over last years, employing two distinct methods, either random genomic insertion or 
gene targeting (Manson and Tuzi, 2001). Mice in which Prnp has been 
experimentally disrupted (knock-out mice or PrP
0/0
) are resistant to prion infection, 
as was proposed by the absence of replication of the prion agent in tissues and lack 
of clinical or neuropathological signs of disease (Brandner et al., 1996a; Brandner et 
al., 1996b). In contrast, mice overexpressing PrP have been shown to have shorter 
incubation periods than wild type mice inoculated with the same prion agent, 
providing useful models for assaying prion infectivity (Prusiner et al., 1990).  
The use of animal models has allowed examination of tissues during pre-clinical 
disease in order to examine the progression of pathological features as well as those 
present at terminal stage of the disease. Employing engineering of transgenic 
animals, it has been possible to investigate important issues of strain or species 
barriers, the effect of disease associated mutations, and the importance of specific 
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parts of the prion protein in terms of normal cellular biology and disease 
transmission (Kimberlin and Walker, 1979; Prusiner et al., 1990; Bueler et al., 1992; 
Prusiner et al., 1993; Manson et al., 1994; Prusiner and Scott, 1997; Scott et al., 
2000; Bishop et al., 2006). 
 
1.4.2 In vitro models for studying prion diseases – Cell cultures 
Transmission studies employing wild-type and transgenic animals have been 
fundamental in investigating the basis of prion diseases. However, these assays tend 
to be long-term, very expensive and require large numbers of animals. Early attempts 
to propagate the prion agent in vitro were complicated by the surprising finding that 
only a very limited number of cell lines were able to replicate prions and that this 
property was prion strain-specific. However, when successful, the cell-based model 
provided a proof of principle that cells could complement or advantageously replace 
animal bioassays to titre prions.  
1.4.2.1 Scrapie cell assay 
Applications of in vitro models allowing the study of particular aspects of the prion 
disease infection process have attracted broad scientific interest and have undergone 
extensive development. A highly sensitive cell-based bioassay, termed scrapie cell 
assay (SCA), has been developed by C. Weisssmann’s group (Klohn et al., 2003). 
SCA was reported to be a quantitative measure of infectious titre, approximately as 
sensitive as a mouse bioassay, ten times faster, more than two orders of magnitude 
less expensive and suitable for automatisation (Klohn et al., 2003; Bedecs, 2008; 
Aguzzi and Calella, 2009). In SCA, the susceptible cells are usually exposed to 
samples containing infectious prions, then grown until confluent and passaged. If 
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infection is successful, a PrP
res
 assay reveals positive cellular foci relating to the 
infectious titre. However, this murine system is susceptible to some, but not all 
murine adapted scrapie strains and has not yet been successfully applied to human 
prion strains or isolates (Bosque and Prusiner, 2000; Solassol et al., 2003; Mahal et 
al., 2007).  
1.4.2.2 Establishment of prion infected cell cultures as a model for studying prion 
diseases 
The initial successful attempts to establish scrapie-infected culture were 
accomplished in 1970 when brain explants derived from mice infected with scrapie 
propagated low levels of prions (Clarke and Haig, 1970). The growth and 
morphological characteristics of the tissue were comparable with those from 
uninfected mice (Field and Windsor, 1965). Employing the explant technique, the 
first successful cell culture termed SMB cells (scrapie mouse brain) was established 
in vitro, remaining its infectivity and this system is still in use today (Field and 
Windsor, 1965; Haig and Pattison, 1967; Clarke and Haig, 1970; Caspary and Bell, 
1971; Birkett et al., 2001; Hooper, 2002; Kanu et al., 2002; Bate et al., 2004a; Bate 
et al., 2004b; Bate et al., 2004c; Uppington and Brown, 2007; Bate and Williams, 
2011). However, one disadvantage of this approach is the lack of uninfected controls 
for comparative purposes. Therefore, cells from several sources and variety of 
experimental systems have been used to try to establish cell cultures chronically 
infected with prions. The most straightforward approach, that proved to be successful 
for certain cell types is the direct exposure of a cell monolayer or cell suspensions to 
scrapie-infected brain homogenates or partly or highly purified preparations (Butler 
et al., 1988; Race, 1991). The majority of the currently used constitutively prion-
Chapter 1   Introduction 
  52 
infected cell cultures have been generated using exactly this approach. Nevertheless, 
repeated attempts to establish constitutively prion–infected (Race, 1991) cell lines 
with stable PrP
Sc
 propagation have been successful in a very small number of cell 
lines (Table 1.4). 
1.4.2.3 Neuronal vs. non-neuronal origin of the cultured cells 
Because the pathogenic isoform of the prion protein accumulates mainly in neurons 
which are also the targets for prion-induced neurodegeneration, the main focus has 
been on the development of cell cultures of neuronal origin or a neuronal phenotype. 
However, non-neuronal cells, for example, the recently developed scrapie infected 
Schwann cell cultures, could be used to investigate the peripheral route of prion 
invasion (Follet et al., 2002; Archer et al., 2004). An interesting feature of the cell 
lines contained in the Table 1.4 is that majority of the cell lines susceptible to chronic 
prion infection are of non-neuronal origin. Among the neuronal cell lines, the 
successful infection has been mostly achieved using mouse passaged sheep scrapie to 
infect rodent neuroblastoma cells (Race, 1991; Solassol et al., 2003). Among these, 
the cells capable of continuous replication of prions are N2a (Race et al., 1987; 
Butler et al., 1988), N1E-115 (Markovits et al., 1983), and C-1300 (Race et al., 
1987) murine neuroblastoma cell lines of common origin, derived from spontaneous 
tumour arising in A/J mice (Klebe and Ruddle, 1969; Markovits et al., 1983) and 
GT1 cell line, originating from hypothalamic neurons immortalised by genetically 
targeted tumorigenesis in transgenic mice (Mellon et al., 1990; Schatzl et al., 1997; 
Nishida et al., 2000; Arjona et al., 2004). Even rat pheochromocytoma PC12 cells 
when differentiated to neuron-like cells can be infected with mouse prions 
(Rubenstein et al., 1984). Mouse cholinergic septal neuronal cell line termed SN56 
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was also shown to be permissive to infection with several mouse-adapted prion 
strains (Baron et al., 2006). Neuronal stem cells derived from conventional or 
transgenic mice were recently shown to propagate mouse-adapted prions (Giri et al., 
2006; Milhavet et al., 2006) and moreover hippocampal-derived HpL3-4 cells 
isolated from PrP
C 
knock-out mouse and transfected with mouse PrP
C 
were shown to 
be susceptible to the mouse adapted strain 22L (Maas et al., 2007). Some fibroblast 
cell lines (Vorberg et al., 2004) and microglial cell line (MG20) established from 
transgenic mice overexpressing PrP
C
 were shown to be susceptible to various murine 
prion strains and also to mouse adapted bovine spongiform encephalopathy agent 
(Iwamaru et al., 2007). Also cells from the peripheral nervous system such as 
Schwann-like cells called MSC80, were shown to replicate low levels of the RML 
strain (Follet et al., 2002).  
A recently established prion-infected cell line originating from skeletal muscle 
(C2C12) could be useful in investigation of prion infection of muscles observed in 
sheep and cervids (Dlakic et al., 2007). The hamster brain HaB cell line was show to 
stably replicate hamster prions (Taraboulos et al., 1990b). 
The first example of natural TSE agent transmission (not previously adapted to 
rodents) occurred in the rabbit epithelial cell line RK13 which expresses ovine PrP
C
 
(variant VRQ associated with a very high susceptibility (Hunter, 1997) when it was 
shown to successfully replicate sheep scrapie prions (Vilette et al., 2001). This model 
also yielded the first evidence that PrP
Sc 
can propagate in vitro in cells of non-
neuronal lineage and since then PrP
Sc 
multiplication has been demonstrated in several 
other non-neuronal cell lines, including fibroblasts (Vorberg et al., 2004; Raymond 
et al., 2006), microglial cells (Iwamaru et al., 2007), muscle cells (Dlakic et al., 
Chapter 1   Introduction 
  54 
2007) and a mule deer cell line were successfully infected with naturally occurring 
chronic wasting disease (Raymond et al., 2006). The mouse neuronal CAD cell line 
was recently recognised as being a robust system for prion propagation in culture 
(Mahal et al., 2007; Dron et al., 2009; Gousset et al., 2009). 
Despite the wealth of data showing that cultured cells of a variety of species and 
phenotypes can propagate animal prions, evidence that human cells have been 
infected with a human prion agent is restricted to a single report from 1995. In this 
Ladogana and colleagues (Ladogana et al., 1995) described their success in infecting 
human neuroblastoma SH-SY5Y (PRNP codon 129 genotype MM) cell line with 1 
ml of 1% brain homogenate originating from sporadic CJD patient (PRNP codon 129 
genotype MM). Eleven of subcloned cells were tested positive for PrP
Sc
 production 







 passage, indicating persistent PrP
Sc 
propagation of human 
neuroblastoma cells. However, occasionally these cells were tested PrP
Sc 
negative in 
passages that subsequently were positive (Ladogana et al., 1995) and this initial 
success in infecting human cells with CJD agent has not been capitalised on, most 
likely because the infection proved to be unstable. Interestingly, neither rabbit kidney 
epithelial cells RK13 expressing human PrP were permissive to infection when 
exposed to sporadic Creutzfeldt–Jakob disease prions (Lawson et al., 2008). 
1.4.2.4 Selective cell tropism of different prion strains  
The cell lineages described above summarised in Table 1.4 appear to be especially 
susceptible to mouse-adapted prion isolates from scrapie. This is even more apparent 
in a view of the large number of neuronal and neural cell lines that could not be 
infected (Markovits et al., 1983; Elleman, 1984; Butler et al., 1988; Race, 1991; 
Chesebro et al., 1993; Vella et al., 2007). Interestingly, GT1 cells are susceptible to 
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prions other than the Chandler or RML isolates and have shown to replicate both the 
scrapie-derived 139A and 22L, as well as familial GSS- and sporadic CJD-derived 
FU and SY prions, whereas only the transfected N2a cells overexpressing PrP
C
 
(N2a#58) are susceptible to infection with other isolates than Chandler or RML 
(Nishida et al., 2000; Arjona et al., 2004). 
N2a Mouse Neuroblastoma Chandler, Fukuoka-1, RML Race et al.,  1987; Butler et al., 1988
N2a #58 Mouse Neuroblastoma Chandler, 139A, 22L Nishida et al.,  2000
C-1300 Mouse Neuroblastoma Chandler Race et al.,  1987
N1E-115 Mouse Neuroblastoma Chandler Race et al.,  1987; Ostlund et al.,  2001
MNB Mouse Neuroblastoma Chandler Race et al.,  1987
HaB Hamster Hamster brain cells Hamster strain Tarabolous et al.,  1990
SN56 Mouse Cholinergic septal neuronal Mouse adapted scrapie, 22L Hammond et al., 1990; Magalhaes et al., 2005
SH-SY5Y Human Neuroblastoma sCJD Ladogana et al., 1995
GT 1-7 Mouse Hypoth. neur. cells 22L, Chandler, 139 A Schatzl et al.,  1997; Nishida et al., 2000
GT 1 Mouse Hypoth. neur. cells Sy-CJD, FU-CJD, Fukuoka Arjona et al.,  2004; Arima et al., 2005
DRG TgovMouse Dorsal root ganglia Natural sheep scrapie Archer et al. , 2002
MovS TgovMouse Schwann-like cells Scrapie Archer et al. , 2002
MovS6//S2 TgovMouse Schwann-like cells PG127 Archer et al., 2004
MSC-80 Mouse Schwann cells Chandler Follet et al.,  2002
T98G Human Glioblastoma natural conversion Kikuchi et al.,  2004
CGN 338, CAS 358 TgovMouse Astrocyte/neurons Scrapie, 139A, ScMov Cronier, 2004
NSC Mouse Neuronal stem cells RML, 22L Giri et al. , 2006; Milhavet et al. , 2006
HpL3-4 Mouse Hippocampal cells 22L Maas et al.,  2007
SMB Mouse Brain cells (mesodermal origin) Chandler Clarke et al.,  1970; Birkett et al.,  2001
L fibroblast Mouse Fibroblast Chandler Clarke et al., 1976
L929 Mouse Fibroblast 22L,ME7 & RLM Vorberg et al.,  2004
L929, NIH/3T3 Mouse Fibroblast 22L Vorberg et al.,  2004
L23 Mouse Unspecified C-506 Cherednichenko et al.,  1985
NS1 Mouse Spleen hybridoma with NS1 Chandler Elleman, 1984
PC12 Rat Pheochromocytoma 139A, ME7 Rubenstein et al.,  1984
Glial cells Rat Glial cells (Gasserian ganglion) Chandler Roikhel et al.,  1984
RK-13 Rabbit Kidney epithelial Natural sheep scrapie Vilette et al.,  2001
moRK13 Rabbit Kidney ephitelial RK13 Fukuoka-1, Chandler, M100 Corageot et al.,  2008; Vella et al. , 2007
voRK13 Rabbit Kidney ephitelial RK13 Vole-adapted BSE Corageot et al.,  2008
MG20 Mouse Microglial Chandler, ME7, mouse BSE Iwamaru et al.,  2007
C2C12 Mouse Myoblasts 22L Dlakic et al.,  2007
MDB Deer Fibroblast-like Chronic waisting disease Raymond et al., 2006
Rov Mouse Kidney epithelial cells PG127, LA404 Vilette et al.,  2001; Sabuncu et al. , 2003
CAD Mouse Catecholaminergic neuronal 139A, 22L Mahal et al.,  2007; Dron et al.,  2009
Reference(s)Cell term Species of 
origin                         
Tissues of origin or cell type TSE strain
 
Table 1.4: Cell culture models established to study prion diseases 
 
GT1 cells have important advantages over the use of N2a cells, particularly for 
studying cytopathological effects induced by prion infection, since they express 
approximately eight times higher levels of endogenous PrP
C
 (Nishida et al., 2000) 
and consequently they are much more susceptible to prion infection than N2a cells. 
Only 2% or less of the prion exposed N2a cells become infected and only low levels 
of PrP
Sc
 are produced in the culture. These cultures frequently loose their infected 
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status after 10-15 passages (Race et al., 1987; Butler et al., 1988; Bosque and 
Prusiner, 2000).  
To obtain chronically prion-infected N2a cultures that produce sufficient levels of 
PrP
Sc
, N2a cultures have to be subcloned prior to prion exposure. Subcloning can 
provide lines with 80-90% of prion-infected N2a cells (Bosque and Prusiner, 2000; 
Nishida et al., 2000; Enari et al., 2001) and these have been shown to be very useful 
in studying the cell biology of prion replication, subcellular localisation of PrP
Sc 
and 
the kinetics of PrP
Sc 
formation (Borchelt et al., 1990; Taraboulos et al., 1990b; 
Caughey and Raymond, 1991; Taraboulos et al., 1995; Gorodinsky and Harris, 1995) 
as well as in the development of inhibitors of PrP
Sc
 formation and antiprion 
prophylaxis (Caughey and Race, 1992; Winklhofer and Tatzelt, 2000; Supattapone et 
al., 2002). The SMB cells that originated from Chandler strain-infected mouse brain 
culture (Clarke and Haig, 1970) were shown to be able to be “cured” of prion 
infection by treatment with pentosan sulphate and were then re-infected with other 
mouse-adapted prion strains (Birkett et al., 2001; Kanu et al., 2002). The L929 
murine fibroblast cell line was shown to be susceptible to 22L, ME7 and RML prion 
strains, whereas the MG20 microglial cell line is susceptible to ME7, Chandler and 
the mouse-adapted BSE agent. The RK13 cell line expressing mouse PrP
C 
was 
shown to be susceptible to several murine prion strains (Courageot et al., 2008). 
However, the observed cell tropism could be illustrated for the ME7 strain which 
could not be replicated in N2a or GT1 cell lines (Bosque and Prusiner, 2000; Klohn 
et al., 2003), although the SN56 (Baron et al., 2006), L929 (Vorberg et al., 2004), 
and MG20 (Iwamaru et al., 2007) were shown to propagate this prion strain. The 
molecular and cellular basis of these effects is not yet understood.  
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1.4.2.5 Prions propagated in cell cultures retain their strain characteristics 
Several murine strains (22F, Chandler, Fukuoka, SY) propagated in N2a, GT1 or 
SMB cell cultures (Birkett et al., 2001; Arjona et al., 2004; Arima et al., 2005) have 
been shown to retain their biological characteristics (incubation time, vacuolisation, 
clinical signs) after passage through cultured cells. Also, biological characterisation 
of sheep, mouse, and vole prion strains replicated in cell line expressing ovine, 
mouse or vole PrP
C 
(RK13 cell line), suggests that these strains are not modified by 
replication in non-neuronal cells (Courageot et al., 2008). The PrP
res
 banding patterns 
of strains generated by infected cell cultures do sometimes differ from those 
generated in the brain (Caughey et al., 1991; Nishida et al., 2000; Vilette et al., 2001; 
Archer et al., 2004; Arima et al., 2005; Milhavet et al., 2006) but return to their 
original pattern upon animal inoculation (Archer et al., 2004; Arima et al., 2005). 
Therefore, the biological properties of the strain are not modified after propagation in 
cultured cells. Interestingly and importantly, although brain and cell generated PrP
res 
patterns are different, strain specific banding pattern differences observed for prion 
brain PrP
res 
have also been reported after serial propagation of certain agents in 
certain cultured cells (Birkett et al., 2001; Arima et al., 2005; Iwamaru et al., 2007; 
Courageot et al., 2008). 
Attempts to study the very early events during infection of cultured cells have proved 
to be rather difficult because a) only a few cell culture systems have been identified 
to be susceptible to prion agents, b) newly formed PrP
Sc 
is difficult to distinguish 
from PrP
Sc 
present in the inoculum, and c) the amount of PrP
Sc 
produced in 
susceptible cell lines at early stage of infection is often very low (Vorberg et al., 
2004).  
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One of the principal objectives in establishing prion-infected cell cultures has been to 
look for the cythopathological and morphological consequences of the prion 
infection. However, a striking feature was the lack on any obvious signs of cell death 
(Clarke and Haig, 1970). Notwithstanding that the establishment of scrapie infected 
cell lines or cell lines expressing mutant PrP
C
 linked to some hereditary prion 
diseases has been crucial for the understanding of the biogenesis and metabolism of 
PrP
Sc
, the handicap in using scrapie-infected cell cultures to study molecular 
mechanism underlying prion-induced neurodegeneration is the lack of obvious signs 
of neurotoxicity in these cells. The discrepancy between in vivo and in vitro PrP
Sc
 
neurotoxicity could be due to the transformed phenotype of the currently available 
cell culture models, thus masking the PrP
Sc 
neurotoxicity that may occur only in 
finally differentiated cells, such as postmitotic cells of the adult CNS. This could 
explain why ScGT1 cells, owning more differentiated neuronal phenotype than 
ScN2a and ScN1E-115 cells, do exhibit certain signs of neurodegeneration, whereas 
ScNa2 and ScN1E-115 cells do not.  
 
1.4.3 In vitro models for studying prion diseases – Cell-free conversion systems 
The prion “protein-only” hypothesis proposes that the fundamental event in prion 
diseases is the conversion of the normal cellular prion protein (PrP
C
) into the 
misfolded disease-associated protein (PrP
Sc
) and that this conversion process is 
PrP
Sc





1998). Studies using model systems have also suggested that host-encoded factors 
other than PrP
C 
may be required to propagate prions in vitro and in vivo (Telling et 
al., 1995; Saborio et al., 1999; Stephenson et al., 2000; Lloyd et al., 2001). 
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Furthermore, the restricted range of neuronal and non-neuronal cell types that are 
susceptible to infection with prions also indicates the existence of prion propagation 
cofactors (Raeber et al., 1999; Bosque and Prusiner, 2000; Enari et al., 2001).  
Although PrP conversion in cultured cells and animal models is clearly possible, it 
has been difficult to reproduce the process in vitro in a cell-free system. To establish 
a cell-free model system that supports misfolding of PrP, a number of assays have 





 conversion process have been studied more fully employing in 
vitro systems implementing chemical and physical treatments of PrP that involve 
denaturation producing a form of PrP that shares some of the properties of PrP
Sc
 
(Jackson et al., 1999). 
1.4.3.1 Protein misfolding cyclic amplification 
The first template dependent cell-free PrP conversion system was devised by B. 
Caughey and colleagues, reviewed by (Jones et al., 2011), but an invaluable 
technical innovation was developed by C. Soto and co-workers in a the form of a 
technique called protein misfolding cyclic amplification (PMCA), in which PrP
Sc
 and 
also infectivity are both amplified (Saborio et al., 2001; Castilla et al., 2005a; Saa et 
al., 2006; Castilla et al., 2006). PMCA recapitulates the prion protein conversion 
process in cell-free conditions and it is a cyclic process consisting of two alternating 
phases - incubation interrupted by sonication at regular intervals leading to 
accelerated prion replication (Saborio et al., 2001; Soto et al., 2002). This suggests 





“substrate” molecules and converts it into PrP
Sc
.  
The sonication step based on ultrasound-induced fragmentation breaking down the 
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PrP
Sc
 aggregates into smaller subunits, each of which acts as a new template for 
recruiting more PrP
C
, which is subsequently converted into PrP
Sc
 (Figure 1.10). 
Potentially exponential amplification is achieved by each successive cycle limited 
only by the availability of substrate and co-factors (Saborio et al., 2001; Bieschke et 
al., 2004). 
 
Figure 1.10: Diagrammatic scheme of the principle of PMCA reaction 
PMCA consists of a phase when a minute amounts PrP
Sc
 multimers (darker green) in the 
presence of excess of PrP
C





conversion. The newly converted polymers (lighter green) are then subjected to additional 




 conversion and subsequent 
incubation-providing amplification of newly converted PrP
Sc
 units. The PrP
Sc
 amplification 
process is limited by availability of PrP
C
 substrate. Figure modiefied from (Catilla et al., 
2006). 
 
PMCA was originally established employing brain material and latter partially 
purified and recombinant PrP
C
 (Atarashi et al., 2007; Kim et al., 2010). PrP
Sc
 
generated by PMCA was shown to be infectious in wild-type animals (Castilla et al., 
2005a) and can be indefinitely propagated preserving properties of the original PrP
Sc
 
(Castilla et al., 2006; Shikiya et al., 2010).  
Furthermore, PMCA was shown to be useful in identifying of conditions and 
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cofactors influencing PrP conversion (Deleault et al., 2003; Lucassen et al., 2003; 
Nishina et al., 2006; Deleault et al., 2007; Geoghegan et al., 2007; Murayama et al., 
2007; Kim et al., 2009; Mays et al., 2009; Mays and Ryou, 2010; Abid et al., 2010), 
and in detecting PrP
Sc
 from biological samples of humans and animals (Soto et al., 
2005; Castilla et al., 2005b; Atarashi et al., 2007; Kurt et al., 2007; Jones et al., 
2007; Thorne and Terry, 2008; Jones et al., 2009; Haley et al., 2009; Rubenstein et 
al., 2010; Tattum et al., 2010a; Tattum et al., 2010b). Supattapone and co-workers 
identified the minimal components (PrP
C
, co-purified lipids and single stranded 
polyanionic molecules) for de novo generation of infectious PK resistant PrP
Sc
 from 
normal hamster brain using PMCA. Inoculation of these reaction products into 
healthy hamsters caused prion disease (Deleault et al., 2007), strongly support the 
prion hypothesis.  
Another recently developed method - involving seeded conversion of the α-helix-rich 
form of bacterially expressed recombinant PrP
C
 to a β-sheet-rich amyloid fibrillar 
form - is termed Quaking-induced conversion (QuIC) (Atarashi et al., 2008; Wilham 
et al., 2010). QuIC and its even more recently introduced real-time variation (RT-
QuIC) are promising diagnostic tests for prion diseases because their sensitivity may 
be sufficient to detect the low levels of PrP
Sc
 thought to occur in body fluids such as 
cerebrospinal fluid (CSF) and blood (Atarashi et al., 2011; Orru et al., 2011). 
 
1.5 PRIONS AND PUBLIC HEALTH  
1.5.1 Human-to-human routes of prion transmission 
 One implication of the humanised transgenic mice experimental models (Telling et 
al., 1995; Manson and Tuzi, 2001; Asante and Collinge, 2001; Weissmann and 
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Flechsig, 2003; Bishop et al., 2006; Beringue et al., 2008) findings is that a 
significant number of individuals in the UK population may be infected with vCJD 
but are asymptomatic and present a risk of disease transmission to others by, for 
example blood transfusion. In the case of the four known cases resulting from prion 
transmission by blood transfusion the incubation time periods from the donation to 
development of clinical signs of vCJD in the donors were 40 months (Llewelyn et 
al., 2004), 20 months (Wroe et al., 2006), and 17 months (HPA, 2007; 
http://www.cjd.ed.ac.uk/TMER/TMER.htm). This re-affirms the suggestions that the 
vCJD pre-clinical phase is lengthy and also that during that time period the 
asymptomatic individual is able to transmit the disease via tissues and fluids.  
Blood transfusion is not the only means of accidental transmission of infectious 
prions. Historically, corneal transplantation, neurosurgical instrument re-use, dura 
mater grafting and growth hormone therapy have all been associated with iatrogenic 
transmission of CJD (Brown, 1990; Collins et al., 2004). More recently concern has 
been expressed about surgery (Ramasamy et al., 2003; Mabbott and Turner, 2005) 
and dentistry (Bennett et al., 2007) as a possible routes of vCJD iatrogenic 
transmission. The potential for future stem cell therapies to transmit prion disease has 
received comparatively little attention. Most current culture systems supporting 
human embryonic stem cell self-renewal and differentiation rely both on direct and 
indirect exposure to animal and human cells, and on the use of cell products such as 
purified human proteins or bovine serum (De Sousa et al., 2006). These components 
can represent a potential risk of prion infection as indeed may the cells themselves, 
depending on their origin. Given the precedent of iatrogenic CJD, it seems prudent to 
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consider the potential risk of prions transmission by the newly emerging cell 
therapies.  
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1.6 AIMS 
A major problem in human prion disease research is the lack of a suitable 
experimental model system in which to study the molecular mechanisms involved in 
cellular susceptibility to infection and the processes involved in prion replication. 
This is largely due to the lack of well characterised cultured human cells that are 
susceptible to infection with human prions, such as those involved in Creutzfeldt-
Jakob disease.  
 
Follicular dendritic cells (FDC) are known to support prion replication in vivo, for 
example in vCJD. Thus this thesis sought to determine whether a human follicular 
dendritic cell-like (FDC-like) cell line (termed HK) had all of the required 
components to support prion replication and to examine the susceptibility of these 
cells to prion infection and their ability to support prion propagation in vitro. The 
mechanisms of exogenous PrP
Sc
 internalisation, intracellular trafficking and its fate 
within the cell were subsequently examined. 
 
Given the known potential for iatrogenic transmission of prion diseases such as CJD, 
a parallel series of experiments considered the susceptibility to prion infection of 
human embryonic stem cells (hESC) by characterising their genetics and expression 
of the normal cellular prion protein and by examining their response to acute 
exposure to prions from a range of sources.  
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2. MATERIALS AND METHODS 
 
2.1 SAFETY AND MANIPULATION REGULATIONS 
All brain tissue sampling procedures were conducted in the class 1 microbiological 
safety cabinet in the National CJD Research & Surveillance Unit (NCJDRSU) 
category 3* High Risk Laboratory. The Advisory Committee on Dangerous 
Pathogens (ACDP) classifies TSE agents in various species as hazard group 3 
(http://www.dh.gov.uk/ab/ACDP/index.htm). Precautions included wearing standard 
splash proof gown and disposable high-risk over-gown, protective footwear, 
protective eyewear and double gloves. Particular care was taken at steps that had the 
potential to cause aerosols. Sealed rotors were used for all centrifugation steps and 
were only opened inside the microbiological safety cabinet.  
The prion agents are resistant to inactivation by conventional chemical and physical 
decontamination methods and exhibit exceptional stability against such treatments. 
Prion decontamination recommended by the ACDP and as required by the 
Laboratory code of practice in NCJDRSU is to incubate infective material with 2 M 
sodium hydroxide (NaOH) for minimum 1 hour before disposal. 
Operations involving cell culture genotyping were performed in the class 2 
microbiological safety cabinet. 
The entire cell culture manipulation has been conducted in by a UV radiation pre-
sterilised class 2 microbiological safety cabinet in the category 3* high risk 
laboratory. All reagents, tools and techniques used throughout were under aseptic 
conditions. Handling cell culture was largely a matter of containment and avoidance 
of aerosols. This is justified by two aspects: first, aseptic technique (protecting the 
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cultures from the researcher) and second, safety (protecting researcher from the 
cultures and brain tissue homogenates). Steps were taken to avoid spills and use of 
secondary containment when transporting cell culture flasks/chamber slides between 
hood, incubator, microscope, etc. Stem cells from MRC Centre for Regenerative 
Medicine were transported to the NCJDRSU by private car or taxi as well as the 
sealed slides containing prion exposed cells for confocal microscope analysis from 
NCJDRSU to the Neuropathogenesis division of the The Roslin Institute & Royal 
(Dick) School of Veterinary Sciences. The samples were transported under the 
regulations for transporting biological substances of category B assigned to UN 3373 
(http://www.docs.csg.ed.ac.uk/Safety/bio/guidance/transport/summary_catB.pdf) in 
accordance with ADR P650 packaging instructions.  
 
2.2 CELL CULTURES 
2.2.1 HK cell line 
The follicular dendritic cell (FDC)-like HK cell line was a kind gift to the National 
CJD Research & Surveillance Unit from Dr. Yong Sung Choi, Cellular Immunology 
Laboratory, New Orleans, USA. This HK cell line was originally established from 
human tonsils to investigate the functional role of FDCs in germinal centres of 
lymphoid follicles. The isolation is described in Kim et al., 1994. In short, freshly 
obtained tissue from human tonsils was enzymatically digested and subjected to 
Percoll gradient centrifugation (Tsunoda et al., 1990; Clark et al., 1992). Cells with 
densities less than 1.050 g/ml were plated on tissue culture dishes. Non-adherent 
lymphoid cells were removed. After growing for two weeks the cultures were 
morphologically homogenous, composed of proliferating non-phagocytic adherent 
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cells with long cytoplasmic protrusions and were termed HK cells. These cells were 
established in the absence of exogenous cytokines (GM-CSF), growth factors or 
EBV-transformation and continue growing over a 180 days without changes in 
viability. Surface phenotype markers of these cells were periodically examined by 
fluorescent microscopy (Kim et al., 1994). 
HK cells at 1-2 days of culturing expressed characteristic FDC antigens including 
DRC-1, HJ2, CD21 and surface Ig. Although the FDC-specific marker, DRC-1 
antigen, was initially expressed by HK cells, it was not detectable after 3 days in 
culture. However expression of another FDC-specific marker, HJ2, was retained. 
Furthermore, HK cells promoted B cell proliferation. The pattern of HK cells surface 
markers expression corresponded to reported FDC phenotype (Schriever et al., 1989; 
Petrasch et al., 1990). 
Besides of resembling FCD cells the HK cells supposedly also shared some 
phenotype and morphologic characteristics of fibroblasts (Kim et al., 1994). The 
requirements of growth factors, growth kinetics and cytokine production of HK cells 
was therefore compared with age-matching human skin and human foetal lung 
fibroblasts. However, the analysis of markers suggested that the HK cells were 
functionally and phenotypically distinct from fibroblasts (Kim et al., 1994). 
Subsequent studies showed that the FDC-like HK cells contribute a favourable 
environment for the growth of follicular lymphoma cells (FLK-1) when cultured 
together (Kagami et al., 2001). FDCs are believed to support lymphoma cell growth 
(Stein et al., 1982; Petrasch et al., 1992; Choe et al., 2000), and this observation has 
been used to support the proposed FDC-like phenotype of HK cells. Nevertheless, it 
is important to note that several B-lymphoma cell lines have been established from 
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follicular lymphoma not requiring FDCs for their growth (Doi et al., 1987; Amakawa 
et al., 1990; Matsumura et al., 1990; Mohammad et al., 1993; Sambade et al., 1995). 
2.2.1.1 Establishing HK cell cultures from frozen stocks 
A cryogenic vial (Corning, UK) containing 1 ml frozen cell culture stock in 100% 
foetal calf serum (FCS, Invitrogen, UK) was removed from -150 °C cryogenic 
freezer (Revco Ultima II, Kendro Laboratory products, USA) and the suspension was 
thawed immediately. The cell suspension was gently dispersed in 9 ml of 37 °C pre-
heated RPMI 1640 culture medium (Invitrogen, UK) containing 1% 
Penicillin/Streptomycin/Amphotericin antibiotics/antimycotic cocktail (100X stock 
contains 10,000 units/ml of penicillin, 10,000 µg/ml of streptomycin and 25 µg/ml of 
amphotericin B as Fungizone® Antimycotic in 0.85% saline, Invitrogen, UK) in a 15 
ml Falcon tube (Fisher Scientific, UK) and then with gentle trituration transferred 
into two T25 cell culture flasks (Corning, UK). Cultures were incubated at 37 °C in a 
5% CO2 cell culture incubator (Binder GmbH, Germany). 
2.2.1.2 Routine cultivation of HK cells  
The HK cells were routinely cultured in complete medium consisted of RPMI 1640 
culture medium supplemented with 10% FCS and 
Penicilin/Streptomycin/Amphotericin antibiotics in T25 flasks and maintained at    
37 °C in a 5% CO2 cell culture incubator. Full medium changes were performed 
every other day with pre-warmed (37 °C) medium. 
2.2.1.3 Passaging HK cell cultures 
Passaging the HK cells was performed when the culture reached 80-90% confluency 
(roughly every ~10 days) at ratio 1:5. Briefly, medium was aspirated and disposed of 
into 2 M sodium hydroxide (NaOH). The cells were rinsed twice with 5 ml             
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1X Hank’s Balanced Salt Solution (HBSS, Invitrogen, UK). 1 ml of 0.05% Trypsin-
EDTA (Invitrogen, UK) was added into the flask with cultures. Trypsin does cleave 
proteins bonding of the cultured cells to the dish and thus facilitating cell’s 
detachment. The process was monitored using an Olympus differential interference 
contrast cell culture microscope with reflected fluorescence system for CKX41 
equipped with Olympus CAMEDIA digital camera C-5060 wide zoom, JVC colour 
video monitor TM-QA14PN-K, Olympus power supply U-RFLT50. Data were 
exported using CAMEDIA Master 4.1 software. After detachment 3 ml of complete 
culturing medium was added and the cell’s suspension was transferred into a sterile 
15 ml Falcon tube. Cells were collected by centrifugation at 884 rpm for 10 minutes 
(rotor 1180, Sigma 3-16K centrifuge, DJB Labcare, UK). The supernatant was 
aspirated and disposed of. The cell pellet was gently resuspended in complete culture 
medium. The cell suspension was transferred into fresh T25 cell culture flask.  
2.2.1.4 Cryopreservation of HK cell cultures 
The cell cultures selected to be frozen down as a stocks were detached from 
individual culture flasks with Trypsin-EDTA (as described in section 2.2.1.3). After 
centrifugation the cell pellet from one near confluent T25 flask was gently 
resuspended in 1 ml of 100% FCS, transferred into cryogenic vial and immediately 
frozen down at -150 °C. 
2.2.1.5 Plating HK cells for immunocytochemistry studies 
For studies involving confocal microscopy, cells were detached from the T25 flask 
with Trypsin-EDTA (as described in section 2.2.1.3) and plated onto chemically pre-
coated 4-welled glass chamber slides Lab-Tek
®
 II – CC
2TM
 (Nalgene Nunc 
International, part of Thermo Fisher Scientific, UK) one day before exposure to brain 
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spiked medium. These chamber slides are pre-treated by manufacturer with 
chemically modified glass growth surface with a positive charge that mimics Poly-D-
Lysine to facilitate better attachment of the cell to the glass surface. 
 
2.2.2 Human embryonic stem cell lines 
The human embryonic stem cells (hESC) used in this study originated and from Dr. 
Paul De Sousa’s laboratory in the MRC Centre for Regenerative Medicine, 
Edinburgh, UK. These cells were originally isolated as a part of a strategy for hESC 
derivation from clinically failed eggs whose developmental potential was rescued by 
parthenogenetic activation. Another goal of that project was to accomodate strategies 
overcoming reliance on some of the most poorly defined and path-critical factors 
associated with hESC derivation. These are for example an animal immune 
complement to isolate embryo inner mass, animal sourced serum products and feeder 
cells helping to sustain hESC growth and attachment.  
Seven new hESC lines (RH1, RH3, RH4, RH5, RH6, RH7, and RCM-1) were 
isolated. The RH1-7 lines were derived by outgrowth from whole blastocyst on an 
extracellular matrix substrate of purified human laminin transitionally relying on 
mitotically inactivated human dermal fibroblast (HDF) feeder cells (Fletcher et al., 
2006) using HDF conditioned medium supplemented with a bovine-sourced serum 
replacement (bSRM, (Martin et al., 2005)).  
The RCM-1 (i.e., Roslin Cells Manchester-1) was derived from a failed-to-fertilize 
inseminated egg recovered by parthenogenetic activation - as a demonstration of 
alternative strategy to generate normal hESC lines from clinically failed eggs to 
minimize the potential conflict with donor reproductive interest to conceive (De 
Chapter 2   Materials and Methods 
  71 
Sousa et al., 2009). This pluripotent hESC line is comparable to hESC lines derived 
from surplus of infertility treatment embryos and is deposited in the UK Stem Cell 
Bank for access by the research community. When the RCM-1 line was compared 
with other diploid female hESC lines previously isolated from supernumerary IVF 
blastocysts by the group of P. De Sousa, namely RH1 and RH3 (Fletcher et al., 
2006), the initial comparison (ISCI, 2007) of these lines showed high overall 
similarity as expected for cells of the same type.  
All three lines were isolated on feeder cells with two (RCM-1 and RH1) in HDF 
conditioned Dulbecco’s minimal essential medium (DMEM) and one (RH3) in a 
chemically defined medium, X-Vivo10 (Fletcher et al., 2006). All three lines 
generally expressed the anticipated panel of pluripotency markers, including 
NANOG, Oct-4, Sox-2, Dnmt3b, Lin28, CD 9, and others while uniformly exhibiting 
low levels of other markers (i.e., NR5A2, Noggin, FoxD3, and FGF5) (De Sousa et 
al., 2009). However the analysis also revealed that RCM-1 and RH1, which were 
isolated under identical culture conditions, were more closely matched in their 
expression of undifferentiated markers than RH1 and RH3, which originated from 
siblings embryos and thus were genetically related (De Sousa et al., 2009). This 
indicated that the methods of hESC line isolation and culture conditions may perhaps 
have a proportionately greater effect on gene expression than genetic identity. 
Because of their exclusive resemblance the RCM-1 and RH1 cell lines were chosen 
as a cell culture study models for this project. 
2.2.2.1 Matrigel coating of flasks and wells 
A primary aliquot of matrigel (Becton Dickinson Biosciences, UK) was thawed at    
4 
o
C for at least 2 hours to avoid formation of a gel. Then the matrigel was diluted at 
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a ratio 1:30 with a cold Knock Out Dulbeco’s Modified Eagles Medium (Invitrogen, 
UK) using a pipette. Matrigel suspension was added to well or flask (1 ml/6 well 
plate, 0.25 ml/4 welled chamber slide) and incubated overnight at 4 °C. These 
prepared flasks or wells were stored at 4 °C and could be use within a time period of 
1 week. Before use the matrigel pre-coated cell culture container was warmed to RT 
and matrigel was aspirated immediately prior adding the cell culture suspension to 
the well.  
2.2.2.2 Routine cultivation of hESC cultures 
The hESC were routinely cultured in matrigel-coated tissue culture plates (Corning, 
UK). Cultures were maintained in an incubator at 37 °C, 5% CO2 in air and 100% 
humidity. The culture medium was a Human Dermal Fibroblast Conditioned 
Medium - HDF-CM+, consisting of: Knock Out Dulbeco’s Modified Eagles Medium 
(KO-DMEM, Invitrogen UK), 20% Knock Out Serum Replacement (KOSR, 
Invitrogen, UK), 0.1 mM MEM-non-essential amino acids (Invitrogen, UK), 1.5 mM 
L-glutamine (Invitrogen, UK), 0.1 mM β-mercaptoethanol (Sigma-Aldrich, UK),    
50 units/ml penicillin and 50 μg/ml streptomycin (Invitrogen, UK) and basic 
fibroblast growth factor (bFGF, Peprotech, UK) at final concetration 4 ng/ml. This 
medium was conditioned for 24 hours using inactivated human fibroblasts (hbFGF). 
The medium was stored frozen. Before use it was thawed and further supplemented 
with 4 ng/ml bFGF and 1.5 mM L-glutamine and filtered. Full medium changes were 
performed daily with water-bath pre-warmed (37 °C) medium.  
2.2.2.3 Passaging of hESC cultures 
The hESC were passaged when the colonies were large, and began to merge and had 
centres that were dense and phase-bright when compared to the edges. Morphology 
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was best viewed under low magnification using a differential interference contrast 
microscope.  
Depending on the size and density of seeded aggregates, cultures were typically 
passaged at a ratio 1:2, usually every 5-7 days, by wash with PBS (Sigma-Aldrich, 
UK), treatment with 200 units/ml collagenase IV (Invitrogen, UK) in      KO-
DMEM, followed by incubation at 37 °C for around 5 minutes, until the edges of the 
colonies began to lift. The collagenase IV was then aspirated, the cells washed again 
with PBS and conditioned medium + hbFGF was added. The cells were then scraped 
(Cell scraper, Costar
®
, Corning, UK) and transferred into a 15 ml Falcon tubes. 
Gentle trituration was performed to break up colonies, and the cells were plated into 
new matrigel-coated (section 2.2.2.1) wells. The conditioned medium + hbFGF was 
added to each well and wells were gently agitated to allow even distribution of cells 
in a cell culture well. 
2.2.2.4 Cryopreservation of hESC cultures 
Cells from hESC cultures selected to be frozen down as a stocks were detached from 
plates by the method described previously in the section 2.2.2.3. After the cell 
suspension was transferred to a 15 ml Falcon tube, cells were collected by 
centrifugation at 1,000 rpm for 5 minutes. Next, the supernatant was aspirated and 
disposed of, and the cell pellet was gently re-suspended in 4 °C freezing solution 
CryoStorTM CS10 (Cell Cryogenics Ltd, UK). The cell suspension was transferred 
into pre-chilled cryogenic vials, frozen down at -80 °C overnight or longer and then 
transferred to liquid nitrogen storage. 
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2.2.2.5 Plating hESC cultures for immunocytochemistry studies 
For immunocytochemistry assays the hESC were plated on glass chamber slides 
(Lab-Tek
®
 II, Nalgene Nunc International, part of Thermo Fisher Scientific, UK), 
which were coated with mixture composed of 5% matrigel (Becton Dickinson 
Biosciences, UK) and 95% Hyaluronic acid (Sigma-Aldrich, UK) one day before 
plating. This base was used to minimise background and non-specific sticking of the 
brain homogenate and antibodies to the matrix. Cells were detached from plates (as 
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2.3 BRAIN MATERIALS 
2.3.1 Brain tissue selection criteria 
2.3.1.1  Human brain tissues used throughout the study 
Frozen brain material, from autopsy-proven, neuropathologically well characterised 
cases of vCJD, iCJD
GHT
, sCJD were selected for the studies. A non-CJD (AD) and 
non-CJD World Health Organisation (WHO) (Minor et al., 2004) standard cases 
were used as controls. The basic informations of the tissues are summarised in Table 
2.1. All tissues were handled exclusively in the category 3* containment facility 
according to stringent health and safety protocols. All samples had consent for use in 
research. All samples were taken from the temporal cortex (TC). Tissue homogenates 
(10% w/v) were stored at -80 °C. 
TYPE












vCJD  MM 2B TC 8 F 31
iCJD
GHT
1  VV 2A TC 5 M 27
iCJD
GHT
2 VV 2A TC 5 M 25
iCJD
GHT
3 MV 2A TC 7 M 29
sCJD1 MM 1 TC 4 F 86
sCJD2 MM 1 TC 24 F 57
sCJD3 VV 2A + 1 TC 5 M 74
AD MM not appl. TC 228 M 44
non-CJD (WHO st.) MM not appl. TC not avail. M 68
human
 
Table 2.1: Human brain tissues used in the study 
 
2.3.1.2.  Animal brain tissues used throughout the study 
The study also used animal brain materials. The basic informations of the tissues are 
summarised in Table 2.2 and 2.3. 
The cattle brain tissue was a generous gift from the VLA Biological Archive 
(http://vla.defra.gov.uk/services/ser_tse_archive.htm). The positive BSE cases were 
field suspects that had been identified through passive surveillance. These have been 
transported to VLA Weybridge for cull and extended post mortem examination. The 
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bovine (BSE negative) sample came from a known source with limited or no 
exposure to BSE, reared under controlled conditions and acquired as an additional 
tissue for the VLA archive. 
TYPE SPECIES BREED









bovine BSE1 bovine friesian cow MM BSE suspect positive brain stem
bovine BSE2 bovine friesian cow MM BSE suspect positive brain stem
bovine negative bovine friesian cow MM BSE-non-exposed control negative brain stem
animal
 
Table 2.2: Bovine brain tissues used in the study 
 
Gene-targeted PRNP humanised transgenic mice were used in this study. These 
unique mice lines were developed by the Neuropathogenesis Division of the Roslin 
Institute, Edinburgh, (Bishop et al., 2006), using a methodology called gene 
targeting. The method involves direct replacement of mouse prion protein Prnp open 
reading frame for an exogenous human PRNP sequence. All three variations of the 
human PRNP polymorphisms at the codon 129 (MM, MV, and VV) were established 
in three Ola129 inbred mice lines with an identical genetic background. The human 
PRNP sequence is therefore under the expression control of the host, and encodes the 
human prion protein (Bishop et al., 2006). 
This study employed the humanised transgenic mice line Ola129 carrying the human 
PRNP at codon 129 MM genotype (Hu MM Tg) as the substrate for the PMCA 
reaction. Hu MM Tg substrate sample was either seeded with PrP
Sc 
originating from 
vCJD brain material (a positive control for amplification) or un-seeded (a negative 
control) in PMCA reactions alongside the cell culture test samples. 
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TYPE SPECIES LINE









Hu tg mouse murine 129 Ola MM TSE-non-exposed control negative half brain
animal
 
Table 2.3: Humanised transgenic mice tissue used in the study 
 
 
2.4 ANTIBODIES AND MARKERS USED THROUGHOUT THE STUDY 
Table 2.4 summarises primary and secondary antibodies and markers used for 
experimental investigations in the studies described in this thesis. 
ID Description Epitope Type Application Concentration Provided
Primary mAb's
3F4 anti-prion protein mAb human            
a.a.109-112
mouse IgG2a WB                     
ICC
0.2 µg/ml          
4 µg/ml
Millipore, UK
6H4 anti-prion protein mAb human                    
a.a. 144-152
mouse IgG1κ WB                     
ICC




8H4 anti-prion protein mAb human                    
a.a. 175-185
mouse IgG1κ ICC 2 µg/ml AllPrion, 
Switzerland
Antibodies




ICC 1.6 µg/ml Dako, UK
NANOG anti-human Nanog - 
stem cells pluripotency 
human Nanog - 
homeobox family 
goat IgG ICC 10 µg/ml R&D 
Systems, UK
caveolin 1 caveolae antibody caveolin 1 rabbit 
polyclonal
ICC 2 µg/ml Abcam, UK






ICC 1 µg/ml Abcam, UK
EEA1 early endosome 
antibody
human EEA1 rabbit 
polyclonal
ICC 2 µg/ml Abcam, UK
giantin golgi antibody human giantin rabbit 
polyclonal
ICC 1 µg/ml Abcam, UK
calnexin ER membrane antibody human calnexin i.e. 
IP90, p88 & p90
rabbit 
polyclonal
ICC 20 µg/ml Abcam, UK




ICC 2.25 µg/ml Abcam, UK
LAMP2b lysosome antibody human LAMP2b rabbit 
polyclonal
ICC 1.25 µg/ml Abcam, UK
rab11A protein trafficking 
antibody




ICC 2.5 µg/ml Abcam, UK
DAPI nucleic acid stain AT regions of DNA n/a ICC 0.2 µg/ml Invitrogen, UK
Secondary Ab's
HRP linked Ab horseradish peroxidase 
conjugated Ab
mouse IgG sheep anti-
mouse IgG
WB 0.1 µg/ml GE 
Healthcare, 
UKAlexa Fluor 488 fluorescent bright green 
dye labeled Ab




ICC 10 µg/ml Invitrogen, UK
Alexa Fluor 568 fluorescent bright 
orange-red dye labeled 
Ab




ICC 5 µg/ml Invitrogen, UK
Alexa Fluor 546 fluorescent bright red 
dye labeled Ab




ICC 10 µg/ml Invitrogen, UK
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2.5 CELL CULTURE GENOTYPING 
DNA was extracted from cell culture samples and genetic data obtained by 
restriction fragment length polymorphism analysis (RFLP) of the prion protein gene 
(PRNP) using restriction enzymes specific to the gene polymorphism under 
investigation as described previously (Bishop et al., 2009). 
 
2.5.1 Isolation of DNA 
DNA from cell cultures was obtained by lysis of cell pellets (approximate volumes of 
cell pellets was 40 µl) and column purification using the DNA Blood Mini Kit 
(Qiagen, UK) according to manufacturer’s instruction. 
 
2.5.2 PCR-RFLP Analysis 
Amplification of the PRNP gene sequence (NCBI Accession: AL133396) by the 
polymerase chain reaction (PCR) involved a forward primer (5’-TGA TAC CAT 
TGC TAT GCA CTC ATT C-3’) and reverse primer (5’-GAC ACC ACC ACT AAA 
AGG GCT GCA G-3’) at 5 pM each per reaction (Eurofins MWG Operon, 
Germany), that are specific for a 956 bp sequence. Each reaction contained 2 mM 
MgCl2 (Qiagen, UK), 0.2 mM dNTPs (Promega, UK), and 1 unit of Taq Polymerase 
– HotStarTaq (Qiagen, UK). The thermal cycling program included an annealing 
temperature step-down from 65 °C to 60 °C over ten cycles followed by 30 cycles at 
60 °C. The PCR product was analysed by 1.5% agarose gel electrophoresis and 
SYBR green staining. 
Confirmation of the codon 129 genotype was performed by restriction enzyme 
digestion at 37 °C with NspI (New England Biolabs, UK). This enzyme cleaves the 
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amplicon at PRNP codon 155 and at codon 129 only when the latter sequence codes 
for valine (-GTG-). This allowed for discrimination of the three genotypes: MM, 
MV, and VV by 1.5% agarose gel electrophoresis and SYBR green staining. Images 
were captured using ChemiDoc XRS imaging system (BioRad, UK). 
 
2.6 SAMPLE PREPARATION FOR WESTERN BLOT ANALYSIS 
2.6.1 Brain sample preparation for Western blot analysis 
Detection of PrP
Sc
 in brain homogenates was confirmed by proteinase K digestion 
and Western blot analysis as described previously (Yull et al., 2006). 
In short, wet tissue weighing of 90 – 100 mg was taken from frozen samples. Micro-
pestles (Eppendorf, UK) were used to homogenise each sample at 4 °C in extraction 
buffer (0.5% NP-40, 0.5% sodium deoxycholate, PBS-T pH 7.4, dH2O) to obtain a 
10% weight/volume (w/v) brain homogenate. A non-ionic detergent insoluble pellet 
(nucleocytoskeletal fraction) was cleared from the supernatant by centrifugation at 
2,000 rpm for 5 minutes at 4 °C (Eppendorf 5417R, UK). 100 µl of the detergent 
soluble supernatant (cytoplasmic and membrane fraction) was digested using 
proteinase K (PK) (VWR International, UK) at a final concentration of 50 µg/ml at 
37 °C for 1 hour. Protease digestion was terminated by the addition of Pefabloc SC 
(Roche, UK) to a final concentration of 1 mM and the sample was stored at -80 °C or 
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2.6.2 Harvesting HK cells for Western blot analysis  
2.6.2.1 Detecting PrP
C 
in HK cell culture  
Cells at around 90% confluence in a T25 flask were washed twice with 4 °C PBS 
then lysed for 15 minutes with 100 µl of 4 °C extraction buffer and collected using a 
cell culture scraper (Fisher Scientific, UK) into safe-lock Eppendorf tubes. An 
appropriate volume of cell culture suspension (1-5 µl) was mixed with sample buffer, 




in cultures exposed to brain homogenate 
Cells at around 90% confluence were washed twice with 4 °C PBS then lysed for    
15 minutes with 100 µl of 4 °C extraction buffer and collected using a cell culture 
scraper into safe-lock Eppendorf tubes. Then the samples were digested with PK at a 
concentration 50 µg/ml at 37 °C for 60 minutes. The digestion was terminated by 
incubating with 1 mM Pefablock SC. A centrifugation step of 14,000 rpm for 60 
minutes at 4 
o
C was applied to concentrate the lower levels of PrP
Sc
 in the samples 
(Lee et al., 2000). The pellets were resuspended in an appropriate volume of sample 
buffer boiled at 100 °C for 10 minutes and then analysed by Western blotting.  
 
2.6.3 Detection of PrP
Sc 
in culture medium and cell PBS washes 
Brain spiked medium (or control medium) incubated with cell cultures for the 
desired time period was aspirated and transferred into safe-lock Eppendorf tubes. 
Then the cells were rinsed with 1 ml of PBS (4X) which was then also transferred to 
individual safe-lock Eppendorf tubes. The samples were PK digested (concentration 
50 µg/ml) at 37 °C for 60 minutes. The digestion was terminated by incubation with 
1 mM Pefablock SC, pellets were collected by centrifugation at 14,000 rpm for 60 
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minutes. The supernatant was aspirated and disposed of. Pellets were resuspended in 
an appropriate volume of sample buffer, boiled at 100 °C for    10 minutes and 
analysed by Western blotting.  
 
2.7 WESTERN BLOT ANALYSIS 
An equal volume of 4X NuPAGE LDS sample buffer (Invitrogen, UK) was added to 
each sample aliquot to a final concentration 1X and boiled at 100 °C for 10 minutes. 
Samples were briefly collected by centrifugation and loaded onto a NuPAGE Novex 
10% Bis-Tris gel (Invitrogen, UK) and subjected to electrophoresis for 50 minutes at 
200 volts using pre-set gel cassettes (Invitrogen, UK) and NuPAGE MES-SDS 1X 
running buffer (Invitrogen, UK). A benchmark (Pre-stained Protein Ladder, 
Invitrogen, UK) and a Magic Marker (Western Protein Standard, Invitrogen, UK) 
were run alongside the samples. The former is visible during electrophoresis and on 
the transfer, the latter is detected by the secondary antibody on the blot. 
The gels were then electroblotted onto polyvinylidene diflouride (PVDF) membrane 
(Hybond-P, Amersham Pharmacia Biotechnology, UK) for 1 hour at 30 volts. Prior 
to electrobloting the PVDF membrane was wet in MeOH (Fisher Scientific, UK), 
rinsed with dH2O and equilibrated for 10 minutes in 1X Transfer buffer consisted of 
4% 20X NuPAGE
® 
Transfer Buffer (Invitrogen, UK), 16% MeOH, 80% dH2O. Gel 
was sandwiched into a transfer cassette in the following manner: 3 sponges pre-
soaked in transfer buffer/2 pre-soaked blotting papers/gel/PVDF membrane/2 pre-
soaked blotting papers/3 pre-soaked sponges. 
For immunodetection, the PVDF membrane was blocked with solution of 5% (w/v) 
non-fat milk powder (Sigma-Aldrich, UK) dissolved in TBS-T (2 mM Tris/HCl, pH 
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7.6, 150 mM NaCl, containing 0.1% Tween 20) (Sigma-Aldrich, UK) for 60 
minutes. Then the PVDF membrane was washed three times with TBS-T and 
incubated with anti-PrP monoclonal antibody 3F4 or 6H4 diluted in TBS-T for 60 
minutes. The PVDF membrane was washed three times (3 minutes each wash) with 
TBS-T and incubate with horseradish peroxidise conjugated sheep anti-mouse IgG 
antibody diluted in TBS-T for 60 minutes. Following four washes (5 minutes each) 
in TBS-T, the membranes were developed using ECL Plus (Amersham Pharmacia 
Biotechnology, UK) and imaged on Hyperfilm ECL X-ray film (Amersham 
Pharmacia Biotechnology, UK) using a Konica-Minolta Hyperprocessor. X-ray film 
images were captured using a Bio-Rad GS-800 scanning densitometer. 
 
2.8 PROTEIN-MISFOLDING CYCLIC AMPLIFICATION (PMCA) 
2.8.1 Preparation of substrate 
Preparation of the substrates for PMCA is the most critical step in achieving 
successful amplification. HK cell homogenates were prepared as a substrate for 
PMCA as follows: confluent cell cultures in T25 flasks were washed twice with 4 °C 
sterile PBS and scraped in 1 ml of PBS using cell scraper. The cell suspension was 
collected in a 50 ml Falcon tube (Corning, UK) and centrifuged at 2,400 rpm for 15 
minutes at 4 °C using rotor 11180 in Sigma 3-16K centrifuge. The supernatant was 
aspirated and the cell pellet was homogenised (10% w/v) at 4 °C in PMCA 
conversion buffer (PBS, 0.15 M NaCl, 1% Triton X-100, EDTA, 1X Complete
TM
 
protease inhibitor cocktail-Roche, UK) by vortexing and used straight away as a 
substrate for PMCA. The Complete
TM
 Mini EDTA-free protease inhibitor is a 
mixture of several protease inhibitors and was used for inhibition of proteolytic 
activity where EDTA may interfere with protein stability, specially inhibition of 
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serine, cysteine, but not metalloproteases at a concentration 1 tablet/10 ml PMCA 
conversion buffer.  
Humanised MM transgenic (Hu MM Tg) sagittally bisected frozen half brain tissue 
(stored at -80 °C) was homogenised (10% w/v) using an Eppendorf micro-pestle in 4 
°C PMCA conversion buffer. The homogenate was cleared of particulate matter by 
centrifugation at 2,000 rpm for 10 seconds at 4 °C and the collected supernatant was 
used straight away as a substrate for PMCA.  
 
2.8.2 Preparation of brain extracts for PMCA experiment (seeds) 
Human brain (temporal cortex) or animal brain tissues were homogenised in 4 °C 
PMCA conversion buffer at 10% w/v using eppendorf micro-pestles. The 
homogenates were cleared of particulate matter by centrifugation at 4,300 rpm for    
5 minutes at 4 °C, supernatants were divided into aliquots and retained for further 
use in PMCA experiment at -80 °C. An aliquote of the sample was PK digested and 
analysed by Western blot as described in section 2.6.1 and 2.7 
 
2.8.3 PMCA reaction 
Design of PMCA reactions was as follows: substrate was seeded with a dilution of 
brain homogenate (previously titrated by Western blot) such that the seed material 
contained sufficient PrP
res
 to be detectable at the lower end of the linear range of a 
standard Western blot. Reactions were prepared in duplicate. The negative control 
(unamplified aliquot) was immediately frozen at -80 °C and the PMCA aliquot was 
subjected to the PMCA reaction in a sealed 96 well PCR plate (Sarsted, UK). The 
experiment reaction consists from 48 cycles of 40 seconds sonication at 80% total 
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power output and 29 minutes 20 seconds incubation at 37 °C for 24 hours using a 
Sonicator (Model 3000, Misonix, USA). 
 
2.8.4 Analysis of PMCA product by western blotting 
SDS was added at a final concentration of 0.04% to thawed non-PMCA control 
reaction and to the PMCA reaction products. This was followed by PK digestion of 
samples at a concentration 50 μg/ml at 37 °C for 60 minutes. The digestion reaction 
was terminated by addition of 1 mM Pefabloc SC. Samples were mixed with an 
appropriate volume of 4X NuPAGE LDS sample buffer and boiled at 100 °C for    
10 minutes before Western blot analysis.  
 
2.9 INFECTION STUDIES OF HK CELLS  
2.9.1  Preparation of brain homogenates for cell exposure studies 
Brain tissues were homogenised at 10% (w/v) in a sterile 4 °C PBS/5% glucose 
solution using Eppendorf micro-pestles. The homogenates were cleared of particulate 
matter by centrifugation at 2000 rpm for 5 minutes at 4 °C. Supernatants were 
divided into aliquots and stored at -20 °C for further use. One aliquot of each brain 
homogenate was retained, PK digested and analysed by Western blotting for the 
detection and typing of PrP
Sc
 in the sample. 
HK cells were challenged with infectious brain homogenates in many sets of 
experiments, using different methodologies previously described to result in 
successful infections in vitro (Nishida et al., 2000; Sabuncu et al., 2003; Cronier et 
al., 2004; Lehmann and Milhavet, 2004; Weissmann and Aguzzi, 2005; Milhavet et 
al., 2006; Dlakic et al., 2007; Courageot et al., 2008). Cells were incubated with 
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brain homogenates and then tested for PrP
Sc 
production after each passage or at 
stated time points. 
 
2.9.2 Attempts at infection of HK cells 
General method 
HK cells were routinely cultured in T25 flasks and after reaching 50-60% 
confluence, the cultures were exposed to brain spiked media prepared according to 
one of following descriptions (or see Tables 2.5-11 in this section - 2.9.2). The 
method by which cells were harvested and pre-treated for detection of PrP
Sc
 by 
Western blot is described in section 2.6.2.2.  
 
Methodological variations 
2.9.2.1 First set  
♦ In the first set of experiments the HK cells were challenged with 0.1% dilution of 
disease brain homogenates (Table 2.5: 1.1–1.8) according to the published methods 
(Sabuncu et al., 2003; Cronier et al., 2004; Milhavet et al., 2006; Dlakic et al., 
2007). Cells were exposed to medium containing brain homogenate for 24 hours. To 
avoid contaminations by conventional agents partial decontamination of the 
homogenates with two alternative methods was attempted (Lehmann and Milhavet, 
2004; Milhavet et al., 2006): 
a). The 10% brain homogenate was warmed for 20 minutes at 60 °C in a heat-block 
and the clumps of brain tissue resulting from the heating were resuspended and 
broken up. 
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A few flasks of HK cells were also incubated with 0.1% dilution of the brain 
homogenate in the medium without any pre-treatment.  
Cells were harvested after 16 days of culturing for Western blot analysis using the 
6H4 antibody (the medium had been changed five times and cells had been passaged 
once). 
16 days: 1 passage, 5 med. changes (1x time point)24 hours+0.1% AD1. 
8








16 days: 1 passage, 5 med. changes (1x time point)24 hours+0.1% vCJD1.
5
16 days: 1 passage, 5 med. changes (1x time point)24 hours+0.1% vCJD1. 
4

























Table 2.5: Conditions used in the first set of HK cell challenges 
 
2.9.2.2 Second set 
♦ The second set of HK cell challenges (Table 2.6: 2.1-2.16) tested three different 
concentrations of infectious brain homogenates – 0.1%, 0.5% and 1% treated with 
1X extraction buffer (0.5% NP-40, 0.5% sodium deoxycholate, PBS-T pH 7.4, 
dH2O) or 1X Triton-DOC lysis buffer (150 mM NaCl, 0.5% Triton X-100, 0.5% 
sodium deoxycholate, 50 mM Tris-HCl – pH 7.5, 2 mM EDTA + protease inhibitors) 
according to published methods (Nishida et al., 2000; Milhavet et al., 2006). Cells 
were also exposed to untreated brain homogenates. The incubation time in this 
experiment was 24 hours. In this set, freshly passaged cells were also exposed to 
infectious brain homogenates – a pellet of HK cells was gently resuspended in brain 
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spiked medium and cells in this suspension were then plated into fresh culture flask. 
Cells were harvested for Western blot analysis after 26 days of culturing (medium 
had been changed 10 times and cells were passaged once). 
 
26 days:1 passage, 10 med. changes (1x time point)24 hours++1% AD2.
16
26 days:1 passage, 10 med. changes (1x time point)24 hours++1% AD2. 
15
















26 days:1 passage, 10 med. changes (1x time point)24 hours+0.5% AD2. 
10




26 days:1 passage, 10 med. changes (1x time point)24 hours+0.1% AD2.
8













































Table 2.6: Conditions used in the second set of HK cell challenges  
*- freshly passaged cells 
 
2.9.2.3 Third set 
♦ The third set of HK challenges (Table 2.7: 3.1-3.7) included modifications in the 
treatment of the brain homogenates prior to incubation with the HK cells. According 
to successful infection using the method of Courageot et al., (2008) the 10% w/v 
disease brain homogenates were homogenised in a Ryboliser (FastPrep FP120, 
Germany) for 45 seconds at speed 5.5 and then subsequently sonicated by a 
Sonicator (Model 3000, Misonix, USA) at total power output ~ 300 watts for 1 
minute. These treated brain homogenates were diluted into culture media in three 
different concentrations: 0.1%, 0.5% and 2%. The inoculum was removed after 24 or 
68 hours of incubation with the cells and cells were harvested for Western blot 
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analysis after 22 days of culturing (the medium had been changed eight times and 
cells were passaged once).  
22 days:1 passage, 8 med. changes (1x time point)24 hours+++2% AD3.
7












22 days:1 passage, 8 med. changes (1x time point)68 hours+++0.1% AD3.
3























Table 2.7: Conditions used in the third set of HK cell challenges 
*- freshly passaged cells 
 
2.9.2.4 Fourth set 
♦ In the fourth set of experiments the HK cells were challenged (Table 2.8: 4.1-4.14) 
with ribolysed and sonicated disease brain homogenates at five different 
concentrations (2%, 1.5%, 1%, 0.5% and 0.1%). After 24 hours, the inoculum was 
removed, cells were washed and fresh (brain-free) culture medium was added. The 
challenged cells were then cultivated for four days, then split 1:2 and cultured for 
additional four days when they were harvested for Western blot analysis. The 
experiment was carried out in duplicate. Approximately every five days one flask 
from each type of the challenge was used for subcultivation, whilst the other was 
used to prepare a cell lysate for Western blot analysis (see Figure 2.1). The cells were 
cultured for 42 days in total (medium had been changed 15 times and cells passaged 
eight times).  
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Figure 2.1: Methodology used for detecting any de novo formed PrP
Sc
 by HK cells 
exposed to infectious brain homogenate 
 
42 days:8 passages, 15 med. changes (8x time point)24 hours+++2% AD4.
14




42 days:8 passages, 15 med. changes (8x time point)24 hours+++2% vCJD4. 
12































































Table 2.8: Conditions used in the fourth set of HK cell challenges 
 *- freshly passaged cells 
 
2.9.2.5 Fifth set 
♦ The fifth set of experiments the HK cell challenges (Table 2.9: 5.1-5.13) included 
using an immobilised infectious brain homogenate. The 10% w/v brain homogenates 
were either treated with minute amount of Triton X-100, or rybolised and 
subsequently diluted in PBS. The brain dilutions (100 μl of either a 1% or 0.5 % 
homogenate) were “painted” on the bottom of the T25 flasks and dried overnight in 
antiseptic conditions. The next day, the flasks were washed once with PBS and HK 
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cells were plated onto the base thus prepared. Cells were incubated with inoculum 
for four days, then rinsed with PBS, supplied with fresh culture medium and further 
maintained for three days before first harvesting for Western blot analysis. The 
experiment was carried out in duplicate. Cells were harvested for PrP
Sc
 analysis by 
Western blot six times and passaged (1:2) five times over the 26 days of culturing.  
26 days:5 passages, 9 med. changes (6x time point)4 days+++0.5% AD5.
13




26 days:5 passages, 9 med. changes (6x time point)4 days+++0.5% vCJD5. 
11
















26 days:5 passages, 9 med. changes (6x time point)4 days+++0.5% AD5. 
6




26 days:5 passages, 9 med. changes (6x time point)4 days+++0.5% vCJD5. 
4































Table 2.9: Conditions used in the fifth set of HK cell challenges 
 
2.9.2.6 Sixth set 
♦ In sixth set of experiments (Table 2.10: 6.1) the pellet of HK cells was gently 
resuspended in ribolysed and sonicated 0.5% iCJD2 brain spiked medium with 
omitted Penicillin/Streptomycin/Amphotericin antibiotics/antimycotics and cells 
were plated into fresh cell culture flasks. This strategy was inspired by preliminary 
results from a cell culture studies (Mange et al., 2000a; Mange et al., 2000b; Mange 
and Lehmann, 2002; Weissmann and Aguzzi, 2005; Soler et al., 2008). Freshly 
passaged cells were incubated with 2 ml of this inoculum for four days (3 days, then 
2 ml of fresh, no antibiotics containing, medium was added and cells were cultured 
for one additional day). Then the cells were washed, given fresh, no antibiotics 
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containing, medium and cultured for another 4 days before first harvesting for 
Western blot analysis. The experiment was carried out in duplicate. One flask of cells 
was harvested for Western blot analysis and the other flask was split into two flasks 
and cultured until confluent when harvesting and splitting process was repeated. 
Cells were passaged four times and harvested for Western blot analysis at five time 
points in total (29 days, passage every ~ 5 days). 



















Table 2.10: Conditions used in the sixth set of HK cell challenges 
*- freshly passaged cells 
 
2.9.2.7 Seventh set  
♦ The seventh set of experiments (Table 2.11: 7.1-7.2) investigated the potential of 
increasing the cell susceptibility to infection with prions after being cultured in 
nutrient-low conditions. HK cells were either maintained in normal medium 
(containing 10% Foetal Calf Serum, FCS) or nutrition-low medium (containing 0.5% 
FCS) for 3 days prior exposure to growth hormone associated sonicated 1% iCJD1 
brain spiked medium. The brain homogenate was diluted in a medium either 
containing 10% or 0.5% FCS, according to the type of medium cells were cultured 
prior to exposure. The experiment was carried out in duplicate. Cells were incubated 
with the brain spiked medium for 48 hours. Cells were harvested for Western blot 
analysis using 3F4 primary antibody at 24 and 48 hours time period of continuous 
exposure. The brain spiked medium was then removed, cells were rinsed with PBS 
and further maintained with fresh culture medium (containing either 10% or 0.5% 
FCS) for 3 days.  At this time point (3
rd
 day of recovery) the challenged HK cells 
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were also harvested for Western blot analysis. In the next medium change, all the 
challenged cells were given complete culture medium (containing 10% FCS). 
Medium changes took places every three days. Analysis for PrP
Sc










 and second passage on 40
th
 day of recovery. Cells were 
passaged two times and harvested for Western blot analysis at eight time points in 
total (42 days, passage every 20 days). 
In this assay the medium cultured with the cells was also retained and analysed for 
PrP
Sc
 by Western blot (as described in section 2.6.3). 






























 UPTAKE BY HK CELLS ANALYSED BY WESTERN BLOT  
HK cells were challenged with dilutions of crude sonicated extract of iCJD or vCJD 
brain homogenates (preparation described in section 2.11.1.1). The exposed cells 
were harvested (method described in section 2.6.2.2) at early and late time points 
during continuous exposure and analysed by Western Blot. In addition to the exposed 
cells, the brain spiked medium (incubated with the cells for defined time periods), the 
1
st
 PBS wash and 4
th
 PBS wash were collected (section 2.6.3) and analysed by 
Western blot. Four different experimental designs were used (section 2.10.1-4). 
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2.10.1 Scheme of HK cell culture analysis after incubation with brain spiked 
medium (time points: 30 minutes, 1, 2, 4, 6, 24 and 48 hours) 
HK cells were exposed to a complete cell culture medium containing prion disease 
brain homogenate (iCJD1 or vCJD). The cells were analysed for cell associated PrP
Sc
 
at various time points after continuous incubation with brain-spiked medium          
(30 minutes, 1, 2, 4, 6, 24, and 48 hours) (Figure 2.2). Samples analysed at each time 





 PBS wash (carried out prior to cell harvesting). Samples were treated with PK 
for 60 minutes at 37 °C at a concentration 50 μg/ml, then pelleted by centrifugation 
at 14,000 rpm for 60 minutes and subjected to Western blot analysis with anti-PrP 
mAb 3F4. 
 
Figure 2.2: Scheme of HK cell culture analysis after incubation with brain spiked 
medium (time points: 30 minutes - 48 hours) 
 
2.10.2 Scheme of HK cell culture analysis after incubation with brain spiked 







cell passage post exposure – 51 days) 
Pelleted HK cells were gently resuspended in complete cell culture medium 
containing iCJD1 brain homogenate. Cells were plated into fresh cell culture flasks 
and continuously incubated with the infectious medium until harvested for analysis 
of cell associated PrP
Sc
 at specific time points (1, 3, 6, 24, and 48 hours). After        
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48 hours of continuous exposure, the cells were extensively washed, split at a ratio of 
1:2 and allowed to grow until confluent. At this point one flask of cells was 
harvested as another time point for Western blot analysis and the other flask was 
again split into two further flasks. Cells were again allowed to grow until confluent 
when harvesting and splitting process was repeated. Samples analysed from each 
time points (Figure 2.3) were: exposed cells (extensively washed), medium 




 PBS wash (carried out prior cell harvesting). 
Samples were treated with PK for 60 minutes at 37 °C at a concentration 50 μg/ml. 
Then insoluble proteins were pelleted by centrifugation at 14,000 rpm for 60 minutes 
and subjected to Western blot analysis with anti-PrP mAb 3F4. 
 
Figure 2.3: Scheme of HK cell culture analysis after 48 h continuous incubation with 
iCJD brain spiked medium followed by culturing of the cells for 51 days  
 
2.10.3 Scheme of HK cell culture analysis after incubation with brain spiked 
medium (time points: 1, 3, 6, 24 hours of continuous exposure followed by a 24 




 passage – 177 
days) 
HK cells were continuously exposed to the complete cell culture medium spiked with 
iCJD1 brain homogenate and analysed for cell associated PrP
Sc
 at 1, 3, 6 and 24 hours 
time points. At the 24 hour time point the cells were extensively washed and allowed 
to grow in fresh (brain homogenate free) medium for 24 hours – recovery (48 hours 
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time point). Then the cells were split at ratio 1:2 and cultured until confluent. One 
flask of cells was harvested for Western blot analysis, the other flask was again split 
into two flasks and the cells were allowed to grow until confluent when harvesting 
and splitting process was repeated. This process was repeated until passage 19 (p19, 
177 days post exposure to brain homogenate) (Figure 2.4) when cells became 
senescent and stopped dividing. At this point the experiment was terminated. 
Samples analysed from each time point: exposed cells (extensively washed), medium 




 PBS wash (carried out prior cell harvesting). 
Samples were treated with PK for 60 minutes at 37 °C at a concentration 50 μg/ml, 
then insoluble proteins were pelleted by centrifugation at 14,000 rpm for 60 minutes 
and subjected to Western blot analysis with anti-PrP mAb 3F4.  
 
Figure 2.4: Scheme of analysis of cell associated PrP
Sc
 after HK cells continuous 
incubation with iCJD brain homogenate for 24 hours followed by a 24 hour recovery 
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2.10.4 Scheme of HK cell culture analysis after incubation with brain spiked 
medium (time points: 1, 5, 24, 48 hours of continuous exposure followed by a 1, 3, 
24, 48, 120 hours recovery and 1
st
 passage) 
HK cells were continuously exposed to complete cell culture medium containing 
iCJD1 brain homogenate up to 48 hours and analysed for cell associated PrP
Sc
 at 1, 5, 
24, and 48 hours of the exposure time. The cells were then extensively washed and 
allowed to grow in fresh complete medium up to 120 hours with three medium 
changes - recovery. Cells were analysed for cell associated PrP
Sc
 at 1, 3, 24, 48, and 
120 hours of the recovery time. Subsequently, the cells were split at ratio 1:2 and 
grown until confluent when analysed as another time point (1
st
 passage) (Figure 2.5). 
Samples analysed from each time point were: exposed cells (extensively washed), 




 PBS wash (carried out prior cell 
harvesting). Samples were treated with PK for 60 minutes at 37 °C at a concentration 
50 μg/ml, then insoluble proteins were pelleted by centrifugation at 14,000 rpm for 
60 minutes and subjected to Western blot analysis with anti-PrP mAb 6H4. 
 
Figure 2.5: Scheme of analysis of cell associated PrP
Sc
 after HK cells continuous 
incubation with iCJD brain homogenate for 48 hours followed by a 120 hour recovery 
and one cell passage 
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2.10.5 Densitometric evaluation of PrP
Sc
 uptake by HK cells analysed by Western 
blot 
The uptake of PrP
Sc
 by HK cells exposed to medium containing prion diseased brain 
homogenates was monitored by Western blot analysis and the results were evaluated 
by densitometry. This was performed to provide a quantitative assessment of any 
increase of the cell associated PrP
Sc 
with time of cell exposure to prion spiked 
medium. However, it is important to note the limitations of this approach and that 
Western blotting is well recognised to be a semi-quantitative method at best.  The 
dynamic range of Western blotting (as performed in this thesis) is circumscribed by 
the use of X-ray film, which has a linear range of less than 1 log (as can be 
determined empirically). In practice the main constraint tends to be that of saturation 
at high signal, when all local silver grains have been activated and further activation 
only results from lateral spread and increased size of a band rather than increased 
density. Because PrP
res
 typically has a three band pattern, each with different 
abundance, the linear range of response is further constrained when all three bands 
are being measured. The background signal on individual blots is also an important 
consideration since this can vary and must be subtracted before data is compared. 
Individual identical and non-identical experiments were therefore analysed 
seperately. For these reasons the data can only legitimately be viewed in support of a 
trend rather than as a quantitative measure.  
The analysis was carried out as follows: the images from the X-ray films were 
scanned using a ChemiDoc™ XRS+ System (Bio-Rad) with Image Lab
TM
 2.0 
software and the manufacturer’s instructions. The individual bands were then 
bracketed using the volume tool of the software and analysed. A background value 
for each blot was then determined and subtracted from the samples on the individual 
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blots. The volume intensity is the pixel value of each investigated band. The 







 UPTAKE STUDIES ANALYSED BY IMMUNOCYTOCHEMISTRY  
2.11.1 Preparation of brain spiked medium 
2.11.1.1  Cell culture medium spiked with sonicated brain homogenates 
Brain tissues were homogenised (10% w/v) in 4 °C PBS/5% glucose (Fisher 
Scientific, UK) using Eppendorf micro-pestles. The homogenates were cleared of 
particulate matter by centrifugation at 2,000 rpm for 5 minutes at 4 °C. Then they 
were disrupted by sonication at total power output ~ 300 watts for 1 minute, and 
diluted into complete cell culture medium.  
2.11.1.2  Cell culture medium spiked with rybolised, sonicated and filtered brain 
homogenates 
Brain tissues were homogenised (10% w/v) in 4 °C PBS/5% glucose using 
Eppendorf micro-pestles and then ribolysed for 45 seconds at speed 5.5. The 
homogenates were cleared of particulate matter by centrifugation and sonicated as 
described in section 2.11.1.1. The resultant homogenate was filtered by spin filters - 
pore size 220 nm, (Agilent Technoligies, UK) or pore size 450 nm, (Thermo Fisher 
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2.11.2 Cell culture exposure to brain spiked medium analysed by 
immunocytochemistry 
2.11.2.1  Continuous exposure studies 
Routinely, cells were exposed continuously to brain homogenate at a final w/v 
concentration of 1% in complete culture medium for desired time periods up to       
72 hours, followed by immunocytochemistry for prion protein (and other proteins) 
and analysed by confocal microscopy. 
2.11.2.2  Continuous exposure and recovery studies 
In the case of recovery studies the brain spiked medium was withdrawn (after desired 
continuous exposure), cells were extensively washed with 1X HBSS and allowed to 
continue growing in the complete cell culture medium (control medium), which was 
changed every 24 h. Cells were immunostained at desired recovery time points and 
also passaged, and further cultured until the culture reached 70% confluence, and 
then immunostained for PrP.  
2.11.2.3  PrP
Sc
 “pulse-chase” studies 
The method is illustrated in Figure 2.6. Cells were exposed to a medium containing 
6H4 (1 µg/ml), either control (unspiked) or brain spiked (sonicated 1% brain 
homogenate), for 30 minutes at 4 °C and additional 15 minutes at 37 °C, to initiate 
the internalisation process – “pulse” (A). Then the cells were extensively washed to 
remove any material deposited on the cells surface and further cultured in control 
medium for desired time period – “chase” (B). The cells were then immunostained at 
a different time point of the “chasing” phase. It should be noted that the incubation 
with anti-prion primary antibody is no longer needed in the immunostaining 
protocol. The fixed and permeabilised cells were blocked and then incubated with the 
FITC secondary antibody Alexa 488 labelling the uptaken PrP-6H4 complexes.  
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Another important fact is that the immunocytochemical procedure often included 





(D). Subsequently, the samples were washed and immunostained with cell organelle 
antibodies overnight, which were revealed by incubation with Alexa 546 for 60 
minutes. The nuclei were counterstained with DAPI and the slides were then 
mounted with mounting media and examined by confocal microscopy.  
 
Figure 2.6: Diagrammatic representation of the “pulse and chase” experiment 
Cells were incubated with either control or brain spiked medium containing the anti-PrP 
primary antibody 6H4 (1 µg/ml) for 30 minutes at 4 °C to create an antigen/antibody 
complex. Then the cells were placed at 37 °C for additional 15 minutes to initiate the 
internalisation of the antigen/antibody complex – “pulse” (A). The cells were then 
extensively washed with 1X HBSS solution, fresh control medium was added to cultures and 
cells were subsequently cultured at 37 °C for desired time period – “chase” (B). Then the 
medium was aspirated, cells were extensively washed and immunolabeled as described in 
section 2.12.5. In short, cells were fixed, permeabilised, blocked and either pre-treated with 
guanidine - enhancing the PrP
Sc
 signal (D) or not treated (C), followed by incubation with 
Alexa 488 for 60 minutes. Subsequently the samples were washed and immunostained with 
cell organelle antibodies overnight, which were revealed by incubation with Alexa 546 for 
60 minutes. The nuclei were counterstained with DAPI, slides were then mounted with 
mounting media and examined by confocal microscopy.  
 
2.12 IMMUNOCYTOCHEMISTRY (ICC) 
2.12.1 Immunocytochemistry of live cells  
Cell culture samples for live cell staining were washed with PBS, blocked with 
blocking solution 3% bovine serum albumin (BSA, Invitrogen, UK) in Dulbecco’s 
PBS (D’PBS, Invitrogen, UK), and incubated with the primary antibody 6H4 for     
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60 minutes at RT with shaking at 60 rpm in an orbital shaker. The cells were washed 
and subsequently incubated with the Alexa 488-conjugated secondary antibody for 
60 minutes in blocking solution, followed by counterstaining with DAPI (Invitrogen, 
UK) for 15 minutes. The slides were mounted with Vectashield mounting media 
(Vector Laboratories LTD, UK) and examined by confocal microscopy. 
 
2.12.2 Immunocytochemistry of fixed and permeabilised cells 
Cell cultures intended to be immunostained fixed and permeabilised were washed 
with PBS (Invitrogen, UK), fixed in chamber slides for 10 minutes with                 
4% paraformaldehyde (PFA, GPR, UK) in PBS and permeabilised with 0.1% Triton 
X-100 (Sigma-Aldrich, UK) in PBS. The cells were then washed and blocked with 
blocking solution 3% BSA in D’PBS, incubated with the PrP primary antibody in 
blocking solution for 30 minutes at 37 
o
C and then 30 minutes at RT with shaking at 
60 rpm in an orbital shaker. The cells were subsequently incubated with the Alexa 
488-conjugated secondary antibody for 60 minutes followed by counterstaining with 
DAPI for 15 minutes. The slides were mounted with Vectashield mounting media 
and examined by confocal microscopy.  
 
2.12.3 Immunocytochemistry of fixed, permeabilised and denaturated cells 
Cells were washed with PBS, fixed with 4% PFA in PBS and permeabilised with 
0.1% Triton X-100 in PBS. Protein denaturation was performed by incubation with 
PK at a concentration 0.3 µg/ml for 9 minutes at 37 °C, digestion was stopped by 
incubation with 1mM Pefabloc SC for 5 minutes and samples were subsequently 
incubated with 4 M Guanidine thiocyanate (Gnd, Sigma-Aldrich, UK) for 10 minutes 
Chapter 2   Materials and Methods 
  102 
at RT with shaking. The cells were then washed and blocked with blocking solution 
3% BSA in D’PBS, and incubated with primary antibodies to PrP in blocking 
solution for 30 minutes at 37 
o
C and then 30 minutes at RT with shaking at 60 rpm in 
an orbital shaker. Alexa 488-conjugated secondary antibody was used for 60 minutes 
followed by counterstaining with DAPI for 15 minutes. The slides were mounted 
with Vectashield mounting media and examined by confocal microscopy.  
 
2.12.4 Immunocytochemistry of sub-cellular localisation by double labelling  
Cells intended for double immunostaining (PrP and one of following proteins: 
GFAP, NANOG, EEA1, giantin, calnexin, LAMP1, LAMP2b, rab11A, caveolin1, 
and clathrin) were washed, fixed and permeabilised, (denaturated if desired, as 
described in the section 2.12.3). Immunostaining for PrP was performed as described 
previously in section 2.12.2). The cells were then subsequently incubated with an 
antibody against the second cell protein overnight at 4 
o
C with shaking at     60 rpm 
in an orbital shaker, followed by the Alexa 546-conjugated secondary antibody 
incubation for 60 minutes. The cells were counterstained with DAPI for    15 
minutes. The slides were mounted and examined by confocal microscopy. 
 
2.12.5 Immunocytochemistry “pulse/chase” experiments  
The processing of cells for immunostaining in the PrP pulse/chase experiments was 
carried as described previously (sections 2.12.2 or 2.12.3) except that no primary PrP 
antibody incubation step was performed and the cells were processed directly to 
blocking and labelling with Alexa 488. Then samples were incubated overnight at    
4 
o
C, with shaking with one of following primary antibodies: EEA1, giantin, 
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calnexin, LAMP1, LAMP2b, rab11A, caveolin1, and clathrin, followed by 
incubation with the Alexa 546-conjugated secondary antibody for 60 minutes. The 
nuclei were courterstained with DAPI for 15 minutes. The slides were mounted with 
Vectashield mounting media and examined by confocal microscopy.  
 
2.13 CONFOCAL MICROSCOPY  
Immunostained cultures were examined at 23°C using a laser scanning confocal 
microscope Nikon Eclipse TE2000-U with a 40X 0.75 Plan Fluor DIC M/N2 dry and 
60X 1.40 Plan Apo VC oil objectives. Images were exported via EZ-C1 Gold version 
3.30 software in an 8-bit tagged image file format. The entire hESC study was 
analysed with an LSM5 Pascal laser scanning confocal Zeiss microscope.  
Image files were processed with ImageJ (National Institute of Health) and Photoshop 
(Adobe) programs without altering settings for brightness/contrast or any other 
colour manipulations. 
 
2.14 QUANTITATIVE IMAGE ANALYSIS AND STATISTICAL ASSESSMENT 
OF THE PRP
SC
 COLOCALISATION DATA 
Two methods were used to test the true colocalisation of PrP
Sc
 with cell organelles. 
The first was a pixel-based method in which the observed amount of green and red 
pixel colocalisation was compared to the value expected to arise if the colour pixels 
were uniformly randomly distributed. The statistical significance of the result was 
then determined.  
In the second method colocalisation was assessed using the particle-based approach 
of Bolte and colleagues (Bolte et al., 2006), which assesses the distance between the 
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centres of mass of particles in the image. Manders’ M1 coefficient (Manders, et al., 
1992) was then calculated. Both methods were applied to representative examples of 
the data generated in the immunocytochemistry experiments.  
 
2.14.1 Pixel-based colocalisation analysis 
The analysis was carried out on three individual images of each time point from one 
experiment. The pixel colocalisation analysis was carried out on three pictures 
(containing 1 to 4 cells) in which HK cells had been exposed to vCJD brain 
homogenate and then double immunostained for markers of early endosomes, Golgi 
complex or lysosomes and PrP
Sc 
at 1h, 24h, 48h, 72h post-exposure (36 images in 
total). The endoplasmic reticulum data was not included in the analysis because the 
immunostaining of this cellular organelle was too weak to bear quantitative 
colocalisation analysis.  
Analysis of colocalisation of the exogenous PrP
Sc
 within the cellular organelles was 
carried out using the ImageJ program, “Colocalisation Analysis” plugin (National 
Institute of Health, USA). The method evaluates observed colour pixels for cellular 
organelles (red) and PrP
Sc
 (green) and cell nuclei (blue) from the total pixel value. 
The measured pixel values enabled the calculation of the expected random 
distribution of colocalisation measure and the observed colocalisation of green 
(PrP
Sc
) and red (cell organelle) pixels.  
 
The observed colocalisation was measured as follows: 
1. Open picture in ImageJ→Image→Colour→Split channels 
- Red channel picture→Analyse→Histogram→Sum all red pixel values 
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- Green channel→Analyse→Histogram→Sum all green pixel values 
Values for Mean and Standard deviation (Σ) were recorded to calculate Fay’s 
threshold = Mean + 2xΣ, following (Fay et al., 1997). This is a heuristic for setting a 
threshold for each channel that aims to eliminate background noise. It was used to 
calculate observed colocalisation values for all images.  
2. Plugin→Colocalisation analysis→Colocalisation finder→OK 
A picture will reflect colocalisation points in a correlation diagram. The colour signal 
thresholds were then adjusted according to value calculated by the Fay’s formula. 
The plugin then evaluated observed colocalisation of the red and green pixels. 
 
The expected colocalisation was calculated as follows: 
1. The value of total red and total green pixels was measured in each channel. The % 
of red pixels was calculated as the total red pixels/total number of pixels. The % of 
green pixels was calculated as the total green pixels/total number of pixels. 
2. The value of expected random distribution of colocalisation was calculated as the 
% of red pixels multiplied by % of green pixels. 
 
The statistical significance of the results was assessed by making the null hypothesis 
that the red and green pixels are randomly uniformly distributed. This implies that 
the number of colocalised pixels follows a binomial distribution. This allows 
calculation of the P-value, the probability for the observed or greater value arising 
from the null hypothesis. The P-values for each image were calculated using Excel 
(Binom.dist function) and checked using the open-source statistical package R (using 
the binom.test function).  
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2.14.2 Particle-based colocalisation analysis 
The analysis was performed on the same data set as the previous pixel-based analysis 
(early endosomes and lysosomes). The particle-based technique is particularly well 
suited to these structures because identifying them can be done automatically by the 
software and does not require complex image segmentation or edge detection. 
However, the same method cannot be applied to Golgi complex data because the 
software was not able to identify the centres of mass for more complex 
morphological structures such as the Golgi complex.  
 
The colocalisation of PrP
Sc 
(green) within cell organelles (red) was measured using 
the ImageJ plugin “Just another Colocalisation Plugin” (JACoP) as follows: 
1. Open picture in ImageJ→Image→Colour→Split channels 
2. Plugins→Jars→JACoP 
- Particle size and signal threshold was measured by framing of investigated particles 
(Figure 2.7). Analyse→Measure. The Mean for each channel revealed the signal 
threshold the investigated particles are corresponding to and the size of the 
investigated particles (in pixels).  
Red channel - lysosomes Green channel - PrPSc
 
Figure 2.7: Example of framing the investigated particle to measure its size and signal 
threshold  
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Then the signal threshold and the size (usually 10-100 pixels) of the investigated 
particles were set according to these measured values (Figure 2.8).  
Red channel - lysosomes Green channel - PrPSc
 
Figure 2.8: The signal threshold and the size of the investigated particles were set 
according to measured values  
 
The JACoP features allow a set of commonly used co-localisation indicators such as 
Pearson’s coefficient, Manders’ coefficient, the overlap coefficient, and so on to be 
calculated. The plugin also produces a centres map of the colocalised particles and a 
log containing the calculated values. 
A rigorous statistical analysis of the particle colocalisation would require developing 
a detailed mathematical understanding of the two-dimensional spatial statistics of 
both lysosome and endosome structures, which is beyond the scope of the present 
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3. RESULTS 
 
3.1 CHARACTERISTICS OF THE CELL CULTURES USED IN THE STUDY 
 
3.1.1 Objectives 
To confirm the PRNP codon 129 genotype, characterise the morphology and 
evaluate PrP
C 
expression in the cells used in this study. 
  
3.1.2 Rationale 
Thus far, the mechanisms involved in cellular susceptibility and human prion 
replication have not been studied in cultured human cells due to the apparent absence 
of any well characterised human cells susceptible to human prion infection in vitro. 
The histopathological, biochemical and epidemiological evidence suggest that the 
variant Creutzfeldt–Jakob disease (vCJD) is most likely to be a result of oral 
ingestion of the bovine spongiform encephalopathy (BSE) agent (Will et al., 1996; 
Collinge and Rossor, 1996; Bruce et al., 1997; Hill et al., 1997a; Prusiner, 1998). 
Cells of the lymphoreticular system, specifically FDCs and B lymphocytes, are also 
known to be involved in prion pathogenesis (Fraser and Farquar, 1987; Fraser et al., 
1989; McBride et al., 1992; Klein et al., 1997; Brown et al., 1999; Montrasio et al., 
2000; Weissmann et al., 2001) and there is also a great deal of evidence to suggest 
that this is also true in vCJD (Kitamoto et al., 1991; Hilton et al., 1998; reviewed in 
Mabbott and MacPherson, 2006). This suggests that the FDC-like HK cells, derived 
from human tonsils and having FDC-like characteristics, are a potentially useful cell 
line to study cell response to exposure of infectious prions.  
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In human prion diseases the phenotype, susceptibility and incubation period are all 
governed, in part, by host genetics, in particular by the methionine/valine (MV) 
polymorphism at codon 129 of the human prion protein gene (PRNP) (Collinge and 
Alpers, 2006; Bishop et al., 2006; Parchi et al., 2009; Mastrianni, 2010). PrP
C
 
expression levels also affect susceptibility (Bueler et al., 1993).  
As the aim of this study was to directly examine the cellular response of 
extraneuronal lymphoreticular FDC-like HK cells and undifferentiated human 
embryonic stem cells to exposure to infectious prions from human (variant, sporadic, 
iatrogenic Creutzfeldt-Jakob disease) and animal (bovine spongiform 
encephalopathy) brains, analysis of the cell lines for their PRNP codon 129 
polymorphism and level of PrP
C
 expression was an important consideration. Thus 
PRNP codon 129 genotype is an indicator of relative cell susceptibility and PrP
C
 an 
obligatory prerequisite for cells to replicate infectious prions. Hence determining the 
PRNP polymorphic status and the level of PrP
C
 expression of the studied cells were 
matters of great interest. 
Determining the PRNP codon 129 genotype of seven hESC lines available in this 
study (Table 3.1) was necessary in order to select representative lines of each 
genotype for in vitro challenge experiments. The results were as follows: 






Identity of the hESC 
lines tested2 
MM 44% 3/7 (43%) RCM-1, RH3, RH4 
MV 44.5% 3/7 (43%) RH1, RH5, RH73 
VV 11.5% 1/7 (14%) RH6 
Table 3.1 PRNP codon 129 polymorphisms of seven hESC lines available for the study 
1
 - Data published in Bishop et al., 2009 
2
 - Isolation described in Fletcher et al., 2006 and De Sousa et al., 2009 
3
 - Showing a non-pathogenic 24 bp deletion of the 129-M allele 
 
Chapter 3   Results 
  110 
The representation of the three common polymorphic groups among the seven tested 
hESC was found to be consistent with that of the general UK population as a whole 
(44% MM, 44.5% MV, 11.5% VV) (Bishop et al., 2009). However one cell line was 
identified to carry deletion on one of the PRNP 129-M alleles, and accordingly was 
not investigated further. 
 
3.1.3 Experimental results 
Three hESC cell lines, differing in their PRNP codon 129 genotype, were selected 
for the study: RCM-1 (homozygous for methionine), RH1 (heterozygous), and RH6 
(homozygous for valine). Unfortunately, the only VV hESC line available to this 
study proved to have very slow growth and showed poor viability in culture. 
Although it would be interesting to obtain data on all three hESC lines differing in 
their PRNP codon 129 genotype, the RH6 line would have presented considerable 
practical difficulties and possibly yielded incomparable results with the two other 
hESC cell lines. Consequently, the study focused on RCM-1 (MM) and on RH1 
(MV) hESC lines, both originating from clinically failed eggs rescued by 
parthenogenetic activation.  
Interestingly, despite the fact these two normal euploid and biparental pluripotent 
hESC lines were not genetically related, they revealed the closest match in their 
expression of markers of an undifferentiated state. This phenomenon is most likely to 
result from their method of isolation. Moreover, because of the known susceptibility 
of methionine homozygous individuals to the BSE/vCJD agent and because the 
PRNP codon 129 heterozygosity is the most frequently occurring genotype in the 
general UK population, the choice of one MM and one MV representative cell line 
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seemed sufficient for the purposes of this study. The available follicular dendritic 
cell-like cell line (HK) was found to be VV somewhat completed the repertoire to be 
able to investigate the cell susceptibility to prion in regards to PRNP codon 129 
genotype.  
3.1.3.1 PRNP codon 129 genotyping of the cells used throughout the study 
To confirm the polymorphism at the codon 129 of the prion protein gene (PRNP), the 
high molecular weight DNA was extracted from the cell pellets of the hESC RCM-1 
and RH1 lines and the FDC-like HK cell line as described in section 2.5.1 and a 
fragment containing the PRNP coding sequence was amplified by PCR as described 
in section 2.5.2. The PCR products were visualised by agarose gel electrophoresis 
and SYBR green gel staining (Figure 3.1). Successful amplification was observed in 
all three studied cell lines: the hESC of the RCM-1 (lane 1) and RH1 (lane 2) cell 
lines and the FDC-like HK cells (lane 3). The PCR products for the three different 
codon 129 polymorphisms (lane 4-6) served as a positive control for the PCR 
reaction process.  
 
Figure 3.1: PCR amplification of the PRNP gene sequence 
DNA from the hESC RCM-1 (lane 1), RH1 (lane 2) cell lines and the FDC-like HK cells 
(lane 3) was obtained by cell pellet lysis and column purification using the DNA Blood Mini 
Kit according to manufacturer instructions. The amplification of the PRNP gene sequence by 
PCR was performed as described in section 2.5.2. PCR of the control PRNP gene sequence 
samples (lane 4-6) served as a positive control for the PCR reaction. Detection of the PCR 
products was performed by agarose gel electrophoresis and SYBR Green gel staining using 
the ChemiDoc XRS imaging system. The DNA mass, in bp, is marked left. 
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The amplified DNA was then digested with restriction enzyme NspI (Figure 3.2) 
cleaving the amplicon at PRNP codon 155 and at codon 129 only when the latter 
sequence coded for valine (-GTG-). The restriction fragment length polymorphisms 
(RFLP) allowed discrimination of the three genotypes of the studied cell lines RCM-
1 (lane 1), RH1 (lane 2) and HK (lane 3) by agarose gel electrophoresis and SYBR 
Green gel staining. The positive controls for the PRNP codon 129 genotype MM 
(lane 4), MV (lane 5) and VV (lane 6) also served as a positive controls for the 
restriction digest. Comparison of the results obtained using the cell lines with the 
positive controls confirmed that the hESC of the RCM-1 line was of the PRNP codon 
129 genotype MM (lane 1), the RH1 line was of the PRNP codon 129 genotype MV 
(lane 2) and the FDC-like HK cell line was VV (lane 3). 
 
Figure 3.2: RFLP analysis of the PRNP codon 129 polymorphism 
Confirmation of the PRNP codon 129 genotypes of the hESC of RCM-1 (lane 1) and RH1 
(lane 2) cell lines and the FDC-like HK cells (lane 3) was performed by restriction enzyme 
digestion at 37 °C with NspI allowing discrimination of the three genotypes paradigms MM, 
MV and VV by agarose gel electrophoresis and SYBR Green gel staining. The controls for 
each PRNP codon 129 polymorphism type: MM (lane 4), MV (lane 5) and VV (lane 6) also 
served as a positive control of the digestion reaction. The DNA ladder, in 100 bp fragments, 
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3.1.3.2 Morphological characterisation of the cells used in the study 
Morphological analysis of the cultured cells is important in several respects. In a 
culture, cellular morphology can reflect the status of the cells, both in terms of the 
health of the culture and, in the case of cultured embryonic stem cells, it is an 
indicator of their state of differentiation. Undifferentiated stem cells are primitive 
cells with a regulated capacity for self-renewal, multilineage proliferation and 
differentiation, precise control of which in vivo is essential for development and 
tissue renewal. In vitro embryonic stem cells are heterogeneous, containing a self-
renewing population (or populations) of cells but also showing evidence of low level, 
presumably random, differentiation. 
These hESC RCM-1 and RH1 cell lines were established from whole blastocysts 
without exposure to animal immune complement to recover embryo inner cell mass, 
on an extracellular matrix substrate of purified human laminin with transitional 
reliance on mitotically inactivated human fibroblast feeder cells. Isolation of these 
cells was the first example of a new derived hESC without direct exposure to any 
animal cell products.  
Cultured cells were readily observed in their native state using differential 
interference contrast microscopy (Figure 3.3). Undifferentiated hESC of RCM-1 (A) 
and RH1 (B) cell lines shared a common morphology in forming densely packed 
round colonies with clear margins. Based on the location of the cells in colonies, 
different morphological features could be identified. Cells at the centre of the colony 
were rounded and lay tightly packed against each other, suggesting a relatively an 
undifferentiated state and close cell membrane contact. Compared to the cells at the 
core, stem cells at the periphery of these masses appeared to be in the initial stage of 
cytodifferentiation as judged by their flattened morphology (arrows). The cells were 
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maintained as described in section 2.2.2. Cells were always plated one day before 
exposure to brain spiked medium. The passage numbers of the hESC used in the 
experiments varied between 45 to 65 for RCM-1, and 60 to 85 for RH1.  
 
Figure 3.3: Morphology of human embryonic stem cells 
Two day old culture of the hESC of RCM-1 (A) and RH1 (B) cell lines shared common 
morphology consisting of cells densely packed in round colonies surrounded by more 
flattened cells (arrows). The cultured hESC were observed by a differential interference 
contrast microscope. Scale bars represent 50 µm.  
 
The extraneuronal lymphoreticular FDC-like HK cell line is a primary cell line 
derived from human tonsils (Figure 3.4). The cells were cultured in a complete cell 
culture medium supplemented with foetal calf serum (FCS) and antibiotics (as 
described in section 2.2.1). This serum was sourced from TSE-free herds in New 
Zealand that have been classified by the Medicines and Healthcare products 
Regulatory Agency (MRHA) and from comparable health agencies throughout the 
world. Therefore, it was unlikely to be contaminated by prions that could interfere 
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with results of this study. Passaging of the HK cells was performed roughly every 10 
days and cells were always transferred to fresh flask or chamber slide one day before 
exposure to prions.  
The cells in culture display a relatively homogenous morphology (A). They are large 
adherent cells displaying typically elongated and bipolar morphology with numerous 
cellular projections and slender cytoplasmic protrusions (B) and heterochromatic 
oval nuclei with conspicuous nucleoi. Once the HK cells underwent a certain number 
of passages (~10) they became senescent, stopped dividing, but remained viable. 
 
Figure 3.4: Morphology of the FDC-like HK cells  
The extraneuronal lymporeticular HK cells derived from human tonsils by Dr Y.S. Choi 
(New Orleans) displayed morphology typically elongated and bipolar with numerous cellular 
projections. The cultured cells were observed by a differential interference contrast 
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3.1.3.3 Expression of normal prion protein (PrP
C
) in undifferentiated hESC of   
RCM-1 and RH1 lines and FDC-like HK cells 
The analysis of the PrP
C
 expression was carried out by Western blot using mAb 3F4, 
an anti-PrP primary antibody recognising human PrP amino acid residues 109-112 
(Figure 3.5). Pellets of the hESC RCM-1 (lane 1) and RH1 (lane 2) lines and the 
FDC-like HK cells (lane 3) were homogenised in extraction buffer to 10% w/v 
suspensions and the same volume of the cell lysates were loaded on the gel. The 
Western blot procedure was routinely performed as described in section 2.7. 
The PrP
C
 expressed by undifferentiated hESC of RCM-1 (lane 1) and RH1 (lane 2) 
was not detectable by Western blot under the conditions used. In contrast, HK cells 
(lane 3) appeared to express abundant amounts of prion protein with the expected 
molecular weight of around 30 kDa.  
 
Figure 3.5: Western blot analysis of PrP
C
 expression level in hESC and FDC-like cells 
The hESC of RCM-1 (lane 1) and RH1 (lane 2) cell lines and the FDC-like HK cells (lane 3)  
were cultured until confluent before harvesting for Western blot analysis. The cell pellets 
were homogenised in extraction buffer to 10% w/v suspensions and same amounts of the cell 
lysates mixed with loading buffer were loaded onto gel. The immunobloting procedure was 
carried out according to the standard method as described in section 2.7 and the PrP
C
 was 
detected using 3F4 monoclonal antibody. The molecular weight, in kilodaltons (kDa), is 
marked left. 
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The level of PrP
C
 expressed by HK cells was compared to the level of PrP
C 
present in 
a normal brain from the World Health Organisation (WHO) (Minor et al., 2004) 
(Figure 3.6). Densitometric evaluation of the PrP
C
 signal (method described in 
section 2.10.5) revealed that the HK cells (lane 5) express 1.3 times more of PrP
C 
than is present in the normal brain (WHO, lane 1) as equal volumes of the 10% w/v 
suspensions were loaded onto gel in these two lines. Doubling dilution series of the 
WHO standard brain are shown in lanes 2-4.  
 
Figure 3.6: Comparison of PrP
C
 expression level in normal brain and HK cells 
Level of PrP
C
 in the 10% WHO normal brain standard (lane 1-4, doubling dilution series 
lane 2-4) and 10% HK cell lysate (lane 5) were analysed by Western blot using 3F4 
monoclonal antibody. WHO standard (lane 1) and HK cell lysate (lane 5) contain equal 
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3.1.4 Summary 
 The available human FDC-like cell line (HK) was found to be VV.  
 The human embryonic stem cell lines chosen for this study were of the MM 
(RCM-1) and MV (RH1) genotypes at codon 129 of PRNP. The only line 
with a VV genotype found in the seven available hESC lines had poor growth 
characteristics and therefore was not included in these studies. 
 The HK cells isolated from human tonsils are large adherent cells displaying 
typically elongated and bipolar morphology with numerous slender 
cytoplasmic protrusions.   
 hESC formed rounded colonies of tightly packed cells suggesting an 
undifferentiated state, surrounded by spontaneously differentiating flattened 
cells at the periphery.  
 The level of PrPC expression in the RCM-1 and RH1 lines seems to be below 
detection by Western blot when compared to the abundant PrP
C
 expression 
level of the FDC-like HK cells.  
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3.2 PROTEIN MISFOLDING CYCLIC AMPLIFICATION 
 
3.2.1 Objectives 
To investigate potential for conversion of PrP
C
 from HK cells into its pathologic 
PrP
Sc
 isoform and to determine whether these cells have the minimal required 





Prior to performing the actual attempts for cell culture infection with prions, it was of 
interest to test whether HK cells have all the required components to propagate PrP
Sc
. 
The method chosen to determine this is called protein misfolding cyclic amplification 
(PMCA) (described in section 2.8). Previous successful PrP
Sc 
amplification by 
PMCA using substrate PrP
C 
contained in brain homogenates (Saborio et al., 2001; 
Soto et al., 2002; Castilla et al., 2005a) suggests that PrP
C
 obtained from cell culture 
lysate may also support PrP
Sc
 formation (Castilla et al., 2006).  
 
3.2.3 Experimental results 
3.2.3.1 Preparation of the substrate and seeds for PMCA 
In order to determine whether HK cell PrP
C
 can be converted to PrP
Sc
 and therefore 
also whether HK cells have the minimal required components for PrP
Sc
 formation, a 
PMCA experiment was performed on HK cell homogenates seeded with iCJD, sCJD, 
BSE and vCJD brain homogenates. For optimal PMCA efficiency, aspects of both 
seed and substrate preparation had to be carefully considered (Castilla et al., 2005a; 
Castilla et al., 2005b; Castilla et al., 2006). The most important aspects included the 
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composition of the conversion buffer (Castilla et al., 2006), the choice and 
preparation of the substrate (material stored exclusively at -80 °C), which had to be 
prepared just before setting up the reaction (Figure 3.7; A), and titration of the PrP
Sc
 
seeds to a level detectable at the lower end of the linear range of a standard Western 
blot after limited PK digestion (Jones et al., 2009). The seed titration step (Figure 
3.7; B) allowed us to asses the degree of newly amplified PrP
Sc
 by PMCA. 
Therefore, the HK cell culture substrate was always freshly prepared directly prior 
the PMCA reaction (described in section 2.8.1) and the brain homogenate used for 
seeding the reaction was added to the reaction at amount just detectable by Western 
blot (described in section 2.8.2) as shown (Figure 3.7; B, lane 5, 8, 11, 14) so that all 




Figure 3.7: Western blot analysis of substrate and dilution series of seeds for PMCA 
(A) Western blot analysis of the substrates for PMCA: the PrP
C
 level contained in 7% w/v 
HK cells lysates (lane 1), the PrP
C
 level contained in 10% w/v Hu (MM) Tg mouse brain 
homogenate (lane 2). In both cases 1.5 µl of substrate suspension was loaded onto the gel. 
Western blot was performed by the standard method and the PrP
C
 was detected with the 
monoclonal antibody 6H4. (B) Doubling dilution series of the brain homogenates iCJD (lane 
3-5), sCJD (lane 6-8), BSE (lane 9-11), vCJD (lane 12-14) – seeds used in the PMCA 
reaction. Samples were PK treated at a PK concentration of 50 µg/ml and the presence of 
PrP
Sc
 was detected using 6H4 monoclonal antibody. The molecular weight, in kDa, is 
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3.2.3.2. PMCA experiment 
It is important to mention that the HK cell lysate used as a substrate for PMCA 
(Figure 3.7; A, lane 1) reaction was not supplemented with a PrP inert substrate such 
as PrP
0/0
 brain homogenate in putative order to enhance the level of amplification 
(Castilla et al., 2006), as our goal was to determine whether the HK cells themselves 
have all the required components to sustain PrP
Sc
 replication. The reaction mixtures 
were prepared at a seed-to-substrate ratio of 1:7 and the mixtures were divided into 
two duplicates. The control (unamplified aliquot) was immediately frozen at -80 °C 
and the PMCA aliquot was subjected to the PMCA reaction. The experiment reaction 
consisted from 48 cycles of 40 seconds sonication at 80% total power output and 29 
minutes 20 seconds incubation at 37 °C for 24 hours. 
Positive PrP
Sc
 amplification was observed when iCJD and sCJD seed was used 
(codon 129 VV) (Figure 3.8; lane 2 and 4), whereas no PrP
Sc
 amplification could be 
detected in the case of BSE and vCJD (codon 129 MM) (Figure 3.8; lane 6 and 8). 
The successful amplification may be due to the prion protein compatible 129 codon 
genotype of these two cases with the 129 codon genotype of the HK cells (VV type) 
(Jones et al., 2007). The AD brain (MM type) homogenate was used as a negative 
control (Figure 3.8; lane 9-10).   
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Figure 3.8: Western blot analysis of PMCA using HK cell culture as a substrate   
Each type of seed has an un-amplified control sample (lane 1, 3, 5, 7, 9, 12, 14, 16) and a 
sample subjected to 48 cycles of PMCA (lane 2, 4, 6, 8, 10, 13, 15, 17) (described in section 
2.8.3). AD was used as a negative control (lane 9-10). All samples were subjected to PK 
digestion (50 µg/ml for 60 minutes at 37 °C) prior Western blot analysis performed by the 
standard method and the PrP
Sc
 was detected with the 6H4 monoclonal antibody (lanes 1-11) 
and 3F4 monoclonal antibody (lanes 12-17). The vCJD 2B standard (lane 11) was used as a 
control of PrP migration and blotting procedure. The marked molecular weight is in kDa. 
 
The vCJD brain seed (PRNP codon 129 genotype is MM) in transgenic humanised 
MM mouse brain substrate (Tg Hu MM) (PRNP codon 129 genotype is also MM) 
(Figure 3.8; lane 15) was used as a positive control for the PMCA reaction, alongside 
an appropriate negative control samples (Figure 3.8; lane 13 and 17). Negative 
controls, as expected, lacked amplification (Colby et al., 2007) in the unseeded Tg 
Hu MM mouse substrate (Figure 3.8; lane 13) and also no amplification could be 
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3.2.4 Summary 
 The extracts from the extraneuronal, lymphoreticular, FDC-like HK cells 
support PrP
Sc
 amplification in PMCA reaction, in a PRNP codon 129-
depended manner. 
 Whether PMCA could be viewed as a rapid indicator of a cell type’s potential 
susceptibility to prion infection in vitro has been tested in following assay by 
directly challenging HK cells in vitro with some of the brain homogenates 
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3.3 INFECTION STUDIES OF HK CELLS 
 
3.3.1 Objectives 
To evaluate whether the extraneuronal lymphoreticular FDC-like HK cells are 
capable of PrP
Sc
 replication in vitro and PrP
Sc
 propagation in the longer term. 
 
3.3.2 Rationale 
The known involvement of FDCs in variant CJD and the high levels of PrP
C
 
expressed by HK cells indicate that these cells may be susceptible to prion infection 
and competent to propagate that infection in vitro. HK cells were therefore exposed 
to infectious brain homogenates taken from a variety of prion infected brain sources, 
prepared by different methods and exposed under different culture conditions. 
Human CJD brain homogenates were used to exclude the possibility that the so 
called “species barrier” would prevent infection. The experimental set up also 
provided the opportunity to infect HK cells using brain homogenates from cattle 
BSE, which is the most likely source of variant CJD infection in humans and for 
which species specific PrP antibodies exist.  
 
3.3.3 Experimental results 
3.3.3.1 PrP
res
 analysis of brain tissue used for infection studies 
Western blot analysis served as confirmation of the distinct prion agents as well as an 
evaluation of the level of PrP
res
 in the brain homogenates used for cell exposure prior 
each in vitro infection study. The presence of PrP
res
 was confirmed by partial 
proteolytic degradation of all brain homogenates and the characteristic PrP
res
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glycosylation patterns associated with different prion diseases and phenotypes were 
confirmed by Western blotting. The 10% w/v brain homogenates were digested with 
PK for 60 minutes at 37 °C. Western blots (Figure 3.9) showing levels of total PrP 
(samples without PK treatment) (lane 1-4) and levels of PrP
res
 (samples after treated 
with PK) (lane 5-8). Two anti-prion monoclonal antibodies 3F4 (Figure 3.9; A) or 
6H4 (Figure 3.9; B) recognising different epitopes were used. The PrP
res 
type 
nomenclature of Parchi and Gambetti (Parchi et al., 1997) was used throughout. 
The AD brain homogenate (Figure 3.9; lane 1 and 5) was used in the study as a 
negative control for presence of PrP
res
 and as a positive control of any changes in cell 
morphology caused by exposure to brain tissue components. The human growth 
hormone associated iCJD (Figure 3.9; lane 2 and 6) used in the cell infection studies 
was of the same PRNP codon 129 genotype as the HK cell culture (VV). Western 
blot analysis of PrP
res
 (lane 6) showed this case to be type 2A. The anti-PrP antibody 
3F4 identifies human PrP, but not bovine PrP, whereas the anti-PrP antibody 6H4 
recognizes both human and bovine PrP. The 3F4 antibody binds strongly to human 
and hamster PrP with specific requirement of two methionine residues at positions 
109 and 112 in the human PrP (Lund et al., 2007). Bovine PrP constitutes of 
different epitope at these corresponding positions. Brain stem homogenate from a 
case of bovine spongiform encephalopathy (BSE) was not recognised by 3F4 (Figure 
3.9; A, lane 3 and 7), whereas the 6H4 antibody (Figure 3.9; B) recognised PrP (lane 
3) and showed the characteristic predominance of di-glycosylated PrP
res
 (lane 7) in 
the BSE case. The predominance of the di-glycosylated band of PrP
res
 is a feature 
shared by BSE and vCJD. The vCJD brain homogenate was recognised by both 3F4 
and 6H4 primary antibodies (Figure 3.9; A and B, lane 4 and 8). The migration 
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position of the non-glycosylated band of the PrP
res
 classified this case was type 2, 
and therefore the vCJD case was found to be, as expected, a type 2B (Figure 3.9; lane 
8). These analyses confirmed that PrP
res
 was abundantly present in these brain 
samples and was of the expected PrP
res
 types. The findings also confirmed that the 
3F4 antibody can be used to distinguish any newly formed PrP
Sc
 if human cells were 
to be successfully infected with BSE. 
 
Figure 3.9: Western blot analysis of brain homogenates using two different anti-prion 
protein primary antibodies 3F4 and 6H4 
Dissected brain tissues were homogenised in ice cold extraction buffer to 10% w/v brain 
suspensions and cleared from nucleocytoskeletal fraction by brief centrifugation. Samples 
were either allowed to remain undigested (lane 1-4) or digested (lane 5-8) with PK and 
loaded onto gel, as marked on the figure, at equal volumes. (A) Western blot was analysed 
with anti-prion monoclonal antibody 3F4 (recognising human, but not bovine, PrP amino 
acid residues 109-112). (B) Western blot was analysed with anti-prion monoclonal antibody 
6H4 (recognising PrP residues 142-155). The molecular weight, in kDa, is marked on the 
sides. 
 
The HK cells were plated 1-3 days prior exposure and after reaching 50-60% 
confluence, the cultures were exposed to brain material. This was to ensure that 
maximum cell surface would be exposed to brain homogenate, which might not have 
been achieved at a higher confluence, when cells are tightly packed together and 
have a more condensed morphology. 
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3.3.3.2 First set of HK cell challenges  
In the first investigation to determine the HK cell’s potential to propagate human 
prions, the cells were exposed to clarified suspensions of iCJD, vCJD and BSE brain 
homogenates. The AD case was used as a negative control. To avoid contamination 
by conventional, bacterial and fungal agents, a partial decontamination of the 
homogenates was attempted by heat pre-treatment or filtration as described in section 
2.9.2.1. Each case was incubated with the cells at very low homogenate 
concentrations, with and without any pre-treatment (non-sterilised), to estimate the 
potential for possible toxicity and contamination depending on the origin of the 
homogenate, as well as the cellular response to exposure of crude brain material. The 
brain homogenates were diluted to 0.1% suspensions with complete (including 
serum) cell culture medium and incubated with cells for 24 hours. The brain spiked 
medium was then removed, cells were rinsed, given fresh (unspiked) culture medium 
and further maintained for 16 days, including one cell passage (split 1:2) and five 
medium changes. No obvious effects on cell morphology or growth rate were 
observed between challenged and unchallenged cell cultures. Interestingly, the non-
sterilised brain homogenate did not result in noticeable bacterial, viral or fungal 
infection in these experiments. 
The cells were then harvested for Western blot analysis using anti-PrP monoclonal 
antibody 6H4 (Figure 3.10). No detectable PrP
res
 accumulation was seen in lysates of 
cells challenged with iCJD, vCJD, or BSE. None of the brain homogenate pre-
treatment seemed to have effects on cell susceptibility or to prion infection (Figure 
3.10; lane 1-7). 
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Figure 3.10: HK cells infection studies – first set 
HK cells were exposed to 0.1% dilutions of iCJD1, vCJD, BSE1 or AD (control) brain 
homogenates which were either filtered (lane 1, 4, 6), heat pre-treated (lane 2), or used 
without pre-treatment (lane 3, 5, 7, 8). After an incubation period of 24 hours, the brain 
spiked medium was removed and cells were allowed to grow in fresh culture medium for 16 
days with media changes every third day. The method is described in section 2.9.2.1. The 
cells were then harvested, PK treated and PrP
res
 collected by centrifugation as described in 
section 2.6.2.2 and subjected to Western blot analysis for PrP
res
 using primary antibody 6H4. 
The vCJD 2B standard (lane 9) was used as a control of PrP migration and blotting 
procedure. The molecular weight, in kDa, is marked on the left.   
 
3.3.3.3 Second set of HK cells challenges  
The methodology of the second attempt to infect the HK cells with prions (described 
in section 2.9.2.2) was modified by using three different concentrations of the iCJD1 
brain homogenate. This was an attempt to define the tolerance of challenged cells to 
brain homogenate diluted with medium as well as to investigate whether higher 
concentration of infectious brain homogenate will trigger prion infection of the HK 
cell culture. For this set of challenges, the growth hormone associated iCJD1 brain 
(PRNP codon 129-VV), was selected to match the endogenous PrP
C
 genotype of the 
HK cells (which was also VV). In addition, the PrP
res
 of this iCJD1 case was readily 





 conversion (Figure 3.8; lane 2). The objective was now to evaluate whether the 
challenged cells would replicate prion infection and therefore the positive in vitro 
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PrP
res
 amplification by PMCA could be used as an indication of cell culture 
susceptibility to infection with prions in vitro.  
0.1%, 0.5%, and 1% dilutions of the brain spiked medium were treated with a very 
low concentration of Triton X-100 containing lysis buffer or extraction buffer to 
achieve partial extraction of the homogenates and to avoid excessive sticking of 
brain material on the cell surface. Some brain samples were also filtered or used 
without any pre-treatment to evaluate the contamination level (if any) caused by 
viruses or bacteria originating from the brain material. The AD brain homogenate 
was used as a negative control. Some HK cells were exposed to brain spiked medium 
when freshly passaged (Figure 3.11; marked *). This was to test whether changes in 
culture conditions would induce cells to become more vulnerable to infection with 
prions.  
Cells were incubated with the brain spiked medium for 24 hours. The medium was 
then removed, the cells were rinsed, given fresh (brain-free) culture medium and 
further maintained for 26 days, which included one cell passage (split 1:2) and ten 
medium changes. The harvested cells were processed as described in section 2.6.2.2 
and subjected to a routine Western blot analysis using anti-PrP monoclonal antibody 
3F4 as described in section 2.7. Surprisingly, no cell-associated PrP
res
 could be 
observed at detectable levels in the HK cells challenged with the iCJD1 homogenate 
in any of the treated conditions in this set of challenge (Figure 3.11). No obvious 
changes were observed in cell morphology caused by the use of higher brain 
homogenate concentrations or the buffer treatments employment, although the cell 
growth appeared to be slightly slower when compared to the previous experiment 
(First set; section 3.3.2). Contamination with conventional agents did not seem to be 
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an issue, even when using non-sterilised brain homogenates at 1% dilution. 
Therefore, the heat pre-treatment and filtration steps were omitted from subsequent 
experiments. 
 
Figure 3.11: HK cells infection studies – second set 
The HK cells were exposed to different dilutions of iCJD1 and AD (control) brain 
homogenates: 0.1% (A), 0.5% (B, lane 1 and 2), or 1% (B, lane 3-8). These were either 
filtered (A lane 1-4; B lane 3-5) or used untreated (A lane 5-8; B lane 1, 2, 6-8) and 
additionally either treated with extraction buffer (A lane 1, 6, 8; B lane 3, 6) or triton lyses 
buffer (A lane 2-5, 7; B lane 4, 5, 7, 8) (as described in section 2.9.2.2). Cells were incubated 
with brain spiked medium for 24 hours. (*) Pellets of HK cells were gently resuspended in 
brain spiked medium and cells were plated into cell culture flask. After 24 hours, the brain 
spiked medium was removed, the cells were washed and allowed to grow in a fresh complete 
medium for 26 days, with medium changed 10x and one cell passage. When cells reached 
confluence, they were harvested and PK treated (as described in section 2.6.2.2) for Western 
blot analysis using the anti-prion protein primary antibody 3F4 to detect PrP
res
. The vCJD 2B 
standard (lane 9) was used as a control of PrP migration and blotting procedure. The 
molecular weight, in kDa, is marked left on each blot.   
 
3.3.3.4 Third set of HK cells challenges  
The third set of challenges employed another modification in pre-treatment of the 
brain homogenates prior to exposure of the HK cell cultures (section 2.9.2.3). The 
10% w/v brain homogenates in a sterile 5% glucose solution were additionally 
homogenised by ribolysation and sonication as an attempt to break up aggregated 
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PrP
Sc
 multimers found in brain tissue and perhaps therefore to facilitate easier 
infection. Cells were analysed after incubation with three different dilutions of iCJD1 
brain homogenate – 0.1%, 0.5% and 2%. The AD case served as a negative control. 
HK cells were incubated with the brain spiked medium for 24 hours. The incubation 
period was in some cases prolonged to 68 hours. The purpose was to test whether the 
longer exposure time will trigger prion infection in these cells. Freshly passaged cells 
were also challenged (Figure 3.12; marked *). After the incubation period, the brain 
spiked medium was removed, the cells were rinsed, given fresh (unspiked) complete 
medium and cultured for additional 22 days, consisting in total of one cell passage 
(split 1:2) and eight medium changes. The cell lysates were then analysed for any 
cell associated PrP
res
 by Western blot using the 3F4 antibody (Figure 3.12).  
Upon incubation with different dilutions of ribolysed and sonicated iCJD1 brain 
homogenate PrP
res
 signal was detected in cell lysates of HK cells incubated with 
ribolysed and sonicated 0.5% iCJD1 for 68 hours (Figure 3.12; lane 4) and 2% iCJD1 
for 24 hours (Figure 3.12; lane 6). However, the detection of PrP
res
 in cell lysates 
appeared to depend on the brain homogenate concentration used in cell challenge. As 
expected, PrP
res
 was not detected in the cell pellets from HK cells incubated with 
ribolysed and sonicated 0.1% and 2% AD brain material for 68 and 24 hours, 
respectively (Figure 3.12; lane 3 and 7). 
 
Chapter 3   Results 
  132 
 
Figure 3.12: HK cells infection studies – third set 
The HK cells were challenged with ribolysed and sonicated iCJD1 and AD (control) brain 
homogenates diluted with complete cell culture medium to 0.1% (lane 1-3), 0.5% (lane 4, 5) 
and 2% (lane 6, 7). Cells were incubated with brain spiked medium for 68 hours (lane 1-4) or 
24 hours (lane 5-7) as described in 2.9.2.3. (*)Pellet of HK cells was gently resuspended in 
brain spiked medium and cells were plated into cell culture flask. After exposure the brain 
spiked medium was withdrawn, cells were washed, given fresh complete medium and 
cultured for 22 days with medium changed eight times and one cell passage. Then the cells 
were harvested for PrP
res
 detection by Western blot analysis (as described in section 2.6.2.2) 
using primary antibody 3F4. The molecular weight (left) is in kDa.  
 
3.3.3.5 Fourth set of HK cells challenges  
Based on the PrP
res
 detection in cell lysate of HK cells exposed to ribolysed and 
sonicated 0.5% and 2% iCJD1 and cultured for additional 22 days (Figure 3.12; lane 
4 and 6), this set of cell challenges addressed the question whether the previously 
detected PrP
res
 (Figure 3.12) is newly produced, or represents remaining inoculum 
with a dose response effect. This set also investigated whether PrP
res
 from ribolysed 
and sonicated iCJD2 (VV), iCJD3 (MV), vCJD (MM), BSE2 brain homogenates 
could cause prion infection of the challenged HK cells. The cells were exposed to a 
range of 0.1% - 2% brain homogenate dilutions (described in section 2.9.2.4, marked 
on the Figure 3.13) for 24 hours. Most of the cell infection studies are limited by the 
difficulty of specifically distinguishing the PrP
res
 of the inoculum from the PrP
res 
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newly produced in the infected cells. To assess whether PrP
res 
in HK cell lysates is 
newly formed or not, this set of challenges was designed as a time-course study (with 
the expanded times of culturing the cells, cell lysates were periodically analysed for 
presence of any PrP
res 
by immunoblot performed with the 3F4 monoclonal antibody). 
The advantage was taken of using BSE brain homogenate to infect cells and 3F4 
primary antibody (recognising human but not bovine PrP) for detection of any newly 
formed PrP
res
 in HK cells. The experiment was carried out in duplicate. Cells from 
one flask were harvested for Western blot analysis, whilst cells in the other flask 
were split into two flasks and were allowed to grow until confluent, when the 
harvesting and splitting processes were repeated. This was repeated up to eight 
passages (Figure 3.13; A, B, C, D; only first four time points are shown). The 
immunoblot from the first time point (Figure 3.13; A) shows cell lysates analysed 
after 24 hours incubation of HK cells with brain spiked medium, followed by a PBS 
rinse and additional eight days cultivation, including one 1:2 cell passage and three 
changes of culture medium. Abnormal PrP in the PK digested cell lysates was 
detected in cells challenged with 2% iCJD2 (VV) and 2% vCJD (MM) brain 
homogenates (Figure 3.13; A, lane 9 and 13, respectively). At the second (Figure 
3.13; B) and third time points (Figure 3.13; C) the signal was reduced. PrP
res 
was 
further reduced after only a few passages and was not detected in cells exposed to 
BSE analysed by the 3F4 antibody, suggesting that the initial PrP
res 
signal in cell 
lysates was due to the residual material from the original input inoculum. 
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Figure 3.13: HK cells infection studies – fourth set 
HK cells, at passage number nine (p9) and 50% confluence, were exposed to various 
dilutions of ribolysed and sonicated brain homogenates: iCJD1 (lane 1-7), iCJD2 (lane 9-11), 
iCJD3 (lane 12), vCJD (lane 13), BSE2 (lane 14) and AD (control) (lane 15), as marked on 
the figure. In one case the iCJD1 brain homogenate (analysed at lane 7) was only treated with 
Triton X-100. (*) A pellet of HK cells was gently resuspended in brain spiked medium and 
cells were plated into cell culture flask. The cells were incubated with the brain spiked 
medium for 24 hours, then the medium was withdrawn, the cells were washed and given 
fresh (brain-free) medium. First analysis for the PrP
res
 was carried out 8 days after exposure 
including one passage of the cultures (A). The experiment was performed in duplicates (as 
described in section 2.9.2.4), cells in one flask were used for subcultivation, whilst the other 
flask was used to prepare cell lysate for Western blot analysis (B, C, D). Note that only four 
time points from eight in total are shown. The cells were harvested and PK digested as 
described in section 2.6.2.2. To detect PrP
res
, a primary antibody 3F4 was used. The vCJD 
2B standard (lane 8, 16) was used as a control of PrP migration, blotting procedure and as an 
internal standard to establish a constant film exposure time from time point to time point in 
order to quantify the data within the linear range of the film. The molecular weight, in kDa, 
is marked left on each blot.   
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The loss of the PrP
res
 signal from the cells after subsequent passaging in this assay 
was obvious, but it is difficult to draw concrete conclusions from the results. They do 
suggest that clearance of PrP
res
 from the cells exposed to prion diseased brain 
material does occur, but whether this represents a transient infection or not warranted 
further investigation.  
3.3.3.6 Fifth set of HK cells challenges  
In the fifth set of experiments the cell challenge method was modified by using an 
immobilised brain homogenate. Newly passaged cells were plated onto 0.5% or 1% 
either Triton X-100 treated (Figure 3.14; A) or ribolysed (Figure 3.14; B) brain 
homogenates. The brain homogenates were “painted” on the bottom of the cell 
culture flask, dried overnight and rinsed with PBS prior plating the cells (as 
described in section 2.9.2.5). The immobilised inoculum was visualised by 
differential interference contrast microscopy (Figure 3.14). In both cases abundant 
amounts of brain material was present at the cell culture flask surface. This step was 
employed as an attempt to obtain a high local concentration of PrP
Sc
 at the basal 
surface of the cell. The untreated plastic surface of the cell culture flask is shown for 
comparison (Figure 3.14; C). 
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Figure 3.14: Photograph of brain homogenate “painted” on the bottom of the cell 
culture flask 
Immobilised inoculum was observed using a differential interference contrast microscope. 
PBS dilutions (100 µl) of brain homogenates, either Triton X-100 treated (A) or ribolysed 
(B) were “painted” on the bottom of the flasks and dried overnight in aseptic conditions. 
Next day the flasks were rinsed with PBS and HK cells were plated onto the prepared 
immobilised inoculum. Scale bar, 25 µm. 
 
The incubation time of the HK cell cultures with immobilised inoculum was in this 
set of experiments prolonged to four days, when the cells were given fresh medium. 
The experiment was performed in duplicate, thus cells in one flask were used for 
subcultivation, whilst the other flask was used to prepare cell lysates for Western blot 
analysis. Cultures in this assay were analysed at six time points in total. These 
consisted of the first analysis performed after four days incubation with inoculum, 
followed by one change of medium and then three days of additional incubation 
(Figure 3.15; a) and five cell passages (split 1:2), each representing an analytical time 
point (Figure 3.15; b, c, d, e, f). The subsequent passaging was performed to rule out 
the detection of the remaining PrP
Sc
 from the inoculum and to examine whether PrP
Sc
 
replication might increase concomitantly with the loss of the original inoculum. Cells 
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were harvested using routine method (described in section 2.6.2.2) and the Western 
blot analysis (described in section 2.7) was performed using anti-PrP monoclonal 
antibodies 6H4 (Figure 3.15) and 3F4 (Figure 3.16 and 3.17).  
A high level of PK resistant PrP
res
 was demonstrated in the first time point analysis 
of cells exposed to immobilised Triton X-100 treated prion disease inoculum (Figure 
3.15; Aa). A marked difference in the amount of cell-associated PrP
res
 in the 
individual cell lysates was observed (Figure 3.15; Aa, lane 1-5). This was considered 
to be a dose response effect of PrP
res
 present in the inoculum (Figure 3.9; B). In 
contrast, cell lysates of cells exposed to the same concentrations, but of immobilised 
ribolysed inoculum displayed much weaker cell-associated PrP
res
 signal (Figure 3.15; 
Ba). PrP
res
 successively diminished after first passage analysed six days from the first 
time point (Figure 3.15; b) and was lost completely after repeated passages during 
the following 20 days of culturing of the challenged cells (Figure 3.15; b, c, d, e, f).  
Carry-over of the inoculum was presumably minimised by multiple passaging, and 
production of newly formed PrP
res
 in the cells was not detected. 
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Figure 3.15: HK cells infection studies – fifth set (I.)  
HK cells were plated onto immobilised dilutions of iCJD, vCJD, BSE or AD (control) brain 
homogenates (as marked on the figure), either Triton X-100 treated (A) or ribolysed (B) 
and incubated for 4 days. The medium was then changed for fresh (unspiked) medium and 
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cells were cultured for further 3 days, as described in section 2.9.2.5. The cells were then 
rinsed and harvested for Western blot analysis (a). The experiment was carried out in 
duplicate. Cells from one flask were harvested for Western blot analysis, whilst cells in the 
other flask were split into two flasks and were allowed to grow until confluent when 
harvesting and splitting process was repeated. This process was repeated up to five passages 
(b-f). Cell samples were PK digested and collected by hard spin (as described in section 
2.6.2.2) before analysis by Western blot using the anti-prion primary antibody 6H4 
(recognising PrP amino acid residues 144-152) to detect PrP
res
. The vCJD 2B standard (A, 
lane 7; B, lane 8) was used as a control of PrP electrophoretic mobility, blotting procedure 
and as an internal standard to establish a constant film exposure time from time point to time 
point in order to quantify the data within the linear range of the film. The molecular weight, 
in kDa, is marked left on each blot. 
 
To further confirm whether the presence of PrP
res 
in early time points originated from 
the inoculum or represented prion infection, another Western blot analysis was 
performed using the 3F4 monoclonal antibody (Figure 3.16). The cell lysates of the 
HK cells exposed to BSE inoculum were investigated, specifically the three cell 






 time points 
respectively, were analysed (with 6H4 in Figure 3.15; c, d, e). If the previously 
detected PrP
res
 originated from newly established infection, it should be detectable by 
the 3F4 antibody which would only detect human PrP
res
, but not PrP
res 
of the 
remaining bovine inoculum. The Western blot of HK cells exposed to BSE 
immobilised inoculum, either Triton X-100 treated (Figure 3.16; lane 1, 3, 5) or 
ribolysed (Figure 3.16; lane 2, 4, 6), did not show detectable, newly formed PrP
res
 
over three weeks post exposure to the brain spiked medium. No PrP
res
 was observed 
when cells were exposed to BSE and analysed by 3F4, suggesting that Western blots 
analysed using 6H4 was actually monitoring the rate at which the inoculum was 
diluted out from the cell cultures. It was concluded from the analysis that PrP
res
 in 
HK cells was lost in long term incubation after repeated passages. 
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Figure 3.16: HK cells infection studies – fifth set (II.) 







), either Triton X-100 treated (lane 1, 3, 5) or ribolysed (lane 2, 4, 6) (as described in 
section 2.9.2.5 or description of figure 3.15; c, d, e) were also analysed using anti-prion 
protein 3F4 monoclonal antibody (recognising human, but not bovine, PrP amino acid 
residues 109-112). Cell samples were routinely processed as described before (section 
2.6.2.2). The vCJD 2B standard (lane 7) was used as a control of PrP migration and blotting 
procedure. The molecular weight, in kDa, is marked left. 
 
3.3.3.7 Sixth set of HK cells challenge with prions 
The strategy of the sixth set of HK challenges was based on the preliminary results of 
reducing of PrP
res
 levels in constitutively infected cell cultures, prion infected mice 
and delay of PrP
res
 formation caused by certain antibiotics or polyene antimycotics 
(Mange et al., 2000a; Mange et al., 2000b; Mange et al., 2002; Weissmann and 
Aguzzi, 2005; Soler et al., 2008). Therefore, in attempt to facilitate PrP
res
 formation 
in the HK cells exposed to prion material, the challenged cells were cultured in the 
cell culture medium without a Penicillin/Streptomycin/Amphotericin 
antibiotics/antimycotics cocktail as Amphotericin B have been reported (Mange et 
al., 2000b; Weissmann and Aguzzi, 2005; Soler et al., 2008) to interfere with 
successful PrP
res
 formation in cultured cells (Figure 3.17). To test whether HK cells 
grown in conditions without antibiotics (ATB) would be more susceptible to 
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infection with prions, the cultures were exposed to ribolysed and sonicated 0.5% 
iCJD2 brain spiked medium without ATB for 4 days (Figure 3.17; A). HK cells 
grown in the culture medium not containing ATB and containing brain homogenate 
for four days showed no differences in morphology when compared to cells cultured 
in complete culture medium. The HK cells given fresh (no ATB) containing medium 
(Figure 3.17; B) and further cultured for three days (Figure 3.17; C) showed some 
contamination with bacterial or fungal conventional agents in the medium and 
moderate (Figure 3.17; B and C) to severe (Figure 3.17; D) changes in cell 
morphology and growth rate could be observed. Despite that, the cultures did not 
undergo apoptosis and were maintained up to 29 days post challenge with prion 
material (Figure 3.17; D) when the cultured cells started to show severe changes in 
morphology and the experiment was terminated. However, staining for presence of 
bacteria in the culture was not performed to verify this assumption. 
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Figure 3.17: Photographs of HK cells cultured in medium without antibiotics after 
exposure to iCJD brain homogenate - HK cells infection studies – sixth set 
Pellets of HK cells were gently resuspended in ribolysed and sonicated 0.5% iCJD2 brain 
spiked medium with omitted Penicillin/Streptomycin/Amphotericin antibiotics/antimycotics 
cocktail (ATB) and plated into fresh cell culture flasks. The cells were incubated with the 
infectious medium for 4 days (A). Then the medium was removed, the cells were washed 
with PBS and further cultured with fresh medium not containing antibiotics for another 4 
days, when the cells were harvested for Western blot analysis. The experiment was carried 
out in duplicate. Cells from one flask were harvested for Western blot analysis and the cells 
from the other flask were split into two flasks and cultured until confluent (B, C) when 
harvesting and splitting process was repeated (as described in section 2.9.2.6). This process 
was repeated up to four passages from cells being exposed to brain material, when the 
experiment was terminated (D). Challenged HK cells given fresh medium not containing 
antibiotics (B) and maintained in this medium for 3 days is shown in (C). The cells were 
observed by a differential interference contrast microscope. Scale bar, 100 µm. 
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HK cells were exposed to the ribolysed and sonicated 0.5% iCJD2 brain spiked 
medium when freshly passaged and were incubated in the infectious medium for four 
days (three days and one day with additional 2 ml of fresh medium, as described in 
section 2.9.2.6). The medium was then withdrawn, cells were rinsed with PBS, given 
fresh (brain-free) culture medium not containing ATB and further maintained for 
four days, when the culture was harvested for PrP
res
 detection by Western blot using 
the 6H4 antibody (Figure 3.18; lane 1). The experiment was carried out in duplicate. 
Cells were maintained for an additional three weeks, consisting of four passages 
representing time points of cell lysates analysed for PrP
res
 (Figure 3.18; lane 2-5). 
The PrP
res
 signal seemed to slowly diminish from the challenged cells by repeated 
passaging. Interestingly, the process of clearance of the PrP
res
 signal seemed to be 
slower when compared with data observed in previous experiments. 
 
Figure 3.18: HK cells infection studies – sixth set  
A pellet of HK cells was gently resuspended in ribolysed and sonicated iCJD2 brain 
homogenate diluted in a cell culture medium without Penicillin/Streptomycin/Amphotericin 
antibiotics (ATB) to 0.5% brain suspension. The cells were subsequently plated into fresh 
cell culture flasks and incubated with the infectious medium for 4 days. The medium was 
then removed, cells were washed and maintained for additional 4 days in a fresh medium 
(free of ATB), when they were harvested for Western blot analysis (lane 1). Experiment was 
carried out in duplicate and as described in section 2.9.2.6. One flask of cells was harvested 
for Western blot analysis and the other flask was split into two flasks and cultured. This 
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procedure was repeated every ~ 5 days (lane 2, 3, 4, 5). The experiment was terminated after 
four passages (p17, lane 5). At each harvesting time point, the cells were extensively 
washed, lysed with extraction buffer, digested with 50 μg/ml PK for 60 minutes at 37 °C and 
then collected by centrifugation at 14,000 rpm for 60 minutes as described in section 2.6.2.2. 
Western blot analysis was routinely carried out using 6H4 primary antibody (as described in 
section 2.7). The molecular weight, in kDa, is marked left. 
 
3.3.3.8 Seventh set of HK cell challenges 
The seventh set of challenges investigated the effect of changes in cell culture 
conditions on cell susceptibility to infection with prions. This attempt was designed 
to examine whether cells grown in poor nutritional conditions (serum starvation - 
low Foetal Calf Serum content, 0.5% FCS) would be more sensitive to infection with 
prion than those grown in complete cell culture medium containing normal level of 
Foetal Calf serum (10% FCS).  
The HK cells were either maintained in a normal medium containing 10% FCS 
(Figure 3.19; A) or a nutrition-low medium containing 0.5% FCS (Figure 3.19; B) 
for 3 days, prior exposure to sonicated 1% iCJD1 brain spiked medium. The brain 
homogenate was diluted in a medium either containing 10% or 0.5% FCS, according 
to the type of medium, the cells were cultured in prior to the exposure. The cells 
were incubated with the brain spiked medium for 48 hours. Homogeneity in HK cell 
morphology could be observed in cell populations maintained under both culture 
conditions, although as anticipated cells grown in poor nutritional conditions (Figure 
3.19; B and D) were observed to have a slower growth during the period of poor 
nutritional conditions, when compared to cells grown in normal conditions (Figure 
3.19; A and C). 
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Figure 3.19: Photomicrograph of HK cells cultured in normal or low nutrient medium  
Pellets of HK cells were resuspended in medium containing normal level of foetal calf serum 
(FCS) – 10% and cultured for 3 days. Then one group of the cells continued culturing in the 
normal medium (A) and the second group was washed with PBS and cultured in poor 
nutritional conditions – medium containing 0.5% FCS (B) for 3 days. The cells were then 
exposed to 1% iCJD1 brain homogenate diluted either in the medium containing 10% FSC 
(C) or 0.5% FCS (D) for 48 hours. The cells were exposed to dilution type corresponding to 
the type of medium they were cultured prior challenge with brain spiked medium. The cells 
were observed using a differential interference contrast microscope. Scale bar, 100 µm. 
 
HK cells were analysed for PrP
res
 by Western blot at 24 (Figure 3.20; Aa and Ba, 
lane 1) and 48 hours (Figure 3.20; Aa and Ba, lane 2) of exposure to the brain spiked 
medium. At this time point, a strong signal for cell-associated PrP
res
 was observed in 
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cells maintained in normal nutritional conditions (Figure 3.20; Aa, lane 1 and 2). 
Interestingly, the signal of cell-associated PrP
res
 in cell lysates from cells cultured in 
poor nutritional conditions appeared weaker (Figure 3.20; Ba, lane 1 and 2) when 
compared to cells grown in normal conditions. This may be the result of a lower rate 
of cell division, and therefore fewer cells being present at the time of harvesting 
when compared to normal cell growth conditions.  
After 48 hours the brain spiked medium was removed, cells were rinsed with PBS 
and given fresh (brain-free) cell culture medium containing either 10% or 0.5% FCS. 
The cultures were allowed to grown for a further three days.  
The experiment was carried out in duplicate. One flask of cells was then harvested 
for Western blot analysis (Figure 3.20; Aa and Ba, lane 3) at a three day recovery 
time point. At that point, all challenged cells were given complete cell culture 
medium (containing 10% FCS). Medium changes took places every three days. 
Analysis for PrP
res
 was then carried out on the 6
th
 (Figure 3.20; Aa and Ba; lane 4) 
and the 9
th
 (Figure 3.20; Aa and Ba, lane 5) days of culturing with complete and 
brain-free medium. Another analysis for PrP
res
 was performed after the first passage 
on the 12
th
 (Figure 3.20; Aa and Ba, lane 6), 24
th
 (Figure 3.20; Aa and Ba, lane 7) 
and in the second passage on the 40
th
 day of recovery (Figure 3.20; Aa and Ba, lane 
8). In both groups, 10% FCS and 0.5% FSC, the previously observed cell-associated 
PrP
res
 signal was seen to slowly diminish. In this assay, the medium cultured with the 
cells was also analysed for PrP
res
, to determine whether the previously cell-associated 
PrP
res
 was then shed back to the culture medium, or whether it might be degraded by 
the cell’s proteolytic machinery. A gradual loss of PrP
res
 from the medium was 
observed (Figure 3.20; Ab and Bb, lane 1 and 2) concomitant with its appearance as 
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cell-associated PrP
res
 (Figure 3.20; Aa and Ba, lane 1 and 2). However, the analysis 
of the medium at recovery time points did not show any detectable PrP
res
 shed back 
to the medium (Figure 3.20; Ab and Bb, lane 3-8). Neither could it be detected as cell 
associated in cell lysates at these later time points (Figure 3.20; Aa and Ba, lane 5-8). 
 
Figure 3.20: Seventh set of HK cells infection (cells cultured in normal or nutrient-low 
conditioned medium) 
HK cells were either maintained in a normal medium (containing 10% FCS) (A) or a 
nutrition-low medium (0.5% FCS) (B) for 3 days prior exposure to the 1% iCJD1 brain 
spiked medium for 48 hours. This brain spiked medium contained either 10% or 0.5% FCS, 
according to the type of medium cells were cultured in prior exposure. Cells were harvested 
for Western blot analysis at 24 (lane 1) and 48 hours (lane 2) of continuous exposure. The 
medium was then removed, the cells were washed and further cultured with a fresh culture 
medium (containing either 10% or 0.5% FCS) for 3 days and then the cells were harvested 
for Western blot analysis (lane 3). At this point, both groups of cells were given a fresh 
medium containing 10% FCS. Analysis for PrP
res
 was carried out on, the 6
th
 (lane 4), the 9
th
 
(lane 5) days of culturing with complete and brain-free medium, also after 1
st
 passage and on 
the 12
th
 (lane 6), the 24
th
 (lane 7) and the 2
nd
 passage on the 40
th
 day of recovery (lane 8). At 
each harvesting time point, the medium cultivated with cells was retained (b) and the cells 
(a) were extensively washed and lysed with extraction buffer. Both (cells and medium) were 
then digested with PK and then collected by centrifugation as described in sections 2.6.2.2 
and 2.6.3. Western blot analysis was routinely carried out using 3F4 primary antibody (as 
described in section 2.7). The vCJD 2B standard (lane 9) was used as a control of PrP 
migration and blotting procedure. The molecular weight, in kDa, is marked left on each blot. 
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3.3.3.9 Evaluation of PrP
res
 tendency to bind to the plastic surfaces 
A control experiment investigating the potential of PrP
res
 binding to plastic was also 
carried out. This was to determine whether there was any potential of PrP
res
 in these 
experiments to strongly bind to the plastic surface of the cell culture flasks, which 
could be wrongly considered as cell associated PrP
res
 when cells were exposed to 
infection brain material and harvested for Western blot analysis. Cell culture flasks 
(not containing cells) were incubated with either 0.15% ribolysed, sonicated and 
filtered (ryb/son/filt) iCJD1 or 0.05% Triton X-100 treated brain spiked medium for 
28 hours. The input of ryb/son/filt 0.15% iCJD is shown in Figure 3.21; lane 1. The 
input of 0.05% Triton X-100 treated iCJD is shown in Figure 3.21; lane 5 (note that 
this sample was not PK treated before Western blot analysis). The flasks were 
washed with PBS and then scraped with extraction buffer, like in all previous 
experiments, as they would contained cell culture (as described in section 2.6.2.2) 
and the suspensions were retained. The suspensions were then PK treated and 
analysed by Western blot using the 6H4 antibody. No PrP
res
 was detected after 28 
hours of incubation of the iCJD brain spiked medium (both ryb/son/filt 0.15% or 
0.05% Triton X-100 treated) on the surface of the plastic cell culture flasks (Figure 
3.21; lane 2, 6, respectively). The medium incubated for 28 hours in the flasks was 
also retained, PK treated and processed for Western blot analysis (as described in 
section 2.6.3). PrP
res
 was detected in the medium (Figure 3.21; lane 3 and 7). The 4
th
 
PBS rinse of the cell culture flasks was also retained and analysed (Figure 3.21; lane 
4 and 8). No PrP
res
 could be detected in the 4
th
 PBS rinse, which confirmed that four 
PBS washes were sufficient enough to wash any unbound prion material from the 
cell culture surface in the infection assays.  
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Figure 3.21: Evaluation of PrP
res
 tendency to bind to the plastic surfaces  
Two cell culture T25 flasks were incubated with the brain spiked medium: 0.15% ribolysed 
and sonicated iCJD1 (lane 1-4) and 0.05% Triton X-100 treated iCJD1 (lane 5-8) for 28 
hours. The medium was then withdrawn and transferred in tubes, flasks were rinsed four 
times with PBS and the 4
th
 wash was retained. Volume of 100 µl extraction buffer was added 
to the flasks and scraped into tubes. All samples were then PK digested and then collected by 
centrifugation as described in sections 2.6.2.2 and 2.6.3. Western blot analysis was carried 
out using 6H4 primary antibody (as described in sections 2.7). The vCJD 2B standard (lane 
9) was used as a control of PrP migration and blotting procedure. The molecular weight, in 
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3.3.4 Summary 
 Despite the wide variety of inoculum and exposure protocols employed, these 
data lead to the conclusion that HK cells are largely resistant to infection with 
human and bovine prions or that they are not able to sustain prion infection.  
 Even when human adapted prions (iatrogenic CJD) of the appropriate PRNP 
codon 129 genotype were used, no evidence was found for a stable infection 
of the HK cells.  
 The most likely explanation for the PrPres signal observed in Western blots of 
the cell lysates from cells exposed to prion disease brain material at early 
time points is that it represents residual inoculum, which was then lost during 
longer term culturing and subsequent passages and analysis using the 3F4 and 
6H4 antibody in cells exposed to BSE is consistent with this explanation.  
 The mechanism by which cell-associated PrPSc is lost during this process is 
not known, but is of interest and was investigated later in this project. 
 Despite the findings in here, it cannot be completely discounted that some 
HK cells may suffer a transitory or perhaps fatal prion infection within the 
exposed cultures.  
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3.4  WESTERN BLOT ANALYSIS OF HK CELLS FOR PRP
SC
 UPTAKE 
AFTER ACUTE EXPOSURE TO PRION DISEASED BRAIN MATERIAL 
 
3.4.1 Objectives 
To attempt to quantitate HK cell uptake of exogenous PrP
Sc
 after an acute exposure 
to prion diseased brain material. 
 
3.4.2 Rationale 
The previous experiments (section 3.3) showed that after exposure to infectious prion 
brain material, regardless of the prion agent, the HK cells were not able to support 
PrP
Sc
 replication and propagate prion infection in vitro. It was therefore of interest to 
examine the interactions between PrP
Sc
 and human FDC-like HK cells during the 
acute stage of exposure to infectious prions and also to investigate whether there was 
any evidence of an initially successful, although transient, infection. 
 
3.4.3 Experimental results 
To determine the rate the exogenous PrP
Sc 
is taken up by HK cells, the infectious 
brain homogenate was diluted in medium and incubated with the cells for a range of 
times (as described in section 2.10). At each time point the medium incubated with 
the cells was withdrawn (and retained for analysis), cells were extensively washed 






 PBS wash were retained 
for analysis) and the cells were solubilised in detergent-containing lysis buffer. Then 
the samples were PK digested and insoluble material pelleted by hard spin as 
described in sections 2.6.2.2 and 2.6.3 and the pellet was assayed for PrP
Sc
 by 
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 uptake by HK cells analysed by WB is representative of eight independent, 
but non-identical experiments (in the case of cells exposure to iCJD) and three 
independent, non-identical experiments in the case of cells exposure to vCJD. The 
differences involved the time points assayed (not all data are shown). 
 
3.4.3.1 Uptake of PrP
Sc
 by HK cells after incubation with iCJD brain homogenate 
(time points: 30 minutes – 48 hours of continuous exposure) 
Firstly, to investigate the rate at which the PrP
Sc 
was taken up, the cells were exposed 
to 0.05% iCJD brain homogenate and analysed for presence of any cell associated 
PrP
Sc
 as described in section 2.10.1 and summarised in Figure 3.22.  
The results showed that PrP
Sc 
uptake is very rapid. Cell associated PrP
Sc 
was faintly 
detectable in cell lysates at 1 hour (A, lane 4) and readily detectable after 2 hours of 
incubation (A, lane 5). The intensity of cell-associated PrP
Sc
 signal increased with 
time of exposure (A, lane 4-9), while the PrP
Sc
 signal started to reduce in the medium 
at 6 hours of incubation (B, lane 7) and became undetectable in the iCJD brain 
spiked medium after 24 – 48 hours of incubation (B, lane 8, 9). A faint PrP
Sc
 signal 
was present in the 1
st
 PBS wash of exposed cells (C), but PrP
Sc 
could not be detected 
in 4
th
 PBS wash (D), indicating that any residual unbound PrP
Sc 
was effectively 
removed from the cell monolayer by four rinses of PBS and that the PrP
Sc 
signal 
detected in cell lysate (A) was firmly cell-associated.  
The remaining PrP
Sc 
from the input could be detected in the medium analysed from 
this time point only faintly (B, lane 8), suggesting that the remainder of the PrP
Sc 
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from the input was most likely poorly cell associated (bound to the cell surface) and 
was effectively washed off by the four PBS rinses foregoing cell harvesting. 
 
 
Figure 3.22: Representative Western blot analysis of cell associated PrP
Sc
 after HK cells 
incubation with iCJD brain homogenate (time points: 30 minutes – 48 hours of 
continuous exposure) 
HK cells continuously incubated with a 0.05% iCJD1 brain spiked medium were harvested 
for Western blot analysis at various time points (as described in section 2.10.1 and marked 
on the figure). Briefly, cell samples (A) were extensively washed, lysed with extraction 
buffer, digested with 50 μg/ml PK for 60 minutes at 37 °C and then collected by 





 (D) PBS wash of each time point were also retained, PK treated and collected by 
centrifugation. (A, lane 1) corresponds to the exact iCJD input of each time point. Pellets of 
all samples were resuspended in an appropriate volume of sample buffer and subjected to 
Western blot analysis using mAb 3F4. The vCJD 2B standard (lane 10) was used as a control 
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3.4.3.2 Uptake of PrP
Sc
 by HK cells after incubation with vCJD brain homogenate 
(time points: 30 minutes – 48 hours of continuous exposure) 
vCJD was also used to investigate potential strain-specific differences in PrP
Sc
 
uptake by HK cells after acute exposure to prion diseased medium. The HK cells 
were exposed to 0.02% vCJD brain homogenate as described in section 2.10.1 and 
analysed for the rate of PrP
Sc
 uptake from this brain homogenate is shown in Figure 
3.23. Preparation of the samples was the same as described in the previous 
experiment. 
The result of PrP
Sc
 uptake from vCJD spiked medium was qualitatively similar to the 
previous observations using iCJD. (A, lane 1) corresponds to the exact vCJD input 
for each time point. The signal of cell-associated PrP
Sc
 was already detectable at 1 
hour of exposure (A, lane 4) and the amount of cell-associated PrP
Sc
 increased with 
time of exposure (A, lane 4-9). In addition, the PrP
Sc
 signal was lost from the brain 
spiked medium after 48 hours of incubation (B, lane 9). PrP
Sc
 was just detectable in 
the pellet from high speed spin of the 1
st
 PBS wash (C), but could not be detected in 
the 4
th
 PBS wash (D), indicating that any residual unbound PrP
Sc 
was effectively 
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Figure 3.23: Western blot analysis of cell associated PrP
Sc
 after HK cells incubation 
with vCJD brain homogenate (time points: 30 minutes – 48 hours of continuous 
exposure) 
HK cells continuously incubated with a 0.02% vCJD brain spiked medium were harvested 
for Western blot analysis at various time points (as described in section 2.10.1 and marked 
on the figure). The cell samples (A) were extensively washed, lysed with extraction buffer, 
digested with 50 μg/ml PK for 60 minutes at 37 °C and then collected by centrifugation at 
14,000 rpm for 60 minutes as described in section 2.6.2.2. (A, lane 1) corresponds to the 
exact vCJD input for each time point. The medium (B), 1
st
 (C) and 4
th
 (D) PBS wash of each 
time point were also retained, PK treated and collected by centrifugation as described in 
section 2.6.3. The pellets were resuspended in an appropriate volume of sample buffer and 
subjected to Western blot analysis using mAb 3F4. The vCJD 2B standard (lane 10) was 
used as a control of PrP migration and blotting procedure. The molecular masses are shown 
in kDa, left on each blot. 
 
 
3.4.3.3 Uptake of PrP
Sc
 by freshly plated HK cells and incubated with iCJD brain 







passage post exposure – 51 days) 
The next experiment was designed to investigate whether passaging of the cells 
delays the PrP
Sc
 uptake into the freshly plated cells. The experiment was designed as 
described in section 2.10.2. Cell pellets of the HK cells were gently resuspended in 
0.05% iCJD brain spiked medium. Then the cells were plated into fresh cell culture 
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flasks and continuously incubated with the infectious medium up to 48 hours or until 
harvested for analysis for cell associated PrP
Sc
 at a range of early time points as 
shown in Figure 3.24. The samples analysed by Western blot were the same as in 




 PBS wash. 
A cell associated PrP
Sc 
signal was detected at 6 hours of exposure (A, lane 4). Then 
the infectious medium was withdrawn, cells were washed, split at a ratio of 1:2 by 
passaging and allowed to grow in fresh (unspiked) complete cell culture medium 
until 51 days from exposure, which consisted of three cell passages analysed at each 
time point (A, lane 7-9). The amount of cell-associated PrP
Sc
 increased with time of 
exposure (A, lane 2-6) and the PrP
Sc
 signal became barely detectable in the brain 
spiked medium after 48 hours of incubation with HK cells (B, lane 6). However, the 
cell associated PrP
Sc 
could not be detected at any time points following the first cell 
passage and culturing of the cells for 18 days (A, lane 7). Neither was it detectable 
after the next two passages (A, lane 8, 9). PrP
Sc 





 (D) PBS wash either. 
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Figure 3.24: Western blot analysis of cell associated PrP
Sc
 after HK cells incubation 







 cell passage post exposure – 51 days) 
Pellets of HK cells (after centrifugation step in cell culture passaging procedure) were 
resuspended in a complete cell culture medium containing iCJD1 brain homogenate at 
concentration 0.05% (A, lane 1 – input) and incubated at 37 °C. Cells were then harvested at 
various time points (as described in section 2.10.2 and marked on the figure). Harvested cells 
(A), medium (B), 1
st
 (C) and 4
th
 (D) PBS wash of each time point were retained, PK treated 
and collected by centrifugation at 14,000 rpm for 60 minutes. The pellets were resuspended 
in an appropriate volume of sample buffer and subjected to Western blot analysis using mAb 
3F4. The cell passages analysed at days from exposure to brain spiked medium are marked 
as p13 (lane 7), p14 (lane 8), and p15 (lane 9). The vCJD 2B standard (lane 10) was used as 
a control of PrP migration and blotting procedure. The molecular weight, in kDa, is marked 
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3.4.3.4 Analysis of PrP
Sc
 uptake after HK cells were continuously incubated with 
iCJD brain homogenate for 24 hours followed by a 24 hours recovery and culturing 
of the cells until senescent  
It was of interest to re-test whether the iCJD exposed HK cells might be replicating 
PrP
Sc
 at levels undetectable by Western blot at earlier time points post-exposure and 
culturing, and whether the PrP
Sc 
signal would appear in the cells at detectable levels 
after long-term culturing. Accordingly, the cells were cultured and analysed until 
becoming senescent at 177 days post-exposure to iCJD brain spiked medium. The 
experiment was designed as described in section 2.10.3 and the HK cells were 
analysed for cell-associated PrP
Sc
 as shown in Figure 3.25. The cells were 
continuously exposed to 0.05% iCJD1 brain spiked medium for 24 hours. The 
intensity of cell-associated PrP
Sc
 signal increased with time of exposure (A, lane 2-
5), while the PrP
Sc
 signal was barely detectable in the medium after 24 hours of 
incubation (B, lane 5). Then the infectious medium was removed, and the cells were 
washed and cultured in fresh (unspiked) complete culture medium for 24 hours. PrP
Sc
 
was detected in the cell lysate after the 24 hours recovery (A, lane 6).  
Interestingly, the signal at this time point appeared to be more intense than in the cell 
lysate of cells analysed after the 24 hours exposure (A, lane 5).  
No PrP
Sc
 could be detected in medium cultured with the cells after 24 of hours 
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Figure 3.25: Western blot analysis of cell associated PrP
Sc
 after HK cells continuous 
incubation with iCJD brain homogenate for 24 hours followed by a 24 hours recovery 
and culturing of the cells until senescent  
HK cells continuously incubated with the 0.05% iCJD1 brain spiked medium (A, lane 1 – 
input) were harvested for Western blot analysis of any cell associated PrP
Sc
 at 1, 3, 6, and 24 
hours of incubation (lane 2, 3, 4, and 5 respectively). The cells were then extensively washed 
and cultured with fresh medium for another 24 hours - recovery (48 hours time point, lane 
6). Subsequently the cells were split at 1:2 ratio and continuously cultured until senescent 
(p19, lane 13) preserving each passage as a time point for Western blot analysis (lane 7-13). 
Scheme of the experiment was shown in 2.10.3. Harvested cells (A), medium (B), 1
st
 (C) and 
4
th
 (D) PBS wash of each time point were treated as described previously in sections 2.6.2.2 
and 2.6.3 and subjected to Western blot analysis using mAb 3F4. The vCJD 2B standard 
(lane 14) was used as a control of PrP migration and blotting procedure. The molecular 
weight, in kDa, is marked left on each blot. 
 
3.4.3.5 Detailed course of the uptake and clearance of exogenous PrP
Sc 
by HK cells 
exposed to iCJD  
To determine the course of PrP
Sc 
uptake by HK cells exposed to prion diseased 
medium and its subsequent loss from the cells after the medium was withdrawn, a 
further experiment was designed as shown in Figure 3.26. Based on previous 
observations, the time points in this assay were considered sufficiently frequent 
enough to allow the course to be ascertained. The cells were firstly continuously 
exposed to a 0.05% iCJD brain-spiked medium for 48 hours (A, lane 2-5). The 
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medium was then removed, cells were washed and allowed to grow in fresh (prion 
disease brain-free) medium for up to 120 hours of the recovery (with media changes 
every 24 hours) (A, lane 6-10). The analysis was terminated after the 1
st
 passage of 
the cells (A, lane 11).  
The observations indicated a gradual PrP
Sc 
uptake from the brain-spiked media by the 
exposed cells (A, lane 2-5). Interestingly, the cell-associated PrP
Sc 
signal was more 
intense in cell lysate at the 1, 3, and 24 hours recovery time points (A, lane 6-8) 
when the cells were transferred into fresh medium (when compared to 24-48 hours of 
continuous exposure; A, lane 4, 5), but the signal gradually diminished with further 
recovery time (A, lane 9-10). After the 1
st
 passage, the cell-associated PrP
Sc 
could not 
be detected in the cell lysate any more (A, lane 11). The medium incubated with the 
cells (B), 1
st
 (C) and 4
th
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Figure 3.26: Representative Western blot analysis of cell associated PrP
Sc
 after HK cells 
continuous incubation with iCJD brain homogenate for 48 hours and subsequent 
culturing in fresh medium for 120 hours - recovery 
HK cells were continuously exposed to a 0.05% iCJD1 brain spiked medium (A, lane 1 – 
input) for 48 hours and analysed for cell associated PrP
Sc
 at 1, 5, 24, and 48 hours (lane 2, 3, 
4, and 5 respectively). The cells were then extensively washed and allowed to grow in fresh 
complete medium for 120 hours with three medium changes - recovery. Cells were analysed 
at 1, 3, 24, 48, and 120 hours of the recovery time (lane 6, 7, 8, 9, and 10 respectively). 
Subsequently the cells were split at ratio 1:2 and grow until confluent when analysed as 
another time point (lane 11 – 1
st
 passage). Harvested cells (A), medium (B), 1
st
 (C) and 4
th
 
(D) PBS wash of each time point were treated as described previously in sections 2.6.2.2 and 
2.6.3 and subjected to Western blot analysis using 6H4 monoclonal antibody. The molecular 
weight, in kDa, is marked left on each blot. 
 
3.4.3.6  Densitometric assessment of the time-course of PrP
Sc
 uptake by HK cells 
after incubation with iCJD or vCJD brain homogenate  
The uptake of PrP
Sc
 by HK cells exposed to medium containing iCJD or vCJD brain 
homogenates monitored by Western blot analysis was also evaluated by 
densitometry. This was carried out to support the observation that the level of cell 
associated PrP
Sc
 does increase with the time of cell exposure to prion spiked medium 
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(Figure 3.27 and 3.28). The assessment method is described in Materials and 
Methods section (2.10.5).  
 
Figure 3.27: Assessment of the time-course of PrP
Sc
 uptake by HK cells after incubation 
with iCJD or vCJD brain homogenates 
(A) Western blot analysis of the the PrP
Sc
 uptake by HK cells in the period of 48 hours 
exposure to either iCJD or vCJD brain homogenates. (B) PrP
Sc
 signal values assesed by 
densitometry. (C) The graph represents a quantitative assessment of vaules of PrP
Sc
 signal 




Another example of densitometric assessment of the time-course of PrP
Sc
 uptake by 
HK cells after incubation with iCJD brain homogenate is shown in Figure 3.28. 
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Figure 3.28: Assessment of the time-course of PrP
Sc
 uptake by HK cells after incubation 
with iCJD brain homogenate  
(A) Western blot analysis of the the PrP
Sc
 uptake by HK cells in the period of 48 hours 
exposure to iCJD brain homogenate. (B) PrP
Sc
 signal values assesed by densitometry. (C) 
The graph represents a quantitative assessment of vaules of PrP
Sc
 signal portrayed as an 




The densitometric assessments of the Western blots revealed a rising trend of the cell 
associated PrP
Sc
 signal increasing with the time of HK cells exposure to a medium 





Chapter 3   Results 
  164 
3.4.4 Summary 
 This study shows that the HK cells exposed to medium containing CJD brain 
homogenate gradually take up PrP
Sc
, and presumably prion infectivity, 
present in the medium.  
 The uptake of PrPSc was rapid and the amount of HK cell-associated PrPSc 
increased with time of exposure to the spiked medium. This trend was also 
confirmed by a densitometric assessment. 
 Judged by the gradual uptake and subsequent loss of PrPSc in the cells 
exposed to prion infectious medium and then cultured in fresh medium, it 
appears that the PrP
Sc 
is most likely actively internalised and then either 
degraded or excreted by the cells.  
 Interestingly, the cell-associated PrPSc signal appeared to be more intense in 
initial hours of recovery than in the cell lysate just before the removal of 
infectious medium. Nevertheless, the signal diminished by the 48 hours 
recovery and was lost completely after the 1
st
 passage. 
 Whether an acute new PrPSc formation can be initiated in these cells without 
leading to sustainable PrP
Sc 
formation in these cells needs to be investigated 
further. 
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3.5 PRP
SC
 UPTAKE ANALYSED BY IMMUNOCYTOCHEMISTRY 
 
3.5.1 Objectives 




The study of prion transmission and targeting are major scientific issues with 
important consequences for public health. Although cells persistently infected with 
infectious prion agent have provided important insights into the cellular biology of 
PrP
Sc
 formation during infection, very little is known about how exogenous PrP
Sc
 is 
initially taken up by the cell.  
To address this, the exogenous PrP
Sc
 uptake was earlier analysed by Western blot 
(3.4). This method provides valuable results, but for a more precise examination and 
visualisation of how cells (the HK cells and hESC) respond to acute exposure of 
prion disease brain material, fluorescent immunocytochemistry visualised by 
confocal microscopy was used. Moreover, the hESC cultures are expensive and time-
consuming to prepare in bulk and analysing them by ICC was considered to be a 
practical and highly informative alternative to Western blot. 
The PrP
Sc
 uptake by HK cells and hESC analysed by ICC shown below is 
representative of more than twelve independent identical and non-identical 
experiments. The differences included the time points assayed, the origin of the 
inoculum and the use of pre-treatments during the immunocytochemical procedure 
(not all data are shown). 
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3.5.3 Experimental results 
3.5.3.1 Immunocytochemistry as a tool for analysing the cell response to exposure 
with prion infected brain homogenates 
For the investigation of the exogenous PrP uptake by hESC or HK cells following 
experimental design was applied (Figure 3.29). Cells were plated one day before 
exposure at low density as immunocytochemical analysis is more clear and 
informative in cells which are spread out rather than tightly packed next to each 
other. The inocula were composed of sonicated brain homogenate (BSE, vCJD, 
iCJD, sCJD, AD, bovine negative) diluted to 1% with complete culture medium. The 
sonication step was applied to break down the PrP
Sc
 aggregate size as this can 
strongly affect the efficiency of cellular uptake, the mode of endocytosis and the 
subsequent efficiency of particle processing along the endocytic pathway (Magalhaes 
et al., 2005; Baron et al., 2006; Greil et al., 2008) (our previous Western blot 
observations). Cells were exposed to spiked medium for the desired time period and 
then extensively washed and immunostained for PrP (as described in section 2.12) 
with one of the anti-PrP protein primary antibodies 3F4 (recognising human amino 
acid residues 109-112), 6H4 (recognising PrP residues 142-155) or 8H4 (recognising 
human PrP epitope 175-185). The slides were then examined by fluorescent confocal 
microscopy. It is important to note that the photomicrographs presented in this thesis 
truly reflect the overall situation of the whole cell culture population observed in the 
analysed well.  
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Figure 3.29: Immunocytochemistry as a tool for analysing the cell response to exposure 
with prion diseased brain homogenates  
Cells were plated onto glass chamber slides one day before exposure to brain spiked 
medium. The 10% prion diseased brain homogenates were sonicated to reduce aggregate size 
and diluted in complete cell culture medium to 1% of the brain spiked medium. The cells 
were then continuously exposed to this prepared inoculum for the desired time and 
extensively rinsed before immunostaining procedure. Cells were stained; either live (2.12.1); 
or fixed and permeabilised (2.12.2) (as shown on this figure-right); or fixed, permeabilised 
and denaturated (2.12.3). Primary anti-PrP antibodies employed in throughout this assay 
were 8H4, 6H4, or 3F4. Secondary antibody used for detection the PrP was FITC Alexa 488. 
The nuclei were counterstained with DAPI (blue). Scale bar, 20 µm.  
 
3.5.3.2 Morphology of hESC of the RCM-1 cell line, RH1 cell line and the human 
FDC-like HK cells analysed prior and post exposure to brain spiked medium 
Firstly, a general cellular response to exposure of brain material was examined 
(Figure 3.30). The undifferentiated hESC of the RCM-1 cell line (top row), RH1 cell 
line (centre row) and the FDC-like HK cells (bottom row) were grown in a control 
medium (left column) or exposed to vCJD brain spiked medium (right column) for 
48 hours. Exposure to brain homogenate did not result in gross changes in cell 
morphology or viability as judged by regular observation of the cultures using 
differential interference contrast microscopy and parallel comparison with unexposed 
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control cultures. Although brain homogenate is likely to contain both trophic and 
toxic molecular stimuli, no gross observable changes were seen even with prolonged 
exposure under the conditions used.  
 
Figure 3.30: Morphology of hESC of the RCM-1 cell line and RH1 cell line and human 
FDC-like HK cells prior and post exposure to brain spiked medium 
The cells were monitored using a differential interference contrast cell culture microscope 
prior (left column) and post 48 hours incubation with 1% vCJD brain spiked medium (right 
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3.5.3.3 Adjustment of the signal threshold characteristic for PrP
Sc
  
Due to the lack of PrP
Sc 
specific antibodies to specifically visualise cell-associated 
exogenous PrP
Sc
, a denaturation step with guanidine pre-treatment (Gnd) was 
required. This pre-treatment diminishes PrP
C
 and enhances PrP
Sc
 signal in exposed 





Therefore, a stringent approach of advanced fluorescence microscopy imaging 





 by adjusting the immunofluorescence signal threshold characteristic 
for PrP
Sc
 in cells exposed to prion infectious brain homogenates was employed 
(Figure 3.31). 
A similar thresholding approach discriminating the lower PrP
C 
fluorescence in order 
to extract only the higher fluorescence signal of PrP
Sc
 was recently proved useful by 
Veith and colleagues (Veith et al., 2009).  
First, unexposed HK cells were stained without employing a digestion/denaturation 
step by PK/Gnd pre-treatment (A) or with pre-treatment (B) and the detectable level 
of PrP
C
 expressed by these cells was visualised. Faint punctuate staining of 
unexposed HK cells in the absence of the digestion/denaturation pre-treatment was 
indicative of PrP
C
 (A). Loss of this signal following digestion/denaturation pre-
treatment confirmed that the signal is PrP
C
 (B). The HK cells exposed to vCJD 
spiked medium for 48 hours were also immunostained without (C) or with (D) the 
PK/Gnd pre-treatment. Extensive diffuse and granular staining of vCJD brain 
homogenate exposed HK cells in the absence of digestion/denaturation pre-treatment 
was indicative of mixture of PrP
Sc
 (C-bright green) and PrP
C 
(C-faint green). Very 
bright granular peri-nuclear staining in vCJD brain homogenate exposed HK cells 
following digestion/denaturation pre-treatment suggesting specific detection of PrP
Sc
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under these conditions (D). The analysis of cells exposed to vCJD and pre-treated 
with PK/Gnd showed the signal intensities characteristic of PrP
Sc
 staining (D) and 
this threshold was taken in account for further detection of PrP
Sc
 only in cells 
exposed to prion infected brain material.  
 
Figure 3.31: Signal threshold characteristic for PrP
Sc
  





 signals by immunofluorescence. Control HK cells were cultured in 
control medium and immunostained without (A) or with denaturation step (PK/Gnd) (B). 
Cells exposed to 1% vCJD for 48 hours and immunostained without denaturation step (C) 
and with denaturation step (D). Cells were immunostained for PrP with the antibody 6H4 
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3.5.3.4 Progressive PrP
Sc
 uptake by the hESC of the RCM-1 line continuously 
exposed to BSE and vCJD brain homogenates analysed by immunocytochemistry 
In order to ascertain how hESC respond to acute exposure of infectious brain 
material and to monitor the fate of exogenous PrP
Sc
 in the culture (Figure 3.32), the 
hESC of the RCM-1 cell line (PRNP codon 129-MM genotype) were continuously 
exposed to crude sonicated 1% extracts of BSE (A, E, I), vCJD (B, F, J) and AD (C, 
G, K) brain homogenates, or grown in a control medium (D, H, L) for 1 (A-D), 24 
(E-H), and 48 hours (I-L). The presence and the intracellular distribution of PrP
Sc
 
within individual cells was then visualised by routine immunostaining employing 
8H4 antibody and confocal analysis. Unexposed hESC and those exposed to AD 
brain homogenate showed no detectable PrP
C
 under the immunostaining conditions 
used in this experiment. However, RCM-1 cells exposed to BSE (A, E, I) and vCJD 
(B, F, J) brain material showed intense staining of PrP
Sc
, increasing with exposure 
time, suggesting uptake of PrP
Sc 
from the spiked medium.  
The staining pattern of cells exposed to BSE or vCJD brain were similar indicating 
no pronounced species or strain-related selectivity of the internalisation process. PrP
C 
expressed by the hESC was not detectable under these experimental conditions (D, 
H, L). 
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Figure 3.32: Progressive PrP
Sc
 uptake in hESC RCM-1 line continuously exposed to 
BSE and vCJD brain homogenates analysed by immunocytochemistry 
RCM-1 cells (PRNP codon 129-MM genotype) were exposed to BSE (A, E, I), vCJD (B, F, 
J), or AD (C, G, K) 1% brain homogenate, or grown in control medium without brain 
homogenate (D, H, L) for 1 hour (A-D), 24 hours (E-H) or 48 hours (I-L). The cells were 
then extensively washed, fixed, permeabilised and immunostained for PrP with the antibody 
8H4 recognising human PrP epitope 175-185 (green), and the nuclei counterstained with 




 uptake by the hESC of the RH1 line continuously exposed 
to BSE and vCJD brain homogenate analysed by immunocytochemistry 
The results were similar when hESC of the RH1 line (PRNP codon 129-MV 
genotype) (Figure 3.33) were exposed to BSE (A, E, I), vCJD (B, F, J), AD (C, G, K) 
or grown in control medium (D, H, L). The pattern of PrP
Sc
 immunostaining was 
observed in both vCJD and BSE, increasing with exposure time, as previously 
observed in RCM-1 line.  
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PrP
Sc
 uptake into the undifferentiated human embryonic stem cells for each given 
time point showed that in both cell lines, there were no apparent differences in PrP
Sc
 
uptake amongst the different prion strains. It seemed that majority of the cells in 
cultures after exposure to either BSE or vCJD were positive for cell associated PrP
Sc
, 





Figure 3.33: Progressive PrP
Sc
 uptake in hESC RH1 line continuously exposed to BSE 
and vCJD brain homogenate analysed by immunocytochemistry 
RH1 cells (PRNP codon 129-MV genotype) were exposed to BSE (A, E, I), vCJD (B, F, J), 
or AD (C, G, K) 1% brain homogenate, or grown in control medium without brain 
homogenate (D, H, L) for 1 hour (A-D), 24 hours (E-H) or 48 hours (I-L). The cells were 
then extensively washed, fixed, permeabilised and immunostained for PrP with the antibody 
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3.5.3.6 Undifferentiated hESC retain their pluripotent state after being exposed to 
brain homogenate 
To ascertain how the undifferentiated human embryonic stem cells react to exposure 
of infectious brain material, their pluripotent state was examined at 48 hours post 
exposure to prion infectious brain material (Figure 3.34). To put it briefly, the hESC 
of the RCM-1 line were exposed to vCJD spiked medium for 48 hours. Then the 
medium was removed, the cells were washed, fixed, permeabilised and double 
immunolabeled for PrP using the 6H4 antibody (A) and the NANOG antibody 
detecting stem cell pluripotency factor (B).  
The stem cell pluripotency factor is only expressed in nucleus of stem cells retaining 
their undifferentiated phenotype (Pan and Thomson, 2007). The merge of the 
channels is shown in (C). The majority of cells which showed positive intracellular 
PrP
Sc
 immunostaining (suggesting uptake of exogenous PrP
Sc
) (green, A-arrow) also 
displayed the pluripotency factor in their nucleus (pink, B-arrow). Stem cell cultures 
are, however, not homogeneous and do produce partially differentiated derivative 
cells as a normal part of their growth. These cells do not produce pluripotency factor 
any more and are negative for staining with NANOG (blue, B). The merge (red, C) 
indicates that majority of cells positive for PrP
Sc
 uptake were the undifferentiated 
hESC (arrow), and exposure to brain material did not encourage them to differentiate 
towards a random phenotype in the observed 48 hours of exposure.  
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Figure 3.34: Undifferentiated hESC retain their pluripotent state after being exposed to 
brain homogenate  
The RCM-1 cell line was exposed to 1% vCJD brain spiked medium for 48 hours. The cells 
were then washed, fixed, permeabilised and immunostained for PrP with mAb 6H4 (A) 
(green) and stem cell pluripotency marker NANOG (B) (pink) as described in section 2.12.4. 
Merge of FITC (PrP
Sc
) and red (NANOG) channels is shown in (C). The cells’ nuclei were 





 uptake in extraneuronal lymhoreticular FDC-like HK cell line 
continuously exposed to iCJD, sCJD and vCJD brain homogenates analysed by 
immunocytochemistry  
To visualise how the HK cells (PRNP codon 129-VV genotype) respond to acute 
exposure of infectious brain material, the fate of PrP
Sc
 added to these culture was 
also monitored by immunocytochemistry (Figure 3.35). Cells were exposed to crude 
sonicated extracts of iCJD1 (A), sCJD3 (B), vCJD (C), AD (D) or cultured 
unchallenged (E) for 48 hours. Then the cells were fixed, permeabilised and 
immunostained by routine immunocytochemistry. At the 48 hours time point, an 
apparently similar PrP
Sc
 immunostaining signal could be observed in cells exposed to 
iCJD, sCJD, or vCJD (A, B, C, respectively). Unexposed HK cells (E) and those 
exposed to AD brain homogenate (D) showed faintly detectable cell own PrP
C
 under 
the immunostaining/confocal microscopy conditions used in this experiment. 
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 uptake in extraneuronal lymhoreticular FDC-like HK cell line 
continuously exposed to iCJD, sCJD and vCJD brain homogenates analysed by 
immunocytochemistry 
HK cells (PRNP codon 129-VV genotype) were exposed to iCJD1 (A), sCJD3 (B), vCJD (C), 
AD (D) 1% brain homogenate, or grown in control medium without brain homogenate (E) 
for 48 hours. The cells were then fixed, permeabilised and immunostained for PrP with the 
antibody 8H4 (green), and the nuclei were counterstained with DAPI (blue) as previously 
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3.5.3.8 Analysis of the HK cell line exposed to BSE-positive and BSE-negative brain 
homogenates  
In next assay was investigated the HK cells response to BSE and bovine (BSE-
negative) brain homogenate (Figure 3.36) after 24 hours of continuous exposure. The 
bovine brain homogenate was used as an additional negative control for exogenous 
PrP
Sc
 uptake experiments alongside the non-CJD (Alzheimer diseased, AD) brain 
homogenate used earlier. The cells were fixed, permeabilised and immunolabeled 
with 8H4 antibody using a routine immunocytochemistry procedure. HK cells 
challenged with BSE showed intense immunostaining of PrP
Sc
 (Figure 3.36; A) 
whereas cells challenged with bovine brain material showed no detectable PrP
Sc
 
(Figure 3.36; B). 
 
Figure 3.36: HK cell line exposed to BSE and bovine negative brain homogenates 
HK cells analysed by immunocytochemistry after 24 hours of continuous exposure to 1% 
BSE brain spiked medium (A) and 1% bovine (BSE-negative) medium (B). The cells were 
then extensively washed, fixed, permeabilised and immunostained for PrP with the mAb 
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3.5.3.9 Morphology of PrP
Sc
 immunostaining observed at a high magnification in 
RCM-1 and HK cells continuously exposed to vCJD brain spiked medium for 24 
hours  
To gain insight into the precise localisation of exogenous PrP
Sc 
in cells exposed to 
infectious brain material, the immunostained cells were examined at high 
magnification (Figure 3.37 and 3.38). Both cell types (Figure 3.37), the 
undifferentiated hESC (A, B) and the FDC-like HK cells (C, D), were investigated. 
After 1 day in culture, cells were incubated with vCJD brain homogenate (A, C) or 
grown in control medium (B, D) for 24 hours and immunostained with either the 8H4 
(A, B) or 6H4 (C, D) using standard protocols of fixation and permeabilisation. 
Examination of the challenged cells by high magnification fluorescent microscopy 
revealed the majority of the granular staining of PrP
Sc
 was found at perinuclear 
regions (A, C). The PrP
Sc
 immunostaining of exposed cells was very intense, when 
compared to the fainter patchy presumably PrP
C
 immunostaining of the unexposed 
cells (B, D). 
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Figure 3.37: Morphology of PrP
Sc
 immunostaining observed at a high magnification in 
RCM-1 and HK cells continuously exposed to vCJD brain spiked medium for 24 hours 
The hESC RCM-1 cells (A, B) and FDC-like HK cells (C, D) were exposed to 1% vCJD 
brain spiked medium (A, C) or grown in control medium (B, D) for 24 hours. The cells were 
then washed, fixed, permeabilised and immunostained for PrP with the antibody 8H4 (A, B) 
and 6H4 (C, D) (green). The nuclei were counterstained with DAPI (blue). The scale bars 
represent 20 µm. 
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3.5.3.10 Morphology of PrP
Sc
 immunostaining observed at a high magnification in 
HK cells continuously exposed to vCJD brain spiked medium for 48 or 72 hours  
Next, the PrP
Sc
 distribution profile in HK cells continuously exposed to vCJD spiked 
medium for 48 (Figure 3.38; A) and 72 (Figure 3.38; B) hours was analysed. As 
identical results were obtained with either the 8H4 or 6H4 anti-PrP antibody in 
previous assays, the 6H4 antibody was further used in most of the experiments. The 
immunostained cells were analysed by high magnification fluorescent microscopy. 
The PrP
Sc 
at 48 and 72 hours was found to be intracellular, as previously observed, 
with strong perinuclear accumulation with a coarse granular morphology. A faint 
patchy PrP
C
 signal could be observed at the periphery of the HK cell cytoplasm. It is 
important to note that a prominent juxtanuclear deposition pattern of the PrP
Sc
 taken 
up by cells exposed to various prion disease brain homogenates (BSE, vCJD, iCJD, 
sCJD) was typically observed. 
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Figure 3.38: Morphology of PrP
Sc
 immunostaining observed at a high magnification in 
HK cells continuously exposed to vCJD brain spiked medium for 48 or 72 hours 
HK cells were continuously incubated with 1% vCJD brain spiked medium for 48 hours (A) 
and 72 hours (B). The cells were then washed, fixed, permeabilised and immunostained for 
PrP with the antibody 6H4 (green). The nuclei were counterstained with DAPI (blue). The 
scale bar represents 20 µm. 
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3.5.3.11 Immunofluorescent staining of non-permeabilised and non-denatured living 
hESC and FDC-like cells after incubation with brain spiked medium  
In order to eliminate the possibility that the immunostaining patterns obtained 
depend upon brain material, including PrP
Sc
, adhering to the cell surface, but is rather 
internalised via an active cellular process such as endocytosis, staining of living cells 
was conducted with hESC of the RCM-1 line and the FDC-like HK cells exposed to 
infectious brain material (Figure 3.39). Immunocytochemistry of fixed and 
permeabilised hESC and HK cells exposed to prion infectious brain material 
previously resulted in a strong PrP
Sc
 immunostaining signal. However, the non-
permeabilised and non-denatured live cells only showed a very faint immunostaining 
signal (Figure 3.39; B) which is thought to be the cell’s own PrP
C
 anchored at the 
plasma membrane. 
The hESC of the RCM-1 line (A) and FDC-like HK cells (B) were exposed to BSE 
(Aa), iCJD1 (Ba), vCJD (b), AD (c) brain spiked medium or grown in a control 
medium (d) for 48 hours. Then the brain spiked medium was removed, the cells were 
washed, blocked and immunolabeled with anti-PrP antibody 8H4 (A), or 6H4 (B).  
Confocal fluorescence microscopy of live cells showed no immunostaining of 
undifferentiated hESC (A), or only a very faint patchy signal of consistent with PrP
C
 
in HK cells when viewed at higher magnification (B). Therefore, live cell 
immunostaining confirmed that the earlier observed PrP
Sc
 immunostaining signal of 
cells exposed to infectious brain material was indeed cytoplasmic rather than 
material attached or deposited on the cell surface.  
It is important to note that immunostaining of live cells resulted in an analysis of 
fewer cells when compared to immunostaining of fixed cells. This was a simple 
matter of unfixed cells not being strongly adhered to the slide and being washed off 
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during the immunostaining procedure. Also, these cells had to be analysed on the day 
of immunolabeling as they easily sensitised to apoptotic insults and were therefore 
not analysable. 
 
Figure 3.39: Immunofluorescent staining of non-permeabilised and non-denatured 
living hESC and FDC-like cells after incubation with brain spiked medium 
(A) hESC of the RCM-1 line were exposed to 1% BSE (a), vCJD (b), AD (c) or grown in 
control medium (d) for 48 hours. The cells were then washed and immunostained as 
described in section 2.12.1 with anti-PrP monoclonal antibody 8H4. (B) Immunostaining of 
living HK cells with anti-PrP monoclonal antibody 6H4 showed very faint signal on the 
surface of cells challenged with infectious brain material (a, b), AD (c) brain material and 
those left unchallenged (d). The cells’ nuclei were counterstained with DAPI (blue) and the 
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3.5.3.12 Optical sectioning of HK cell exposed to vCJD brain material  
To visualise and confirm the intracellular localisation of exogenous PrP
Sc
 taken up 
by cells exposed to prion diseased brain homogenates, confocal microscopy Z-stack 
sections were performed (Figure 3.40). This method (optical sectioning) samples a 
series of planes within the cell separately, which can then be assembled into a series 
or Z-stack. HK cells were exposed to vCJD brain homogenate for 24 hours and 
immunolabeled with 8H4 anti-PrP antibody after standard conditions of fixation and 
permeabilisation. The three selected Z-stack sections, the bottom of the cell (left), 
middle of the cell (centre) and top of the cell (right), confirmed that the PrP 
immunostained material in prion disease brain homogenate exposed cells is indeed 
present within the cell and accumulated in the juxtanuclear area of the cell.  
Note in the bottom Z-stack section (left) the periphery of the HK cell cytoplasm is 




Figure 3.40: Optical sectioning of HK cell exposed to vCJD brain material 
The exogenous PrP
Sc
 taken up by HK cells exposed to 1% vCJD for 24 hours was visualised 
by Z-stack (optical sectioning) allowing insight into various depths throughout the 
immunostained cell – bottom (left), middle (centre) and top (right) sections of the exposed 
cell are shown. The cells were washed, fixed, permeabilised and immunostained for PrP with 
the antibody 8H4 (green). The cells’ nuclei were counterstained with DAPI (blue) and the 
scale bar (left) is 20 µm. 
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3.5.3.13 Western blot analysis of spin filtered and crude brain homogenates  
The next experiment examined whether different particle sizes of exogenous PrP
Sc
 
would alter the uptake and intracellular site of PrP
Sc 
accumulation (Figure 3.41). The 
BSE brain material was prepared as a 10% w/v homogenate using a ribolyser (as 
described in section 2.11.1.2). The homogenate was then cleared and the supernatant 
was further sonicated and then either filtered through 220 nm (Figure 3.41; lane 1), 
450 nm (Figure 3.41; lane 2) spin filters or allowed to remain as a cleared unfiltered 
homogenate (Figure 3.41; lane 3). As expected, filtration resulted in a decrease of 
PrP
Sc
 in the brain homogenate (lane 1 and 2). The 220 nm pore sized spin filter 
removed a large proportion of the PrP
Sc 
present in the cleared homogenate, although 
a small amount of PrP
Sc 
was still detectable in the filtrate. 
 
Figure 3.41: Western blot analysis of spin filtered and crude brain homogenates 
The 10% brain homogenates (Western blot of BSE is shown) were rybolised and sonicated 
(as described in section 2.11.1.2) in order to break down the PrP
Sc 
aggregates, then spin 
filtered using 220 nm (lane 1) or 450 nm (lane 2) spin filters by centrifugation at 10,000 rpm 
for 5 minutes or retained crude (lane 3). Then the samples were treated with PK (50 µg/ml) 
and analysed by standard Western blot with anti-PrP primary antibody 6H4. The quantity of 
individual brain homogenates loaded onto gel was equivalent. The molecular weight, in kDa, 
is marked left. 
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3.5.3.14   HK cells exposed to filtered and crude vCJD brain spiked medium  
Next, the above prepared homogenates were diluted to concentration of 1% with 
complete cell culture media and continuously incubated with the HK cells for 48 
hours. Then the medium was withdrawn, and the cells were extensively washed, 
fixed, permeabilised, immunolabeled with the anti-PrP antibody 6H4 and examined 
with confocal microscopy (Figure 3.42). The intensity of the PrP immunostaining 
signal (bright green) corresponded to the quantity of PrP
Sc
 remained in the vCJD 
homogenate after filtration with either 220 nm (B) or 450 nm (C) pore sized spin 
filters and in the crude brain homogenate (D). The PrP
Sc
 immunostaining resulted in 
the typical accumulation site at the juxtanuclear area in cells exposed to either 
filtered, or crude spiking material (B-D). Interestingly, the immunostaining signal of 
PrP
Sc
 in cells exposed to vCJD brain spiked medium filtered through the 220 nm spin 
filter (B) was finer when compared to the typical coarse granular morphology of 
PrP
Sc
 immunostaining in cells exposed to the crude vCJD brain homogenate (D). The 
unexposed control cells are shown in (A). Note the periphery of the HK cell is 
visualised by faint patchy PrP
C




 uptake from filtered vCJD brain spiked medium by the HK cells 
PrP
Sc
 from vCJD filtered through spin filters of pore size 220 nm (B) or 450 nm (C) or crude 
brain homogenate (D) adopt the same perinuclear localisation after being taken up by HK 
cells. The cells were continuously exposed to the brain homogenates for 48 hours, then fixed, 
permeabilised and immunolabeled for PrP with 6H4 primary antibody. Control unexposed 
cells (A) showing cell’s faint patchy PrP
C
 immunostaining. DAPI staining (blue) locates 
nuclei. Scale bar (left), 20 µm. 
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3.5.3.15 HK cell survival and morphology monitoring after immunostaining 
procedure using proteinase K and guanidine thiocyanate pre-treatments  




 by monitoring the 
characteristic fluorescent signal threshold in the quantitative confocal image analysis 
system. But to specifically recognise only PrP
Sc
, a digestion/denaturation step with 
proteinase K (PK) and guanidine thiocyanate (Gnd) was employed (Taraboulos et al., 
1990). Optimisation of the standard immunocytochemistry protocol was performed 
by testing variations of the denaturant concentrations and times of pre-treatments 
resulting in specifically PrP
Sc
 detection and exposing PrP
Sc
 epitopes that were 
previously masked (Figure 3.43). Cell morphology was carefully monitored after 
each pre-treatment step and recorded. The final optimised protocol was composed of 
extensive washes with PBS (A), fixation with 4% paraformaldehyde (B), 
permeabilisation with 0.1% Triton X-100 (C), denaturation with very low 
concentration of proteinase K (0.3 µg/ml) (D), subsequent pre-treatment with 4 M 
guanidine thiocyanate (E), blocking with 3% BSA (F), incubation with anti-PrP 
primary antibody (G) followed by incubation with FITC secondary antibody (H).  
Although PK digestion is a harsh procedure, the majority of the cells remained intact.  
The result using a protocol in which only Gnd pre-treatment (without PK treatment) 
was used, is shown in (I). This methodological variation became useful in 
experiments where cell organelle structural integrity needed to be preserved (3.7-8).  
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Figure 3.43: HK cell survival and morphology monitoring after immunostaining 
procedure using proteinase K and guanidine thiocyanate pre-treatments 
The cellular response was carefully monitored with the differential interference contrast 
culture microscope after each step of the immunostaining procedure. Cell morphology after 
(A) extensive wash with PBS, (B) incubation with 4% paraformaldehyde (PFA), (C) 
treatment with 0.1% Triton X-100, (D) treatment with proteinase K (PK) (0.3 µg/ml), (E) 
treatment with 4 M guanidine thiocyanate (Gnd), (F) blocking with 3% bovine serum 
albumin (BSA), (G) incubation with primary mAb, (H) incubation with secondary Ab. Cell 
morphology where treatment with PK was excluded from protocol and only treatment with 
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3.5.3.16 Confirmation that PrP
Sc
 signal corresponded to exogenous PrP
Sc
 taken up 
by exposed cells  
In order to confirm whether the PrP immunostaining results upon the cellular uptake 
of exogenous PrP
Sc
 from the brain spiked media, or whether the signal is a result of 
already established infection, we took advantage of immunocytochemical pre-
treatment with PK and Gnd and use of two anti-PrP primary antibodies 6H4 and 3F4 
(Figure 3.44). The benefit in using the 3F4 antibody is that it recognises human, but 
not bovine PrP.  
Cells of either hESC RCM-1 line (A) or the FDC-like HK cell line (B) were exposed 
to BSE (a, d), vCJD (b, e) or AD (c, f) brain spiked medium for 48 hours. The cells 
were subsequently fixed, permeabilised, PK and Gnd pre-treated and immunostained 
with anti-PrP primary antibodies 6H4 (a-c) or 3F4 (d-f). 
Positive PrP
Sc
 immunostaining signal was observed in cells exposed to vCJD brain 
spiked medium in both cell types (b, e). The absence of immunostaining in BSE 
exposed cells with 3F4 (d) confirmed that the immunostaining with antibody 6H4 (a, 
b) resulted upon uptake of exogenous PrP
Sc 
from the spiked media by challenged 
cells, rather than from endogenous human cellular PrP
C 
already converted into PrP
Sc
 
as a result of BSE exposure. Cells exposed to AD brain material (c, f) remained 
negative as expected (a few background spots were present). 
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Figure 3.44: Confirmation that PrP
Sc
 signal corresponded to exogenous PrP
Sc
 taken up 
by exposed cells 
 (A) hESC of the RCM-1 cell line (PRNP codon 129-MM genotype) and (B) the HK cells 
(PRNP codon 129-VV genotype) were exposed to BSE (a, d), vCJD (b, e) or AD (c, f) 1% 
brain homogenate for 48 hours. The cells were then fixed, permeabilised, treated with PK 
and Gnd and immunostained for PrP with either the 6H4 antibody (a, b, c) or 3F4 (d, e, f) 
(green) and the nuclei counterstained with DAPI (blue). The scale bars (a) represent 20 µm. 
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3.5.3.17 Analysis of cells exposed to medium spiked with sCJD brain  
To test whether the cells are equally able to take up PrP
Sc
 originating from other than 
acquired prion strain (iCJD, vCJD), the hESC and HK cells were exposed to sporadic 
CJD brain material. 
The same immunocytochemical pre-treatment (PK and Gnd) and PrP
Sc
 detection 
with 3F4 or 6H4 antibody was used for analysis of cells exposed to sCJD brain 
material (Figure 3.45). Exposure of hESC of the RCM-1 line (A-F) and HK cells (G) 
to medium containing crude extracts of sCJD brain material of either of the most 
common subtypes MM1 (A, B, D, E, G) and VV2 (C, F) resulted in a quantitatively 
and morphologically similar immunostaining of internalised exogenous PrP
Sc
. The 
typical perinuclear accumulation of PrP
Sc
 with a coarse granular morphology was 
observed in both cell types exposed to sCJD (A-G).  
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Figure 3.45: Exposure of cells to medium spiked with the sCJD (MM) and (VV) 
PrP
Sc
 uptake from sporadic CJD (sCJD) brain by hESC and HK cells was analysed by 
immunocytochemistry. The method was featuring with PK/Gnd denaturation step (A-F). 
Briefly, the hESC of the RCM-1 cell line (A-F) and HK cell line (G) were exposed to sCJD1 
(MM1) subtype (A, D, G), sCJD2 (MM1) subtype (B, E), or sCJD3 VV2 subtype (C, F) 1% 
brain homogenate for 48 hours. Then the cells were fixed, permeabilised, treated with PK 
and Gnd and immunostained for PrP
Sc
 with the 6H4 antibody (A, B, C), or 3F4 antibody (D, 
E, F) or the 8H4 antibody (G) (green). The nuclei were counterstained with DAPI (blue) and 
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3.5.3.18 Immunostaining for glial filaments in cells exposed to brain spiked medium 
The data accumulated thus far raised the question of whether other proteins are taken 
up with PrP
Sc
 or whether the uptake mechanism was specific for PrP
Sc
. To address 
this question (Figure 3.46), hESC of the RCM-1 cell line (A) and the FDC-like HK 
cells (B) were continuously exposed to vCJD (left column), AD (centre column) or 
cultured unexposed (right column) for 48 hours. The cells were then fixed, 
permeabilised, PK treated and double immunolabeled for PrP
Sc
 with 6H4 (green) 
(only in B) and glial filaments (glial fibrillary acidic protein, GFAP) (red) (A, B).  
Immunostaining for glial filaments was observed in hESC cells exposed to vCJD 
(Aa) and to AD (Ab). Double immunolabeling in the HK cells (B) showed the same 
phenomenon. The merged channels show the typical juxtanuclear accumulation of 
PrP
Sc
 and GFAP material in vCJD exposed cells (Bg) and GFAP in AD exposed cells 
(Bh). This indicates that the material taken up by the hESC and HK cells is complex, 





 and GFAP uptake is representative of four independent, non-identical 
experiments. The differences involved type of cell line and the choice of antibodies 
used in the immunocytochemistry procedure (not all data are shown). 
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Figure 3.46: Immunostaining for glial filaments in cells exposed to brain spiked media 
hESC of the RCM-1 cell line (A) and HK cells (B) were exposed to vCJD (Aa, B-left 
column), AD (Ab, B-middle column) 1% brain homogenate or grown in control medium 48 
hours (Ac, B-right column). RCM-1 cells (A) were then fixed, permeabilised, treated with 
proteinase K and immunostained with an antibody for glial fibrillary acidic protein (GFAP, 
red). The HK cells (B) were fixed, permeabilised, treated with PK and double 
immunolabeled for PrP with the 6H4 antibody (Ba, Bb, Bc) (green) and GFAP (Bd, Be, Bf) 
(red) as described in section 2.12.4. Merge of the channels (PrP
Sc
/GFAP) is shown in (Bg, 
Bh, Bi). Any colocalisation of PrP
Sc
 and GFAP appeared yellow. The nuclei were 
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3.5.3.19 Controls for the immunostaining procedures  
The controls for the immunocytochemical procedures in both hESC (Figure 3.47; A-
C) and HK (Figure 3.47; D-F) cell lines for antibody false positivity (A, B, D, E) or 
cellular auto-fluorescence (C, F) were negative and confirmed that all the previous 
results show genuine signals dependent on the specificity of the primary antibodies 
employed.  
 
Figure 3.47 Controls for the immunostaining procedures 
The hESC RCM-1 cell line (A-C) and HK cell line (D-F) were exposed to 1% vCJD brain 
spiked medium for 24 hours. Then cells were washed, fixed, permeabilised and 
immunostained omitting specific steps such as the FITC-labelled secondary antibody (A, D), 
the primary antibody 8H4 (B, E) and both primary and secondary antibodies (C, F). The 
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3.5.4 Summary  
 Undifferentiated hESC cells and FDC-like HK cells display a readily 
detectable time dependent uptake of PrP
Sc
 from medium spiked with prion 
disease brain homogenates. 
 Cells challenged with infectious brain material showed strong intracellular 
accumulation of PrP
Sc
 with a course granular morphology.  
 Morphological examination of cells exposed to prion spiked medium 
concluded that these cells did not suffer any observable damage that could be 
responsible for unusual localisation of PrP and the cells did not reveal any 
gross changes in cell morphology or viability caused by PrP
Sc
 uptake and 
accumulation in the cytosol. 
 No differences in the uptake were observed which could be attributed to 
differences of cell type (FDC-like vs. stem cells). 
 It was concluded that the uptake is neither dependent on the species origin of 
the brain homogenate nor the PRNP codon 129 genotype of the cell. The 
intense intracellular staining of exogenous PrP
Sc
 within cells exposed to BSE, 
vCJD, iCJD, sCJD further confirmed previous observations that PrP
Sc
 uptake 
by cells at each given time point showed no observed differences amongst the 
different prion agents. 
 The live cell staining resulted in no PrPSc immunostaining, indicating the 
positive immunostaining is material accumulated intracellularly, rather than 
resulting from brain material deposited on the external surface of the cells. 
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 Immunostaining for glial filaments in exposed and unexposed cells indicated 
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3.6 KINETICS OF EXOGENOUS PRP
SC
 UPTAKE AND CLEARANCE 
ANALYSED BY IMMUNOCYTOCHEMISTRY 
 
3.6.1 Objectives 
To examine the kinetics of exogenous PrP
Sc 
taken up by human embryonic stem cells 
and the FDC-like HK cells.  
 
3.6.2 Rationale 
Following on from the previous findings (section 3.3-4), - that exogenous PrP
Sc
, once 
taken up, was subsequently lost when the HK cells were allowed to grow in control 
medium, - it was of interest to examine whether the human embryonic stem cells 
exposed to infectious prion material behave similarly. It was shown earlier (section 
3.5.4) that these cells (RCM-1) are able to rapidly take up prion material. Whether 
the human embryonic stem cells are also able to clear this material as HK cells do, or 
whether prion infection becomes established remains to be demonstrated. These data 
do provide a valuable insight into the potential for prion propagation in 
undifferentiated stem cells. The comparison of the PrP
Sc
 clearance in human 
lymphoreticular FDC-like cells with human undifferentiated stem cells may also 
provide important insights into the cell biology of these two cultured cell types. 
Based on previous experience, immunocytochemistry was chosen as the best tool to 
employ in this investigation.  
The PrP
Sc
 uptake and clearance by HK cells and hESC analysed by ICC is 
representative of two independent, non-identical experiments. 
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3.6.3 Experimental results 
3.6.3.1  Clearance of PrP
Sc
 from exposed hESC analysed by immunocytochemistry 
To determine the kinetics of PrP
Sc
 clearance in hESC, we exposed the cells of the 
RCM-1 line (Figure 3.48) to BSE (A, E, I, M, R), vCJD (B, F, J, N, S) and AD (C, 
G, K, O, T) 1% brain spiked medium, or cultured cells in control medium (D, H, L, 
P, U). The immunostaining protocol, which included Gnd pre-treatment, was used to 
diminish the PrP
C
 and enhance the detection of PrP
Sc
 immunostaining in the analysed 
samples. After 48 hours of continuous exposure the PrP
Sc
 immunostaining signal 
indicated an intracellular localisation in hESC exposed to infectious prion material 
(A, B). The medium was then withdrawn (and retained for further analysis) and cells 
were cultured in fresh (unspiked) medium for 24 hours.  
The PrP
Sc
 signal in BSE and vCJD exposed cells was observed to have fallen 
considerably (E, F). The signal was further reduced after another change of fresh 
control medium followed by a further 24 hours incubation (48 hours recovery) (I, J). 
By 72 hours of recovery and three changes of control medium, only low or 
background staining was present in the majority of cells exposed to BSE and vCJD 
(M, N). However, above background levels of PrP
Sc
 could be still observed in less 
common clusters of cells in the 72 hours’ recovery time point (R, S). The staining 
pattern of the cell-associated PrP
Sc
 changed over the time of recovery from a bright 
perinuclear PrP
Sc
 “cloud” to discrete dot like appearance. Cells exposed to AD brain 
homogenate remained negative for PrP
Sc
 immunostaining throughout the experiment 
(C, G, K, O, T), as did the control unexposed cells (D, H, L, P, U). 
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Figure 3.48: Clearance of PrP
Sc
 from exposed hESC analysed by immunocytochemistry 
The RCM-1 cells were exposed to BSE (A, E, I, M, R), vCJD (B, F, J, N, S), AD (C, G, K, 
O, T) 1% brain homogenate or grown in a control medium (D, H, L, P, U) for 48 hours (A-
D). The medium was then withdrawn, the cells were washed and given fresh control medium 
and allowed to continue growing for a further 24 hours (E-H), 48 hours (I-L) or 72 hours (M-
U) with medium changes every 24 hours. The cells were then washed, fixed, permeabilised, 
pre-treated with PK and immunostained for PrP using the antibody 6H4 (green) and the 
nuclei counterstained with DAPI (blue). The fields shown in (M-P) are typical of the cultures 
observed at the 72 hours recovery time point, whereas less common clusters of cells 
immunostaining for PrP
Sc
 are shown in (R, S). The scale bar represents 50 µm. 
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3.6.3.2 Western blot analysis of PrP
Sc
 in culture medium incubated with RCM-1 cells 
during exposure and recovery 
To determine whether the loss of the PrP
Sc
 immunostaining signal from the hESC 
cells was due to an effective exocytosis, a Western blot analysis of the retained 
medium incubated with cells was performed (Figure 3.49). Analysis of BSE (A) and 
vCJD (B) PrP
Sc
 before (lane 1) and after 48 hours of incubation with the cells (A and 
B, lane 2) showed an apparent loss of the PrP
Sc
 from the media. At this same time 
point PrP
Sc
 could be detected intracellularly, as analysed by ICC (Figure 3.48; A and 
B). Figure 3.49; lane 3, 4, 5 corresponded to the 24 hours recovery intervals of fresh 
media incubated with the exposed cells, yet show no signs of detectable amounts of 
the cell-associated PrP
Sc
 shed back into the medium.  
 
Figure 3.49: Western blot analysis of PrP
Sc
 in culture medium incubated with RCM-1 
cells during exposure and recovery  
The hESC RCM-1 cells were exposed to 1% BSE (A), vCJD (B) or AD (C) spiked medium 
for 48 hours. After incubation the medium was withdrawn and retained for Western blot 
analysis. The process was repeated also at every 24 hours recovery time point, up to the total 
72 hours recovery time period. Equivalent volumes of the cell culture medium (incubated 
with the cells during the experiment) were digested with PK and analysed by Western 
blotting for PrP
Sc
 presence using the antibody 6H4. The culture media analysed were: the 
brain input into the culture medium prior to incubation with the cells (lane 1), the same 
culture medium after 48 hours of incubation with the cells (lane 2), fresh medium after a 24 
hours of incubation (24 hours recovery) (lane 3), the second change of fresh medium after a 
further 24 hours of incubation (48 hours recovery) (lane 4), and the third change of fresh 
medium after a further 24 hours of incubation (72 hours recovery) (lane 5). The molecular 
weight, in kDa, is marked left on each blot. 
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Interestingly, the loss of the PrP
Sc
 immunostaining signal from the cells was rapid 
(Figure 3.48; BSE - I, J, M, R; vCJD - F, J, N, S) and it is unlikely that the material 
could be simply diluted out by cell division given that the typical doubling time of 
these hESC is around 35 hours (Beattie and Hayek, 2004; Gearhart, 2004). 
 
3.6.3.3 Clearance of PrP
Sc
 from exposed HK cells monitored up to 72 hours recovery 
analysed by immunocytochemistry 
The immunocytochemical visualisation of the kinetics of PrP
Sc
 clearance in the 
human FDC-like HK cells is shown in Figure 3.50. HK cells were continuously 
exposed to BSE (A, E, I, M), vCJD (B, F, J, N), AD (C, G, K, O) 1% brain 
homogenate or grown in control medium (D, H, L, P). The immunostaining protocol 
including a Gnd pre-treatment was used to enhance the PrP
Sc
 signal. The time of 
exposure was 48 hours (A-D). The PrP
Sc
 immunosignal in cells exposed to BSE (A) 
and vCJD (B) could be observed intracellularly. Then the brain spiked medium was 
removed and cells were allowed to grow in control (unspiked) medium up to 72 
hours with medium changes at 24 hours intervals. The kinetics of PrP
Sc
 clearance 
examined after the 24 hours recovery (E-H), 48 hours recovery (I-L) and 72 hours 
recovery (M-P) in BSE (E, I, M) and vCJD (F, J, N) exposed HK cells appeared to be 
slower in these cells when compared to the hESC (Figure 3.48). The typical PrP
Sc 
immunostaining signal represented by coarse granular morphology in the cells 
exposed to the crude BSE or vCJD brain homogenates (A, B) could be observed in 
the cytosol of the cells within the whole course of the recovery period (72 hours). 
Therefore the clearance was considered to be less effective by the HK cells when 
compared to the hESC.  
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Figure 3.50: Clearance of PrP
Sc
 from exposed HK cells monitored up to 72 hours 
recovery analysed by immunocytochemistry 
The HK cells were exposed to BSE (A, E, I, M), vCJD (B, F, J, N), AD (C, G, K, O) 1% 
brain homogenate or grown in a control medium (D, H, L, P) for 48 hours (A-D). The 
medium was then withdrawn, the cells were washed and given fresh control medium and 
allowed to continue growing for a further 24 hours (E-H), 48 hours (I-L) or 72 hours (M-P) 
with medium changes at 24 hours intervals. The cells were then washed, fixed, 
permeabilised, pre-treated with Gnd and immunostained for PrP using the antibody 6H4 
(green). The nuclei were counterstained with DAPI (blue) and the scale bar represents 20 
µm. 
 
3.6.3.4 Western blot analysis of PrP
Sc
 in culture medium incubated with HK cells 
during exposure and recovery 
The media incubated with the HK cells in the experiment described above were also 
retained and analysed by Western blot for PrP
Sc
 presence (Figure 3.51). The input of 
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BSE (A), vCJD (B) and AD (C) is shown in lane 1. PrP
Sc 
uptake is indicated by the 
loss of the signal from media after 48 hours incubation (lane 2) with the HK cells 
(appeared as an intracellular signal, Figure 3.50; A and B). The medium was changed 
at 24-hour intervals (lane 3, 4, 5), representing 72 hours of recovery in total. The 
analysis showed no signs of detectable PrP
Sc
 shed back to the medium. It is important 
to note that the PrP
Sc
 clearance in HK cells appears to be a slow process and a longer 
recovery time was required to draw firm conclusions about the clearance rate (see 
following section 3.6.3.5).  
 
Figure 3.51: Western blot analysis of PrP
Sc
 in culture medium incubated with HK cells 
during exposure and recovery  
The medium incubated with HK cells exposed to 1% BSE (A), vCJD (B), AD (C) spiked 
medium or grown in control medium (D) for 48 hours and during the recovery time was 
retained. Equivalent volumes of the medium were digested with PK and analysed by 
Western blotting using the antibody 6H4. The culture media analysed were: the brain input 
into the culture medium prior to incubation with the cells (lane 1), the same culture medium 
after 48 hours of incubation with the cells (lane 2), a fresh medium after a 24 hours of 
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incubation (24 hours recovery) (lane 3), the second change of fresh medium after a further 
24 hours of incubation (48 hours recovery) (lane 4), and the third change of fresh medium 
after a further 24 hours of incubation (72 hours recovery) (lane 5). The vCJD 2B standard 
(lane 6) was used as a control of PrP migration and blotting procedure. The molecular 
weight, in kDa, is marked left on each blot. 
 
3.6.3.5 Clearance of PrP
Sc
 from the exposed HK cells monitored at long term 
recovery analysed by immunocytochemistry  
Based on the observations from the study above, a further experiment examining the 
kinetics of PrP
Sc
 clearance in HK cells at longer term of recovery was undertaken 
(Figure 3.52). The optimised immunostaining protocol (including Gnd pre-treatment) 
was used to examine the kinetics of PrP
Sc
 clearance. HK cells were exposed to 1% 
iCJD1 brain spiked medium for 48 hours (A). The switch from BSE or vCJD to iCJD 
was performed in an attempt to visualise the previously observed clearance of PrP
Sc
 
from HK cells analysed by Western blot (section 3.4). PrP
Sc 
immunostaining 
resulting from iCJD1 gave a quantitatively weaker signal when compared to BSE and 
vCJD (Figure 3.50; A, B) exposed cells. In this assay the exposed cells were given a 
96 hours recovery period with fresh medium changes at 24-hour intervals (B, C, D, 
E) and again only slight PrP
Sc
 clearance could be observed even at this slightly 
longer recovery time. This was followed by a subsequent culturing including three 
passages (every 7 days) (F, G, H). Gradual and progressive loss of PrP
Sc
 
immunostaining signal from HK cells could be observed with subsequent passaging. 
The clearance of PrP
Sc 
immunostaining signal first represented by the typical coarse 
granular morphology in the cells exposed to the crude iCJD brain homogenate (A) 
progressed to a finer patchy signal after 1
st
 passage (F) and was lost from the cells 
after the 3
rd
 passage (H). 
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Figure 3.52: Clearance of PrP
Sc
 from exposed HK 
cells monitored at longer term recovery analysed by 
immunocytochemistry 
HK cells were continuously exposed to 1% iCJD1 brain 
spiked medium for 48 hours (A). The medium was then 
withdrawn, the cells were washed and given fresh 
medium (without brain homogenate) and allowed to 
continue growing for a further 24 hours (B), 48 hours 
(C), 72 hours (D), or 96 hours (E) with medium 
changes at 24 hours intervals. After reaching 70-80% 
confluence, the cells were split in a manner where a 
small fraction of cells was plated onto a chamber slide 
for the ICC analysis (F) and the rest of the cells were 
plated into fresh T25 cell culture flask and allowed to 
grow until confluent. This passaging process was then 
repeated twice (G, H). The immunostaining procedure 
was routinely performed. In short, the cells were 
washed, fixed, permeabilised, pre-treated with PK and 
immunostained for PrP using the antibody 6H4 (green) 
and the nuclei were counterstained with DAPI (blue). 
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3.6.4 Summary 
 Judging by the sensitive immunostaining of the PrPSc in exposed cells and the 
loss of the protease-resistant prion protein from the brain spiked medium, as 
shown by Western blots, the hESC and HK cells appear to have mechanisms 
that allow a rapid uptake of brain material (including a disease-associated and 
most likely infectious form of the prion protein).  
 Based on findings from this recovery assay, these cells are equally able to 
clear PrP
Sc
 at a rapid rate, suggesting that they also have an efficient 
mechanism to presumably degrade, or otherwise process the material taken 
up. 
 Interestingly, the clearance of infectious prions from the human FDC-like HK 
cells appeared to be a slower process when compared to the hESC. 
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3.7 KINETICS AND MECHANISM OF ENDOCYTOSIS OF EXOGENOUS 
PRP
SC
 IN HK CELLS ANALYSED BY IMMUNOCYTOCHEMISTRY  
 
3.7.1 Objectives 
To determine the time dependent mechanism of internalisation by which exogenous 
PrP
Sc
 is taken up from brain spiked media by extraneuronal lymphoreticular FDC-
like HK cells.  
 
3.7.2 Rationale 
The mechanism of PrP
Sc
 internalisation, trafficking and the cellular site of 
conversion remain unresolved questions in prion disease pathogenesis. The available 
evidence suggests a variety of routes and these may be influenced by the cell type 
under examination and other factors specific to the experimental design. Endocytosis 
is a basic cellular process that is used by cells to internalise a variety of molecules. 
Identification of the mechanism by which PrP
Sc
 enters the cell is a vital aspect in 
understanding the prion infection mechanism. Based on the results from sections 3.4-
6, the PrP
Sc
 from brain spiked media does indeed enter the exposed cells and the 
mechanism of this process was investigated here by examining the extraneuronal 
lymhoreticular FDC-like HK cells when acutely exposed to prions. 
 
3.7.3 Experimental results 
3.7.3.1  ICC of caveolae-coated vesicles and clathrin-coated pits in HK cells  
To clarify the routes of internalisation of the exogenous PrP
Sc
 into the HK cells, a 
series of experiments were designed, concentrating on the two main elements of the 
endocytic mechanisms, i.e. the caveolae-coated vesicles (Figure 3.53; A) and 
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clathrin-coated pits (Figure 3.53; B). Caveolae-coated vesicles were densely 
represented at the HK cell plasma membrane (A-red), as were the invaginations of 
the clathrin coated pits (B-red).  
 
Figure 3.53: Immunostaining of caveolae-coated vesicles and clathrin-coated pits in HK 
cells  
HK cells were washed, fixed, permeabilised and immunostained for caveolae-coated vesicles 
(A) with antibody caveolin1 and clathrin coated pits (B) with clathrin, these were revealed 
by incubation with Alexa 546 conjugated secondary antibody for 60 minutes as described in 
section 2.12.4. The nuclei were counterstained with DAPI (blue). The scale bar, 20 µm.  
 
3.7.3.2  Double immunolabeling of PrP
Sc
 and caveolae-coated vesicles after 
continuous exposure of HK cells to vCJD brain spiked medium 
In order to determine the possible involvement of caveolae-coated vesicles in the 
uptake of PrP
Sc
 from brain spiked media, the HK cells were incubated with medium 
containing sonicated 1% vCJD brain homogenate for 2, 4 and 48 hours. Unexposed 
control cells were incubated with unspiked medium. The cells were analysed by 
confocal microscopy after being double immunolabeled for PrP with primary 
antibody 8H4 (green) and caveolae-coated vesicles with anti-caveolin1 (red) (Figure 
3.54). The merging of the channels is shown and any colocalisation of PrP with 
caveolae-coated vesicles appears in yellow.  
The 2-hour time point of exposure to vCJD spiked medium (B) appeared to have a 
same amount of PrP (green) as the control cells (A) and no positive colocalisation of 
Chapter 3   Results 
  210 
exogenous PrP
Sc
 and caveolae-coated vesicles could be observed at this early point. 
However, the time points analysed at 4 (C) and 48 hours (D) showed some evidence 
of positive colocalisation of exogenous PrP
Sc
 with caveolae-coated vesicles (yellow 
dots and clumps). Therefore, from the 4-hour and 48-hour time points it could be 
presumed that caveolae-coated vesicles of HK cells might be implicated in the PrP
Sc
 
uptake. It must be noted that the incubation with brain spiked medium in this case 
was continuous, like in all previous experiments. Ideally, a reconstruction of the 
principle for future experiments investigating the internalisation and trafficking 
mechanisms of PrP
Sc
 was needed. Having considered the objective purpose of this 
investigation, a different approach for this experiment was therefore formatted. 
 
Figure 3.54: Double immunolabeling of PrP
Sc
 and caveolae-coated vesicles after 
continuous exposure of HK cells to vCJD brain spiked medium 
HK cells were continuously exposed to medium containing 1% vCJD brain homogenate for 
2 (B), 4 (C) and 48 hours (D), or grown in a control medium (A). The cells were then 
washed, fixed, permeabilised and double labelled for PrP with antibody 8H4 (green) and 
caveolae-coated vesicles with caveolin1 antibody (red). The nuclei were counterstained with 
DAPI (blue). Shown is the merge of all channels. The scale bar represents 20 µm. 
 
In the new approach the so called “pulse and chase” principle was applied. This 
approach - for mapping prion uptake and its trafficking over time - was designed to 
provide a better definition of the processes involved. It avoids potential 
complications of material continually entering the trafficking system and obscuring 
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the processing of previously taken up materials. The principle of a “pulse and chase” 
experiment is described in schematic form in section 2.11.2.3. 
Briefly, cells were exposed to medium containing 6H4 (either control or brain 
spiked) for short time period, 30 minutes at 4 °C and additional 15 minutes at 37 °C, 
to initiate the internalisation process – the “pulse”. Then the cells were extensively 
washed to remove any material deposited on the cell surface and further cultured in 
control medium for desired time period – the “chase”. The cells were then 
immunostained at different time points of the “chasing” phase. It should be noted 
that the incubation with anti-prion primary antibody is therefore no longer needed in 
the immunostaining protocol. The fixed and permeabilised cells were blocked and 
subsequently incubated with the FITC secondary antibody Alexa 488 labelling the 
PrP-6H4 complexes taken up during the “pulse” phase. An immunocytochemical 
pre-treatment with guanidine (enhancing PrP
Sc
 and diminishing PrP
C
 signal) was 
used when needed to distinguish exogenous PrP
Sc
 from the cellular PrP
C
. 
Subsequently, the samples were washed and immunostained with caveolin1 or 
clathrin antibodies overnight, which were revealed by incubation with Alexa 546 for 
60 minutes. The nuclei were counterstained with DAPI and slides were then mounted 
with mounting media and examined by confocal microscopy. 
3.7.3.3 Preliminary “pulse and chase” experiment (3 hours “chase” period) 
The preliminary “pulse and chase” experiment was designed with the “chasing” 
period consisting of 3 hours. This was primarily aimed to identify any PrP signal 
differences of the unexposed and exposed cells to brain spiked medium (showing 
exogenous PrP
Sc
 to be cell-associated), determining that the “pulse” time period was 
long enough for cells to initialise internalisation of the antibody-antigen (6H4-vCJD 
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PrP
Sc
) complex. This also allows to observe whether the 3 hours “chase” period 
would reveal which mechanism of internalisation was predominantly implicated in 
the early time point of PrP uptake and which in the latter (Figure 3.55). The HK cells 
were then immunolabeled for caveolae coated vesicles with caveolin1 (Figure 3.55; 
A and B) or clathrin-coated pits with clathrin (Figure 3.55; C and D).  
A clear difference could be observed in the PrP signal (green) of the cells incubated 
with unspiked medium (A, C) when compared to the vCJD exposed cells (B, D), 
indicating that the individual time settings of the “pulse and chase” experiment were 
sufficient.  However, the most interesting observation was the positive colocalisation 
(yellow) of PrP
Sc
 with caveolae-coated vesicles at 3 hours chase period (B), but no 
detectable evidence of PrP
Sc
 colocalisation with clathrin-coated pits (D) at this time 
period. This suggests that additional investigation of earlier and latter time points 
might reveal a possible time dependent involvement of those two uptake mechanisms 
or the alternative possibility that the clathrin-coated pits may not be involved in 
exogenous PrP
Sc 
endocytosis at all in the HK cells. 
The difference in the PrP (green) signal of unexposed cells (A, C) compared to the 
PrP signal of the cells exposed to brain spiked medium (B, D) indicates that the 
vCJD PrP-6H4 is taken up together as a complex, rather than the 6H4 primary 
antibody being taken up on its own. The results show that this was not the case, and 
the colocalisation of exogenous PrP
Sc
 with endocytic vesicles implicated in the 
internalisation process was convincingly demonstrated. Nevertheless, the observed 
very faint sign of colocalisation (yellow) in unexposed cells (A) could indicate that 
the HK cellular PrP
C
 is being recycled via caveolae-coated vesicles in these cells. 
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Figure 3.55: Preliminary “pulse and chase” experiment (3 hours “chase” period) 
HK cells were incubated with either control medium (A, C) or 1% vCJD spiked medium (B, 
D) already containing anti-PrP primary antibody 6H4 (1 µg/ml) for 30 minutes at 4 °C – 
“pulse”. Then the cells were washed and fresh control medium was added. Cells were 
subsequently placed at 37 °C for 3 hours to initiate the internalisation of the antigen-antibody 
complex (vCJD/PrP-6H4) – “chase”. The cells were then fixed, permeabilised, blocked and 
incubated with Alexa 488 labelling PrP-6H4 complexes (green) for 60 minutes. 
Subsequently the samples were immunostained for caveolae-coated vesicles (A, B) with 
caveolin1 antibody or for clathrin coated pits (C, D) with clathrin antibody which were 
revealed by incubation with Alexa 546 (red) as described in section 2.12.5. Positive 
colocalisation of PrP (green) and endocytic vesicles (red) appeared yellow. Insets represent 
magnification of the boxed areas. The nuclei were counterstained with DAPI (blue). The 
scale bar represents 20 µm. 
 
3.7.3.4  “Pulse and chase” experiment - (24 hours “chase” period) 
Following the pilot “pulse and chase” study, a further experiment was conducted to 
determine the involvement of these two different elements of the endocytic 
machinery at a later time point. A “pulse and chase” experiment was performed 
using a 24-hour “chasing” time period (Figure 3.56). The HK cells exposed in 
“pulse” to 6H4-vCJD brain spiked medium and a 24-hour “chase” were double 
immunolabeled for caveolae-coated vesicles (A, B) or clathrin-coated pits (C, D) 
(red) and prion protein (green). During the immunostaining, the cells were either 
guanidine pre-treated (B, D) to accentuate PrP
Sc
 or left untreated (A, C). A positive 
Chapter 3   Results 
  214 
colocalisation (yellow) of the exogenous PrP
Sc
 taken up and “chased” for 24 hours 
through the HK cells “pulsed” with vCJD brain spiked medium was clearly shown to 
be colocalised with caveolae-coated vesicles at this time point. The observation was 
evident in cells not pre-treated with guanidine (A) and also in cells pre-treated with 
guanidine in which case the cells own PrP
C
 was diminished and the exogenous PrP
Sc
 
staining signal was enhanced (B). At this time point, a positive colocalisation of 
exogenous PrP
Sc
 with clathrin-coated pits was also observed (yellow patches) in cells 
either pre-treated with guanidine (D) or left untreated (C). 
The outcome of this experiment indicates that the caveolae-coated endocytic 
machinery may be still involved in prion internalisation even after 24 hours post 
exposure (A and B) (as shown by positive colocalisation of PrP
Sc
 with caveolin1 in 
yellow). But more interestingly, the clathrin-coated pits also seem to be involved in 
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Figure 3.56: “Pulse and chase” experiment - (24 hours “chase” period) 
HK cells were incubated with 1% vCJD brain spiked medium containing antibody 6H4 (1 
µg/ml) for 30 minutes at 4 °C. Then the cells were placed at 37 °C for additional 15 minutes 
to initiate the internalisation of the antigen/antibody complex – “pulse”. Subsequently, the 
cells were extensively washed with HBSS solution. Fresh control medium was added to the 
cultures and the cells were then cultured at 37 °C for 24 hours – “chase”. The medium was 
then aspirated, the cells were extensively washed and double immunolabeled for PrP (green) 
and endocytic vesicles (red) as marked on the figure and previously described in section 
2.12.5. Merge of the channels is shown. Insets represent magnification of the boxed areas. 
The double labelling and colocalisation (yellow) for PrP (A, C), or PrP
Sc
 after guanidine pre-
treatment (B, D) with caveolae coated vesicles is shown in the top row (A, B) and for 
clathrin coated pits in the bottom row (C, D). The nuclei were counterstained with DAPI 
(blue). The scale bars, 20 µm. 
 
In order to quantitatively define the respective involvement of caveolae and clathrin 
mediated endocytosis in the PrP
Sc
 uptake, more elaborate designs of the “pulse and 
chase” assays were performed (Figure 3.57-61). The aim was to examine time-
dependent changes in the involvement of the two endocytic pathways and better 
distinguish PrP
Sc 
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3.7.3.5  PrP
Sc
 colocalisation with caveolae coated vesicles in “pulse and chase” 
study (I.) 
Firstly, the involvement of caveolae-coated vesicles in the endocytosis of the 
exogenous PrP
Sc
, without guanidine pre-treatment during immunolabeling, was 
investigated (Figure 3.57). HK cells were “pulsed” with medium containing 6H4 
primary antibody – either control (Figure 3.58; A-D) or vCJD spiked (Figure 3.58; E-
H, insets of boxed areas). The cells were then double immunolabeled for PrP (green) 
and caveolae-coated vesicles (red) at 1 (A, E), 3 (B, F), 24 (C, G) and 48 hours (D, 
H) of the “chasing” time period as described in section 2.12.5. The merge of the 
channels is shown. Positive colocalisation of prion proteins and caveolae-coated 
vesicles appears in yellow.  
The exogenous PrP
Sc
 was clearly demonstrated to be colocalised with caveolae-
coated vesicles at 1 (E), 3 (F), and 24 hours (G) of the “chasing” period in HK cells 
exposed to vCJD spiked medium. This could be observed as yellow patches and 
clusters. The 48-hour time point also showed a positive colocalisation, although the 
signal of exogenous PrP
Sc
 appeared to be slightly weaker (H). The difference in the 
PrP signal (duller green) of unexposed cells (A-D) compared to the PrP signal of the 
cells exposed to brain spiked medium (intense green) (E-H) indicated, that the 
vCJD/PrP-6H4 was efficiently taken up together as a complex. This allowed us to 
clearly distinguish between the exogenous PrP
Sc
 (intense green, E-H, insets) taken up 
by cells exposed to brain material from the recycling cell own PrP
C
 (duller green, A-
D). The results convincingly demonstrated that the caveolae-coated endocytic 
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 colocalisation with caveolae coated vesicles in “pulse and chase” 
study (I.) 
HK cells were incubated with medium containing 6H4 (1 µg/ml), either control (A-D) or 1% 
vCJD spiked (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C – “pulse”. 
The cells were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – “chase”. 
The medium was then aspirated and the cells were double immunolabeled for PrP (green) 
and caveolae coated vesicles (red) as was previously described in section 2.12.5. The merge 
figures of the channels are shown, any colocalisation appeared as yellow colour and the high 
magnifications of the boxed areas in (E-H) are shown right (inset). The nuclei were 
counterstained with DAPI (blue) and the scale bar represents 20 µm. 
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3.7.3.6  PrP
Sc
 colocalisation with caveolae coated vesicles in a “pulse and chase” 
study (II.) 
More convincing endocytic parameters for PrP
Sc
 internalisation could be observed by 
using guanidine pre-treatment in immunostaining protocol (Figure 3.58) in the same 
experimental design as shown in previous investigation (section 3.7.3.5). Positive 
colocalisation of the exogenous PrP
Sc
 (green) (E-H, inset of boxed areas) with 
caveolae-coated vesicles (red) at 1-24 hours post exposure was observed (yellow). 
The PrP
Sc
 signal at the 48 hours “chasing” period (H) was not convincingly 
demonstrated to colocalise with caveolae-coated vesicles. As expected, after 
guanidine pre-treatment, the PrP
C
 signal was reduced when compared to untreated 
cells in the previous experiment (section 3.7.3.5).  
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 colocalisation with caveolae coated vesicles in “pulse and chase” 
study (II.) 
HK cells were incubated and treated as described in Figure caption 3.57 with the additional 
inclusion of guanidine pre-treatment step during the immunocytochemistry procedure. The 
cells were double immunolabeled for PrP (green) and caveolae coated vesicles (red) as was 
described previously in section 2.12.5. The merge of the channels is shown, any 
colocalisation of PrP
Sc
 with caveolae-coated vesicles is indicated by yellow and the high 
magnifications of the boxed areas in (E-H) are shown right (inset). The nuclei were 
counterstained with DAPI (blue) and the scale bar represents 20 µm. 
 
Chapter 3   Results 
  220 
From this study it is apparent that the caveolae-coated vesicles are involved in the 
PrP
Sc
 internalisation not only at the early (1 and 3 hours), but also at the later time 
points of endocytosis (24 hours). However, after 48 hours, the PrP
Sc
 signal could not 
be considered to be colocalised with caveolae-coated vesicles. 
3.7.3.7  PrP
Sc
 colocalisation with clathrin coated pits in “pulse and chase” study (I.) 
Having previously observed the possible role of clathrin-coated pits in the 
endocytosis of the exogenous PrP
Sc
 (section 3.7.3.4), the same “pulse and chase” 
experimental design as above, but with cells double immunolabeled for PrP (green) 
and clathrin-coated pits (red) with clathrin antibody was analysed (Figure 3.59). The 
cells were either unexposed (A-D) or vCJD exposed (E-H, insets of the boxed areas). 
The merge of the channels is shown. The exogenous PrP
Sc
 was clearly present in 
cells exposed to vCJD (E-H, bright green). Some positive colocalisation of the 
exogenous PrP
Sc
 with clathrin-coated pits suggesting involvement in endocytosis in 
cells exposed to vCJD brain material could be observed at all examined time points 
(E-H, yellow). However, the involvement appears to be less intense then the 
endocytosis via caveolae-coated vesicles observed earlier (section 3.7.3.5; Figure 
3.57; E-H).  
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 colocalisation with clathrin coated pits in “pulse and chase” study 
(I.) 
HK cells were incubated with medium containing 6H4, either control (A-D) or 1% vCJD 
spiked (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C – “pulse”. Then 
the cells were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – “chase”. 
The medium was then aspirated and cells were double immunolabeled for PrP (green) and 
clathrin coated pits (red) as was described previously in section 2.12.5. The merge of the 
channels is shown and any colocalisation of PrP with clathrin-coated pits appeared yellow. 
Insets represent magnifications of the boxed areas in (E-H). The nuclei were counterstained 
with DAPI (blue) and the scale bar represents 20 µm. 
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3.7.3.8 PrP
Sc
 colocalisation with clathrin coated pits in “pulse and chase” study (II.) 
In order to more precisely determine and quantify the involvement of clathrin-coated 
pits in the uptake of PrP
Sc
, the guanidine pre-treatment generally used to diminish 
PrP
C
 and accentuate the PrP
Sc
 signal was used in the immunostaining protocol 
(Figure 3.60). The same experimental design of the “pulse and chase” assay as in 
3.7.3.7 was used. The merge of the channels is shown, PrP is shown (green) and the 
clathrin-coated pits are shown (red). Any positive colocalisation of PrP
Sc
 and 
clathrin-coated pits is in yellow and this could be weakly observed at the 24 (G) and 
48 hours (H) of “chasing” period in the HK cells exposed to vCJD spiked medium. 
The result supports the data observed earlier showing the peak of PrP
Sc
 
internalisation via clathrin-coated pits at the later times after exposure (24 and 48 
hours). 
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 colocalisation with clathrin coated pits in “pulse and chase” study 
(II.) 
HK cells were incubated and treated as described in Figure caption 3.59 including a 
guanidine pre-treatment step during immunocytochemistry procedure. The cells were double 
immunolabeled for PrP (green) and clathrin coated pits (red) as was described previously in 
section 2.12.5. The merge of the channels is shown, any colocalisation of PrP
Sc
 and clathrin 
coated pits appeared yellow and the high magnifications of the boxed areas (E-H) is shown 
right (inset). The nuclei were counterstained with DAPI (blue) and the scale bar, 20 µm. 
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3.7.4  Summary 
 The use of immunocytochemistry to study internalisation of vCJD PrPSc-6H4 
complexes in HK cells has provided the first direct evidence that both 
caveolae and clathrin-mediated endocytic pathways may be involved in the 
uptake process of exogenous PrP
Sc
 into the cell. 
 The evidence here further suggests that the kinetics of uptake differ, with 
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3.8 TRAFFICKING OF PRP
SC




To investigate the intracellular fate and the subcellular sites of accumulation of the 
exogenous prion protein endocytosed by HK cells. 
 
3.8.2 Rationale 
The earlier observations (section 3.3) showed that exposure of HK cells to prion 
infected brain material was not able to establish a long term prion infection in these 
cells, although they possess all the required components (section 3.2) to support 
PrP
Sc 
formation. Interestingly, these cells also showed high levels of PrP
C
 (section 
3.1.3), and to have the mechanisms to allow a rapid uptake of the infectious brain 
material (section 3.4, 3.5 and 3.7). However, the findings of the recovery studies 
(section 3.6) that HK cells are also able to clear the endocytosed PrP
Sc
, suggests that 
they have mechanism to degrade, or otherwise process the infectious material. 
Interestingly, the endocytosed PrP
Sc
 material could not be detected to be shed back 
into the culture media (section 3.6). An earlier study (section 3.5) showed that 
exogenous PrP
Sc
 taken up by HK cells was mostly found in the juxtanuclear region 
of cytoplasm. Therefore sub-cellular localisation of exogenous PrP
Sc
 and 
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3.8.3 Experimental results  
Identifying the intracellular compartments and the mechanisms involved in the 
trafficking of the prion material is important for characterisation of the exact 
intracellular localisation of the exogenous PrP
Sc
 after being taken up.  
Therefore, to investigate the subcellular distribution of the exogenous PrP
Sc 
in 
regards to its cell organelle colocalisation in prion exposed HK cells, a study 
defining the exogenous prion protein trafficking through HK cells was performed 
and examined by immunofluorescence microscopy. Standard conditions of fixation 
and permeabilisation, with a short pre-treatment with guanidine thiocyanate (Gnd), to 
expose the PrP
Sc




were used. Moreover, this 
study also employed the previously used fluorescent signal thresholding procedure to 
reveal the intracellular distribution of all PrP
Sc 
taken up by cells exposed to brain 
spiked medium. Detection of prion protein was performed using the anti-prion 
protein primary antibody 8H4 or 6H4. Antibodies were carefully selected for the 
detection of PrP and cell organelles in the double immunolabeling method based on 
their properties and their use in published reports.  
The ICC colocalisation data shown in this chapter are representative of seven 
independent non-identical experiments. The differences included the time points 
assayed and the origin of the inoculum used. 
3.8.3.1. Cell organelle structures of HK cells examined by immunofluorescence  
The possibility of exogenous PrP
Sc
 trafficking via early endosomes, as tested using 
the EEA1 antibody (Figure 3.61; A) (Wilson et al., 2000; Peters et al., 2003; 
Campana et al., 2005; Pimpinelli et al., 2005; Marijanovic et al., 2009; Veith et al., 
2009) was investigated as first.  
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Based on findings from earlier observations (section 3.5.3.9-10), exogenous PrP
Sc
 
taken up by HK cells is mostly found in the perinuclear region that partially overlaps 
the Golgi complex or endoplasmic reticulum. Therefore, it was of interest to evaluate 
their co-localisation by using giantin - a Golgi complex specific monoclonal antibody 
(Figure 3.61; B) (Campana et al., 2005; Dron et al., 2009; Marijanovic et al., 2009) 
and calnexin - an endoplasmic reticulum specific monoclonal antibody (Figure 3.61; 
C) (Campana et al., 2005). Note that the calnexin antibody gave only a very faint 
signal, even when the antibody concentration was increased up to four times that 
recommendation by the manufacturer. 
The rab11A antibody, labeling recycling endosomes (Figure 3.61; D) (Urbe et al., 
1993; Ullrich et al., 1996; Marijanovic et al., 2009) localised to juxtanuclear and 
peripheral endocytic vesicles and regulating vesicular transport, was also used for 
examining colocalisation with the exogenous PrP
Sc
.  
To further clarify PrP
Sc 
clearance (section 3.6) from HK cells and taking into account 
the previous observation that lysosomal proteases would, to some extent, degrade 
PrP
Sc 
in prion infected cells in culture (Supattapone et al., 2001), or in cell culture of 
bovine macrophages exposed to mouse adapted scrapie and BSE (Sassa et al., 2010), 
it was of interest to examine whether the PrP
Sc 
clearance could be ascribed to 
lysosomal degradation process in HK cells. The antibodies LAMP1 (Figure 3.61; E) 
(Sun et al., 1997; Brauer et al., 2004; Wilson et al., 2004; Falcon-Perez et al., 2005; 
Kristiansen et al., 2007; Godsave et al., 2008; Okemoto-Nakamura et al., 2008) and 
LAMP2b (Figure 3.61; F) were used to label lysosomes in this experiment.  
An Alexa 546-conjugated secondary antibody was used throughout. 
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Figure 3.61: Immunostaining of organelles chosen for the trafficking study of 
exogenous PrP
Sc 
in HK cells 
HK cells were washed, fixed, permeabilised and immunolabeled (following the standardised 
ICC protocol as described in section 2.12.2) for early endosomes (A) with EEA1 antibody, 
the Golgi complex (B) with giantin, endoplasmic reticulum (C) with calnexin, recycling 
endosomes (D) with rab11A antibody, lysosomes with LAMP1 antibody (E) and LAMP2b 
antibody (F). The cells were then incubated with Alexa 546 (red) and the nuclei were 
counterstained with DAPI (blue). The scale bar represents 20 µm.  
 
3.8.3.2 PK pre-treatment has a destructive effect on the cell organelle integrity 
In this study, the PK pre-treatment during the immunocytochemical procedure had to 
be omitted as it turned out to severely affect the structurality of cell organelles. The 
characteristic structures (without PK pre-treatment) of the Golgi complex (Figure 
3.62; A) and the endoplasmic reticulum (Figure 3.62; C) in HK cells are shown. The 
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PK pre-treatment caused the cell organelle structures to collapse (Figure 3.62; B) and 
the relevance of observations upon PK pre-treatment therefore could be not evaluated 
accurately (Figure 3.62; D). 
Fortunately, PK pre-treatment was not essential, as PrP
Sc 
could be easily 
distinguished from PrP
C
 when necessary by a guanidine pre-treatment and using 
uniform signal threshold in the course of all confocal microscope analysis, to 
maximise the PrP
Sc
 detection. It is important to note that the Gnd pre-treatment 
neither affected the cell organelle structures, nor interfered with the PrP
C
 staining, 
whereas it was necessary for the detection and enhancement of the PrP
Sc
 signal. All 
further experiments in this section were undertaken without PK pre-treatment.  
 
Figure 3.62: Proteinase K pre-treatment has a severe destructive effect on the cell 
organelles integrity 
The HK cells were immunostained as described previously (section 2.12.3) and either 
allowed to remain not pre-treated with PK/Gnd (A, C) or treated (B, D). Antibody giantin 
was used to visualise the Golgi complex (A, B) and calnexin to visualise the endoplasmic 
reticulum (C, D) (red). The nuclei were counterstained with DAPI (blue). Scale bar, 20 µm. 
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To investigate the intracellular fate of exogenous PrP
Sc
 in HK cells exposed to prion 
diseased brain homogenates, a series of uptake experiments were performed. It is 
important to note that pre-treatment of the examined cells with guanidine was used in 
these studies only when specifically mentioned. 
3.8.3.3 Investigation of PrP
Sc
 colocalisation with early endosomes after continuous 
exposure of HK cells to vCJD brain material  
The first investigation was focused on whether endocytosed exogenous PrP
Sc
 
intersects with the classical early endocytic recycling pathway involving early 
endosomes, the Golgi complex or the endoplasmic reticulum. This was examined at 
four time points from the 1-72 hours of continuous exposure to prion diseased brain 
spiked medium.  
The HK cells were subjected to continuous exposure to vCJD brain spiked medium 
for 1, 24, 48 and 72 hours and labelled with 8H4 (Figure 3.63; left column) and 6H4 
(Figure 3.63; right column) anti-prion protein primary antibody.  
The cell-associated PrP signal (green) could be observed, as in earlier studies, to 
increase in the cells with the time of exposure. Identical results for cell-associated 
PrP, (regarding time-dependent uptake of PrP
Sc
 from brain spiked media), were 
observed by both anti-PrP antibodies. Early endosomes are visualised in red colour. 
All micrographs represent the merge of the green and red channels and any positive 
colocalisation of early endosomes (red) with PrP (green) should appear as yellow. No 
obvious evidence of positive colocalisation of PrP
Sc
 with early endosomes was seen 
at any time point of continuous exposure to vCJD spiked medium, although some 
limited evidence of overlap at the 24 hours time point analysed by 6H4 antibody was 
detected (Figure 3.63; right column).  
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Figure 3.63: Investigation of PrP
Sc
 colocalisation with early endosomes after continuous 
exposure to vCJD brain material 
HK cells were continuously exposed to 1% vCJD brain spiked medium for 1, 24, 48 and 72 
hours. The cells were then washed and double immunolabeled for PrP with antibody 8H4 
(left column) or 6H4 (right column) (green) and early endosomes antibody EEA1 (red). The 
merge of the channels is shown. The nuclei were counterstained with DAPI (blue). The scale 
bar represents 20 µm. 
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3.8.3.4 Investigation of PrP
Sc
 colocalisation with the Golgi complex after continuous 
exposure of HK cells to vCJD brain material 
The same experimental design was used to examine whether the endocytosed 
exogenous PrP
Sc
 is trafficked to the Golgi complex during the four examined time 
points (1-72 hours) of continuous exposure to prion infected brain spiked medium 
(Figure 3.64). The anti-PrP primary antibodies 8H4 (Figure 3.64; left column) and 
6H4 (Figure 3.64; right column) were used to detect PrP (green). The Golgi complex 
was visualised with antibody giantin (red). All micrographs represent the merge of 
the green and red channels and any positive colocalisation of the Golgi complex (red) 
with PrP (green) should appear as yellow.  
The time dependent increase of cell-associated exogenous PrP
Sc
 was unambiguous 
and uniform when visualised by both anti-PrP protein antibodies. No obvious 
evidence of colocalisation of the exogenous PrP
Sc
 with the Golgi complex could be 
observed at any examined time point using either 8H4 or 6H4 antibody.  
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Figure 3.64: Investigation of PrP
Sc
 colocalisation with the Golgi complex after 
continuous exposure of HK cells to vCJD brain material 
HK cells were continuously exposed to 1% vCJD brain spiked medium for 1, 24, 48 and 72 
hours. The cells were then washed and double immunolabeled for PrP with antibody 8H4 
(left column) or 6H4 (right column) (green) and the Golgi complex with antibody giantin 
(red). The merge of the channels is shown. The nuclei were counterstained with DAPI (blue). 
Scale bar, 20 µm. 
 
 
Chapter 3   Results 
  234 
3.8.3.5  Investigation of PrP
Sc
 colocalisation with the endoplasmic reticulum after 
continuous exposure of HK cells to vCJD brain material  
Next the question of whether the endoplasmic reticulum contains any endocytosed 
exogenous PrP
Sc
 was addressed (Figure 3.65). The experimental design was the same 
as applied previously. PrP was detected using 8H4 (Figure 3.65; left column) and 
6H4 antibody (Figure 3.65; right column) (green). The endoplasmic reticulum was 
visualised using antibody calnexin (faint red). The merge of the channels is shown. 
The time dependent increase of cell-associated PrP
Sc
 after continuous exposure to 
vCJD brain spiked medium was clearly shown (green). The exogenous PrP
Sc
 did not 
obviously colocalise with endoplasmic reticulum in HK cells at any examined time 
point, although calnexin staining was faint.  
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Figure 3.65: Investigation of PrP
Sc
 colocalisation with the endoplasmic reticulum after 
continuous exposure of HK cells to vCJD brain material 
HK cells were continuously exposed to 1% vCJD brain spiked medium for 1, 24, 48 and 72 
hours. The cells were then washed and double immunolabeled for PrP with antibody 8H4 
(left column) or 6H4 (right column) (green) and the endoplasmic reticulum with antibody 
calnexin (red). The merge of the channels is shown. The nuclei were counterstained with 
DAPI (blue). The scale bar represents 20 µm. 
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In the above investigations, no evidence of exogenous PrP
Sc
 colocalisation with 
markers of the endocytic pathway, such as EEA1, giantin and calnexin was found. 
To demonstrate that these findings were not the result of a technical artefact, it was 
decided to perform a series of “pulse-chase” studies (described in sections 2.11.2.3 
and in section 2.12.5). Therefore, based on the assumption that the trafficking of 
endocytosed prion material could be more precisely evaluated by the “pulse-chase” 
study, it was proposed to repeat the investigation of the PrP
Sc
 colocalisation with the 
early endosomes, the Golgi complex and the endoplasmic reticulum by applying this 
principle (Figure 3.66-3.68). Firstly, HK cells were “pulsed” with complete 
(unspiked) medium containing 6H4 primary antibody (1 µg/ml) – as a control 
(Figure 3.66-3.68; A-D) or with vCJD PrP
Sc
-6H4 complexes (Figure 3.66-3.68; E-H, 
insets of boxed areas). The “pulse” period was composed of 30 minutes incubation at 
4 °C and additional 15 minutes incubation at 37 °C to initiate the internalisation of 
the antibody-antigen complex. The cells were then extensively washed and incubated 
with a fresh complete medium (not containing 6H4) for the desired “chase” time 
period before double labelling immunocytochemistry for PrP and cell organelles was 
carried out (as described in section 2.12.5).  
3.8.3.6 Investigation of PrP
Sc
 colocalisation with early endosomes in the “pulse and 
chase” study  
The cells were double immunolabeled for PrP (green) and early endosomes (red) 
with the EEA1 antibody (Figure 3.66) at 1 (A, E); 3 (B, F); 24 (C, G) and 48 hours 
(D, H) of the “chasing” period. The merge of the channels is shown and any positive 
colocalisation of endocytosed exogenous PrP
Sc
 with early endosomes should appear 
as yellow.  
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An overlap or positive colocalisation of exogenous PrP
Sc
 with early endosomes could 
be observed in the form of few yellow dots.  
The difference in the PrP signal (green) of the unexposed cells (dull green) (A-D) 
compared to the PrP signal of the cells exposed to prion diseased medium (bright 
green) (E-H) indicates that the vCJD PrP
Sc
-6H4 is taken up together as a complex, 
rather than the 6H4 primary antibody being taken up on its own.  
At steady-state (data not shown) and also after “pulse-chase” when HK cells were 
“pulsed” with complete (unspiked) medium containing 6H4 mAb (Figure 3.66; A-
D), the early endosome antibody EEA1 did not colocalise with endogenous cellular 
PrP
C 
(even when the fluorescence signal threshold was set to extreme values). 
However, it is possible that level of PrP
C 
in the early endosomes was below the 
detection limit. In this respect, the investigations obtained thus far showed no 
evidence of endogenous PrP
C 
and some (but inconclusive) evidence that the 
endocytosed exogenous PrP
Sc 
may be trafficked via early endosomes in HK cells. 
Whether this colocalisation was real or random was assessed by a quantitative image 
analysis study in this thesis (section 2.14 and 3.8.3.19). 
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Figure 3.66: Investigation of PrP
Sc
 colocalisation with early endosomes in the “pulse 
and chase” study 
HK cells were incubated with medium containing 6H4 (1 µg/ml), either control (A-D) or 
spiked with 1% vCJD brain (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 
37 °C – “pulse”. Then the cells were washed and incubated with fresh medium for 1, 3, 24 
and 48 hours – “chase”. The medium was then aspirated and the cells were double 
immunolabeled for PrP (green) and early endosomes (red) as was described previously in 
section 2.12.5. The merge of the channels is shown, any colocalisation appeared in yellow 
colour and the high magnification of the boxed areas in (E-H) is shown right (inset). The 
nuclei were counterstained with DAPI (blue). Scale bar, 20 µm. 
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3.8.3.7 Investigation of PrP
Sc
 colocalisation with the Golgi complex in the “pulse 
and chase” study 
The next “pulse-chase” study evaluated colocalisation of exogenous PrP
Sc
 with the 
Golgi complex (Figure 3.67). The experimental design was the same as previously 
applied (section 3.8.3.6), except the cell organelle examined was the Golgi complex 
labelled with antibody giantin (red) at 1 (A, E); 3 (B, F); 24 (C, G) and 48 hours (D, 
H) of the “chasing” time period. Merge of the channels is shown. The exogenous 
PrP
Sc
 (green) in cells spiked with vCJD brain homogenate was clearly present 
intracellularly at all examined time points and increasing in a time dependent manner 
(E-H, inset – high magnification of the boxed areas). 
However, no evidence of positive colocalisation (yellow) of endocytosed exogenous 
PrP
Sc
 with the Golgi complex was observed in cells exposed to vCJD medium 
(Figure 3.67; E-H). This observation is consistent with the earlier results obtained 
after continuous exposure to brain spiked medium (section 3.8.3.4). Moreover, no 
positive colocalisation of the HK cell’s own PrP
C 
with the Golgi complex could be 
observed in the conditions used (Figure 3.67; A-D). 
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Figure 3.67: Investigation of PrP
Sc
 colocalisation with Golgi complex in the “pulse and 
chase” study 
HK cells were incubated with control medium containing 6H4 (A-D) or 1% vCJD-6H4 (E-
H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C – “pulse”. Then the cells 
were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – “chase”. The 
medium was then aspirated and cells were double immunolabeled for PrP (green) and the 
Golgi complex (red) as was described previously in section 2.12.5. The merge of the 
channels is shown, any colocalisation appeared as yellow and the high magnification for (E-
H) is shown right (inset). The nuclei were counterstained with DAPI (blue) and the scale bar 
represents 20 µm. 
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3.8.3.8 Investigation of PrP
Sc
 colocalisation with the endoplasmic reticulum in the 
“pulse and chase” study  
The “pulse-chase” study also re-examined the possible colocalisation of endocytosed 
exogenous PrP
Sc
 with endoplasmic reticulum in the HK cells (Figure 3.68). 
Experimental design of this “pulse-chase” assay was used as before (sections 3.8.3.6-
7). The endoplasmic reticulum was detected with antibody calnexin (red). The merge 
of the channels is shown. The exogenous PrP
Sc
 in cells spiked with vCJD brain 
homogenate was present at all examined time points (E-H, inset – high magnification 
of the boxed areas) (green). No convincing evidence of positive colocalisation 
(yellow) of endocytosed exogenous PrP
Sc
 within the endoplasmic reticulum of HK 
cells exposed to vCJD medium could be observed (Figure 3.68; E-H). This 
observation is consistent with our earlier results (section 3.8.3.5) although 
immunostaining of the endoplasmic reticulum with the calnexin antibody was faint.  
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Figure 3.68 Investigation of PrP
Sc
 colocalisation with the endoplasmic reticulum in the 
“pulse and chase” study 
HK cells were incubated with medium containing 6H4, either control (A-D) or 1% vCJD 
spiked (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C - pulse. Then 
the cells were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – chase. 
The medium was then aspirated and the cells were double immunolabeled for PrP (green) 
and the endoplasmic reticulum (red) as was described previously in 2.12.5. The merge of the 
channels is shown, any colocalisation appeared yellow and the high magnification of the 
boxed areas in (E-H) is shown right (inset). The nuclei were counterstained with DAPI 
(blue). Scale bar, 20 µm. 
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The immunocytochemical studies of exogenous PrP
Sc
 trafficking and colocalisation 
with early endosomes, the Golgi complex and the endoplasmic reticulum were 
carried out either after continuous exposure to brain spiked medium or by the “pulse-
chase” format. Confocal analysis showed that, in juxtanuclear areas, Golgi complex 
or endoplasmic reticulum and PrP
Sc 
labelling occured in the same general region, but 
did not truly colocalise. It was concluded that these compartments did not contain 
substantial amounts of endocytosed PrP
Sc
.  
It was therefore thought that exogenous PrP
Sc
 might be trafficked by the late 
endosomal/lysosomal route after being endocytosed by caveolae-coated vesicles. 
3.8.3.9 Investigation of PrP
Sc
 colocalisation with lysosomes after continuous 
exposure of HK cells to vCJD brain material (I.) 
HK cells were exposed to vCJD brain spiked medium for 1-72 hours and then double 
immunolabeled with anti-PrP (green) primary antibody 8H4 (Figure 3.69; left 
column) and 6H4 (Figure 3.69; right column) and the anti-lysosomal antibody 
LAMP2b (red). The merge of the channels is shown and positive colocalisation 
(yellow) of endocytosed exogenous PrP could be clearly observed when the 8H4 
primary antibody was used (left column). In this case, when the 6H4 antibody was 
used (right column) the positive colocalisation could be also observed, but only after 
the fluorescence signal threshold was set to a higher level than for 8H4. The same 
signal threshold are shown for both antibodies to maintain consistency within the 
studies. 
It is important to note that the HK cells challenged with vCJD brain material showed 
intensely positive colocalisation of endocytosed exogenous PrP
Sc
 with lysosomes. It 
is also interesting to note that number of lysosomal structures within the cells 
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appeared to increase with the exposure time. Longer exposure times (24-72 hours) 
gave the most convincing colocalisation.  
 
Figure 3.69: Investigation of PrP
Sc
 colocalisation with lysosomes after continuous 
exposure to vCJD (I.) 
HK cells were continuously exposed to 1% vCJD brain spiked medium for 1, 24, 48 and 72 
hours. The cells were then washed and double immunolabeled for PrP with antibody 8H4 
(left column) or 6H4 (right column) (green) and lysosomes using antibody LAMP2b (red). 
The merge if the channels is shown, any colocalisation of PrP
Sc
 with lysosomes appeared in 
yellow colour. The nuclei were counterstained with DAPI (blue). Scale bar, 20 µm. 
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3.8.3.10 Investigation of PrP
Sc
 colocalisation within lysosomes after continuous 
exposure of HK cells to vCJD brain material (II.) 
Further study of PrP
Sc
 colocalisation within lysosomes after (1-72 hours) continuous 
exposure, in a more detailed display (the individual immunostaining channels, as 
well as the merge channel and inset of the boxed areas of the merge figure) is shown 
in Figure 3.70. Under standard conditions, the vCJD exposed HK cells were fixed, 
permeabilised and double immunolabeled for PrP with 8H4 primary antibody (green) 
(far left) and lysosomes with LAMP2b antibody (red) (left from the centre). 
Apparent colocalisation of PrP
Sc
 within the lysosomal structures (yellow) can be seen 
in the merge channels (right from the centre) and higher magnification view is shown 
in the inset (far right).  
The time dependent increase of cell-associated PrP
Sc
 (green) could be clearly 
observed (column far left). Almost all visible structures labelled as lysosomes were 
positive for exogenous PrP
Sc
 at 48 and 72 hours post exposure (right from the centre; 
48 and 72 hour time point). Again, an exponentially increasing number of cellular 
lysosomal structures with exposure time (left from the centre, red channel) was 
observed. 
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Figure 3.70: Investigation of PrP
Sc
 colocalisation within lysosomes after continuous 
exposure of HK cells to vCJD brain material (II.) 
More detailed display of PrP
Sc
 colocalisation within lysosomes after continuous exposure of 
HK cells to vCJD brain spiked medium. The cells were incubated and treated same as 
described previously (Figure descriptions 3.63-3.65), PrP antibody used was 8H4 (green). 
Individual channels (green/PrP and red/lysosomes) are shown. Yellow colour in merged 
channels (green and red) indicates colocalisation of PrP
Sc
 with lysosomes. Insets (far right) 
represent magnification of the boxed areas. Scale bar, 20 µm. 
 
3.8.3.11 Investigation of PrP
Sc
 colocalisation within lysosomes after continuous 
exposure of HK cells to iCJD, vCJD and AD brain spiked medium  
To investigate whether colocalisation of PrP
Sc
 with HK cell lysosomal structures was 
specific to vCJD, cells exposed to iCJD brain spiked medium (Figure 3.71; Ab and 
Ac) unexposed control cells (Figure 3.71; Aa) were examined. Cells were 
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continuously exposed for 48 hours and immunolabeled either under standard 
conditions (Aa, Ab) or with guanidine pre-treatment (Ac). Strong PrP
Sc
 
immunostaining was seen in the lysosomes of iCJD exposed cells. The results were 
similar to those observed with vCJD and the positive colocalisation of endocytosed 
exogenous iCJD PrP
Sc
 with cell lysosomes suggests that this event is not specific for 
vCJD. The PrP
Sc
 colocalisation with lysosomes was more intense in the cells pre-
treated with guanidine (Figure 3.71; Ac), indicating the efficiency of the pre-
treatment in regards of exposing the PrP
Sc
-specific epitopes to anti-PrP primary 
antibody. It was observed that there were fewer numbers of lysosomes in unexposed 
cells (Figure 3.71; Aa) than in those HK cells exposed to vCJD and iCJD. 
Furthermore, they were PrP negative using the thresholding criteria. 
To determine whether the observed difference in the number of lysosomal structures 
between brain homogenate exposed and unexposed cells resulted from exposure to 
brain material, or to exposure to vCJD derived brain material, the HK cells were 
exposed to AD (Figure 3.71; Ba) and vCJD (Figure 3.71; Bb) brain homogenates for 
48 hours. Cells were immunostained under standard conditions with the 6H4 
antibody (green) and lysosomal antibody LAMP2b (red). The merge of the channels 
is shown. The results indicate that the higher numbers of cell lysosomes resulted 
from cell exposure to brain homogenates rather than CJD brain homogenates. For 
comparison, see unexposed cells (Figure 3.71; Aa) and cells exposed to AD brain 
spiked medium (Figure 3.71; Ba). This investigation suggested that the observed 
higher number of cell lysosomes is caused by the cell exposure to any brain material, 
rather than being specifically related to exposure to prion diseased brain homogenate. 
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Figure 3.71: Investigation of PrP
Sc
 colocalisation with lysosomes after continuous 
exposure of HK cells to iCJD, vCJD and AD brain spiked medium 
(A) The HK cells were grown in control medium (a) or exposed to 1% iCJD brain spiked 
medium for 48 hours (b, c). (B) The HK cells were continuously exposed to 1% AD (a) or 
vCJD brain spiked medium (b) for 48 hours. The cells were then double immunolabeled for 
PrP with antibody 6H4 (green) and lysosomes with LAMP2b antibody (red) without Gnd 
pre-treatment (Aa, Ab) or pre-treated with Gnd (Ac, Ba, Bb). The merge of the channels is 
shown and colocalisation of PrP
Sc
 with lysosomes is in yellow colour. The nuclei were 
counterstained with DAPI (blue). Scale bars, 20 µm. 
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3.8.3.12 Investigation of PrP
Sc
 colocalisation with lysosomes in the “pulse and 
chase” study (I.) 
The next experiment was to investigate whether the results of positive colocalisation 
of exogenous PrP
Sc
 with lysosomes would be qualitatively similar when HK cells 
were immunostained after the “pulse-chase” experimental design (Figure 3.72). The 
cells were “pulsed” for 30 minutes at 4 °C and 15 minutes at 37 °C with either 
control (unspiked) complete medium (Figure 3.72; A-D) or vCJD brain spiked 
medium (Figure 3.72; E-H, insets of boxed areas) containing 6H4 primary antibody. 
Then the cells were double immunolabeled for PrP (green) and lysosomes (red) after 
1 (A, E), 3 (B, F), 24 (C, G) and 48 hours (D, H) of the “chasing” period. The merge 
of the channels is shown. Positive colocalisation of PrP
Sc
 with lysosomes appeared as 
yellow. Cell-associated PrP
Sc
 was clearly detected in cells exposed to vCJD spiked 
medium (green). The results show the appearance of colocalisation (yellow signal) at 
the 48 hours time point in the cells exposed to vCJD spiked medium denoting PrP
Sc
 
colocalisation within lysosomes. Therefore, the endocytosed exogenous PrP
Sc
 has 
most likely reached the lysosomes after 48 hours of trafficking through the exposed 
HK cells (Figure 3.72; H, inset).  
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Figure 3.72: Investigation of PrP
Sc
 colocalisation with lysosomes in the “pulse and 
chase” study (I.) 
HK cells were incubated with medium containing 6H4, either control (A-D) or 1% vCJD 
spiked (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C – “pulse”. Then 
the cells were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – “chase”. 
The medium was then aspirated and the cells were double immunolabeled for PrP (green) 
and lysosomes with LAMP2b antibody (red) as described in section 2.12.5. The merge of the 
channels is shown. Colocalisation of PrP
Sc
 with lysosomes is in yellow colour and the high 
magnification of the boxed areas in (E-H) is shown right (inset). The nuclei were 
counterstained with DAPI (blue). Scale bar, 20 µm. 
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3.8.3.13  Investigation of PrP
Sc
 colocalisation with lysosomes after 48 h exposure to 
vCJD brain material 
To unambiguously demonstrate and further confirm the association of exogenous 
PrP
Sc
 with lysosomes, these structures were immunolabelled with another antibody 
used to detect lysosomes – the LAMP1 antibody (Figure 3.73).  
Cells were continuously exposed to vCJD brain spiked medium for 48 hours and then 
double immunolabeled for PrP with the primary antibody 6H4 (green) and lysosomes 
with the LAMP1 antibody (red), both without guanidine pre-treatment (Figure 3.73; 
A) and with pre-treatment (Figure 3.73; B). Detailed display of the individual 
immunostaining channels is shown. The exogenous PrP
Sc
 taken up by the exposed 
cells was clearly demonstrated (A, B, top row).  Clear evidence of exogenous PrP
Sc
 
presence within the lysosomes immunolabeled with LAMP1 was observed  after 48 
hours exposure to the vCJD brain spiked medium (A, merged figure, inset of the 
boxed area and B, merged figure, inset of the boxed area). This observation further 
confirmed that the exogenous PrP
Sc
 is directed to lysosomal structures after being 
endocytosed by cells exposed to prion-spiked medium. 
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Figure 3.73: Investigation of PrP
Sc
 colocalisation with lysosomes after 48 h exposure to 
vCJD brain material 
HK cells were continuously exposed to 1% vCJD brain spiked medium for 48 hours. The 
cells were then washed and double immunolabeled for PrP with antibody 6H4 (green) and 
lysosomes using antibody LAMP1 (red). Individual immunostaining channels are shown 
(A,B; top row, second row). Insets represent magnification of the boxed areas in the figures 
of merged channels (green and red). Colocalisation of PrP
Sc
 (A, B) in the merged channels 
(bottom half) is indicated in yellow. The nuclei were counterstained with DAPI (blue). Scale 
bar, 20 µm. 
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3.8.3.14 Investigation of PrP
Sc
 colocalisation with lysosomes in the “pulse and 
chase” study (II.) 
The next experiment aimed to further confirm the association of the exogenous PrP
Sc
 
with lysosomes labelled with the LAMP1 antibody by the “pulse-chase” study 
(Figure 3.74). The design of the experiment was the same as used before and cells 
were analysed at routinely used time points, after being double immunolabeled for 
PrP (green) and lysosomes (red) with LAMP1, at 1 (A, E); 3 (B, F); 24 (C, G) and 48 
hours (D, H) of the “chasing” period. Exogenous PrP
Sc
 taken up by cells exposed 
vCJD spiked medium was clearly shown (E-H, inset of the boxed areas). Positive 
colocalisation of endocytosed exogenous PrP
Sc
 with lysosomes appeared yellow. 
This study further confirmed previous observations that endocytosed exogenous 
PrP
Sc
 colocalise with cellular lysosomal structures after 24-48 hours of trafficking 
through cells exposed to vCJD brain material and therefore after endocytosis is most 
likely directed to lysosomes. Under conditions used in this study, no positive 
colocalisation of HK cell’s own PrP
C 
with lysosomal structures could be observed in 
the unexposed cells (Fifure 3.74; A-D). 
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Figure 3.74: Investigation of PrP
Sc
 colocalisation with lysosomes in the “pulse and 
chase” study (II.) 
HK cells were incubated with medium containing 6H4, either control (A-D) or 1% vCJD 
spiked (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C – “pulse”. Then 
the cells were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – “chase”. 
The medium was then aspirated and cells were double immunolabeled for PrP (green) and 
lysosomes using antibody LAMP1 (red) as described in section 2.12.5. The merge of the 
channels is shown, colocalisation of PrP
Sc
 with lysosomes is in yellow colour and insets 
represent magnification of the boxed areas in (E-H). The nuclei were counterstained with 
DAPI (blue) and the scale bar represents 20 µm. 
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3.8.3.15 Investigation of PrP
Sc
 colocalisation with lysosomes in the “pulse and 
chase” study (III.) 
To unambiguously demonstrate that the PrP signal colocalising within lysosomes 
results from exogenous PrP
Sc
, an additional “pulse-chase” study was performed and 
the immunocytochemical pre-treatment with guanidine to enhance visualisation of 
PrP
Sc
 was used (Figure 3.75). The merge of the channels is shown. 
Indeed, the observation showed yellow clumps in the cells exposed to vCJD spiked 
medium at the 24-hour “chasing” period (Figure 3.75; G, inset). This observation 
implies that the detected PrP immunostaining signal results from exogenous PrP
Sc 
taken up by these cells. It also confirmed that the endocytosed PrP
Sc 
is trafficked to 
lysosomes and it reaches the lysosomal compartments approximately 24 hours after 
being introduced to HK cell culture. Interestingly, the colocalisation of PrP
Sc 
with 
LAMP1 was not apparent at the 48 hours time point.  
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Figure 3.75: Investigation of PrP
Sc
 colocalisation with lysosomes in the “pulse and 
chase” study (III.) 
Experimental design and treatment of the cells was the same as described before (section 
3.8.14), except a guanidine pre-treatment step was included during the 
immunocytochemistry procedure. The cells were double immunolabeled for PrP
Sc
 (green) 
and lysosomes using antibody LAMP1 (red) as described in section 2.12.5. The merge of the 
channels is shown, colocalisation of PrP
Sc
 within lysosomes is in yellow and the high 
magnification of the boxed areas in (E-H) is shown right (inset). The nuclei were 
counterstained with DAPI (blue). Scale bar, 20 µm. 
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3.8.3.16  Investigation of PrP
Sc
 colocalisation with recycling endosomes in the 
“pulse and chase” study (I.) 
As endocytosed exogenous PrP
Sc
 colocalised with lysosomal structures, a further 
search for an endocytic intermediate in the endosomal pathway responsible for the 
delivery of prion material to the lysosomes was performed.  
The investigation was carried out by a “pulse-chase” study (Figure 3.76). Cells were 
double immunolabeled for PrP (green) and recycling endosomes (red) with the 
rab11A antibody at 1 (A, E); 3 (B, F); 24 (C, G) and 48 hours (D, H) of the “chasing” 
period. The merge of the channels is shown and positive colocalisation of 
endocytosed exogenous PrP
Sc
 with recycling endosomes appears yellow.  
These vesicles appeared to be positive for the exogenous PrP
Sc
 at about 24 to 48 
hours after the prion material has been introduced to cells (Figure 3.76; G, inset). 
This experiment showed that cellular structures positive by rab11A immunostaining 
and resembling recycling endosomes did accumulate the endocytosed PrP
Sc
 protein. 
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Figure 3.76: Investigation of PrP
Sc
 colocalisation with recycling endosomes in the 
“pulse and chase” study (I.) 
HK cells were incubated with medium containing 6H4, either control (A-D) or 1% vCJD 
spiked (E-H) for 30 minutes at 4 °C, then for additional 15 minutes at 37 °C – “pulse”. Then 
the cells were washed and incubated with fresh medium for 1, 3, 24 and 48 hours – “chase”. 
The medium was then aspirated and cells were double immunolabeled for PrP (green) and 
recycling endosomes (red) as was described previously in 2.12.5. The merge of the channels 
is shown, any colocalisation of PrP and recycling endosomes is indicated in yellow colour 
and insets represent magnification of the boxed areas in (E-H). The nuclei were 
counterstained with DAPI (blue) and the scale bar represents 20 µm. 
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3.8.3.17 PrP
Sc
 colocalisation with recycling endosomes in the “pulse and chase” 
study (II.) 
To demonstrate that PrP positively labelled in the recycling endosomes truly 
represents the exogenous PrP
Sc
 an additional “pulse-chase” study using the 
immunocytochemical pre-treatment with guanidine to diminish PrP
C 
staining and 
enhance visualisation of PrP
Sc
 was performed (Figure 3.77). Colocalisation (yellow) 
was observed at the 24-48 hour time point of the “chasing” period (Figure 3.77; G, 
H, insets). These results suggest that exogenous PrP
Sc 
is indeed present in the 
recycling endosomes 24-48 hours after the brain spiked material was introduced to 
the cultures.  
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Figure 3.77: Investigation of PrP
Sc
 colocalisation with recycling endosomes in the 
“pulse and chase” study (II.) 
Experimental design and treatment of the cells were same as described before (section 
3.8.3.16) except a guanidine pre-treatment step was included during the 
immunocytochemistry procedure. The cells were double immunolabeled for PrP
Sc
 (green) 
and recycling endosomes (red) as described in section 2.12.5. The merge of the channels is 
shown, any colocalisation of PrP
Sc
 with recycling endosomes appeared in yellow and the 
high magnification of the boxed areas in (E-H) is shown right (inset). The nuclei were 
counterstained with DAPI (blue). Scale bar, 20 µm. 
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3.8.3.18 Controls for double labelling immunocytochemistry  
The results of these assays were confirmed by carrying out the following controls for 
the immunocytochemical procedures (Figure 3.78). The combinations of antibodies 
tested were mixtures of the anti-PrP protein primary antibody with the secondary 
antibody for labelling cellular organelle antibody (A), the secondary antibody for 
anti-PrP protein primary antibody-FITC with the primary antibody for cellular 
organelle (B), anti-PrP protein primary antibody with the primary antibody for 
cellular organelle marker (C). The merge of the channels is shown. No signal 
appearance in the FITC channel confirmed that the previously observed fluorescent 
signal (green) was specific. Also, no signal was observed in the red channel 
indicating that signals in the cell organelle colocalisation studies were specific. 
Therefore, all PrP
Sc
 (green) colocalisation with cell organelles (red) indicated in 
yellow colour were considered to represent colocalisation of the antigens recognised 
by the primary antibodies used. 
 
Figure 3.78: Controls of double labelling immunocytochemistry 
HK cells were exposed to 1% vCJD brain spiked medium for 48 hours. Then the cells were 
washed, fixed, permeabilised and immunostained leaving out individual steps of adding: PrP 
mAb (B); FITC secondary antibody (A, C); cell organelle antibody (A); Alexa 564 (B, C). 
No interaction between antibodies was observed (A: mouse/rabbit anti-donkey) (B: goat-anti 
mouse/donkey) (C: mouse/donkey). The nuclei were counterstained with DAPI (blue). The 
scale bar represents 50 µm.  
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3.8.3.19 Quantitative image analysis and statistical assessment  
In this study, two methods were used to confirm the observation that the PrP
Sc 
was 
truly colocalised with markers of particular intracellular structures. This was because 
in some circumstances the localisation of some of the cell organelle markers was 
widely distributed within the cell, which could appear as false positive colocalisation.  
 The methods used were pixel-based and particle-based colocalisation analyses. They 
were carried out as described in detail in the Material and Methods (section 2.14). 
The analysis was performed on three individual images of each time point. The data 
are representative and correspond to observations of six independent experiments, 
identical in their design. The raw data of this analysis is attached (in electronic form 
only) as Appendix 2 of this thesis. The statistical significance of the results is 
summarised below in Table 3.2 and 3.3. 
 
The pixel-based colocalisation analysis was carried out on data in which HK cells 
were exposed to vCJD brain homogenate and double immunolabelled for PrP
Sc
 and 
cell organelles: early endosomes, Golgi complex or lysosomes. The endoplasmic 
reticulum analysis was not carried out as the immunostaining for this cellular 
organelle was too faint to bear quantitative colocalisation analysis. 
To assess whether the observed colocalisation was random or real the pixel values 
for cellular organelles (total red pixels) and PrP
Sc
 (total green pixels) were evaluated 
from the total pixel values (raw data as electronic Appendix 2 of this thesis). The 
values for random pixel colocalisation were calculated (method described in section 
2.14.1). The observed pixel colocalisation was compared to the expected random 
pixel colocalisation. The statistical significance was assessed by considering the null 
hypothesis that the red and green pixels are randomly uniformly distributed.  The 
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calculation of the P-values, the probability for the observed or greater value arising 
from the null hypothesis, is summarised in Table 3.2. In all cases the P-value was 
smaller than 2 x 10
-16
 (beyond the limits of the numerical accuracy of the software), 
indicating that the null hypothesis should be rejected (the usual significance level for 
rejection is 0.05 or 0.01). The anomalous P-value suggests that this method is 
uninformative for comparing preferential co-localisation of PrP
Sc
 with the 
intracellular components in the observed negative (early endosomes or Golgi 
complex colocalising with PrP
Sc
) and positive results (lysosomes colocalising with 
PrP
Sc
) against each other and the only conclusion that could be drawn is that the null 
hypothesis should be rejected. This was supported by the observation that cellular 
structures tend to be clustered and are unlikely to be well approximated by a uniform 
random distribution of pixels. Many pixel intensity-based methods (Pearson’s 
correlation coefficient, for example) are known to suffer from similar problems 
(Bolte et al., 2006). This also suggested that a more appropriate method for 
quantifying colocalisation would be to take the structure in the image into account 
rather than averaging over the entire image. 
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Table 3.2: Pixel-based colocalisation analysis 
 
Below is described the results of the analysis, based on a particle-based method of 
Bolte and colleagues (Bolte et al., 2006), of preferential co-localisation of PrP
Sc
 with 
the intracellular components. The method is described in detail in the Material and 
Methods (section 2.14.2). The analysis was performed on the same data set as the 
pixel-based analysis (early endosomes and lysosomes). However, the method could 
not be applied to Golgi complex data as the software was unable to identify the 
centres of mass in such a complex morphological structures as is the Golgi complex.  
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The features of the software allowed calculating of a commonly used colocalisation 
indicator “the Manders’ colocalisation coefficient” (M1, which always has values 
between 0 and 1). The main goal was to evaluate the amount of the red particles (cell 
organelles) colocalising with the green particles (PrP
Sc
) from the total number of 
present particles. The result is summarised in Table 3.3 and the raw data of this 
analysis are attached in electronic form as an Appendix 2 of this thesis. The 
confirmation of the preferential colocalisation of PrP
Sc
 with cell organelles was 
drawn from the values of the Manders’ coefficient M1 (red particles colocalising with 
green). The negative group (observed PrP
Sc 
not co-localising with early endosomes) 
and positive (observed PrP
Sc 
co-localising with lysosomes) are clearly distinct both in 
terms of the Manders’ coefficient M1 and the numbers of colocalised particles. The 
M1 values are closer to value 0 in case of EEA1 (early endosomes colocalising with 
PrP
Sc
) and closer to value 1 in case of Lamp2b (lysosomes colocalising with PrP
Sc
). 
Also it is important to note the rising trend of the M1 value within the Lamp2b data 
which correlates with increasing time of exposure of HK cells to vCJD brain 
homogenate and indicates a time dependent increase of lysosomes-associated PrP
Sc
.  
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3.8.4  Summary  
 After introducing the prion diseased brain material to HK cells, PrPSc uptake 
and its dynamical transport to the perinuclear region was observed as in 
earlier studies (3.3-5).  
 The HK cells appeared to show trafficking of exogenous PrPSc to recycling 
endosomes and then to lysosomal structures.  
 Roles for the Golgi complex and the endoplasmic reticulum in exogenous 
PrP
Sc
 trafficking were excluded. 
 However, some yellow particles indicating positive colocalisation of the 
exogenous PrP
Sc
 with early endosomes was observed at the 24 hours time 
point of continuous exposure and the 3-48 hours time point of the “pulse-
chase” study. That this colocalisation was random was comfirmed by a 
quantitative image analysis study in this section. 
 The endosomal recycling compartment and lysosomes were identified as the 
likely sites of prion intracellular trafficking and degradation. This 
phenomenon could be observed both in the continuous exposure and in the 
“pulse-chase” studies.  
 PrPSc colocalisation with the LAMP1 and LAMP2b antibodies gave a closely 
similar pattern in cells continuously exposed to brain homogenate and in the 
“pulse-chase” studies, indicating that the vCJD PrP
Sc
-6H4 complex did not 
change or delay the trafficking of exogenous PrP
Sc
 into lysosomes.  
 The exogenous PrPSc was shown structures positively immunolabeled with 
the rab11A antibody, resembling recycling endosomes, after 24 hours 
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trafficking through the cell. At the same time, it was also observed within the 
lysosomal structures. 
 
Chapter 4   Discussion 
  269 
4. DISCUSSION 
 
The initial aims of this thesis were to characterise two different non-neuronal cell 
types in respect of their prion protein genetics, expression level and cell biology and 
subsequently to determine whether these cells could be infected with selected human 
prions after exposure to post-mortem human brain homogenates. The findings of this 
study are discussed in relation to what is beginning to be learnt about the cell biology 
and trafficking of normal and abnormal PrP
Sc
 and how this might relate to cellular 
susceptibility to prion infection and to cytotoxicity. 
 




The Prnp gene that encodes PrP
C
 was identified in 1985 (Oesch et al., 1985; Basler 
et al., 1986) and the first Prnp knockout mice were established in 1992 (Bueler et al., 
1992). However, the function of the prion protein is not known with certainty. In 
spite of the extensive research the molecular mechanisms that result in neuronal 
damage, neuronal dysfunction and ultimately widespread neuronal loss in the brain 
in prion diseases remain poorly understood (Wilson, 2005; Wilson et al., 2007). 
There is a growing consensus that neuronal damage does not result from a loss of 
functional PrP
C
, because its depletion is not detrimental and does not trigger any 
gross pathology in various experimental settings. For example, PrP
C 
is essential for 
propagation of infectious prions and neurotoxicity (Bueler et al., 1993), PrP
C 
knockout in the adult mouse brain does not result in overt phenotypic anomalies 
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(Mallucci et al., 2002) and embryonic PrP
C 
knockout models exhibit normal 
development (Bueler et al., 1992; Manson et al., 1994). Based on those observations, 
PrP
C 
knockout studies argue against the loss of PrP
C 
function in neurones as a 
substantial mechanism in prion-mediated neurodegeneration. However, the 
possibility of compensation for the depleted PrP
C
 by a shadoo protein has been 
proposed (Watts and Westaway, 2007). 
A toxic gain of function by PrP
Sc
 is an attractive alternative hypothesis. The 
neurotoxicity of PrP
Sc
 aggregates is debatable (Lansbury and Lashuel, 2006). Both 
full-length PrP
Sc 
(Hetz et al., 2003; Novitskaya et al., 2006) but also shorter PrP
Sc
 
peptides (Forloni et al., 1993) have been proposed to be toxic to cells in vitro, but the 
relevance of their toxicity in vivo is not clear. Several lines of evidence suggest that 
PrP
Sc 
may not be the toxic species. PrP-null tissue can be in the vicinity of PrP
Sc 
deposits without suffering deleterious effects (Brandner et al., 1996a; Mallucci et al., 
2003), and no direct correlation between neuronal loss and PrP
Sc
 plaques in the 
brains of individuals affected with sCJD can be demonstrated (Parchi et al., 1996; 
Kristiansen et al., 2005; Kong and Bessen, 2008; Deriziotis and Tabrizi, 2008). 
Furthermore, cases of prion diseases (FFI, VPSPr) in which disease associated PrP is 
hardly detectable after PK digestion (termed PrP
sen
) were reported (Medori et al., 
1992b; Parchi et al., 1999a; Gambetti et al., 2003; Gambetti et al., 2008; Head and 
Ironside, 2009; Jansen et al., 2010; Zou et al., 2010; Head et al., 2010), examples of 
infectivity in the absence of detectable PrP
Sc 
have been described (Collinge et al., 
1995; Wille et al., 1996; Lasmezas et al., 1997; Shaked et al., 1999) and transgenic 
mouse models have shown that several aberrant conformers of PrP distinct from 
PrP
Sc 
can evoke neuronal cell death in the absence of infectious prion propagation 
Chapter 4   Discussion 
  271 
(Muramoto et al., 1997; Chiesa et al., 1998; Hegde et al., 1998; Shmerling et al., 
1998; Ma et al., 2002; Flechsig et al., 2003; Baumann et al., 2007). Moreover, 
subclinical infection, in which high levels of PrP
Sc 
accumulate in the absence of 
clinical symptoms have also been described (Hill et al., 2000; Race et al., 2001; Race 
et al., 2002; Hill and Collinge, 2003; Piccardo et al., 2007). In addition, prion-
infected mice expressing PrP
C 
lacking the GPI anchor, were shown to produce 
infectious prions followed by accumulation of extracellular PrP amyloid plaques, but 
surprisingly did not succumb to disease (Chesebro et al., 2005; Trifilo et al., 2006). 
These data thus argue against accumulated PrP
Sc
 being the cytotoxic species. 
 
4.1.2 Subcellular localisation and topology 
Targeting of PrP to the cytosol was shown to cause a rapidly lethal 
neurodegeneration, although accumulation of PrP
Sc 
was not detected (Ma et al., 
2002; Chesebro et al., 2005; Trifilo et al., 2006; Rane et al., 2008; Rane et al., 2010). 
Moreover, proteasome inhibition in vitro was shown to induce formation of a 
slightly-protease resistant cytoplasmic PrP form in cultured cells (Ma and Lindquist, 
2002). Based on these findings, prion toxicity was proposed to initiate with 
retrotranslocation of PrP
C 
from the endoplasmic reticulum to the cytosol as a 
consequence of impaired proteasomal function. Subsequent studies have shown that 
cytosolic PrP (cyPrP) retains its secretory signal peptide and moreover is devoid of a 
GPI anchor, indicating that it cannot enter the endoplasmic reticulum (Drisaldi et al., 
2003).  
The basic phenomenon of toxicity of cytosolic PrP has been contested (Roucou et al., 
2003; Heller et al., 2003; Fioriti et al., 2005). Lingappa and colleagues proposed that 
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PrP
C
 can assume two different endoplasmic reticulum trans-membrane topologies 
(
Ctm
PrP transmembrane PrP with an extracellular C-terminus and 
Ntm
PrP 
transmembrane PrP with an extracellular N-terminus), where 
Ctm
PrP concentrations 
was shown to correlate with neurotoxicity and 
Ctm
PrP was suggested to represent a 
major toxic moiety (Hegde et al., 1998; Hegde et al., 1999). However, these 
observations are controversial, with evidence both for (Ma et al., 2002; Heller et al., 
2003; Rane et al., 2004; Wang et al., 2005; Rambold et al., 2006) and against 
(Roucou et al., 2003; Drisaldi et al., 2003; Fioriti et al., 2005) this neurotoxic 




4.1.3 Toxic intermediates or by-products 
A recent study by Collinge and co-authors has again raised the important point that 
the infectious and toxic forms of PrP need not be identical (Sandberg et al., 2011). 
The gain of toxicity by a PrP moiety, other than conventional PrP
Sc
, remains a 





toxic intermediate may be produced (Safar and Prusiner, 1998; Hill et al., 2000; 
Tzaban et al., 2002; Caughey and Lansbury, 2003; Haass and Selkoe, 2007; 
Thackray et al., 2007; Godsave et al., 2008; Cronier et al., 2008; Sanghera et al., 
2008; Pirisinu et al., 2010; D'Castro et al., 2010; Sandberg et al., 2011; Arellano-
Anaya et al., 2011). This intermediate or toxic side product has been termed PrP
L
 by 
Collinge and co-workers (Hill and Collinge, 2003; Kristiansen et al., 2007; Collinge 
and Clarke, 2007). This model considers PrP
Sc 
as a moderately inert end-product, 
whereas the steady state level of PrP
L 
determines the rate of neurodegeneration (Hill 
and Collinge, 2003; Sandberg et al., 2011). It predicts that PrP
L 
levels are regulated 
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by natural clearance mechanisms and its accumulation occurs only when PrP
L 
overwhelms the clearance capacity, then resulting in neurodegeneration.  
A proposed candidate for such a toxic species is a soluble monomeric or oligomeric 
conformer of the prion protein (Hill and Collinge, 2003). It is unclear how PrP
L
 
might relate to the “silent prions” demonstrated biochemically in normal human 




 signalling  
Tatzelt and colleagues have demonstrated that PrP
C 
localised at the cell surface is 
able to mediate toxic signalling, without being converted into PrP
Sc
 by interaction 
with β-sheet-rich conformers and that this event is dependent on the N-terminal 
domain of PrP
C 
and the C-terminal GPI anchor (Solforosi et al., 2004; Resenberger et 
al., 2011). The data is apparently in conflict with previous findings that PrP
C 
can 
activate neuroprotective signalling pathways (Kuwahara et al., 1999; Brown et al., 
1999; Bounhar et al., 2001; Chiarini et al., 2002; McLennan et al., 2004; Shyu et al., 
2005; Spudich et al., 2005; Weise et al., 2006; Mitteregger et al., 2007; Rangel et al., 
2007) and that the C-terminal GPI anchor and the N-terminal domain are essential 
for this physiological activity (Rambold et al., 2006; Mitteregger et al., 2007). Thus, 
it could be concluded that PrP
C 
acts as a signalling molecule at the cell surface to 
promote stress-protective signalling under physiological conditions, which can be 
switched to toxic signalling initiated by interaction with β-sheet-rich conformers and 
that PrP
C 
most probably acts as a co-receptor in concert with a transmembrane 
protein to transduce the signal into the cell (Winklhofer and Tatzelt, 2000; Flechsig 
and Weissmann, 2004; Roucou and LeBlanc, 2005; Resenberger et al., 2011). 
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The proposal that accumulation of PrP
Sc
 in the cytosol of chronically infected cells is 
generally innocuous in vitro (Haigh et al., 2011) is in close agreement with 
observations in this thesis (section 3.5). The two distinct non-neuronal cell systems 
used in this study - the FDC-like HK cells and undifferentiated hESC - showed 
uptake and substantial accumulation of exogenous PrP
Sc 
from a medium spiked with 
prion disease brain homogenates. No difference in signal between cells exposed to 
brain material and control cells in live cells staining – as opposed to a notable 
difference between exposed and control cells in fixed and permeabilised cells - 
indicates that the PrP
Sc
 signals were indeed intracellular rather than material from the 
medium deposited or trapped on the surface. The cells displayed strong intracellular 
accumulation of PrP
Sc
 in juxtanuclear region of the cytosol with a coarse granular 
morphology. Examination of these cultures did not reveal any gross changes in cell 
morphology, growth characteristics or viability even after continuous incubation with 
the brain spiked medium for 72 hours and when the cells exhibited substantial 
intracellular accumulation of PrP
Sc
.  
The fact that these cells do not support prion infection and apparently represent 
accumulation of PrP
Sc 
in the cytosol without toxic results is consistent with prion 
toxicity being independent of PrP
Sc
 accumulation in the cell. This observation is not 
unique to the cell types used in this thesis. Similar localisation (prominent 
juxtanuclear staining) can be seen in other studies involving prion infected cells 
(Mange et al., 2004; Kristiansen et al., 2005; Magalhaes et al., 2005; Marijanovic et 
al., 2009; Veith et al., 2009).  
Collectively, these data support the proposal that large aggregates of PrP
Sc 
are neither 
the causal reason nor sufficient for cytotoxicity and the development of prion 
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infection. Instead, attention has turned to soluble (Silveira et al., 2005; Berardi et al., 
2006), more protease-sensitive (Tzaban et al., 2002; Pastrana et al., 2006), and small 
oligomeric forms of the prion protein (Silveira et al., 2005; Novitskaya et al., 2006; 
Kristiansen et al., 2007; Simoneau et al., 2009) as being responsible for toxicity. 
Cell lines susceptible to prion infection and capable of propagating infection 
seemingly without adverse effects have proved valuable for TSE research. Recent 
studies have questioned whether such an infection is free of adverse effects, even 
when the cells appear phenotypically normal (Haigh et al., 2011). This supports an 
earlier report by Schatzl and collaborators who demonstrated that the GT1-7 cell line 
exhibits cytopathology in approximately 20% of cells chronically infected with 
scrapie derived RLM prion strain (Schatzl et al., 1997). The apparent discrepancy 
between effects of in vivo and in vitro PrP
Sc
 formation may perhaps also be due to 
the transformed phenotype of the cell culture models used. This could mask the PrP
Sc 
neurotoxicity, which may manifest itself only in terminally differentiated cells, 
resembling more the post-mitotic phenotype of the central nervous system neurons. 
This may explain why ScGT1 cells, with a more differentiated neuronal phenotype, 
do exhibit signs of neurotoxicity, whereas cells of other phenotypes (eg. ScN2a or 
ScN1E-115) do not. Such cells may therefore offer greater possibilities for the study 
of prion related toxicity and pathogenesis than is currently thought, allowing the 
identification of low-level, but ongoing, cell damage. Alternatively, the formation 
and/or accumulation of PrP
Sc 
may not be neurotoxic per se but rather as “neuro-
stressant” and perhaps requiring interplay with microglia and/or astrocytes to become 
fully neurotoxic.  
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4.1.6 Infection studies  
The work described in this thesis directly examines the cellular response of 
extraneuronal lymphoreticular FDC-like HK cells and undifferentiated human 
embryonic stem cells to exposure to infectious prions from human (variant, sporadic, 
iatrogenic Creutzfeldt-Jakob disease) and animal (bovine spongiform 
encephalopathy) brains and their susceptibility and ability to propagate prions in 
vitro. Susceptibility-and in some instances, disease phenotype-in human prion 
diseases are known to be influenced by the methionine/valine (MV) polymorphism at 
codon 129 of the PRNP gene (Collinge and Palmer, 1991; Goldfarb et al., 1992; 
Monari et al., 1994; Parchi et al., 1996; Zeidler et al., 1997; Deslys et al., 1998; Lee 
et al., 2001; Brandel et al., 2003). Therefore, the analysis of PRNP codon 129 
polymorphism, as well as the level of PrP
C
 expression of the cell lines chosen for 
these studies, was an important consideration (section 3.1).  
The chosen human embryonic stem cell lines were of the MM (RCM-1) and MV 
(RH1) genotypes at codon 129 of PRNP. Unfortunately, the only line with a VV 
genotype within the seven available hESC lines had poor growth characteristics and 
therefore was not used. The available follicular dendritic cell-like cell line (HK) was 
found to be VV. The level of PrP
C
 expression tested before the actual infection 
studies was found to be in the hESC RCM-1 and RH1 lines below the detection limit 
by Western blot, whereas there was abundant PrP
C
 expression by the FDC-like HK 
cells. An initial interest was to test whether the cell lines had all the required 
components to support replication of PrP
Sc 
in vitro. This was carried out by PrP
Sc
 
amplification in cell-free assay (PMCA). Cell extracts of established cell lines of 
neuronal or non-neuronal origins were successfully used as a substrate source for 
PMCA only very recently (Mays et al., 2011). This was in spite of earlier reports that 
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indicated that a cell culture derived substrate is incapable of supporting PrP
Sc 
formation in PMCA unless complemented with brain homogenate that may include 
essential cofactors for PrP conversion (Saborio et al., 1999; Castilla et al., 2006).  
The data gained in this experiment (section 3.3) confirmed previous observation that 
the abundance of PrP
C
, this case in cell lysate, is a critical factor for successful PrP
Sc 
conversion (Bueler et al., 1993). Therefore, it is also a critical factor to drive efficient 
PrP
Sc 
amplification in a cell-free system (Mays et al., 2011). PMCA amplification of 
PrP
Sc
 using the extracts from hESC was not successful (data not shown). Cell 
exctracts from HK cells were capable of supporting PrP
Sc 
formation and therefore 
these cells were considered to have the essential minimal requirements to support 
prion replication in vitro. The ability of HK cell lysate to support PrP
Sc 
formation 
was comparable in efficiency to that of normal brain material under the same 
conditions and demonstrated that cell lysate is sufficient to support PrP
Sc 
amplification in a PRNP codon 129-depended manner. However, it has been shown 
previously that host encoded factors other than PrP
C 
may also be required to 
propagate prions in vitro and in vivo (Telling et al., 1995; Saborio et al., 1999; 
Stephenson et al., 2000; Lloyd et al., 2001; Manolakou et al., 2001; Deleault et al., 
2007). The restricted range of cell types that are susceptible to prion infection also 
suggests the existence of prion propagation co-factors (Raeber et al., 1999; Bosque 
and Prusiner, 2000; Enari et al., 2001).  
These observations could be taken to suggest that PMCA might be viewed as a rapid 
indicator of a cell type’s potential susceptibility to prion infection in vitro and in 
vivo. This proposition was tested by directly challenging HK cells in vitro with some 
of the brain homogenates used to seed the above PMCA reactions. The cell types 
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likely to be involved in propagations of prions in vivo were proposed to be low 
density (Clarke and Kimberlin, 1984), long-lived and mitotically quiescent cells 
(Fraser and Farquhar, 1987; McBride et al., 1992). Follicular dendritic cells (FDCs) 
express PrP
C
 and are suggested to be a major site of prion replication and 
accumulation in the germinal centres of spleen, lymph nodes and mucosa-associated 
lymphoid tissue following experimental or natural infection with prions (Kitamoto et 
al., 1991; McBride et al., 1992; Klein et al., 1998; Hill et al., 1999; Sigurdson et al., 
1999; Andreoletti et al., 2000; Beekes and McBride, 2000; Mabbott et al., 2000; 
Heggebo et al., 2002; Mabbott et al., 2003). However, these cells may not account 
for the entire process of prion neuroinvasion on its own as they are known to 
generate immobile networks. Although nerve ending within the lymphoreticular 
system tissues may provide one route to neuroinvasion (Glatzel et al., 2001; Aguzzi 
et al., 2003; Glatzel et al., 2004), macrophages were also suggested to be able to take 
up infectious prions and sequester infectivity (Carp and Callahan, 1981), and 
dendritic cells may also be responsible for the spread of prions throughout the body 
(Aucouturier et al., 2001; Huang et al., 2002) as they display potential mobility and 
are known to have a close contact with macrophages (Carp and Callahan, 1981; 
Beekes and McBride, 2000; reviewed by Koperek et al., 2002; Beekes and McBride, 
2007; revieved by Kovacs and Budka, 2008).  
The observation that the HK cells employed in this thesis share characteristics with 
FDC cells (Kim et al., 1994; Kim et al., 1995), express PrP
C
 and support PrP
Sc 
replication using their extracts in cell-free system, might be taken to suggest that HK 
cells should support PrP
Sc 
propagation in vitro. The cellular response of the HK cells 
and the hESC to acute exposure of infectious prions was tested. This was monitored 
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by Western blot analysis (section 3.4) and also by immunocytochemical analysis 
(sections 3.6). The HK cells and hESC exposed to a medium containing prion 
diseased brain homogenate progressively take up PrP
Sc
 (and presumably prion 
infectivity) present in the medium. The amount of cell-associated PrP
Sc 
increased 
with the time of exposure to the spiked medium. The uptake of PrP
Sc 
was rapid, and 
the estimation of total PrP
Sc 
uptake into the cells for each given time point showed 
that there were no obvious differences in PrP
Sc 
uptake between the cell types when 
using different brain homogenates.  
However, membrane binding and internalisation of exogenous (inocula-derived) 
PrP
Sc 
may not be sufficient to generate prion infection and PrP
Sc 
production in itself, 






may be required (Deleault et al., 2007; Abid et al., 2010; Goold et al., 
2011). Some previous studies have proposed that as little as four minutes of exposure 
to prions is sufficient for the cell to become infected and distribute PrP
Sc 
at steady-
state in the perinucleus and cell surface (Caughey and Raymond, 1991; Arnold et al., 
1995; Kristiansen et al., 2005). A recent publication indicated that only two minutes 
of exposure is sufficient to generate cells that continue producing PrP
Sc 
in the 
absence of a further prion seed. These studies appear to show that cells can be stably 
infected with prions following a very transitory exposure (Goold et al., 2011). 
Despite the abundant expression of PrP
C
, the ability to support PrP
Sc 
replication using 
the cell extracts in a cell-free system, and the rapid uptake and intracellular 
accumulation of PrP
Sc 
in the cytosol after exposure to prion diseased brain material, 
the HK cells did not show any signs of prion replication and accumulation in vitro 
(section 3.5). A wide variety of inoculum and exposure protocols were employed: 
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usage of different concentrations of brain homogenates, sonication, homogenisation 
in physiological buffers, or even in non-ionic detergents, and culturing the cells in 
low nutritional conditions or in medium without antibiotics, but none were 
successful. The conditions for cell challenge were largely based on previous 
successful prion infections of other cultured cell types. Sonication of brain 
homogenates before cell challenge seemed to facilitate better internalisation and 
trafficking, suggesting that size of exogenous PrP
Sc
 aggregates strongly influences 
the internalisation rate (Magalhaes et al., 2005). PrP
C 
is mainly present in rafts 
(cholesterol rich domains) in the cell membrane and drugs that interfere with the raft 






complex endocytosis and thus 
delay or prevent PrP
Sc 
accumulation in treated cells (Mange and Lehmann, 2002; 
Dormont, 2003). Because Amphotericin B (present in the cell culture 
antibiotic/antimycotic cocktail) can inhibit PrP
Sc 
generation in scrapie-infected GT1-
7 and N2a cells by modifying properties of the detergent-resistant microdomains 
(Mange et al., 2000a; Mange et al., 2000b), it was also decided to test the HK cell 
susceptibility to prion infection when challenged with a medium containing 
infectious prions without the antibiotic cocktail. Other studies inclined to expose 
cells to PrP
Sc
 homogenised in physiological buffers, arguing that PK-digested forms 
might have poor biological relevance.  
Despite numerous attempts, using a series of rationally designed methodological 
variations, PrP
Sc 
was internalised, but no evidence was found for HK cell infection or 
prion replication. This was a disappointing finding, especially since efforts were 
made to avoid transmission barriers based on species and codon 129 genotype. It was 
especially surprising that iatrogenic CJD (VV) prions failed to infect the HK cells, 
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which abundantly expressed PrP
C
 129 VV, but this could perhaps be attributed to the 
sCJD/iCJD prion strain being neurotropic rather than lymphotropic.  
The most likely explanation for the PrP
res
 signal observed in Western blots of the cell 
lysates from cells exposed to prion disease brain material at early time points is that 
it represents a residual inoculum, which was then lost or diluted out during longer 
term culturing and subsequent passages. Analysis using the 3F4 and 6H4 antibodies 
in cells exposed to BSE is consistent with this explanation. However, it cannot be 
ruled out completely that some HK cells may exhibit a transitory or perhaps fatal 
prion infection within the exposed cultures as a whole. Judged by the gradual uptake 
and subsequent loss of PrP
Sc
 in the cells exposed to prion infectious medium and 
then cultured in fresh medium, it appears that the PrP
Sc 
was most likely actively 
internalised and then degraded by the cells, rather than being non-specifically bound 
to the cell surface. Interestingly, the cell-associated PrP
Sc 
signal appeared to be more 
intense in first hours of recovery than in the cell lysate just before the removal of 
infectious medium. Overall, these data lead to the conclusion that HK cells are 
largely resistant to infection with human and bovine prions or that they are not 
competent to sustain an infection.  
Similarly, it was perhaps surprising that 129 MM hESC failed to become infected 
with BSE or vCJD. It is possible that this was a reflection of the very low level of 
PrP
C
 expression by the self-renewing populations of hESC used. The fact that both 
the HK cells and the hESC grow and divide may be relevant, as healthy uninfected 
cells may outgrow any rare infected, and perhaps less healthy, cells. It is noteworthy 
that the main site of prion replication is in a post-mitotic cell, such as neuron or FDC. 
Alternatively, perhaps neither hESC nor HK cells express the correct hypothetical 
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co-factors or the appropriate sub-cellular milieu for efficient conversion. It is worth 
noting that although human FDCs in situ show signs of infection (in 129 MM 
individuals with primary and secondary vCJD), HK cells and FDC differ in several 
important and relevant respects. FDC in situ are largely post-mitotic and have 
functional relationships with surrounding cells in secondary lymphoid cells. FDC 
also have elaborate projections, a highly specialised cell surface, and part of their 
function in the immune response involves the trapping and long-term maintenance, 
rather than endocytosis and degradation of antigens on the cell surface.  
Whether acute but transitory de novo PrP
Sc 
formation can be initiated in these cells 
without leading to sustainable PrP
Sc 
formation merits further investigation as does the 
mechanism by which cell-associated PrP
Sc 
was lost during this process. The latter 
was further investigated in this thesis (sections 3.6 and 3.8). 
 
4.2 CELL BIOLOGY AND PRP TRAFFICKING 
4.2.1 Uptake and endocytosis 
 The trafficking of molecules within cells is most likely dependent on the 
mechanism of internalisation (Conner and Schmid, 2003). The relevant data 





the context of constitutively infected cells, and not naïve cells exposed to 
exogenous prions. Undifferentiated hESC cells and HK cells display a readily 
detectable time dependent uptake of PrP
Sc
 from medium spiked with prion 
disease brain homogenates (sections 3.4, 3.5, 3.7, 3.8). Densitometric 
assessment (3.4) confirmed the rising trend of the cell-associated PrP
Sc
 signal 
increasing with the time of exposure of the cells to the brain spiked medium. 
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The presence, distribution, and time course of uptake of exogenous PrP
Sc
 by hESC 
and HK cells was similar, whether they were exposed to BSE, vCJD, iCJD, or sCJD 
brain homogenates. Moreover, the in vitro experimental evidence presented here is in 
agreement with previous observations that PrP
C 
is not required for internalisation of 
PrP
Sc
 (Vey et al., 1996; Paquet et al., 2007; Dorban et al., 2010). Section 3.1 
demonstrated that the HK cells express abundant level of PrP
C 
whereas the 
undifferentiated hESC express levels below detection by Western blot.  
Nevertheless, the amount of PrP
Sc
 taken up and accumulated by both cell types was 
similar. Furthermore, no differences in the rate of uptake were observed, which could 
be attributed to differences of cell type. Overall it was concluded that uptake is 
neither dependent on the species origin of the brain homogenate, nor the PRNP 
codon 129 genotype of the cell or the prion agent, and that PrP
C 




Endocytosis is known to provide a crucial and dynamic interference between the 
extracellular milieu and the interior of the cell (Mayor and Pagano, 2007; Idone et 
al., 2008). To investigate the precise mechanism HK cells used for internalisation of 
the exogenous PrP
Sc
, immunocytochemical procedures investigating PrP
Sc 
colocalisation with endocytic vesicles visualised by confocal microscopy were 
employed (section 3.7). 
Employing guanidine pre-treatment and continuous exposure or the “pulse-chase” 
paradigm provided direct evidence that both caveolae and clathrin-mediated 
endocytic pathways are involved in the process of exogenous PrP
Sc
 uptake. 
Interestingly, the data presented here indicates that caveolae-coated vesicles are the 
major early route for PrP
Sc 
uptake. The evidence presented here further suggests that 
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the kinetics of uptake differ, with caveolae-mediated uptake preceding that of 
clathrin coated pits. These data are consistent with reports for constitutively infected 
cells in which PrP
Sc 
internalisation is caveolae-mediated (Vey et al., 1996; Wadia et 
al., 2008; Jen et al., 2010). Although PrP
C
 recycling was not studied in this thesis, 
endocytosis, via clathrin-coated pits and via caveolae-coated vesicles have been 
separately implicated by different researchers (Ying et al., 1992; Shyng et al., 1993; 
Shyng et al., 1994; Shyng et al., 1995; Vey et al., 1996; Marella et al., 2002; 
Sunyach et al., 2003; Peters et al., 2003; Griffiths et al., 2007; Sarnataro et al., 
2009). The reported discrepancies in these studies may result from different 
approaches, cell types and experimental paradigms employed. Nevertheless, the 





 (Borchelt et al., 1992; Vey et al., 1996; Kaneko et al., 
1997a; Campana et al., 2005).  
 
4.2.2 Intracellular sorting 
Although the refractory nature of most cell types to prion infection in vitro is a well 
known phenomenon in prion research, the literature contains little evidence of 
rigorous investigation of why this might be the case. The decision to investigate the 
fate of the exogenous PrP
Sc
 revealed an unexpected answer and one that provided a 
major alternative focus for this thesis.  
To examine whether the kinetics of endogenously produced PrP
Sc 
described in the 
literature for constitutively infected cells are different from the kinetics of exogenous 
PrP
Sc 
when cells are acutely exposed to prion disease brain material (section 3.8), 
immunocytochemistry and confocal microscopy were employed. In vivo studies 
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suggest that PrP
Sc 
first accumulates at the cell surface of neurones and dendrites, and 
either released or internalised from there (Jeffrey et al., 1994b). The intracellular fate 
of GPI-anchored proteins (GPI-AP) in the endocytic pathway was proposed to be cell 
type dependent (Fivaz et al., 2002). Differential sorting may be of physiological 
importance for the intracellular delivery of GPI-AP ligands, as well as perhaps the 
infectivity of the prion protein. Indeed, certain cell types cannot be infected with 
prions despite the presence of PrP
C
 (Raeber et al., 1999). 
Despite the high level of PrP
C
 expression, the HK cells failed to support PrP
Sc
 
replication and to propagate a prion infection in this study (section 3.5). The kinetics 
of PrP
Sc
 in challenged cells was analysed by dual labelling immunocytochemistry 
monitored in situ by confocal microscopy in attempt to colocalise exogenous PrP
Sc
 
with sub-cellular organelles during continuous exposure and particularly during 
transient exposure in a “pulse-chase” format to a preformed vCJD brain homogenate 
PrP-6H4 mAb complex. Guanidine pre-treatment was also used to enhance PrP
Sc 
staining and diminish PrP
C 
staining. However, this step did not completely abolish 
PrP
C 
staining (Taraboulos et al., 1990a; Veith et al., 2009). This problem was 





. A similar thresholding approach was 
recently used by Veith and collaborators (Veith et al., 2009). This approach was 
necessary because poteinase K digestion, which is generally used to selectively 
detect PrP
Sc
 interfered with the labelling and integrity of organelles.  
The observations indicate that subcellular trafficking of exogenous PrP
Sc 
into 
perinuclear regions (sections 3.3, 3.4, 3.5) may influence the chances of establishing 
a prion infection. This is in agreement with findings in other studies showing kinetics 
Chapter 4   Discussion 
  286 
of internalised rPrP or exogenous PrP
Sc
 to be directed to perinuclear region of cell 
cytoplasm (Caughey and Raymond, 1991; Arnold et al., 1995; Kristiansen et al., 
2005; Sanghera et al., 2008).  
The HK cells also showed trafficking of exogenous PrP
Sc
 to recycling endosomes 
and late endosomal/lysosomal structures. The data appears to exclude roles for the 
Golgi complex and the endoplasmic reticulum in exogenous PrP
Sc
 trafficking. Some 
positive colocalisation of exogenous PrP
Sc
 with early endosomes was observed at the 
24 hours time point of continuous exposure and the 3 to 48 hours time point of the 
“pulse-chase” study. However, the involvement of early endosomes in exogenous 
PrP
Sc
 trafficking was not conclusively shown for the time points examined. Whether 
this colocalisation was real or random was assessed by a quantitative image analysis 
study in this thesis (section 2.14 and 3.8.3.19). Unfortunately, the pixel-based 
method used was concluded to be uninformative to compare preferential 
colocalisation of PrP
Sc
 with cellular organelles, however a particle-based method 
(which is more appropriate for the analysis of complex morphological structures) 
confirmed that PrP
Sc
 preferentially colocalises with lysosomes, but not early 
endosomes.  
This phenomenon could be observed both in the continuous exposure and in the 
“pulse-chase” studies. The endosomal recycling compartment and late 
endosomes/lysosomes were identified as the likely sites of prion intracellular 
trafficking in the HK cells. The exogenous PrP
Sc
 was observed in structures 
positively immunolabeled with the rab11A antibody, resembling recycling 
endosomes and the late endosomal/lysosomal compartment after 24 hours trafficking 
through the cell. PrP
Sc
 co-localisation with the LAMP1 and LAMP2b (lysosomal 
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associated membrane proteins) antibodies gave closely similar patterns in cells 
continuously exposed to brain homogenate and in “pulse-chase” studies, indicating 
that the vCJD PrP-6H4 mAb complex did not change or delay the trafficking of 
exogenous PrP
Sc
 within the cell. The time-course co-localisation data obtained in this 
part of the thesis is consistent with the following model for PrP
Sc
 trafficking in HK 
cells (Figure 4.1). 
 
4.2.3 The significance of lysosomal localisation 
Recycling endosomes, late endosomes and lysosomes are oxidising environments 
(Austin et al., 2005) and have been implicated in prion pathogenesis, providing a low 
pH environment that may favour the partial unfolding of PrP
C 
and allowing more 
efficient conversion into PrP
Sc 
(Laszlo et al., 1992; Marijanovic et al., 2009; Veith et 
al., 2009). Exposure of naïve PrP
C
 expressing cells to PrP
Sc 
was shown to induce a 
rapid lysosomal reactive oxygen species (ROS) response parallel with the 
internalisation and accumulation of the infectious inoculum in acidic vesicles (Haigh 
et al., 2011). The positive colocalisation of exogenous PrP
Sc 
with late 
endosome/lysosomal structures demonstrated in this thesis is in agreement with 
previous observation of PrP
Sc 
sub-cellular localisation in prion infected cells, or PrP
Sc 
classical intracellular targeting during trafficking (Taraboulos et al., 1990b; 
McKinley et al., 1991; Caughey et al., 1991; Laszlo et al., 1992; Mayer et al., 1994; 
Arnold et al., 1995; Harris et al., 1996; Peters et al., 2003; Pimpinelli et al., 2005; 
Caughey et al., 2009; Veith et al., 2009). Late endosomes, also known as 
multivesicular bodies (MVBs), are mainly spherical, lacking tubules, and containing 
many close-packed luminal vesicles (Mellman, 1996; Piper and Luzio, 2001; Russell 
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et al., 2006). Late endosomes or MVBs fuse directly with lysosomes (Futter et al., 
1996; Bright et al., 1997; Mullock et al., 1998; Luzio et al., 2007) and this occurs in 
the juxtanuclear region of the cell as late endosomes and lysosomes are concentrated 
near the microtubule-organising centre (Luzio et al., 2007).  
The findings in this thesis indicate that uptake of material into the cell is a “complex 
uptake” and different materials can be taken up along the same endocytic pathway. 
This was observed in the study employing dual immunolabelling for PrP
Sc 
and glial 
fibrillary acidic protein (GFAP) (section 3.5). Both PrP
Sc 
and GFAP proteins 
accumulated in the cytosol and were uniformly distributed at the same intracellular 
site of the cell, suggesting a general rather than a specific uptake mechanism. 
Late endosomes are the last sorting station in the endocytic pathway before 
lysosomes (Sobo et al., 2007). The trafficking of late endosome-like vesicles 
containing PrP
Sc 
to lysosomes was proposed to play a crucial role in the 
accumulation or elimination of PrP
Sc 
(Okemoto-Nakamura et al., 2008). Lysosomes 
are dynamic organelles that accept and degrade macromolecules from endocytic, 
autophagic, phagocytic and secretory membrane-trafficking pathways (Luzio et al., 
2007). The observation of the exogenous PrP
Sc 
clearance from HK and hESC in the 
recovery assay (section 3.6) and the documented trafficking of PrP
Sc 
into lysosomal 
vesicles (section 3.8) are consistent with the previous studies implicating lysosomal 
proteases in PrP
Sc 
degradation (Beringue et al., 2000; Supattapone et al., 2001; Luhr 
et al., 2002; Dormont, 2003; Jeffrey et al., 2003; Kiachopoulos et al., 2004; Mallucci 
and Collinge, 2005; Rybner-Barnier et al., 2006; Dron et al., 2009; Sassa et al., 
2010).  
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Figure 4.1: Trafficking of exogenous PrP
Sc 
within the cell  
In summary, the exogenous PrP
Sc 
is predominately taken up by caveolae-coated vesicles 
preceding the uptake by clathrin-coated pits. Trafficking of exogenous PrP
Sc 
in early 
endosomes, Golgi complex and endoplasmic reticulum was shown to be negative in HK 
cells. Trafficking of late endosome vesicles containing PrP
Sc 
to lysosomes was proposed to 
be the path the exogenous PrP
Sc 




 clearance  
The possibility that certain cells have the ability to degrade PrP
Sc 
has recently come 
into focus. Prions are thought to be resistant to proteolytic degradation. However, 
evidence for relatively efficient natural clearance mechanisms has been reported 
(Mallucci and Collinge, 2005). PrP
0/0 
mice that are unable to replicate prion 
infectivity (Bueler et al., 1993) were able to reduce intracerebrally introduced lethal 
dose of prion inoculum (for wild type mice) below detection levels by a natural 
mechanism within two weeks (Mallucci and Collinge, 2005). Moreover, scrapie 
infected N2a cells are able to clear PrP
Sc 
in three days after transient treatment with 
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monoclonal antibodies against PrP. Clearance was suggested to be the result of the 
prevention of formation of new PrP
Sc
 in combination with intracellular degradation 
of existing PrP
Sc
 (Peretz et al., 2001; Enari et al., 2001). 
Spleen and lymph nodes of the lymphoreticular system seem to be critical for PrP
Sc 
replication and neuroinvasion in some murine scrapie models (Blattler et al., 1997; 
Mabbott et al., 2000). Macrophages were implicated as alternative sites of prion 
accumulation and replication in the absence of functional FDCs. However, they were 
also demonstrated to be able to clear both inoculum and newly formed PrP
Sc
 in vitro 
and in vivo (Carp and Callahan, 1981; Beringue et al., 1999; Beringue et al., 2000).  
A recent study demonstrated that bovine phagocytic cells have strong degradation 
abilities against exogenous PrP
Sc 
in vitro (Sassa et al., 2010). Additional to murine 
macrophages (Carp and Callahan, 1981), mouse and rat dendritic cells (DCs) have 
also been shown to degrade TSE agents (Luhr et al., 2002; Huang et al., 2002; 
Rybner-Barnier et al., 2006). Murine bovine marrow-derived DCs were shown to 
degrade PrP
Sc 
in vitro, but are considered to still have the capacity to spread prion 
infectivity (Luhr et al., 2002). Phagocytic cells, such as macrophages, appear to 
degrade PrP
Sc 
(Sassa et al., 2010), but dendritic cells may also have the potential to 
deliver the prion agents to FDCs where early accumulation of PrP
Sc 
occurs (Huang et 
al., 2002; revieved by Mabbot and MacPherson, 2006; revieved by Heikenwalder et 
al., 2007; reviewed by Cobb and Surewicz, 2009). A similar dual function is thought 
to occur in the processing of other pathogens. For example, CSF-1 dependent cells, 
which include population of macrophages and DCs, can protect against systemic 
infection with Listeria monocytogenes, but they have also been shown to facilitate its 
neuroinvasion (Jin et al., 2002).  
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4.3 RELEVANCE TO PRION DISEASE AETIOLOGY, PATHOGENESIS AND 
RISK 
4.3.1 Sporadic and familial forms 
Internalisation of misfolded or aggregated PrP and its subsequent degradation in a 
lysosomal compartment might function as a cellular mechanism to eliminate non-
native, presumably non-functional PrP
 
conformers endocytosed into the cells. This 
process might play an important role in the balance between clearance and 
propagation of prions in an infected host, but it may also play a role in avoiding 
sporadic or spontaneous forms of human prion disease and in delaying familial forms 
in individual that carry mutations in PRNP. Although the evidence is limited, one 
could hypothesize that small amounts of PrP
Sc 
may be produced in cells throughout 
life which are degraded efficiently by the lysosomal machinery. The so called “silent 
prions” described by Yuan et al., (2006) might represent such a molecular species. 
However, when the amount of the protein destine for degradation overloads the 
system (perhaps due to invasive PrP
Sc
 replication) or when the degradative 
machinery begins to fail (due to aging, insult or genetics) the endogenous PrP
Sc
 may 
reach a threshold for developing a self-sustaining pathogenic prion disease. 
Interestingly, HK cells appear to be able to respond to their environment by 
increasing the numbers of LAMP1- and LAMP2b-positive lysosomes. Whether such 
a mechanism occurs in vivo in response to prion propagation is not known. 
The molecular mechanisms involved in neurodegeneration in prion diseases are 
incompletely understood, but are thought to involve multiple processes operating 
simultaneously and synergistically in the brain, including spongiform degeneration, 
synaptic alterations, dendritic atrophy, vacuolisation, autophagy, microglial 
activation, oxidative stress, brain inflammation, neuronal death and the accumulation 
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of protein aggregates. The notion that neurodegeneration is caused by the formation 
and accumulation of PrP
Sc 
is most likely an oversimplification. The formation and 
accumulation of PrP
Sc 
in combination with an inflammatory glial response may have 
a synergistic deleterious effect on neurones producing a fatal threshold level of 
cellular stress and resulting in neuronal apoptosis. It may be desirable to co-culture 
neuronal cells and glial cells infected with prions to help elucidate the mechanism of 
prion-induced neurodegeneration. 
 
4.3.2 Acquired forms 
Acquired human prion diseases occur in the form of vCJD (orally acquired human 
BSE), kuru (orally acquired presumed sCJD) and iatrogenic CJD (acquired through a 
variety of medical routes). It is generally accepted that exposure of the UK 
population to BSE through food was widespread and extensive, but this is not 
reflected in the current incidence of vCJD (Valleron et al., 2001; Ferguson et al., 
2002; Ghani et al., 2003). A poorly recognised but general ability of human cells to 
take up and degrade PrP
Sc
 may be one component part of an explanation for this 
discrepancy, in addition to better recognised potential explanations, such as a 
substantial species barrier existing between cattle and humans (Bishop et al., 2006). 
Recent evidence of asymptomatic infected carriers in the UK population, as well as 
the four cases of transfusion-related secondary vCJD cases suggest a possible 
“underground propagation” of PrP
Sc 
within the human population (Llewelyn et al., 
2004; Peden et al., 2004; Wroe et al., 2006; Bishop et al., 2006; Hewitt et al., 2006; 
HPA, 2007; Peden et al., 2010) (http://www.cjd.ed.ac.uk/TMER/TMER.htm). All 
definite clinical cases of vCJD have the MM rather that MV or VV configuration at 
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the position 129 of the PRNP gene (Zeidler et al., 1997; Mead et al., 2007; Mead et 
al., 2009; Kaski et al., 2011) (http://www.cjd.ed.ac.uk). To date, only one possible 
case of vCJD with an MV genotype has been reported, althoughr the post-mortem 
examination to confirm the diagnosis was not performed (Green et al., 2010; Heath 
et al., 2010). Nevertheless, there have been two reported MV recipients of a vCJD 
implicated blood transfusion and blood products which, despite being clinically 
unaffected, shown signs of secondary vCJD infection, specifically accumulation of 
the prion disease-associated protein in their spleen at the autopsy examination (Peden 
et al., 2004; Peden et al., 2010). Transmission studies of vCJD to the three lines of 
humanised transgenic mice indicated that the MM and MV genotypes might be 
equally susceptible to vCJD (but with different incubation periods) and that VV 
individuals may also be susceptible (including very long incubation times and a 
lengthy subclinical phase) (Bishop et al., 2006). The inability to establish a 
constitutive infection in the FDC-like HK cells (VV) in vitro in this thesis could be 
seen to be consistent with this interpretation.  
Despite the rarity of the prion diseases, the emergence of variant CJD, linked to the 
consumption of cattle infected with BSE, and more recently transmission-associated 
secondary transmission, has brought TSEs to the forefront of human health concerns 
(Will et al., 1996; Bruce et al., 1997; Hill et al., 1997a; Llewelyn et al., 2004; Peden 
et al., 2004; Wroe et al., 2006). Another potential route for accidental person-to-
person transmission of the infection, beside surgery, blood transfusion and tissue 
transplantation, are future stem cell therapies. As most current culture systems 
supporting human embryonic stem cell (hESC) self-renewal and differentiation rely 
on both direct and indirect exposure to animal or human cells, and on the use of cell 
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products such as bovine serum or human purified proteins, (De Sousa et al., 2006) it 
is possible that hESC could represent a potential risk of prion transmission.  
The study carried out in this thesis was the first to explore the response of hESC after 
acute prion exposure and evaluate the observations within the context of inadvertent 
prion transmission by future clinical application of hESC or their differentiated 
derivates and the consequences for public health (section 3.6, 3.7) (Krejciova et al., 
2011). The observations are provocative. Although hESC take up and rapidly clear 
PrP
Sc
, the potential long-term effect of such exposure is not known and further 
investigation is required. The observation that exposure of hESC to prion diseased 
brain material does not result in gross noticeable cytotoxicity was an interesting 
finding in itself. This may be a further confirmation of the non-toxic nature of PrP
Sc
 
when acquired by cells and circumscribed by its sub-cellular localisation. However, 
whether this could result from the nature of the hESC (undifferentiated, i.e. non-
neuronal phenotype) merits further investigation. These experiments were short-
term, did not address infectivity directly and did not involve hESC differentiated to 
relevant phenotypes, such as neurons. Whether all exposed cells are able to clear 
PrP
Sc
 entirely, and whether they do so before a prion infection may be established 
remains, to be explored, as does the consequence of cellular differentiation of hESC 
cells previously exposed to infectious prions. This is important because clinical 
applications of hESC will involve cells that have been subjected to differentiation in 
vitro prior their use in stem cells therapies or transplantation. Differentiation-
associated change in PrP
C 
expression may cause hESC to become susceptible to 
prion infection from media constituents or may permit a low level of contamination 
to become an established infection.  
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The possibility that future therapies based on hESC technology might present a risk 
of prion transmission cannot be discounted out of hand. Despite the low likelihood of 
animal and human prion contamination of hESC, the consequences of any such event 
could be serious, especially when one considers the number of patients that might 
receive cellular therapies from one individual cell line. These concerns coupled with 
our limited knowledge of the potential risks posed by known and emergent human 
and animal TSEs world-wide suggest that further investigation of the potential of 
hESC to harbour and propagate prions are merited. They also provide a rationale for 
the development of methods of hESC derivation and cultivation that minimise 
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6. APPENDIX 1 
 
Some data from this thesis were published in The Journal of Pathology and reprint of 
the article is enclosed in this appendix 1 (358-368). Full permission has been granted 
form the publishing journal and this is enclosed on the page 369. 
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